Any feedback?
Information on EC 3.1.3.48 - protein-tyrosine-phosphatase
for references in articles please use BRENDA:EC3.1.3.48Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.1.3.48 protein-tyrosine-phosphataseIUBMB Comments
Dephosphorylates O-phosphotyrosine groups in phosphoproteins, such as the products of EC 2.7.10.2, non-specific protein-tyrosine kinase.
Specify your search results
Word Map
- 3.1.3.48
- pp2a
- mapks
- autoimmune
- erk
- cyclin
- leukemia
- endothelial
- ras
-
signal-regulated
- lysosomal
-
okadaic
- t-cells
- metastasis
-
checkpoint
- sirna
- obesity
- myeloid
- 3-kinase
- adaptor
- arthritis
- vanadate
- stat3
- tumorigenesis
- prostate
- mellitus
- phosphatidylinositol
-
cyclin-dependent
- c-jun
- pkc
-
rheumatoid
-
tyrosine-phosphorylated
-
hyperphosphorylation
-
nonreceptor
- chk1
-
cytochemical
- autophosphorylation
-
receptor-like
- genistein
- irs-1
-
insulin-stimulated
- phosphopeptide
-
tartrate-resistant
- grb2
- c-src
- jak2
- fyn
- paxillin
- substrate-1
-
myelomonocytic
-
polo-like
- medicine
- pharmacology
- diagnostics
- drug development
The enzyme appears in viruses and cellular organisms
Synonyms
ptp1b, protein tyrosine phosphatase, shp-1, shp-2, tyrosine phosphatase, protein phosphatase 2a, acid phosphatase activity, mkp-1, cdc25a, ptpn22, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
protein tyrosine phosphatase
-
protein tyrosine phosphatase 1B
-
PTP1B
-
70Z-SHP
-
-
-
-
Brain-derived phosphatase
-
-
-
-
BVP
-
-
-
-
CD148 antigen
-
-
-
-
CD45
-
-
-
-
CD45 antigen
-
-
-
-
Cdc25-like protein
-
-
-
-
CDK2-associated dual specificity phosphatase
-
-
-
-
Ch-1PTPase
-
-
-
-
CPTP1
-
-
-
-
DLAR
-
-
-
-
Dual specificity phosphatase Cdc25A
-
-
-
-
Dual specificity phosphatase Cdc25B
-
-
-
-
Dual specificity phosphatase Cdc25C
-
-
-
-
Dual specificity protein phosphatase hVH1
-
-
-
-
Dual specificity protein phosphatase hVH2
-
-
-
-
Dual specificity protein phosphatase hVH3
-
-
-
-
Dual specificity protein phosphatase PYST1
-
-
-
-
Dual specificity protein phosphatase PYST2
-
-
-
-
Dual specificity protein phosphatase VHR
-
-
-
-
Dual-specificity tyrosine phosphatase TS-DSP6
-
-
-
-
Dual-specificity tyrosine phosphatase YVH1
-
-
-
-
ES cell phosphatase
-
-
-
-
HCP
-
-
-
-
Hematopoietic cell protein-tyrosine phosphatase
-
-
-
-
Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP
-
-
-
-
Hematopoietic protein-tyrosine phosphatase
-
-
-
-
HEPTP
-
-
-
-
HPTP beta-like tyrosine phosphatase
-
-
-
-
HPTP eta
-
-
-
-
hPTPE1
-
-
-
-
ICAAR
-
-
-
-
Islet cell autoantigen related protein
-
-
-
-
kinase associated phosphatase
-
-
-
-
L-CA
-
-
-
-
Late protein H1
-
-
-
-
LCA
-
-
-
-
LCA-related phosphatase
-
-
-
-
Leukocyte antigen related
-
-
-
-
Low molecular weight cytosolic acid phosphatase
-
-
-
-
LRP
-
-
-
-
Lymphoid phosphatase
-
-
-
-
LyP
-
-
-
-
M1851
-
-
-
-
MAP-kinase phosphatase CPG21
-
-
-
-
MEG
-
-
-
-
Mitosis initiation protein
-
-
-
-
Mitosis initiation protein MIH1
-
-
-
-
Mitotic inducer homolog
-
-
-
-
MKP-1 like protein tyrosine phosphatase
-
-
-
-
MPTP
-
-
-
-
MPTP-PEST
-
-
-
-
NC-PTPCOM1
-
-
-
-
Neural-specific protein-tyrosine phosphatase
-
-
-
-
ORF5
-
-
-
-
OST-PTP
-
-
-
-
P19-PTP
-
-
-
-
P80
-
-
-
-
PC12-PTP1
-
-
-
-
Phogrin
-
-
-
-
Phosphacan
-
-
-
-
phosphatase, phosphoprotein (phosphotyrosine)
-
-
-
-
phosphatase, phosphotyrosine
-
-
-
-
phosphoprotein phosphatase (phosphotyrosine)
-
-
-
-
phosphotyrosine histone phosphatase
-
-
-
-
phosphotyrosine phosphatase
-
-
-
-
Phosphotyrosine phosphatase 13
-
-
-
-
phosphotyrosine protein phosphatase
-
-
-
-
phosphotyrosylprotein phosphatase
-
-
-
-
protein phosphotyrosine phosphatase
-
-
-
-
Protein tyrosine phosphatase-NP
-
-
-
-
Protein-protein-tyrosine phosphatase HA2
-
-
-
-
Protein-tyrosine phosphatase 1B
-
-
-
-
Protein-tyrosine phosphatase 1C
-
-
-
-
Protein-tyrosine phosphatase 1E
-
-
-
-
Protein-tyrosine phosphatase 2C
-
-
-
-
Protein-tyrosine phosphatase 2E
-
-
-
-
Protein-tyrosine phosphatase 3CH134
-
-
-
-
Protein-tyrosine phosphatase CL100
-
-
-
-
Protein-tyrosine phosphatase D1
-
-
-
-
Protein-tyrosine phosphatase ERP
-
-
-
-
Protein-tyrosine phosphatase G1
-
-
-
-
Protein-tyrosine phosphatase H1
-
-
-
-
Protein-tyrosine phosphatase LC-PTP
-
-
-
-
Protein-tyrosine phosphatase MEG1
-
-
-
-
Protein-tyrosine phosphatase MEG2
-
-
-
-
Protein-tyrosine phosphatase P19
-
-
-
-
Protein-tyrosine phosphatase PCPTP1
-
-
-
-
Protein-tyrosine phosphatase pez
-
-
-
-
Protein-tyrosine phosphatase PTP-RL10
-
-
-
-
Protein-tyrosine phosphatase PTP36
-
-
-
-
Protein-tyrosine phosphatase PTPL1
-
-
-
-
Protein-tyrosine phosphatase striatum-enriched
-
-
-
-
Protein-tyrosine phosphatase SYP
-
-
-
-
Protein-tyrosine-phosphatase SL
-
-
-
-
Protein-tyrosine-phosphate phosphohydrolase
-
-
-
-
PTP IA-2beta
-
-
-
-
PTP-1B
-
-
-
-
PTP-1C
-
-
-
-
PTP-1D
-
-
-
-
PTP-2C
-
-
-
-
PTP-BAS
-
-
-
-
PTP-E1
-
-
-
-
PTP-H1
-
-
-
-
PTP-HA2
-
-
-
-
PTP-NP
-
-
-
-
PTP-SH2beta
-
-
-
-
PTP1C
-
-
-
-
PTP1D
-
-
-
-
PTP2C
-
-
-
-
PTPase YVH1
-
-
-
-
PTPase-MEG1
-
-
-
-
PTPase-MEG2
-
-
-
-
PTPG1
-
-
-
-
PTPN6
-
-
-
-
PTPNE6
-
-
-
-
PY protein phosphatase
-
-
-
-
R-PTP-alpha
-
-
-
-
R-PTP-beta
-
-
-
-
R-PTP-delta
-
-
-
-
R-PTP-epsilon
-
-
-
-
R-PTP-eta
-
-
-
-
R-PTP-gamma
-
-
-
-
R-PTP-kappa
-
-
-
-
R-PTP-mu
-
-
-
-
R-PTP-zeta
-
-
-
-
Receptor-linked protein-tyrosine phosphatase 10D
-
-
-
-
Receptor-linked protein-tyrosine phosphatase 99A
-
-
-
-
RNA/RNP complex-intereracting phosphatase
-
-
-
-
ROL B protein
-
-
-
-
RPTPalpha
-
-
-
-
SH-PTP1
-
-
-
-
SH-PTP2
-
-
-
-
SH-PTP3
-
-
-
-
SHP
-
-
-
-
Small tyrosine phosphatase
-
-
-
-
Small, acidic phosphotyrosine protein phosphatase
-
-
-
-
STEP
-
-
-
-
String protein
-
-
-
-
Syp
-
-
-
-
T-cell protein-tyrosine phosphatase
-
-
-
-
T-DSP11
-
-
-
-
T200
-
-
-
-
TCPTP
-
-
-
-
Testis-and skeletal-muscle-specific DSP
-
-
-
-
tyrosine O-phosphate phosphatase
-
-
-
-
Tyrosine phosphatase CBPTP
-
-
-
-
tyrosylprotein phosphatase
-
-
-
-
[phosphotyrosine]protein phosphatase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
mechanism, role of residue 182
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
in addition to active site, enzyme has a low-affinity noncatalytic aryl phosphate-binding site
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
ping-pong mechanism, catalysis proceeds through a two-step mechanism involving a phosphocysteine intermediate. In the first step, a nucleophilic cysteine thiolate attacks the phosphate ester moiety of the substrate, resulting in formation of a phosphoenzyme intermediate with release of the peptidyl tyrosine. The second step occurs via attack of water on the phosphoenzyme intermediate, and yields the final products inorganic phosphate and the regenerated enzyme. The central binding site for the substrate is the P-loop, a region at the bottom of a pocket that includes the nucleophilic cysteine and backbone amide groups oriented in a horseshoe fashion, catalytic cycle, detailed overview
[a protein]-tyrosine phosphate + H2O = [a protein]-tyrosine + phosphate
for both alkyl and aryl substrates, including the activated substrate 4-nitrophenyl phosphate with its particularly good leaving group, general acid catalysis in PTPs is highly efficient and fully neutralizes the leaving group in the transition state. Mutating the conserved aspartic acid to glutamine causes the expected reductions in rate of several orders of magnitude and loss of the basic limb in pH-rate profiles, kinetic isotope effects, general acid catalysis mechanism, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
protein-tyrosine-phosphate phosphohydrolase
Dephosphorylates O-phosphotyrosine groups in phosphoproteins, such as the products of EC 2.7.10.2, non-specific protein-tyrosine kinase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
79747-53-8
-
97162-86-2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferol + phosphate
-
-
-
?
6,8-difluoro-4-methylumbelliferyl phosphate + H2O
6,8-difluoro-4-methylumbelliferone + phosphate
-
-
-
?
bis-(p-phosphophenyl) methane + H2O
?
synthetic high-affinity low-molecular weight nonpeptide substrate
-
-
?
difluoromethylumbelliferyl phosphate + H2O
difluoromethylumbelliferone + phosphate
-
-
-
?
phosphotyrosine + H2O
tyrosine + phosphate
O14522, P10586, P17706, P18031, P18433, P23467, P23468, P23469, P23470, P23471, P26045, P28827, P29074, P29350, P35236, P43378, P54829, Q05209, Q06124, Q0VAE8, Q12913, Q12923, Q13332, Q15256, Q15262, Q15678, Q16825, Q16827, Q16849, Q4JDK3, Q92729, Q92932, Q99952, Q9H3S7, Q9HD43, Q9UMZ3, Q9Y2R2
-
-
-
?
[epidermal growth factor receptor]-tyrosine phosphate + H2O
[epidermal growth factor receptor]-tyrosine + phosphate
-
-
-
?
[Eps15 peptide846-854]-tyrosine phosphate + H2O
[Eps15 peptide846-854]-tyrosine + phosphate
active with enzyme mutant F182H, wild-type shows poor activity
-
-
?
[insulin receptor kinase]-tyrosine phosphate + H2O
[insulin receptor kinase]-tyrosine + phosphate
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
-
-
-
?
DADE(pY)LIPQQG + H2O
DADEYLIPQQG + phosphate
a physiological phosphopeptide substrate of enzyme PTP1B
-
-
?
DADE(pY)LIPQQG + H2O
DADEYLIPQQG + phosphate
a phosphopeptide substrate of enzyme PTP1B and the modified enzyme asPTP1B. asPTP1B dephosphorylates DADE(pY)LIPQQG at a rate that is only slightly lower than the rate of dephosphorylation induced by wild-type PTP1B
-
-
?
DADE(pY)LIPQQG + H2O
DADEYLIPQQG + phosphate
sequence equivalent to residues 988-998 of the epidermal growth factor receptor
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
additional information
?
-
formation and structure of a transition state analogue for the first catalytic step comprising a ternary complex between the catalytic cysteine of PTP1B, vanadate, and the peptide DADEYL, a fragment of a physiological substrate, overview. The equatorial vanadate oxygen atoms bind to the P-loop, and the apical positions are occupied by the peptide tyrosine oxygen and by the PTP1B cysteine sulfur atom. The vanadate assumes a trigonal bipyramidal geometry in both transition state analogue structures, with very similar apical O-O distances, denoting similar transition states for both phosphoryl transfer steps
-
-
?
additional information
?
-
PTP1B is a classical PTP with a deep active site pocket suited for phosphotyrosine, that also efficiently hydrolyzes other phosphorylated phenols
-
-
?
additional information
?
-
PTP1B is a classical PTP with a deep active site pocket suited for phosphotyrosine, that also efficiently hydrolyzes other phosphorylated phenols
-
-
?
additional information
?
-
PTP1B is a classical PTP with a deep active site pocket suited for phosphotyrosine, that also efficiently hydrolyzes other phosphorylated phenols
-
-
?
additional information
?
-
the [Eps15 peptide]-tyrosine phosphate is a phosphopeptide fragment of substrate epidermal growth factor receptor. Eps15 is a scaffolding adaptor that regulates endocytosis and trafficking of the EGFR and is a substrate for PTP enzyme PTPN3. The catalytic domain of PTP1B cannot dephosphorylate Eps15846-854 or Eps15836-858 efficiently compared with wild-type N3PTP, supporting a critical role of H812 in recognition of Eps15. The position of H812 in PTPN3 is a phenylalanine (F182) in PTP1B, His812 of PTPN3 plays a central role in substrate specificity
-
-
?
additional information
?
-
the [Eps15 peptide]-tyrosine phosphate is a phosphopeptide fragment of substrate epidermal growth factor receptor. Eps15 is a scaffolding adaptor that regulates endocytosis and trafficking of the EGFR and is a substrate for PTP enzyme PTPN3. The catalytic domain of PTP1B cannot dephosphorylate Eps15846-854 or Eps15836-858 efficiently compared with wild-type N3PTP, supporting a critical role of H812 in recognition of Eps15. The position of H812 in PTPN3 is a phenylalanine (F182) in PTP1B, His812 of PTPN3 plays a central role in substrate specificity
-
-
?
additional information
?
-
the [Eps15 peptide]-tyrosine phosphate is a phosphopeptide fragment of substrate epidermal growth factor receptor. Eps15 is a scaffolding adaptor that regulates endocytosis and trafficking of the EGFR and is a substrate for PTP enzyme PTPN3. The catalytic domain of PTP1B cannot dephosphorylate Eps15846-854 or Eps15836-858 efficiently compared with wild-type N3PTP, supporting a critical role of H812 in recognition of Eps15. The position of H812 in PTPN3 is a phenylalanine (F182) in PTP1B, His812 of PTPN3 plays a central role in substrate specificity
-
-
?
additional information
?
-
the [Eps15 peptide]-tyrosine phosphate is a phosphopeptide fragment of substrate epidermal growth factor receptor. Eps15 is a scaffolding adaptor that regulates endocytosis and trafficking of the EGFR and is a substrate for PTP enzyme PTPN3. The catalytic domain of PTP1B cannot dephosphorylate Eps15846-854 or Eps15836-858 efficiently compared with wild-type N3PTP, supporting a critical role of H812 in recognition of Eps15. The position of H812 in PTPN3 is a phenylalanine (F182) in PTP1B, His812 of PTPN3 plays a central role in substrate specificity
-
-
?
additional information
?
-
the [Eps15 peptide]-tyrosine phosphate is a phosphopeptide fragment of substrate epidermal growth factor receptor. Eps15 is a scaffolding adaptor that regulates endocytosis and trafficking of the EGFR and is a substrate for PTP enzyme PTPN3. The catalytic domain of PTP1B cannot dephosphorylate Eps15846-854 or Eps15836-858 efficiently compared with wild-type N3PTP, supporting a critical role of H812 in recognition of Eps15. The position of H812 in PTPN3 is a phenylalanine (F182) in PTP1B, His812 of PTPN3 plays a central role in substrate specificity
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
DADE(pY)LIPQQG + H2O
DADEYLIPQQG + phosphate
a physiological phosphopeptide substrate of enzyme PTP1B
-
-
?
[insulin receptor kinase]-tyrosine phosphate + H2O
[insulin receptor kinase]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
[a protein]-tyrosine phosphate + H2O
[a protein]-tyrosine + phosphate
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
((2-bromo-4-((((2E)-3-phenylprop-2-en-1-yl)sulfanyl)methyl)phenyl)carbonyl)phosphonate
50% inhibition at 810 nM for wild-type, at 1290 nM for mutant S295F
((2-bromo-4-(((4-chlorobenzyl)thio)methyl)phenyl)(difluoro)methyl)phosphonate
50% inhibition at 285 nM for wild-type, at 1644 nM for mutant S295F
((2-phenyl-2-(phenylcarbonyl)propane-1,3-diyl)bis(benzene-4,1-diyl(difluoromethanediyl)))bis(phosphonate)
50% inhibition at 82 nM for wild-type, at 399 nM for mutant S295F
((4-((((3'-(acetylsulfamoyl)biphenyl-4-yl)methyl)sulfanyl)methyl)-2-bromophenyl)(difluoro)methyl)phosphonate
50% inhibition at 2.2 nM for wild-type, at 11 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(difluoro)methyl)phosphonate
50% inhibition at 47 nM for wild-type, at 260 nM for mutant S295F
((4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)phenyl)(fluoro)methyl)phosphonate
50% inhibition at 570 nM for wild-type, at 830 nM for mutant S295F
(1R,5S,6S,6aR,7S,10S,10aS,11S)-10-(acetyloxy)-7-hydroxy-7,10a-dimethyl-4-methylidene-6-[(2-methylpropanoyl)oxy]-3-oxodecahydro-1H-1,5-methano-2-benzoxocin-11-yl 2-methylprop-2-enoate
no inhibition at 0.021 mM
(3alpha,5beta,8alpha,9beta,10alpha,13alpha)-3-[[(2E)-4-phenylbut-2-enoyl]oxy]kaur-16-en-18-oic acid
-
(3aR,4R,4aR,5R,8R,8aR,9S,9aR)-8-(acetyloxy)-5-hydroxy-5,8a-dimethyl-3-methylidene-4-[(2-methylpropanoyl)oxy]-2-oxododecahydronaphtho[2,3-b]furan-9-yl 3-methylbutanoate
no inhibition at 0.020 mM
(3aR,4R,4aR,5R,8R,8aS,9S,9aR)-8-(acetyloxy)-5,9-dihydroxy-5,8a-dimethyl-3-methylidene-2-oxododecahydronaphtho[2,3-b]furan-4-yl 2-methylprop-2-enoate
no inhibition at 0.025 mM
(3aR,4R,4aR,5R,8R,8aS,9S,9aR)-8-(acetyloxy)-5,9-dihydroxy-5,8a-dimethyl-3-methylidene-2-oxododecahydronaphtho[2,3-b]furan-4-yl 2-methylpropanoate
no inhibition at 0.024 mM
(4-((4E)-2-(1,3-benzothiazol-2-yl)-2-(1H-benzotriazol-1-yl)-5-phenylpent-4-en-1-yl)benzyl)phosphonate
50% inhibition at 3260 nM for wild-type, at 5030 nM for mutant S295F
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
(5Z)-3-benzyl-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-3-benzyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-benzyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-butyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-3-butyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-(5-bromo-4-hydroxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]benzylidene]-1,3-thiazolidine-2,4-dione
-
(5Z)-5-[5-bromo-2-methoxy-4-[(4-methylpent-3-en-1-yl)oxy]benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
-
1-(1,3-benzodioxol-5-yl)-2-([1-(4-hydroxyphenyl)-1H-1,2,3,4-tetraazol-5-yl]sulfanyl)-1-ethanone
88% inhibition at 0.2 mM
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
i.e. OATP
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
-
2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid
-
2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
i.e. TCS401, binds to the active site
2-[4,5-bis(1,3,2-dithiarsolan-2-yl)-6-hydroxy-3-oxo-3H-xanthen-9-yl]benzoic acid
i.e. FlAsH
2-[6-chloro-5-(1-naphthalyloxy)-1H-benzimidazol-2-yl]thio-N-(thiazol-2-yl)acetamide
mixed-type inhibition, 99% inhibition at 0.2 mM
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-(1,3-thiazol-2-ylsulfamoyl)phenyl)-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.008 mM, noncompetitive noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-sulfamoylphenyl)-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.022 mM, noncompetitive allosteric inhibitor, prevents formation of the active form of the enzyme by blocking the mobility of the catalytic loop
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide
50% inhibition of PTP1B at 0.35 mM
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-[4-(1,3-thiazol-2-ylsulfamoyl)phenyl]-1-benzofuran-6-sulfonamide
-
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide
i.e. BBR
3-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
3-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4,6-bis(1,3,2-dithiarsolan-2-yl)-7-hydroxy-3H-phenoxazin-3-one
i.e. ReAsH
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenoxyphenyl)methylidene]thiazolidin-3-yl) methyl)benzoic acid
-
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(((5Z)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
-
4-(5-[5-(3,5-dichlorophenoxy)-2-furyl]-1,2,4-oxadiazol-3-yl)phenyl-N,N-dimethylsulfamate
85% inhibition at 0.2 mM
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5E)-5-[3-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2,4-dioxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2,4-dioxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([3-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([4-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
-
4-([(5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
-
4-([(5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
-
4-([(5Z)-5-[4-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
-
4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.073 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6,8-diphenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.0033 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
50% inhibition at 0.0062 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-6-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.014 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
4-[(3-[(E)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(3-[(E)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(4-[(Z)-[(2Z)-3-(4-carboxybenzyl)-4-oxo-2-(phenylimino)-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[(4-[(Z)-[3-(4-carboxybenzyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]phenoxy)methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5E)-5-[3-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(2Z,5Z)-5-[4-(benzyloxy)benzylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5E)-5-(3-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-2,4-dioxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-2,4-dioxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-(4-[[4-(hydroxymethyl)benzyl]oxy]benzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
4-[[(5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
-
5-(1,3,2-dithiarsolan-2-yl)-2-[(1E,3E)-3-[5-(1,3,2-dithiarsolan-2-yl)-3,3-dimethyl-1-(4-sulfobutyl)-1,3-dihydro-2H-indol-2-ylidene]prop-1-en-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium
i.e. AsCy3, 70% inhibition at 250 nM AsCy3, AsCy3 is capable of specifically and potently inhibiting mutant enzyme asPTP1B in the presence of a complex proteome, while AsCy3 does not inhibit wild-type PTP1B activity in a cell lysate
5-(1,3,2-dithiarsolan-2-yl)-2-[(1E,3E,5E)-5-[5-(1,3,2-dithiarsolan-2-yl)-3,3-dimethyl-1-(4-sulfobutyl)-1,3-dihydro-2H-indol-2-ylidene]penta-1,3-dien-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium
i.e. AsCy5
5-chloro-2-[methyl(methylidene)-lambda4-sulfanyl]-6-[(naphthalen-2-yl)oxy]-1H-benzimidazole
65% inhibition at 0.2 mM
5-chloro-N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-1-methyl-2-(methylthio)-1H-benz-imidazole-6-carboxamide
mixed-type inhibition, complete inhibition at 0.2 mM
6,8-dibenzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.013 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-((2-benzyl-1-benzothien-3-yl)methyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0032 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-((E)-1,2-diphenylvinyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0097 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-2-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.006 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0077 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(1-benzothien-3-ylmethyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.06 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0025 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.57 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-(4-((2-benzyl-1-benzothiophen-3-yl)methyl)phenyl)-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.001 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR at 0.52 mM
6-(9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0071 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-benzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.036 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0043 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-biphenyl-4-yl-4-oxo-8-phenyl-4H-chromene-3-carbaldehyde
50% inhibition at 0.002 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases, 50% inhibition of isoform LAR above 1 mM
6-bromo-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.020 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0076 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
the inhibitor is significantly selective for enzyme protein tyrosine phosphatase 1B (PTP1B) versus other phosphatases, i.e. T-cell protein tyrosine phosphatase (TCPTP), megakaryocyte protein tyrosine phosphatase (PTP-MEG2), and src homology phosphatase 2
7-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
-
7-(4-(2-methyl-5-nitro-1H-imidazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
-
7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile
50% inhibition at 230 nM for wild-type, at 886 nM for mutant S295F
8-benzyl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.018 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-4-oxo-6-(2-phenyl-1-benzothien-3-yl)-4H-chromene-3-carbaldehyde
50% inhibition at 0.0078 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(10-bromo-9-anthryl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.011 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-(2-bromo-1-benzothien-3-yl)-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.0082 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-1-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.010 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
8-bromo-6-dibenzo(b,d)thien-4-yl-4-oxo-4H-chromene-3-carbaldehyde
50% inhibition at 0.016 mM, irreversible, selective for isoform PTP1B over other human protein tyrosine phosphatases
abietic acid
a nonpolar inhibitor and weak mixed-type inhibitor of PTP1B, inhibits the enzyme by binding to its active site in a nonsubstrate-like manner that stabilizes the catalytically essential WPD loop in an inactive conformation, modelling of enzyme binding. Upon binding to the active site, abietic acid forms a hydrogen bond with R221 that weakens a bond between R221 and E115 and prevents the formation of a hydrogen bond between W179 and R221 that forms when the WPD loop closes
bis(2-ethyl-maltolato)oxidovanadium(IV)
noncompetitive inhibition of hydrolysis of 4-nitrophenyl phosphate and of phosphorylated undecapeptide substrate EGFR988-998 in the presence of bis(2-ethyl-maltolato)oxidovanadium(IV)
bis(acetylacetonato)oxidovanadium(IV)
acts as an uncompetitive inhibitor of PTP1B with DADEpYLIPQQG as the substrate, but this VO2+-chelate exhibits only apparent competitive inhibition of 4-nitrophenyl phosphate hydrolysis when catalyzed by PTP1B, differing from that observed in the hydrolysis of the phosphotyrosine-containing undecapeptide DADEpYLIPQQG mimicking residues 988-998 of the epidermal growth factor receptor (EGFR). Addition of 4-nitrophenyl phosphate after addition of saturating amounts of bis(acetylacetonato)oxidovanadium(IV) to PTP1B causes complete loss of catalytic activity
BzN-EJJ-amide
50% inhibition at 3.7 nM for wild-type, at 18 nM for mutant S295F
fluorescein arsenical hairpin binder
fluorescein arsenical hairpin binder does not inhibit any wild type PTP, but insertion of a fluorescein arsenical hairpin binder-binding peptide (CCPGCC) at a conserved position in the PTP catalytic-domain's WPD loop confers fluorescein arsenical hairpin binder sensitivity upon divergent PTPs
-
MSI-1436
small molecule inhibitor MSI-1436 binds to the disordered C-terminal domain of PTP1B, C-terminal to the catalytic domain, MSI-1436 functions using an allosteric mechanism to direct the enzymatic activity of PTP1B
N-(3-chloro-4-fluorophenyl)-2-[(6,7-dimethoxy-4-oxo-3-phenyl-3,4-dihydro-2-quinazolinyl)sulfanyl]acetamide
80% inhibition at 0.2 mM
N-(3-[(3,5-difluorobenzyl)oxy]pyridin-2-yl)-4-pentylbenzenesulfonamide
74% inhibition at 0.2 mM
N-1-(2-[(2-oxo-4-propyl-2H-chromen-7-yl)oxy]propanoyl)-3-(trifluoromethyl)benzene-1-sulfonohydrazide
84% inhibition at 0.2 mM
N-[6-chloro-5-(2,3-dichlorophenoxy)-1-methyl-1H-benzimidazol-2-yl]acetamide
70% inhibition at 0.2 mM
N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-2,2,2-trifluoroacetamide
mixed-type inhibition, 92% inhibition at 0.2 mM
vanadate
the equatorial vanadate oxygen atoms bind to the P-loop and assumes a trigonal bipyramidal geometry in both transition state analogue structures, with very similar apical O-O distances, binding structure, overview
additional information
structure derivatives, derived from papaverine, e.g. Pnu177496, in docking simulations, simulated molecular docking method, overview
-
additional information
-
structure derivatives, derived from papaverine, e.g. Pnu177496, in docking simulations, simulated molecular docking method, overview
-
additional information
structure-based optimization of benzoic acids as inhibitors of PTPB1 and LMW-PTP, molecular docking study using crystal structures of PTPB1, PDB ID 1G7G and 1XBO, as templates, overview
-
additional information
4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acid derivatives determined as active potent allosteric inhibitors of protein tyrosine phosphatase 1B, in silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents, binding modes and inhibitory mechanism, docking studies, detailed overview
-
additional information
abietane-type diterpenoids inhibit protein tyrosine phosphatases by stabilizing an inactive enzyme conformation. Abietane-type diterpenoids, a biologically active class of phytometabolites with largely nonpolar structures, are used for the development of pharmaceutically relevant PTP inhibitors. Minor changes in the structures of abietane-type diterpenoids (e.g. the addition of hydrogens) can improve potency (i.e. lower IC50) by several fold. Trodusquemine and benzofuran derivatives bind to C-terminal allosteric sites that attenuate WPD loop dynamics. Mechanisms of inhibition, dynamic docking, modelling, overview
-
additional information
chemical library screening, kinetic and computational studies of mixed-type inhibitors of protein tyrosine phosphatase 1B, docking and molecular dynamic simulations studies, and enzyme interaction analysis, overview. For the inhibition assays, 4-nitrophenyl phosphate is used as enzyme substrate
-
additional information
design and synthesis of azolyl flavonoids as enzyme inhibitors of protein tyrosine phosphatase 1B, molecular modeling and dynamics studies, using the crystal structure of PTP1B (PDB ID 1G1H) reveals the selectivity of triazolyl flavonoid inhibitor 7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one for PTP1B over the closely related T-cell protein tyrosine phosphatase (TCPTP), detailed overview. The inhibitory effects and kinetics analysis of the azoyl flavonoids against PTPs are measured, using 4-nitrophenol phosphate as the substrate
-
additional information
design of non-natural allosteric-inhibition sites in PTPs, in which a tricysteine moiety is engineered within the PTP catalytic domain at a conserved location outside of the active site. Introduction of the tricysteine motif, which does not exist in any wild-type PTP, serves to sensitize target PTPs to inhibition by a biarsenical compound, providing a generalizable strategy for the generation of allosterically sensitized (as) PTPs. Biarsenical reagents as enzyme inhibitors, overview. Enzyme asPTP catalytic domains have differing biarsenical sensitivities, with some being most potently inhibited by biarsenical compounds with large interarsenical distances, whereas others prefer compounds with relatively small interarsenical distances. AsCy3 is an optimized inhibitor of of engineered enzyme asPTP1B
-
additional information
inhibition of protein tyrosine phosphatase-1B by vanadyl (VO2+) chelates, competitive and noncompetitive inhibition modes, overview
-
additional information
the active sites of PTPs are exceptionally conserved and charged, making it nearly impossible to develop PTP inhibitors that are selective. But targeting PTP protein (substrate/regulatory) interaction sites, which are distal from the active sites, are highly viable and suitable drug targets. Domains outside PTP catalytic domains have also been demonstrated to directly alter PTP activity. Development of drugs that bind to intrinsically disordered regions of the enzyme, overview
-
additional information
wedelolide derivatives and structure-activity relationships of protein tyrosine phosphatase 1B inhibitory ent-kaurene diterpenes, determination and analysis of inhibitors isolated from aerial parts of Wedelia prostrata collected in Manado (Indonesia) and Wedelia chinensis collected on Iriomote Island (Okinawa, Japan). For inhibitory assays, 4-nitrophenyl phosphate is used as enzyme substrate
-
additional information
-
wedelolide derivatives and structure-activity relationships of protein tyrosine phosphatase 1B inhibitory ent-kaurene diterpenes, determination and analysis of inhibitors isolated from aerial parts of Wedelia prostrata collected in Manado (Indonesia) and Wedelia chinensis collected on Iriomote Island (Okinawa, Japan). For inhibitory assays, 4-nitrophenyl phosphate is used as enzyme substrate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Non-digestible fraction of beans (Phaseolus vulgaris L.) modulates signalling pathway genes at an early stage of colon cancer in Sprague-Dawley rats.
Abortion, Spontaneous
Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence.
Achondroplasia
Selfish mutations dysregulating RAS-MAPK signaling are pervasive in aged human testes.
Acidosis
Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.
Acidosis
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Acne Vulgaris
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Acne Vulgaris
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
Acquired Immunodeficiency Syndrome
A126: Clusters of Autoimmune Diseases in Children and the Role of PTPN22 C1858T Gene Polymorphism in Pediatric Polyautoimmunity.
Acquired Immunodeficiency Syndrome
Role of the F-BAR Family Member PSTPIP2 in Autoinflammatory Diseases.
Acromegaly
Human nasal septal cartilage: local distribution of different enzyme activities in healthy adults and acromegalic patients.
Acute Coronary Syndrome
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Acute Coronary Syndrome
Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes.
Acute Coronary Syndrome
Protein tyrosine phosphatase receptor-type O expression as a prognostic marker in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A prospective study.
Acute Kidney Injury
Chronic nicotine exposure augments renal oxidative stress and injury through transcriptional activation of p66shc.
Acute Kidney Injury
Eriocitrin attenuates ischemia reperfusion-induced oxidative stress and inflammation in rats with acute kidney injury by regulating the dual-specificity phosphatase 14 (DUSP14)-mediated Nrf2 and nuclear factor-?B (NF-?B) pathways.
Acute Kidney Injury
SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1.
Acute Lung Injury
MAP Kinase Phosphatase 5 Protects Against Sepsis-induced Acute Lung Injury.
Acute Lung Injury
Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury.
Acute Lung Injury
Protein phosphatase 2A activation attenuates inflammation in murine models of acute lung injury.
Addison Disease
Association of Autoimmune Addison's Disease with Alleles of STAT4 and GATA3 in European Cohorts.
Addison Disease
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Addison Disease
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Addison Disease
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease.
Addison Disease
Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency.
Addison Disease
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Addison Disease
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Addison Disease
The tryptophan 620 allele of the lymphoid tyrosine phosphatase (PTPN22 gene) predisposes to autoimmune Addison's disease.
Adenocarcinoma
Allyl isothiocyanate induces G2/M arrest in human colorectal adenocarcinoma SW620 cells through down-regulation of Cdc25B and Cdc25C.
Adenocarcinoma
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Adenocarcinoma
Bicarbonate is essential for protein-tyrosine phosphatase 1B (PTP1B) oxidation and cellular signaling through EGF-triggered phosphorylation cascades.
Adenocarcinoma
Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system.
Adenocarcinoma
Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family.
Adenocarcinoma
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Adenocarcinoma
Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17?-estrodial-induced cell growth in endometrial adenocarcinoma cell.
Adenocarcinoma
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Adenocarcinoma
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Adenocarcinoma
Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73.
Adenocarcinoma
Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis.
Adenocarcinoma
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Adenocarcinoma
Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture.
Adenocarcinoma
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Adenocarcinoma
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
Adenocarcinoma
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Adenocarcinoma
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Adenocarcinoma
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Adenocarcinoma
Increase in receptor-like protein tyrosine phosphatase activity and expression level on density-dependent growth arrest of endothelial cells.
Adenocarcinoma
Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma.
Adenocarcinoma
Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.
Adenocarcinoma
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Adenocarcinoma
Involvement of beta3A subunit of adaptor protein-3 in intracellular trafficking of receptor-like protein tyrosine phosphatase PCP-2.
Adenocarcinoma
Label-free biosensor: a novel phage-modified Light Addressable Potentiometric Sensor system for cancer cell monitoring.
Adenocarcinoma
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
Adenocarcinoma
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Adenocarcinoma
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Adenocarcinoma
NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases.
Adenocarcinoma
Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats.
Adenocarcinoma
Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells.
Adenocarcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Adenocarcinoma
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Adenocarcinoma
Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin.
Adenocarcinoma
Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer.
Adenocarcinoma
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
Adenocarcinoma
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
Adenocarcinoma
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
Adenocarcinoma
R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
Adenocarcinoma
Rapid rise of serum acid phosphatase after irradiation of metastatic carcinoma of prostate.
Adenocarcinoma
Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.
Adenocarcinoma
Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.
Adenocarcinoma
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Adenocarcinoma
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Adenocarcinoma
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
Adenocarcinoma
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Adenocarcinoma
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Adenocarcinoma
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
Adenocarcinoma
Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.
Adenocarcinoma
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
Adenocarcinoma
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Adenocarcinoma of Lung
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
Adenocarcinoma of Lung
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Adenocarcinoma of Lung
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Adenocarcinoma of Lung
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Adenocarcinoma of Lung
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Adenocarcinoma of Lung
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Adenocarcinoma of Lung
MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.
Adenocarcinoma of Lung
MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.
Adenocarcinoma of Lung
MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A.
Adenocarcinoma of Lung
miR-146b Reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells.
Adenocarcinoma of Lung
miR-516a-3p promotes proliferation, migration, and invasion and inhibits apoptosis in lung adenocarcinoma by targeting PTPRD.
Adenocarcinoma of Lung
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Adenocarcinoma of Lung
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Adenocarcinoma of Lung
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.
Adenocarcinoma of Lung
Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans.
Adenocarcinoma of Lung
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
Adenocarcinoma of Lung
SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.
Adenocarcinoma of Lung
The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
Adenocarcinoma of Lung
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Adenocarcinoma of Lung
[LB100 reverses the acquired resistance to gefitinib in lung adenocarcinoma cells with EGFR mutation].
Adenoma
Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Adenoma
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Adenoma
Immunohistochemical and Western blot analysis of two protein tyrosine phosphatase receptors, R and Z1, in colorectal carcinoma, colon adenoma and normal colon tissues.
Adenoma
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Adenoma
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Adenoma
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Adenoma
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Adenoma
miRNA-7a-2-3p Inhibits Neuronal Apoptosis in Oxygen-Glucose Deprivation (OGD) Model.
Adenoma
Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.
Adenoma
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Adenoma
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Adenoma
Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro.
Adenoma
Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
Adenoma
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Adenoma
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Adenoma
USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
Adenoma
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
Adenoma
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Adenoma
[Expression of the zinc finger transcriptional factor Snail in colorectal carcinoma and its significance]
Adenoma, Pleomorphic
Ultrastructural cytochemistry of phosphatases in the ductal component of pleomorphic adenoma of human parotid and submandibular salivary glands.
Adenomatous Polyposis Coli
Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase: the effect of sulindac.
Adenomatous Polyposis Coli
APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.
Adenomatous Polyposis Coli
ARM domain-dependent nuclear import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of protein phosphatase 2A.
Adenomatous Polyposis Coli
BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells.
Adenomatous Polyposis Coli
Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein.
Adenomatous Polyposis Coli
GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin.
Adenomatous Polyposis Coli
Inhibition of Wnt signaling pathway by a novel axin-binding protein.
Adenomatous Polyposis Coli
The mechanism of binding of the second PDZ domain from the Protein Tyrosine Phosphatase-BL to the Adenomatous Polyposis Coli tumor suppressor.
Adenoviridae Infections
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
Albuminuria
Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
Albuminuria
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Albuminuria
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
Alopecia
p66Shc Is a Negative Regulator of Fc{varepsilon}RI-Dependent Signaling in Mast Cells.
Alopecia
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Alopecia Areata
Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata.
Alopecia Areata
Protein tyrosine phosphatase nonreceptor type 22 gene polymorphism in alopecia areata: Does it have an association with disease severity?
Alopecia Areata
PTPN22 gene polymorphism in Egyptian alopecia areata patients and its impact on response to diphencyprone immunotherapy.
Alopecia Areata
The association between rs2476601 polymorphism in PTPN22 gene and risk of alopecia areata: A meta-analysis of case-control studies.
Alopecia Areata
The non-synonymous C1858T substitution in the PTPN22 gene is associated with susceptibility to the severe forms of alopecia areata.
Alopecia Areata
The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata.
alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase deficiency
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Alveolar Bone Loss
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Alveolar Bone Loss
Functionalized nanoparticles containing MKP-1 agonists reduce periodontal bone loss.
Alzheimer Disease
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Alzheimer Disease
A Rare Variant Nonparametric Linkage Method for Nuclear and Extended Pedigrees with Application to Late-Onset Alzheimer Disease via WGS Data.
Alzheimer Disease
Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.
Alzheimer Disease
Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease.
Alzheimer Disease
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.
Alzheimer Disease
Alterations of low molecular weight acid phosphatase protein level in Alzheimer's disease.
Alzheimer Disease
Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology.
Alzheimer Disease
Altered nociception in Alzheimer disease is associated with striatal-enriched protein tyrosine phosphatase signaling.
Alzheimer Disease
Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice.
Alzheimer Disease
Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.
Alzheimer Disease
CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.
Alzheimer Disease
CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease.
Alzheimer Disease
Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease.
Alzheimer Disease
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Alzheimer Disease
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models.
Alzheimer Disease
Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1.
Alzheimer Disease
Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.
Alzheimer Disease
Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis.
Alzheimer Disease
Dynein cleavage and microtubule accumulation in okadaic acid-treated neurons.
Alzheimer Disease
Enhanced expression of protein phosphatase 2A associated with hyper-phosphorylation of histone H1 in Alzheimer's disease brain.
Alzheimer Disease
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Alzheimer Disease
Exploring the Therapeutic Potential of Protein Tyrosine Phosphatase 1B in hAPP-J20 Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.
Alzheimer Disease
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model.
Alzheimer Disease
I1PP2A Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A.
Alzheimer Disease
Immunohistochemical Localization of Fas-associated phosphatase-1 (FAP-1) in Alzheimer disease hippocampus.
Alzheimer Disease
Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease.
Alzheimer Disease
Implication of novel bis-imidazopyridines for management of Alzheimer's disease and establishment of its role on protein phosphatase 2A activity in brain.
Alzheimer Disease
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease.
Alzheimer Disease
Inhibitory evaluation of oligonol on ?-glucosidase, protein tyrosine phosphatase 1B, cholinesterase, and ?-secretase 1 related to diabetes and Alzheimer's disease.
Alzheimer Disease
Lanthionine ketimine-5-ethyl ester provides neuroprotection in a zebrafish model of okadaic acid-induced Alzheimer's disease.
Alzheimer Disease
Leucine Carboxyl Methyltransferase 1 (LCMT1)-dependent Methylation Regulates the Association of Protein Phosphatase 2A and Tau Protein with Plasma Membrane Microdomains in Neuroblastoma Cells.
Alzheimer Disease
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Alzheimer Disease
Metabolically active rat brain slices as a model to study the regulation of protein phosphorylation in mammalian brain.
Alzheimer Disease
Microcystin-Leucine-Arginine Induces Tau Pathology Through B? Degradation via Protein Phosphatase 2A Demethylation and Associated Glycogen Synthase Kinase-3? Phosphorylation.
Alzheimer Disease
MKP-1 reduces A? generation and alleviates cognitive impairments in Alzheimer's disease models.
Alzheimer Disease
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
Alzheimer Disease
Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid ?-Associated Alzheimer's Disease in Mice.
Alzheimer Disease
Neuroprotective effects of donepezil against A?42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3? and nAChRs activity.
Alzheimer Disease
Okadaic acid induced neurotoxicity: an emerging tool to study Alzheimer's disease pathology.
Alzheimer Disease
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.
Alzheimer Disease
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology.
Alzheimer Disease
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease.
Alzheimer Disease
PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus.
Alzheimer Disease
Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells.
Alzheimer Disease
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Alzheimer Disease
Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Alzheimer Disease
Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease.
Alzheimer Disease
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
Alzheimer Disease
Reduced levels of the tyrosine phosphatase STEP block ? amyloid-mediated GluA1/GluA2 receptor internalization.
Alzheimer Disease
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.
Alzheimer Disease
Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A.
Alzheimer Disease
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Alzheimer Disease
Substrate-Based Fragment Identification for the Development of Selective, Nonpeptidic Inhibitors of Striatal-Enriched Protein Tyrosine Phosphatase.
Alzheimer Disease
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Alzheimer Disease
Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP.
Alzheimer Disease
Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.
Alzheimer Disease
The cell cycle Cdc25A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease.
Alzheimer Disease
The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer's Disease and Other Neurological Disorders.
Alzheimer Disease
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.
Alzheimer Disease
Tyrosine phosphatase PTP1B impairs presynaptic NMDA receptor-mediated plasticity in a mouse model of Alzheimer's disease.
Alzheimer Disease
Tyrosine phosphatase STEP61 negatively regulates amyloid ?-mediated ERK/CREB signaling pathways via ?7 nicotinic acetylcholine receptors.
Alzheimer Disease
Weighted burden analysis of exome-sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSK-3? and WNT signalling pathways.
Alzheimer Disease
X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.
Amyotrophic Lateral Sclerosis
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Anaphylaxis
Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids.
Anaphylaxis
PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice.
Anaphylaxis
Protein tyrosine phosphatase 1B (PTP1B) is dispensable for IgE-mediated cutaneous reaction in vivo.
Anaphylaxis
SHP-1 regulation of mast cell function in allergic inflammation and anaphylaxis.
Anaphylaxis
Sirt1 negatively regulates Fc?RI-mediated mast cell activation through AMPK- and PTP1B-dependent processes.
Anaphylaxis
TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions.
Anemia
A naturally occurring point substitution in Cdc25A, and not Fv2/Stk, is associated with altered cell-cycle status of early erythroid progenitor cells.
Anemia
Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
Anemia
Mechanisms of anemia in SHP-1 protein tyrosine phosphatase-deficient "viable motheaten" mice.
Anemia
Phenotypic and quantitative relationship of red cell acid phosphatase with haemoglobin, haptoglobin, and G6PD phenotypes.
Anemia, Hemolytic, Autoimmune
Histiocytic medullary reticulosis with parallel increases in serum acid phosphatase and disease activity.
Anemia, Hemolytic, Autoimmune
The role of glucocorticoid in SIRP alpha and SHP-1 gene expression in AIHA patients.
Anemia, Hemolytic, Autoimmune
The role of glucocorticoid in SIRPalpha and SHP-1 gene expression in AIHA patients.
Anemia, Pernicious
Genome-wide association study identifies five risk loci for pernicious anemia.
Anemia, Sickle Cell
Phenotypic and quantitative relationship of red cell acid phosphatase with haemoglobin, haptoglobin, and G6PD phenotypes.
Aneurysm
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Ankylosis
Microarray Analysis of Differential Gene Expression Between Traumatic Temporomandibular Joint Fibrous and Bony Ankylosis in a Sheep Model.
Anodontia
Orodental, Facial and Clinical Features of Mutation-Positive Noonan Syndrome: A Monocentric Study.
Anthrax
Reduced Expression of CD45 Protein-tyrosine Phosphatase Provides Protection against Anthrax Pathogenesis.
Anti-Glomerular Basement Membrane Disease
Podocyte involvement in human immune crescentic glomerulonephritis.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
The PTPN22 R620W polymorphism in anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexican Mestizos.
Antiphospholipid Syndrome
Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome.
Antiphospholipid Syndrome
PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results.
Aortic Aneurysm
Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.
Aortic Coarctation
Alteration of p66shc is associated with endothelial dysfunction in the abdominal aortic coarctation of rats.
Aortic Coarctation
PTPN11 mutations play a minor role in isolated congenital heart disease.
Aortic Valve Stenosis
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
Arrhythmias, Cardiac
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arteriovenous Malformations
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Arteriovenous Malformations
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Arteritis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Arteritis
Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.
Arteritis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Arteritis
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
Arthritis
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Arthritis
A Highly Sensitive Electrochemiluminescence Biosensor for Pyrophosphatase Detection Based on Click Chemistry-Triggered Hybridization Chain Reaction in Homogeneous Solution.
Arthritis
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Arthritis
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Arthritis
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Arthritis
Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population.
Arthritis
Association of PTPN22 Gene Polymorphisms with Susceptibility to Juvenile Idiopathic Arthritis in Iranian Population.
Arthritis
Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.
Arthritis
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Arthritis
Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Arthritis
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Arthritis
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Arthritis
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Arthritis
Frequency of human leukocyte antigens class II-DR alleles (HLA-DRB1) in Argentinian patients with early arthritis.
Arthritis
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Arthritis
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis.
Arthritis
Genome-wide analysis of histone H3 lysine 4 trimethylation by ChIP-chip in peripheral blood mononuclear cells of systemic lupus erythematosus patients.
Arthritis
In situ formation of fluorescent polydopamine catalyzed by peroxidase-mimicking FeCo-LDH for pyrophosphate ion and pyrophosphatase activity detection.
Arthritis
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Arthritis
Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis.
Arthritis
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
Arthritis
Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.
Arthritis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Arthritis
Molecular cytogenetic characterization of two independent karyotypic anomalies in a patient with severe mental retardation and juvenile idiopathic arthritis.
Arthritis
mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis.
Arthritis
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Arthritis
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Arthritis
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
Arthritis
Receptor Protein Tyrosine Phosphatase ?-Mediated Enhancement of Rheumatoid Synovial Fibroblast Signaling and Promotion of Arthritis in Mice.
Arthritis
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Arthritis
Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Arthritis
Role of HLA-DRB1 and PTPN22 genes in susceptibility to juvenile idiopathic arthritis in Hungarian patients.
Arthritis
Role of PTPN22 1858 C/T Polymorphisms in Juvenile Idiopathic Arthritis in Egyptian Patients.
Arthritis
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Arthritis
SHP-1, a novel peptide isolated from seahorse inhibits collagen release through the suppression of collagenases 1 and 3, nitric oxide products regulated by NF-kappaB/p38 kinase.
Arthritis
Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.
Arthritis
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
Arthritis
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
Arthritis
The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population.
Arthritis
The Association between PTPN22 Genetic Polymorphism and Juvenile Idiopathic Arthritis (JIA) Susceptibility: An Updated Meta-Analysis.
Arthritis
The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis.
Arthritis
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
Arthritis
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
Arthritis
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
Arthritis
The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome.
Arthritis
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
Arthritis
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
Arthritis
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
Arthritis
[Anti-inflammatory effect of Cu-Zn superoxide dismutase on carrageenin-induced arthritis in rabbits]
Arthritis
[Study of acid phosphatase activity in synovial fluid and serum of patients with rheumatoid polyarthritis]
Arthritis, Experimental
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
Arthritis, Experimental
IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Arthritis, Experimental
Inhibition of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 reduces the severity of collagen-induced arthritis.
Arthritis, Infectious
[Content of desoxyribose and acid phosphatase activity in the blood serum of patients with infectious arthritis during electrosleep therapy]
Arthritis, Juvenile
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Arthritis, Juvenile
Acid phosphatase activity in the synovial fluid of children with juvenile rheumatoid arthritis.
Arthritis, Juvenile
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Arthritis, Juvenile
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Arthritis, Juvenile
Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population.
Arthritis, Juvenile
Association of PTPN22 Gene Polymorphisms with Susceptibility to Juvenile Idiopathic Arthritis in Iranian Population.
Arthritis, Juvenile
Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis.
Arthritis, Juvenile
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Arthritis, Juvenile
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Arthritis, Juvenile
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Arthritis, Juvenile
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Arthritis, Juvenile
Molecular cytogenetic characterization of two independent karyotypic anomalies in a patient with severe mental retardation and juvenile idiopathic arthritis.
Arthritis, Juvenile
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Arthritis, Juvenile
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Arthritis, Juvenile
Role of HLA-DRB1 and PTPN22 genes in susceptibility to juvenile idiopathic arthritis in Hungarian patients.
Arthritis, Juvenile
Role of PTPN22 1858 C/T Polymorphisms in Juvenile Idiopathic Arthritis in Egyptian Patients.
Arthritis, Juvenile
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
Arthritis, Juvenile
The Association between PTPN22 Genetic Polymorphism and Juvenile Idiopathic Arthritis (JIA) Susceptibility: An Updated Meta-Analysis.
Arthritis, Juvenile
The association between the functional PTPN22 1858 C/T and MIF -173 C/G polymorphisms and juvenile idiopathic arthritis: a meta-analysis.
Arthritis, Juvenile
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
Arthritis, Juvenile
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
Arthritis, Juvenile
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
Arthritis, Juvenile
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
Arthritis, Psoriatic
Association between the PTPN22 +1858 C/T polymorphism and psoriatic arthritis.
Arthritis, Psoriatic
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Arthritis, Psoriatic
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Arthritis, Psoriatic
Male restricted genetic association of variant R620W in PTPN22 with psoriatic arthritis.
Arthritis, Psoriatic
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
Arthritis, Rheumatoid
1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk in Europeans: A Meta-analysis.
Arthritis, Rheumatoid
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
Arthritis, Rheumatoid
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Arthritis, Rheumatoid
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
Arthritis, Rheumatoid
A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22.
Arthritis, Rheumatoid
A non-parametric method for building predictive genetic tests on high-dimensional data.
Arthritis, Rheumatoid
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Arthritis, Rheumatoid
Acid phosphatase activity in the synovial fluid of patients with rheumatoid arthritis and other joint disorders.
Arthritis, Rheumatoid
Activity of lysosomal enzymes and glycogen content of phytohemagglutinin-stimulated lymphocytes in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Arthritis, Rheumatoid
Anti-tumour necrosis factor-alpha response associated with combined CD226 and HLA-DRB1[*]0404 haplotype in rheumatoid arthritis.
Arthritis, Rheumatoid
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Arthritis, Rheumatoid
Application of bivariate mixed counting process models to genetic analysis of rheumatoid arthritis severity.
Arthritis, Rheumatoid
Application of sequential haplotype scan methods to case-control data.
Arthritis, Rheumatoid
Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis.
Arthritis, Rheumatoid
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Arthritis, Rheumatoid
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Arthritis, Rheumatoid
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Arthritis, Rheumatoid
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Arthritis, Rheumatoid
Association of protein tyrosine phosphatase non-receptor 22 (PTPN22) rs2476601 and Kruppel-like factor 12 (KLF12) rs1324913 single nucleotide polymorphisms with rheumatoid arthritis in a Latvian population.
Arthritis, Rheumatoid
Association of PTPN22 (rs2476601) and STAT4 (rs7574865) polymorphisms with Rheumatoid Arthritis in the Western Algerian population.
Arthritis, Rheumatoid
Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients.
Arthritis, Rheumatoid
Association of PTPN22 1858C?T polymorphism, HLA-DRB1 shared epitope and autoantibodies with rheumatoid arthritis.
Arthritis, Rheumatoid
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Arthritis, Rheumatoid
Association of PTPN22 Haplotypes (-1123G>C/+1858C>T) with Rheumatoid Arthritis in Western Mexican Population.
Arthritis, Rheumatoid
Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Zahedan, Southeast Iran.
Arthritis, Rheumatoid
Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: A meta-analysis update.
Arthritis, Rheumatoid
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Arthritis, Rheumatoid
Association of PTPN22 single nucleotide polymorphism with rheumatoid arthritis but not with allergic asthma.
Arthritis, Rheumatoid
Association of PTPN22 with Rheumatoid Arthritis Among South Asians in the UK.
Arthritis, Rheumatoid
Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect.
Arthritis, Rheumatoid
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
Arthritis, Rheumatoid
Association of STAT4 rs7574865 and PTPN22 rs2476601 polymorphisms with rheumatoid arthritis and non-systemically reacting antibodies in Egyptian patients.
Arthritis, Rheumatoid
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Arthritis, Rheumatoid
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Arthritis, Rheumatoid
Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort.
Arthritis, Rheumatoid
Association of the PTPN22 gene (-1123G > C) polymorphism with rheumatoid arthritis in Chinese patients.
Arthritis, Rheumatoid
Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients.
Arthritis, Rheumatoid
Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort.
Arthritis, Rheumatoid
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Arthritis, Rheumatoid
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.
Arthritis, Rheumatoid
Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
Arthritis, Rheumatoid
Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis.
Arthritis, Rheumatoid
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Arthritis, Rheumatoid
CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians.
Arthritis, Rheumatoid
Computational Molecular Phenotypic Analysis of PTPN22 (W620R), IL6R (D358A), and TYK2 (P1104A) Gene Mutations of Rheumatoid Arthritis.
Arthritis, Rheumatoid
Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Arthritis, Rheumatoid
Corrigendum to "CD28 and PTPN22 are associated with susceptibility to rheumatoid arthritis in Egyptians" [Hum. Immunol. 77 (2016) 522-526].
Arthritis, Rheumatoid
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Arthritis, Rheumatoid
Death Receptor 5-Targeted Depletion of Interleukin-23-Producing Macrophages, Th17, and Th1/17 Associated With Defective Tyrosine Phosphatase in Mice and Patients With Rheumatoid Arthritis.
Arthritis, Rheumatoid
Development and application of a PCR-HRM molecular diagnostic method of SNPs linked with TNF inhibitor efficacy.
Arthritis, Rheumatoid
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Arthritis, Rheumatoid
Effects of PTPN22 C1858T polymorphism on susceptibility and clinical characteristics of British Caucasian rheumatoid arthritis patients.
Arthritis, Rheumatoid
Epidemiology: Interpreting studies of interactions between RA risk factors.
Arthritis, Rheumatoid
Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.
Arthritis, Rheumatoid
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Arthritis, Rheumatoid
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Arthritis, Rheumatoid
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Arthritis, Rheumatoid
Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort.
Arthritis, Rheumatoid
Evidence for PTPN22 R620W polymorphism as the sole common risk variant for rheumatoid arthritis in the 1p13.2 region.
Arthritis, Rheumatoid
Evidence of cis-acting regulatory variation in PTPN22 in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids.
Arthritis, Rheumatoid
Expression of peptidylarginine deiminase 4 and protein tyrosine phosphatase nonreceptor type 22 in the synovium of collagen-induced arthritis rats.
Arthritis, Rheumatoid
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Arthritis, Rheumatoid
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Arthritis, Rheumatoid
Frequency of human leukocyte antigens class II-DR alleles (HLA-DRB1) in Argentinian patients with early arthritis.
Arthritis, Rheumatoid
Functional polymorphisms of PTPN22 and FcgR genes in Tunisian patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis.
Arthritis, Rheumatoid
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Arthritis, Rheumatoid
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
Arthritis, Rheumatoid
Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking.
Arthritis, Rheumatoid
Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility.
Arthritis, Rheumatoid
Genome-wide gene-based analysis of rheumatoid arthritis-associated interaction with PTPN22 and HLA-DRB1.
Arthritis, Rheumatoid
Genome-wide Study Identifies Association between HLA-B?55:01 and Self-Reported Penicillin Allergy.
Arthritis, Rheumatoid
Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis.
Arthritis, Rheumatoid
Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population.
Arthritis, Rheumatoid
Identification of novel putative rheumatoid arthritis susceptibility genes via analysis of rare variants.
Arthritis, Rheumatoid
Identification of the tyrosine-protein phosphatase non-receptor type 2 as a rheumatoid arthritis susceptibility locus in europeans.
Arthritis, Rheumatoid
Influence of female hormonal factors, in relation to autoantibodies and genetic markers, on the development of rheumatoid arthritis in northern Sweden: a case-control study.
Arthritis, Rheumatoid
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Arthritis, Rheumatoid
Inhibition of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 reduces the severity of collagen-induced arthritis.
Arthritis, Rheumatoid
Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis.
Arthritis, Rheumatoid
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
Arthritis, Rheumatoid
IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis.
Arthritis, Rheumatoid
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Arthritis, Rheumatoid
Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis.
Arthritis, Rheumatoid
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.
Arthritis, Rheumatoid
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
Arthritis, Rheumatoid
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Arthritis, Rheumatoid
Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population.
Arthritis, Rheumatoid
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Arthritis, Rheumatoid
Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population.
Arthritis, Rheumatoid
Meta-genetic association of rheumatoid arthritis and PTPN22 using PedGenie 2.1.
Arthritis, Rheumatoid
Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis.
Arthritis, Rheumatoid
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Arthritis, Rheumatoid
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Arthritis, Rheumatoid
Modeling of PTPN22 and HLA-DRB1 susceptibility to rheumatoid arthritis.
Arthritis, Rheumatoid
Modeling the effect of susceptibility factors (HLA and PTPN22) in rheumatoid arthritis.
Arthritis, Rheumatoid
Modulation of PTPN2/22 Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis.
Arthritis, Rheumatoid
Need for clarification of data in the recent meta-analysis about 1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk.
Arthritis, Rheumatoid
NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese.
Arthritis, Rheumatoid
No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey.
Arthritis, Rheumatoid
Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis.
Arthritis, Rheumatoid
Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond.
Arthritis, Rheumatoid
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Arthritis, Rheumatoid
Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Protective Effect of Pinitol Against Inflammatory Mediators of Rheumatoid Arthritis via Inhibition of Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22).
Arthritis, Rheumatoid
Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects.
Arthritis, Rheumatoid
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) +1858 C>T gene polymorphism in Egyptian cases with rheumatoid arthritis.
Arthritis, Rheumatoid
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Arthritis, Rheumatoid
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Arthritis, Rheumatoid
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Arthritis, Rheumatoid
PTPN14 phosphatase and YAP promote TGF? signalling in rheumatoid synoviocytes.
Arthritis, Rheumatoid
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis.
Arthritis, Rheumatoid
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Arthritis, Rheumatoid
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
Arthritis, Rheumatoid
PTPN22 -1123G>C polymorphism and anti-cyclic citrullinated protein antibodies in rheumatoid arthritis.
Arthritis, Rheumatoid
PTPN22 1858 C/T polymorphism is associated with alteration of cytokine profiles as a potential pathogenic mechanism in rheumatoid arthritis.
Arthritis, Rheumatoid
PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis.
Arthritis, Rheumatoid
PTPN22 1858C>T polymorphism is associated with increased CD154 expression and higher CD4+ T cells percentage in rheumatoid arthritis patients.
Arthritis, Rheumatoid
PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
Arthritis, Rheumatoid
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
Arthritis, Rheumatoid
PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis.
Arthritis, Rheumatoid
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
Arthritis, Rheumatoid
PTPN22 Is a Critical Regulator of Fc? Receptor-Mediated Neutrophil Activation.
Arthritis, Rheumatoid
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
Arthritis, Rheumatoid
PTPN22 polymorphisms, but not R620W, were associated with the genetic susceptibility of systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population.
Arthritis, Rheumatoid
PTPN22 R620W genotype-phenotype correlation analysis and gene-environment interaction study in early rheumatoid arthritis: results from the ESPOIR cohort.
Arthritis, Rheumatoid
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Arthritis, Rheumatoid
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
Arthritis, Rheumatoid
PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis.
Arthritis, Rheumatoid
PTPN22?+788 G>A (R263Q) Polymorphism is Associated with mRNA Expression but it is not a Susceptibility Marker for Rheumatoid Arthritis Patients from Western Mexico.
Arthritis, Rheumatoid
PTPome profile of rheumatoid arthritis fibroblast-like synoviocytes: a novel role for SHP-2 as a modulator of invasion and survival.
Arthritis, Rheumatoid
PTPRC mutation associated with response to anti-tNF therapy in rheumatoid arthritis.
Arthritis, Rheumatoid
PTPRC rheumatoid arthritis risk allele is also associated with response to anti-TNF therapy.
Arthritis, Rheumatoid
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Arthritis, Rheumatoid
Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population.
Arthritis, Rheumatoid
Regulation of autoimmune arthritis by the SHP-1 tyrosine phosphatase.
Arthritis, Rheumatoid
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.
Arthritis, Rheumatoid
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.
Arthritis, Rheumatoid
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.
Arthritis, Rheumatoid
Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele.
Arthritis, Rheumatoid
Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Arthritis, Rheumatoid
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Arthritis, Rheumatoid
rs2476601 in PTPN22 gene in rheumatoid arthritis and periodontitis-a possible interface?
Arthritis, Rheumatoid
Single Nucleotide Polymorphism rs 2476601 of PTPN22 Gene and Susceptibility to Rheumatoid Arthritis in Iranian Population.
Arthritis, Rheumatoid
Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population.
Arthritis, Rheumatoid
Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis.
Arthritis, Rheumatoid
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Arthritis, Rheumatoid
Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis.
Arthritis, Rheumatoid
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
Arthritis, Rheumatoid
Targeting Protein Tyrosine Phosphatase PTP-PEST for Therapeutic Intervention in Acute Myocardial Infarction.
Arthritis, Rheumatoid
Testing for linkage and association with rheumatoid arthritis a ptpn22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.
Arthritis, Rheumatoid
The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico.
Arthritis, Rheumatoid
The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population.
Arthritis, Rheumatoid
The association between the PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis update.
Arthritis, Rheumatoid
The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis.
Arthritis, Rheumatoid
The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals.
Arthritis, Rheumatoid
The autoimmunity risk variant LYP-W620 cooperates with CSK in the regulation of TCR signaling.
Arthritis, Rheumatoid
The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls.
Arthritis, Rheumatoid
The functional PTPN22 C1858T polymorphism confers risk for rheumatoid arthritis in patients from Central Mexico.
Arthritis, Rheumatoid
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
Arthritis, Rheumatoid
The non-major histocompatibility complex quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage.
Arthritis, Rheumatoid
The potential of PTPN22 as a therapeutic target for rheumatoid arthritis.
Arthritis, Rheumatoid
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.
Arthritis, Rheumatoid
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
Arthritis, Rheumatoid
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Arthritis, Rheumatoid
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Arthritis, Rheumatoid
The PTPN22 C1858T polymorphism and rheumatoid arthritis: a meta-analysis.
Arthritis, Rheumatoid
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
Arthritis, Rheumatoid
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
Arthritis, Rheumatoid
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
Arthritis, Rheumatoid
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
Arthritis, Rheumatoid
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in caucasian case-control samples.
Arthritis, Rheumatoid
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples.
Arthritis, Rheumatoid
The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status.
Arthritis, Rheumatoid
The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis.
Arthritis, Rheumatoid
The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome.
Arthritis, Rheumatoid
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
Arthritis, Rheumatoid
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Arthritis, Rheumatoid
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
Arthritis, Rheumatoid
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
Arthritis, Rheumatoid
The TT Genotype of the STAT4 rs7574865 Polymorphism Is Associated with High Disease Activity and Disability in Patients with Early Arthritis.
Arthritis, Rheumatoid
The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis.
Arthritis, Rheumatoid
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
Arthritis, Rheumatoid
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Arthritis, Rheumatoid
Utilizing a PTPN22 gene signature to predict response to targeted therapies in rheumatoid arthritis.
Arthritis, Rheumatoid
[Acid phosphatase activity and the autoimmune processes in rheumatism and rheumatoid arthritis]
Arthritis, Rheumatoid
[Association of polymorphisms of PTPN22 and PADI4 genes with rheumatoid arthritis in Yunnan].
Arthritis, Rheumatoid
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
Arthritis, Rheumatoid
[PTPN22 1858C/T polymorphism is associated with rheumatoid arthritis susceptibility in Caucasian population: a meta-analysis].
Asphyxia Neonatorum
Changes in lysosomal hydrolases from cord blood of vigorous and asphyxiated Nigerian newborn infants.
Asthma
Association between PTPN22/CTLA-4 Gene Polymorphism and Allergic Rhinitis with Asthma in Children.
Asthma
Association of PTPN22 single nucleotide polymorphism with rheumatoid arthritis but not with allergic asthma.
Asthma
Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages.
Asthma
Corticosteroids and ?(2) -agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanisms.
Asthma
Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma.
Asthma
Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.
Asthma
Exposure to violence, chronic stress, nasal DNA methylation, and atopic asthma in children.
Asthma
Impact of ozone exposure on the response to glucocorticoid in a mouse model of asthma: involvements of p38 MAPK and MKP-1.
Asthma
Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma.
Asthma
Inhibitors of PDE4, but Not PDE3, Increase ?2-agonist-induced Expression of Anti-inflammatory MKP-1 in Airway Smooth Muscle Cells.
Asthma
LncRNA PTPRE-AS1 modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE.
Asthma
Long-Acting ?2-Agonists Increase Fluticasone Propionate-Induced Mitogen-Activated Protein Kinase Phosphatase 1 (MKP-1) in Airway Smooth Muscle Cells.
Asthma
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Asthma
Mechanism of glutamine inhibition of cytosolic phospholipase A2 (cPLA2 ): Evidence of physical interaction between glutamine-induced MAPK phosphatase-1 and cPLA2.
Asthma
Microarray data analysis to identify differentially expressed genes and biological pathways associated with asthma.
Asthma
Network study of nasal transcriptome profiles reveals master regulator genes of asthma.
Asthma
Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion.
Asthma
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Asthma
Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma.
Asthma
Repeated Allergen Exposure in A/J Mice Causes Steroid-Insensitive Asthma via a Defect in Glucocorticoid Receptor Bioavailability.
Asthma
SHP-1 As a Critical Regulator of Mycoplasma pneumoniae-Induced Inflammation in Human Asthmatic Airway Epithelial Cells.
Asthma
SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung.
Asthma
src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation.
Asthma
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
Asthma
The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity.
Asthma
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
Asthma
The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.
Asthma
The polymorphisms of protein-tyrosine phosphatase receptor-type delta gene and its association with pediatric asthma in the Taiwanese population.
Asthma
The role of protein tyrosine phosphatases in the regulation of allergic asthma: implication of TC-PTP and PTP-1B in the modulation of disease development.
Asthma
Tyrosine phosphatase SHP-1 in oxidative stress and development of allergic airway inflammation.
Asthma
[Acid phosphatase activity of bronchial asthma patients during treatment at a health resort]
Astrocytoma
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase micro.
Astrocytoma
An acid phosphatase in the plasma membranes of human astrocytoma showing marked specificity toward phosphotyrosine protein.
Astrocytoma
Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR? activation.
Astrocytoma
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Astrocytoma
Cytokine-induced transcription of protein-tyrosine-phosphatases in human astrocytoma cells.
Astrocytoma
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Astrocytoma
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
Astrocytoma
Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues.
Astrocytoma
FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.
Astrocytoma
Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes.
Astrocytoma
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Astrocytoma
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Astrocytoma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Ataxia
Caveolin-1 expression is required for the development of pulmonary emphysema through activation of the ATM-p53-p21 pathway.
Ataxia
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Ataxia
Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients.
Ataxia
Gallic acid induces G2/M phase cell cycle arrest via regulating 14-3-3beta release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells.
Ataxia
Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C.
Ataxia Telangiectasia
4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
Ataxia Telangiectasia
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Ataxia Telangiectasia
Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells.
Ataxia Telangiectasia
Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
Ataxia Telangiectasia
Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A.
Ataxia Telangiectasia
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Ataxia Telangiectasia
Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells.
Ataxia Telangiectasia
Hypoxic preconditioning decreases nuclear factor ?B activity via Disrupted in Schizophrenia-1.
Ataxia Telangiectasia
Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Ataxia Telangiectasia
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Ataxia Telangiectasia
Microwave hyperthermia promotes caspase?3-dependent apoptosis and induces G2/M checkpoint arrest via the ATM pathway in non?small cell lung cancer cells.
Ataxia Telangiectasia
N-Hydroxycinnamide derivatives of osthole presenting genotoxicity and cytotoxicity against human colon adenocarcinoma cells in vitro and in vivo.
Ataxia Telangiectasia
PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice.
Ataxia Telangiectasia
PTEN enhances G2/M arrest in etoposide-treated MCF?7 cells through activation of the ATM pathway.
Ataxia Telangiectasia
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Ataxia Telangiectasia
Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells.
Ataxia Telangiectasia
The molecular mechanism of G2M cell cycle arrest induced by AFB1 in the jejunum.
Ataxia Telangiectasia
TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells.
Atherosclerosis
Activity of two enzymes associated with apoptosis and cell aging in arterial hypertension.
Atherosclerosis
Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
Atherosclerosis
Association of protein tyrosine phosphatase-n1 polymorphisms with coronary calcified plaque in the diabetes heart study.
Atherosclerosis
Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN.
Atherosclerosis
Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study.
Atherosclerosis
Decreased p66Shc promoter methylation in patients with end-stage renal disease.
Atherosclerosis
Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice.
Atherosclerosis
Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet.
Atherosclerosis
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Atherosclerosis
Harmine alleviates atherogenesis by inhibiting disturbed flow-mediated endothelial activation via protein tyrosine phosphatase PTPN14 and YAP.
Atherosclerosis
Increased endothelial mitogen-activated protein kinase phosphatase-1 expression suppresses proinflammatory activation at sites that are resistant to atherosclerosis.
Atherosclerosis
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Atherosclerosis
Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis.
Atherosclerosis
Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis.
Atherosclerosis
Mitochondrial DAMPs and altered mitochondrial dynamics in OxLDL burden in atherosclerosis.
Atherosclerosis
Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels.
Atherosclerosis
Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis.
Atherosclerosis
Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects against atherosclerotic plaque formation in the ApoE(-/-) mouse model of atherosclerosis with alterations in IL10/AMPK? pathway.
Atherosclerosis
Overexpression of PTPN2 in Visceral Adipose Tissue Ameliorated Atherosclerosis via T Cells Polarization Shift in Diabetic Apoe-/- Mice.
Atherosclerosis
p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice.
Atherosclerosis
Pharmacological inhibition of protein tyrosine phosphatase 1B (PTP1B) protects against atherosclerotic plaque formation in the LDLR(-/-) mouse model of atherosclerosis.
Atherosclerosis
Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models.
Atherosclerosis
Protein tyrosine phosphatase LMW-PTP exhibits distinct roles between vascular endothelial and smooth muscle cells.
Atherosclerosis
Protein tyrosine phosphatase SHP-2 is positively involved in platelet-derived growth factor-signaling in vascular neointima formation via the reactive oxygen species-related pathway.
Atherosclerosis
Protein Tyrosine Phosphatase SHP-2 Is Positively Involved in Platelet-Derived Growth Factor-Signaling in Vascular Neointima Formation via the Reactive Oxygen Species-Related Pathway.
Atherosclerosis
PTPN22 Gene Polymorphisms Are Associated with Susceptibility to Large Artery Atherosclerotic Stroke and Microembolic Signals.
Atherosclerosis
Regulation of Src homology 2-containing protein tyrosine phosphatase by advanced glycation end products: the role on atherosclerosis in diabetes.
Atherosclerosis
Role of PTP-1B in aortic smooth muscle cell motility and tyrosine phosphorylation of focal adhesion proteins.
Atherosclerosis
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
Atherosclerosis
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Atherosclerosis
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Atherosclerosis
Tyrosine phosphatase epsilonM stimulates migration and survival of porcine aortic endothelial cells by activating c-Src.
Atrial Fibrillation
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Autoimmune Diseases
1858 C/T Polymorphism of the Protein Tyrosine Phosphatase Nonreceptor 22 Gene and Rheumatoid Arthritis Risk in Europeans: A Meta-analysis.
Autoimmune Diseases
A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease.
Autoimmune Diseases
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
Autoimmune Diseases
A functional PTPN22 polymorphism associated with several autoimmune diseases is not associated with IgA deficiency in the Spanish population.
Autoimmune Diseases
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Autoimmune Diseases
A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes.
Autoimmune Diseases
A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases.
Autoimmune Diseases
A switch-variant model integrates the functions of an autoimmune variant of the phosphatase PTPN22.
Autoimmune Diseases
A three-dimensional chemical phase pharmacophore mapping, QSAR modelling and electronic feature analysis of benzofuran salicylic acid derivatives as LYP inhibitors.
Autoimmune Diseases
A variant of PTPN22 gene conferring risk to autoimmune diseases may protect against tuberculosis.
Autoimmune Diseases
A126: Clusters of Autoimmune Diseases in Children and the Role of PTPN22 C1858T Gene Polymorphism in Pediatric Polyautoimmunity.
Autoimmune Diseases
Allele and haplotype frequency distribution in PTPN22 gene across variable ethnic groups: Implications for genetic association studies for autoimmune diseases.
Autoimmune Diseases
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Autoimmune Diseases
Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
Autoimmune Diseases
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
Autoimmune Diseases
Anti-parietal cell antibodies and pernicious anemia in patients with type 1 diabetes mellitus and multiethnic background.
Autoimmune Diseases
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Autoimmune Diseases
Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity?
Autoimmune Diseases
Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases.
Autoimmune Diseases
Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population.
Autoimmune Diseases
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Autoimmune Diseases
Association between a gain-of-function variant of PTPN22 and rejection in liver transplantation.
Autoimmune Diseases
Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy.
Autoimmune Diseases
Association between PTPN22 C1858T polymorphism and alopecia areata risk.
Autoimmune Diseases
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Autoimmune Diseases
Association between the PTPN22 +1858 C/T polymorphism and psoriatic arthritis.
Autoimmune Diseases
Association between the PTPN22 1858C/T gene polymorphism and tuberculosis resistance.
Autoimmune Diseases
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Autoimmune Diseases
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Autoimmune Diseases
Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo.
Autoimmune Diseases
Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.
Autoimmune Diseases
Association of protein tyrosine phosphatase, non-receptor type 22 +1858C?T polymorphism and susceptibility to vitiligo: Systematic review and meta-analysis.
Autoimmune Diseases
Association of PTPN22 1858C/T Polymorphism with Autoimmune Diseases: A Systematic Review and Bayesian Approach.
Autoimmune Diseases
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Autoimmune Diseases
Association of PTPN22 haplotypes with type 1 diabetes in the Japanese population.
Autoimmune Diseases
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Autoimmune Diseases
Association of PTPN22 Single Nucleotide Polymorphisms with Celiac Disease.
Autoimmune Diseases
Association of PTPN22+1858C/T polymorphism with Type 1 diabetes in the North Indian population.
Autoimmune Diseases
Association of susceptible genetic markers and autoantibodies in rheumatoid arthritis.
Autoimmune Diseases
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Autoimmune Diseases
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Autoimmune Diseases
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Autoimmune Diseases
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Autoimmune Diseases
Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete.
Autoimmune Diseases
Association of TNF-?, CTLA4, and PTPN22 polymorphisms with type 1 diabetes and other autoimmune diseases in Brazil.
Autoimmune Diseases
Associations of single nucleotide polymorphisms of PTPN22 and Ctla4 genes with the risk of allergic rhinitis in a Chinese Han population.
Autoimmune Diseases
Autoantibodies specific for different isoforms of CD45 in systemic lupus erythematosus.
Autoimmune Diseases
Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.
Autoimmune Diseases
Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study.
Autoimmune Diseases
Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22).
Autoimmune Diseases
Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways.
Autoimmune Diseases
Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-? receptor signaling.
Autoimmune Diseases
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset.
Autoimmune Diseases
Biochemical and Functional Studies of Lymphoid-Specific Tyrosine Phosphatase (Lyp) Variants S201F and R266W.
Autoimmune Diseases
C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition.
Autoimmune Diseases
C1858T Polymorphism of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22): an eligible target for prevention of type 1 diabetes?
Autoimmune Diseases
Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci.
Autoimmune Diseases
Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening.
Autoimmune Diseases
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.
Autoimmune Diseases
Conjugation of Antisense Oligonucleotides to PEGylated Carbon Nanotubes Enables Efficient Knockdown of PTPN22 in T Lymphocytes.
Autoimmune Diseases
Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland.
Autoimmune Diseases
Crispr/Cas Mediated Deletion of PTPN22 in Jurkat T Cells Enhances TCR Signaling and Production of IL-2.
Autoimmune Diseases
Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17-Dependent Mechanism.
Autoimmune Diseases
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Autoimmune Diseases
Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors.
Autoimmune Diseases
Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice.
Autoimmune Diseases
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Autoimmune Diseases
Differential nanoscale organisation of LFA-1 modulates T cell migration.
Autoimmune Diseases
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells.
Autoimmune Diseases
Do inhibitory immune receptors play a role in the etiology of autoimmune disease?
Autoimmune Diseases
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Autoimmune Diseases
Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.
Autoimmune Diseases
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
Autoimmune Diseases
Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis.
Autoimmune Diseases
Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients.
Autoimmune Diseases
Evidence for PTPN22 R620W polymorphism as the sole common risk variant for rheumatoid arthritis in the 1p13.2 region.
Autoimmune Diseases
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients.
Autoimmune Diseases
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Autoimmune Diseases
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Autoimmune Diseases
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis.
Autoimmune Diseases
Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients.
Autoimmune Diseases
Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes.
Autoimmune Diseases
Gender-specific association of the PTPN22 C1858T polymorphism with achalasia.
Autoimmune Diseases
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Autoimmune Diseases
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci.
Autoimmune Diseases
Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations.
Autoimmune Diseases
Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils.
Autoimmune Diseases
Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort.
Autoimmune Diseases
GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.
Autoimmune Diseases
Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population.
Autoimmune Diseases
Hematopoietic cell phosphatase, SHP-1, is constitutively associated with the SH2 domain-containing leukocyte protein, SLP-76, in B cells.
Autoimmune Diseases
Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22.
Autoimmune Diseases
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Autoimmune Diseases
Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
Autoimmune Diseases
In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.
Autoimmune Diseases
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Autoimmune Diseases
Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.
Autoimmune Diseases
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Autoimmune Diseases
Involvement of the protein tyrosine phosphatase SHP-1 in Ras-mediated activation of the mitogen-activated protein kinase pathway.
Autoimmune Diseases
IRF5, PTPN22, CD28, IL2RA, KIF5A, BLK and TNFAIP3 genes polymorphisms and lupus susceptibility in a cohort from the Egypt Delta; relation to other ethnic groups.
Autoimmune Diseases
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Autoimmune Diseases
Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis.
Autoimmune Diseases
Lack of the phosphatase PTPN22 increases adhesion of murine regulatory T cells to improve their immunosuppressive function.
Autoimmune Diseases
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene.
Autoimmune Diseases
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
Autoimmune Diseases
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
Autoimmune Diseases
MAP kinase phosphatase 1 is necessary for T cell activation and function.
Autoimmune Diseases
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Autoimmune Diseases
MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus.
Autoimmune Diseases
Multi-color Molecular Visualization of Signaling Proteins Reveals How C-Terminal Src Kinase Nanoclusters Regulate T Cell Receptor Activation.
Autoimmune Diseases
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Autoimmune Diseases
Multifunctional roles of the autoimmune disease-associated tyrosine phosphatase PTPN22 in regulating T cell homeostasis.
Autoimmune Diseases
Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele.
Autoimmune Diseases
Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease.
Autoimmune Diseases
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
Autoimmune Diseases
No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjögren's syndrome.
Autoimmune Diseases
Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.
Autoimmune Diseases
Novel associations for hypothyroidism include known autoimmune risk loci.
Autoimmune Diseases
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
Autoimmune Diseases
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Autoimmune Diseases
Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation.
Autoimmune Diseases
Overlap of disease susceptibility loci for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Autoimmune Diseases
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease.
Autoimmune Diseases
p66Shc Is a Negative Regulator of Fc{varepsilon}RI-Dependent Signaling in Mast Cells.
Autoimmune Diseases
Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
Autoimmune Diseases
Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.
Autoimmune Diseases
Proline-serine-threonine phosphatase interacting protein 1 inhibition of T-cell receptor signaling depends on its SH3 domain.
Autoimmune Diseases
Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures.
Autoimmune Diseases
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
Autoimmune Diseases
Protein tyrosine phosphatase PTPN22 regulates IL-1? dependent Th17 responses by modulating dectin-1 signaling in mice.
Autoimmune Diseases
Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses.
Autoimmune Diseases
PTPN22 1858 C/T Exon Polymorphism is not Associated with Graves' Disease in Kashmiri population.
Autoimmune Diseases
PTPN22 1858T is not a risk factor for North American Pemphigus vulgaris.
Autoimmune Diseases
PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.
Autoimmune Diseases
Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice.
Autoimmune Diseases
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
Autoimmune Diseases
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.
Autoimmune Diseases
PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
Autoimmune Diseases
PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases.
Autoimmune Diseases
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
Autoimmune Diseases
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Autoimmune Diseases
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
Autoimmune Diseases
PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children.
Autoimmune Diseases
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
Autoimmune Diseases
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
Autoimmune Diseases
PTPN22 Is a Critical Regulator of Fc? Receptor-Mediated Neutrophil Activation.
Autoimmune Diseases
PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not.
Autoimmune Diseases
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
Autoimmune Diseases
PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.
Autoimmune Diseases
PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome.
Autoimmune Diseases
PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits.
Autoimmune Diseases
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
Autoimmune Diseases
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
Autoimmune Diseases
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Autoimmune Diseases
Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Autoimmune Diseases
Regulation of signal transduction by the Fc gamma receptor family members and their involvement in autoimmunity.
Autoimmune Diseases
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
Autoimmune Diseases
Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes.
Autoimmune Diseases
Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages.
Autoimmune Diseases
Role of C1858T polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian children and adolescents with type 1 diabetes.
Autoimmune Diseases
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Autoimmune Diseases
Single Nucleotide Polymorphism rs 2476601 of PTPN22 Gene and Susceptibility to Rheumatoid Arthritis in Iranian Population.
Autoimmune Diseases
Single Nucleotide Polymorphisms of PTPN22 Gene in Iranian Patients with Ulcerative Colitis.
Autoimmune Diseases
Single-cell profiling reveals dendritic cell signatures associated with autoimmune inflammation.
Autoimmune Diseases
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
Autoimmune Diseases
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Autoimmune Diseases
STAT4 rs7574865 G/T and PTPN22 rs2488457 G/C polymorphisms influence the risk of developing juvenile idiopathic arthritis in Han Chinese patients.
Autoimmune Diseases
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Autoimmune Diseases
Substrate Specificity of Lymphoid-specific Tyrosine Phosphatase (Lyp) and Identification of Src Kinase-associated Protein of 55 kDa Homolog (SKAP-HOM) as a Lyp Substrate.
Autoimmune Diseases
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
Autoimmune Diseases
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
Autoimmune Diseases
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
Autoimmune Diseases
The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population.
Autoimmune Diseases
The association of PTPN22 (rs2476601) and IL2RA (rs11594656) polymorphisms with T1D in Egyptian children.
Autoimmune Diseases
The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
Autoimmune Diseases
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
Autoimmune Diseases
The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals.
Autoimmune Diseases
The Autoimmune-Associated Single Nucleotide Polymorphism Within PTPN22 Correlates With Clinical Outcome After Lung Transplantation.
Autoimmune Diseases
The autoimmunity risk variant LYP-W620 cooperates with CSK in the regulation of TCR signaling.
Autoimmune Diseases
The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis.
Autoimmune Diseases
The balance of expression of PTPN22 splice forms is significantly different in rheumatoid arthritis patients compared with controls.
Autoimmune Diseases
The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase-22 gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese.
Autoimmune Diseases
The common, autoimmunity-predisposing 620Arg > Trp variant of PTPN22 modulates macrophage function and morphology.
Autoimmune Diseases
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
Autoimmune Diseases
The Genotype and Phenotype (GaP) registry: a living biobank for the analysis of quantitative traits.
Autoimmune Diseases
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
Autoimmune Diseases
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
Autoimmune Diseases
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
Autoimmune Diseases
The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete.
Autoimmune Diseases
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Autoimmune Diseases
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
Autoimmune Diseases
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.
Autoimmune Diseases
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Autoimmune Diseases
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Autoimmune Diseases
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
Autoimmune Diseases
The PTPN22 locus and rheumatoid arthritis: no evidence for an effect on risk independent of Arg620Trp.
Autoimmune Diseases
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
Autoimmune Diseases
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
Autoimmune Diseases
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Autoimmune Diseases
The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity.
Autoimmune Diseases
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
Autoimmune Diseases
The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.
Autoimmune Diseases
The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura.
Autoimmune Diseases
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
Autoimmune Diseases
The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human.
Autoimmune Diseases
The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1.
Autoimmune Diseases
Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene.
Autoimmune Diseases
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Autoimmune Diseases
Use of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytes.
Autoimmune Diseases
Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.
Autoimmune Diseases
Why is PTPN22 a good candidate susceptibility gene for autoimmune disease?
Autoimmune Diseases
[Latent forms of adult-onset autoimmune polyglandular syndrome: diagnosis and management of patients].
Azoospermia
Decreased Expression of CDC25A in Azoospermia as the Etiology of Spermatogenesis Failure.
Bacterial Infections
Acute Dietary Restriction Acts via TOR, PP2A, and Myc Signaling to Boost Innate Immunity in Drosophila.
Bacterial Infections
Correlation of acid phosphatase activity with degree of bacterial infection in HELA cells.
Bacterial Infections
Dual-Specificity Phosphatase 12 Targets p38 MAP Kinase to Regulate Macrophage Response to Intracellular Bacterial Infection.
Bacterial Infections
IL-34 regulates the inflammatory response and anti-bacterial immune defense of Japanese flounder Paralichthys olivaceus.
Bacterial Infections
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Bacterial Infections
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Bacterial Infections
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response.
Bacterial Infections
Moesin and myosin IIA modulate phagolysosomal biogenesis in macrophages.
Bacterial Infections
Protein tyrosine phosphatase 1B inhibition as a potential therapeutic target for chronic wounds in diabetes.
Bacterial Infections
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
Bacterial Infections
SHP-1 suppresses the antiviral innate immune response by targeting TRAF3.
Bacterial Infections
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Basal Cell Nevus Syndrome
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Behcet Syndrome
A case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain-of-function mutation in SHP-2.
Behcet Syndrome
Association of genetic variations in PTPN2 and CD122 with ocular Behcet's disease.
Behcet Syndrome
No Association of PTPN22 Polymorphisms with Susceptibility to Ocular Behcet's Disease in Two Chinese Han Populations.
beta-Thalassemia
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
Blast Crisis
Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.
Blast Crisis
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Blast Crisis
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Blister
Acid hydrolases in blister fluid. I. Characterization and quantification of acid phosphatase.
Blister
Inhibition of 5-alpha-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate.
Blister
Programmed cell death in the larval salivary glands of Apis mellifera (Hymenoptera, Apidae).
Blood Group Incompatibility
[Acid phosphatase activity in the neutrophils and peripheral lymphocytes in normal pregnancy and pregnancies complicated by RH-HR blood group incompatibility and toxemia]
Bluetongue
Cellular Casein Kinase 2 and Protein Phosphatase 2A Modulate Replication Site Assembly of Bluetongue Virus.
Bone Diseases
Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
Bone Diseases, Metabolic
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Bone Diseases, Metabolic
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Bone Diseases, Metabolic
Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Bone Diseases, Metabolic
The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.
Bone Neoplasms
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Bone Resorption
A quantitative cytochemical assay for osteoclast acid phosphatase activity in foetal rat calvaria.
Bone Resorption
Alveolar bone loss: mechanisms, potential therapeutic targets, and interventions.
Bone Resorption
An osteoclastic protein-tyrosine phosphatase may play a role in differentiation and activity of human monocytic U-937 cell-derived, osteoclast-like cells.
Bone Resorption
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Bone Resorption
Biochemical markers of bone turnover for the clinical investigation of osteoporosis.
Bone Resorption
Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function.
Bone Resorption
Bone composition and metabolism after hyperbaric oxygenation in rats with 1-hydroxyethylidene-1,1-bisphosphonate-induced rickets.
Bone Resorption
Bone resorption in chronic otitis media. A light-microscopical and histochemical investigation of acid phosphatase activity.
Bone Resorption
Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption.
Bone Resorption
Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.
Bone Resorption
Critical role of MKP-1 in lipopolysaccharide-induced osteoclast formation through CXCL1 and CXCL2.
Bone Resorption
Crocin attenuates methylglyoxal-induced osteoclast dysfunction by regulating glyoxalase, oxidative stress, and mitochondrial function.
Bone Resorption
Dynamin and PTP-PEST cooperatively regulate Pyk2 dephosphorylation in osteoclasts.
Bone Resorption
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Bone Resorption
Effects of magnesium coating on bone-implant interfaces with and without polyether-ether-ketone particle interference: A rabbit model based on porous Ti6Al4V implants.
Bone Resorption
Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
Bone Resorption
Effects of nicotine on bone during orthodontic tooth movement in male rats. Histological and immunohistochemical study.
Bone Resorption
Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice.
Bone Resorption
Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone.
Bone Resorption
Influence of irradiation on the osteoinductive potential of demineralized bone matrix.
Bone Resorption
Morphological changes in periodontal mechanoreceptors of mouse maxillary incisors after the experimental induction of anterior crossbite: a light and electron microscopic observation using immunohistochemistry for PGP 9.5.
Bone Resorption
Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function.
Bone Resorption
Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Bone Resorption
Phosphorylation of a Wiscott-Aldrich syndrome protein-associated signal complex is critical in osteoclast bone resorption.
Bone Resorption
Preventive effects of flaxseed and sesame oil on bone loss in ovariectomized rats.
Bone Resorption
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Bone Resorption
Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts.
Bone Resorption
PTPRJ promotes osteoclast maturation and activity by inhibiting Cbl-mediated ubiquitination of NFATc1 in late osteoclastogenesis.
Bone Resorption
Pulsed electromagnetic fields inhibit osteoclast differentiation in RAW264.7 macrophages via suppression of the protein kinase B/mammalian target of rapamycin signaling pathway.
Bone Resorption
Quantification of osteoclastic resorption of the bovine otic capsule in vitro by an enzyme-linked immunosorbent assay.
Bone Resorption
Strontium ranelate decreases receptor activator of nuclear factor-?B ligand-induced osteoclastic differentiation in vitro: involvement of the calcium-sensing receptor.
Bone Resorption
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
Bone Resorption
T-Cell Protein Tyrosine Phosphatase Regulates Bone Resorption and Whole-Body Insulin Sensitivity through Its Expression in Osteoblasts.
Bone Resorption
Targeted transgenic expression of an osteoclastic transmembrane protein-tyrosine phosphatase in cells of osteoclastic lineage increases bone resorption and bone loss in male young adult mice.
Bone Resorption
The Antiosteoporosis Effects of Zhuanggu Guanjie Pill In Vitro and In Vivo.
Bone Resorption
The effect of carbonic anhydrase inhibition on calcium and bone homeostasis in healthy postmenopausal women.
Bone Resorption
The effect of dental plaque grown in the presence of xylitol or sucrose on bone resorption in vitro.
Bone Resorption
The effects of dietary calcium during lactation on lead in bone mobilization: implications for toxicology.
Bone Resorption
The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro.
Bone Resorption
The tyrosine phosphatase SHP-1 is a negative regulator of osteoclastogenesis and osteoclast resorbing activity: increased resorption and osteopenia in me(v)/me(v) mutant mice.
Bone Resorption
Tooth hard tissue stimulates bone remodeling as a potential motive force during tooth eruption.
Bone Resorption
Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo.
Bone Resorption
Tyrosine-protein phosphatase non-receptor type 2 inhibits alveolar bone resorption in diabetic periodontitis via dephosphorylating CSF1 receptor.
Bone Resorption
[ALKALINE AND ACID PHOSPHATASE ACTIVITY IN PROCESSES OF BONE FORMATION AND BONE RESORPTION (EXPERIMENTAL STUDY).]
Bradycardia
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Bradycardia
Protein phosphatase 1b in the solitary tract nucleus is necessary for normal baroreflex function.
Bradycardia
SHP-2 deletion in postmigratory neural crest cells results in impaired cardiac sympathetic innervation.
Brain Concussion
Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes.
Brain Death
Endoplasmic reticulum stress induces liver cells apoptosis after brain death by suppressing the phosphorylation of protein phosphatase 2A.
Brain Diseases
Developmental epileptic encephalopathy with hypomyelination and brain atrophy associated with PTPN23 variants affecting the assembly of UsnRNPs.
Brain Diseases
Inhibition of the tyrosine phosphatase STEP61 restores BDNF expression and reverses motor and cognitive deficits in phencyclidine-treated mice.
Brain Diseases
Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation.
Brain Diseases
Mitogen-activated protein kinase phosphatase-2 deletion modifies ventral tegmental area function and connectivity and alters reward processing.
Brain Diseases
The 15-deoxy-delta 12,14-prostaglandin J2 suppresses monocyte chemoattractant protein-1 expression in IFN-gamma-stimulated astrocytes through induction of MAPK phosphatase-1.
Brain Injuries
A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.
Brain Injuries
Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes.
Brain Injuries
Combinational Approach of Genetic SHP-1 Suppression and Voluntary Exercise Promotes Corticospinal Tract Sprouting and Motor Recovery Following Brain Injury.
Brain Injuries
Comparison of RPTP zeta/beta, phosphacan, and trkB mRNA expression in the developing and adult rat nervous system and induction of RPTP zeta/beta and phosphacan mRNA following brain injury.
Brain Injuries
Ferulic acid attenuates the injury-induced decrease of protein phosphatase 2A subunit B in ischemic brain injury.
Brain Injuries
Melatonin attenuates decrease of protein phosphatase 2A subunit B in ischemic brain injury.
Brain Injuries
Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.
Brain Injuries
Suppression of SHP-1 promotes corticospinal tract sprouting and functional recovery after brain injury.
Brain Injuries
The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes.
Brain Injuries
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Brain Injuries, Traumatic
Inhibition of EphA/Ephrin-A signaling using genetic and pharmacologic approaches improves recovery following traumatic brain injury in mice.
Brain Injuries, Traumatic
P13BP, a calpain-2-mediated breakdown product of PTPN13, is a novel blood biomarker for Traumatic Brain Injury.
Brain Injuries, Traumatic
Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury.
Brain Injuries, Traumatic
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Brain Ischemia
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
Brain Ischemia
Curcumin treatment recovery the decrease of protein phosphatase 2A subunit B induced by focal cerebral ischemia in Sprague-Dawley rats.
Brain Ischemia
Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia.
Brain Ischemia
Focal Cerebral Ischemia Reduces Protein Phosphatase 2A Subunit B Expression in Brain Tissue and HT22 Cells.
Brain Ischemia
Focal cerebral ischemia upregulates SHP-1 in reactive astrocytes in juvenile mice.
Brain Ischemia
Involvement of the dual-specificity phosphatase M3/6 in c-Jun N-terminal kinase inactivation following cerebral ischemia in the rat hippocampus.
Brain Ischemia
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Brain Ischemia
Neuroprotective effects of bisperoxovanadium on cerebral ischemia by inflammation inhibition.
Brain Ischemia
Neuroprotective effects of protein tyrosine phosphatase 1B inhibitor on cerebral ischemia/reperfusion in mice.
Brain Ischemia
Neuroprotective role of a brain-enriched tyrosine phosphatase, STEP, in focal cerebral ischemia.
Brain Ischemia
Phosphorylation of tau protein over time in rats subjected to transient brain ischemia.
Brain Ischemia
PI3K/Akt-independent negative regulation of JNK signaling by MKP-7 after cerebral ischemia in rat hippocampus.
Brain Ischemia
Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.
Brain Ischemia
Tyrosine kinase and tyrosine phosphatase participate in regulation of interactions of NMDA receptor subunit 2A with Src and Fyn mediated by PSD-95 after transient brain ischemia.
Brain Ischemia
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Brain Neoplasms
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation.
Brain Neoplasms
Association of protein phosphatase 2A with its substrate vimentin intermediate filaments in 9L rat brain tumor cells.
Brain Neoplasms
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Brain Neoplasms
Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Brain Neoplasms
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
Brain Neoplasms
[A histochemical study of the acid phosphatase activity of macroglial brain tumors]
Branchio-Oto-Renal Syndrome
Using Drosophila to decipher how mutations associated with human branchio-oto-renal syndrome and optical defects compromise the protein tyrosine phosphatase and transcriptional functions of eyes absent.
Breast Carcinoma In Situ
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Breast Diseases
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.
Breast Diseases
The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
Breast Neoplasms
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
Breast Neoplasms
17beta-estradiol (E2) induces cdc25A gene expression in breast cancer cells by genomic and non-genomic pathways.
Breast Neoplasms
3,3'-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation.
Breast Neoplasms
3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells.
Breast Neoplasms
3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells: retraction.
Breast Neoplasms
6,7-di-O-acetylsinococuline (FK-3000) induces G2/M phase arrest in breast carcinomas through p38 MAPK phosphorylation and CDC25B dephosphorylation.
Breast Neoplasms
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.
Breast Neoplasms
A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer.
Breast Neoplasms
A high-molecular weight complex with acid phosphatase activity in human breast cancer.
Breast Neoplasms
A microtiter enzyme-linked immunosorbent assay for protein tyrosine phosphatase.
Breast Neoplasms
A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells.
Breast Neoplasms
A novel deep autoencoder based survival analysis approach for microarray dataset.
Breast Neoplasms
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
Breast Neoplasms
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Breast Neoplasms
Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis.
Breast Neoplasms
Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Breast Neoplasms
Acid phosphatase activity in the cytosol fraction of the breast cancer tissue.
Breast Neoplasms
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.
Breast Neoplasms
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase.
Breast Neoplasms
Activation of Src and transformation by an RPTP? splice mutant found in human tumours.
Breast Neoplasms
Activation of Src by Protein Tyrosine Phosphatase 1B Is Required for ErbB2 Transformation of Human Breast Epithelial Cells.
Breast Neoplasms
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Breast Neoplasms
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.
Breast Neoplasms
An Aza-Cope Reactivity-Based Fluorescent Probe for Imaging Formaldehyde in Living Cells.
Breast Neoplasms
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Breast Neoplasms
Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway.
Breast Neoplasms
Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells.
Breast Neoplasms
Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation.
Breast Neoplasms
Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
Breast Neoplasms
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Breast Neoplasms
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.
Breast Neoplasms
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Breast Neoplasms
Breast Cancer Cells Proliferation Is Regulated by Tyrosine Phosphatase SHP1 through c-jun N-Terminal Kinase and Cooperative Induction of RFX-1 and AP-4 Transcription Factors.
Breast Neoplasms
BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data.
Breast Neoplasms
c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer.
Breast Neoplasms
Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion.
Breast Neoplasms
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.
Breast Neoplasms
CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation.
Breast Neoplasms
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Breast Neoplasms
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
Breast Neoplasms
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Breast Neoplasms
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Breast Neoplasms
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Breast Neoplasms
Changes in protein tyrosine phosphatase type IVA member 1 and zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
Breast Neoplasms
Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines.
Breast Neoplasms
Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.
Breast Neoplasms
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Breast Neoplasms
Clinicopathological significance of PTPN12 expression in human breast cancer.
Breast Neoplasms
Coexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cell.
Breast Neoplasms
Colorectal cancer susceptibility variants alter risk of breast cancer in a Chinese Han population.
Breast Neoplasms
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Breast Neoplasms
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Breast Neoplasms
Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
Breast Neoplasms
Covalent Ligand Discovery against Druggable Hotspots Targeted by Anti-cancer Natural Products.
Breast Neoplasms
Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
Breast Neoplasms
D,L-sulforaphane-induced apoptosis in human breast cancer cells is regulated by the adapter protein p66Shc.
Breast Neoplasms
Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.
Breast Neoplasms
Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.
Breast Neoplasms
Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status.
Breast Neoplasms
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Breast Neoplasms
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Breast Neoplasms
Docosahexaenoic Acid Inhibits PTP1B Phosphatase and the Viability of MCF-7 Breast Cancer Cells.
Breast Neoplasms
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Breast Neoplasms
Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis.
Breast Neoplasms
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
Breast Neoplasms
EBP50 suppresses the proliferation of MCF-7 human breast cancer cells via promoting Beclin-1/p62-mediated lysosomal degradation of c-Myc.
Breast Neoplasms
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
Breast Neoplasms
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.
Breast Neoplasms
Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.
Breast Neoplasms
Elimination of ALDH+ breast tumor initiating cells by docosahexanoic acid and/or gamma tocotrienol through SHP-1 inhibition of Stat3 signaling.
Breast Neoplasms
Epidermal growth factor receptor (EGFR)-mediated positive feedback of protein-tyrosine phosphatase epsilon (PTPepsilon) on ERK1/2 and AKT protein pathways is required for survival of human breast cancer cells.
Breast Neoplasms
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells.
Breast Neoplasms
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Breast Neoplasms
erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Breast Neoplasms
ERBB2 and PTPN2 gene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab.
Breast Neoplasms
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Breast Neoplasms
Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Breast Neoplasms
Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.
Breast Neoplasms
Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation.
Breast Neoplasms
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Breast Neoplasms
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Breast Neoplasms
Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer.
Breast Neoplasms
Evaluation of drug-targetable genes by defining modes of abnormality in gene expression.
Breast Neoplasms
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Breast Neoplasms
Exogenous phosphotyrosine modulates epidermal growth factor receptor tyrosine phosphorylation.
Breast Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Breast Neoplasms
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Breast Neoplasms
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Breast Neoplasms
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Breast Neoplasms
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer.
Breast Neoplasms
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Breast Neoplasms
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Breast Neoplasms
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Breast Neoplasms
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Breast Neoplasms
Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer.
Breast Neoplasms
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Breast Neoplasms
Expression Profiling during Mammary Epithelial Cell Three-Dimensional Morphogenesis Identifies PTPRO as a Novel Regulator of Morphogenesis and ErbB2-Mediated Transformation.
Breast Neoplasms
Extracellular signal-regulated kinase 1/2 and protein phosphatase 2A are involved in the antiproliferative activity of conjugated linoleic acid in MCF-7 cells.
Breast Neoplasms
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Breast Neoplasms
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Breast Neoplasms
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity.
Breast Neoplasms
Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Breast Neoplasms
Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium.
Breast Neoplasms
Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
Breast Neoplasms
Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer.
Breast Neoplasms
Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.
Breast Neoplasms
Green Tea Catechins Induce Inhibition of PTP1B Phosphatase in Breast Cancer Cells with Potent Anti-Cancer Properties: In Vitro Assay, Molecular Docking, and Dynamics Studies.
Breast Neoplasms
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.
Breast Neoplasms
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Breast Neoplasms
High-resolution crystal structures of the D1 and D2 domains of protein tyrosine phosphatase epsilon for structure-based drug design.
Breast Neoplasms
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Breast Neoplasms
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Breast Neoplasms
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.
Breast Neoplasms
Identifying the role of PTPN12 expression in predicting the efficacy of capecitabine to neoadjuvant chemotherapy in breast cancer treatment.
Breast Neoplasms
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Breast Neoplasms
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Breast Neoplasms
Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.
Breast Neoplasms
Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells.
Breast Neoplasms
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.
Breast Neoplasms
Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.
Breast Neoplasms
Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Breast Neoplasms
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Breast Neoplasms
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential.
Breast Neoplasms
Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Breast Neoplasms
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.
Breast Neoplasms
Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Breast Neoplasms
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Breast Neoplasms
Isolation of two sesquiterpene glycosides from Sapindus mukorossi Gaertn. with cytotoxic properties and analysis of their mechanism based on network pharmacology.
Breast Neoplasms
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Breast Neoplasms
Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Breast Neoplasms
LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
Breast Neoplasms
Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue.
Breast Neoplasms
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Breast Neoplasms
Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206.
Breast Neoplasms
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Breast Neoplasms
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Breast Neoplasms
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Breast Neoplasms
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Breast Neoplasms
Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation.
Breast Neoplasms
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Breast Neoplasms
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.
Breast Neoplasms
Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.
Breast Neoplasms
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
Breast Neoplasms
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
Breast Neoplasms
MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A.
Breast Neoplasms
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.
Breast Neoplasms
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
Breast Neoplasms
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Breast Neoplasms
MKP-1-induced dephosphorylation of extracellular signal-regulated kinase is essential for triggering nitric oxide-induced apoptosis in human breast cancer cell lines: implications in breast cancer.
Breast Neoplasms
Molecular cloning and characterization of PTP pi, a novel receptor-like protein-tyrosine phosphatase.
Breast Neoplasms
MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells.
Breast Neoplasms
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Breast Neoplasms
NCAPG upregulation mediated by four microRNAs combined with activation of the p53 signaling pathway is a predictor of poor prognosis in patients with breast cancer.
Breast Neoplasms
Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1.
Breast Neoplasms
New prenylated isoflavonoids as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Erythrina addisoniae.
Breast Neoplasms
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Breast Neoplasms
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
Breast Neoplasms
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Breast Neoplasms
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Breast Neoplasms
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Breast Neoplasms
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Breast Neoplasms
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Breast Neoplasms
Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Breast Neoplasms
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
Breast Neoplasms
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Breast Neoplasms
p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
Breast Neoplasms
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Breast Neoplasms
Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells.
Breast Neoplasms
Pectenotoxin-2 induces G2/M phase cell cycle arrest in human breast cancer cells via ATM and Chk1/2-mediated phosphorylation of cdc25C.
Breast Neoplasms
Pez: a novel human cDNA encoding protein tyrosine phosphatase- and ezrin-like domains.
Breast Neoplasms
Phosphoproteomic analysis of interacting tumor and endothelial cells identifies regulatory mechanisms of transendothelial migration.
Breast Neoplasms
Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer.
Breast Neoplasms
PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications.
Breast Neoplasms
PPAR? inhibits breast cancer progression by upregulating PTPRF expression.
Breast Neoplasms
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
Breast Neoplasms
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Breast Neoplasms
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Breast Neoplasms
Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Breast Neoplasms
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Breast Neoplasms
Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
Breast Neoplasms
Prognostic Significance of Metastatic Lymph Nodes Ratio (MLNR) Combined with Protein-Tyrosine Phosphatase H1 (PTPH1) Expression in Operable Breast Invasive Ductal Carcinoma.
Breast Neoplasms
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.
Breast Neoplasms
Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells.
Breast Neoplasms
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Breast Neoplasms
Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells.
Breast Neoplasms
Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk.
Breast Neoplasms
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Breast Neoplasms
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Breast Neoplasms
Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of Akebia quinata.
Breast Neoplasms
Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
Breast Neoplasms
Protein tyrosine phosphatase activity as a diagnostic parameter in breast cancer.
Breast Neoplasms
Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9.
Breast Neoplasms
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Breast Neoplasms
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Breast Neoplasms
Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.
Breast Neoplasms
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Breast Neoplasms
Protein tyrosine phosphatase PTPN9 negatively regulates ErbB2 and EGFR signaling in breast cancer cells.
Breast Neoplasms
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Breast Neoplasms
Protein tyrosine phosphatase receptor-type ? acts as a negative regulator suppressing breast cancer.
Breast Neoplasms
Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.
Breast Neoplasms
Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.
Breast Neoplasms
Protein tyrosine phosphatase-1B and T-cell protein tyrosine phosphatase regulate IGF-2-induced MCF-7 cell migration.
Breast Neoplasms
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Breast Neoplasms
Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
Breast Neoplasms
Protein-tyrosine phosphatase H1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at Tyr537.
Breast Neoplasms
Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells.
Breast Neoplasms
Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors.
Breast Neoplasms
PTP LAR expression compared to prognostic indices in metastatic and non-metastatic breast cancer.
Breast Neoplasms
PTP1B expression is an independent positive prognostic factor in human breast cancer.
Breast Neoplasms
PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p.
Breast Neoplasms
PTP1B phosphatase as a novel target of oleuropein activity in MCF-7 breast cancer model.
Breast Neoplasms
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
Breast Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Breast Neoplasms
PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization.
Breast Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Breast Neoplasms
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Breast Neoplasms
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
Breast Neoplasms
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Breast Neoplasms
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
Breast Neoplasms
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
Breast Neoplasms
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
Breast Neoplasms
PTPRN2 and PLC?1 promote metastatic breast cancer cell migration through PI(4,5)P2-dependent actin remodeling.
Breast Neoplasms
PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
Breast Neoplasms
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Breast Neoplasms
PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.
Breast Neoplasms
Purification and characterization of a rat liver protein-tyrosine phosphatase with sequence similarity to src-homology region 2.
Breast Neoplasms
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Breast Neoplasms
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Breast Neoplasms
Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.
Breast Neoplasms
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Breast Neoplasms
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Breast Neoplasms
Role of intracellular Ca2+ in the epidermal growth factor induced inhibition of protein tyrosine phosphatase activity in a breast cancer cell line.
Breast Neoplasms
Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
Breast Neoplasms
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Breast Neoplasms
Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase.
Breast Neoplasms
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
Breast Neoplasms
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
Breast Neoplasms
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
Breast Neoplasms
Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells.
Breast Neoplasms
Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells.
Breast Neoplasms
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Breast Neoplasms
Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Breast Neoplasms
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
Breast Neoplasms
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
Breast Neoplasms
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2.
Breast Neoplasms
The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
Breast Neoplasms
The effect of treatment with 4-hydroxyandrostenedione or medroxyprogesterone acetate on human breast tumour regression.
Breast Neoplasms
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
Breast Neoplasms
The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14.
Breast Neoplasms
The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling.
Breast Neoplasms
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
Breast Neoplasms
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
Breast Neoplasms
The prognostic significance of protein tyrosine phosphatase 4A2 in breast cancer.
Breast Neoplasms
The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells.
Breast Neoplasms
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
Breast Neoplasms
The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer.
Breast Neoplasms
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.
Breast Neoplasms
The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Breast Neoplasms
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
Breast Neoplasms
Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
Breast Neoplasms
Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).
Breast Neoplasms
Tyrosine phosphatase PTP? contributes to HER2-evoked breast tumor initiation and maintenance.
Breast Neoplasms
Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
Breast Neoplasms
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Breast Neoplasms
Tyrosine phosphatase SHP2 regulates the expression of acyl-CoA synthetase ACSL4.
Breast Neoplasms
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression.
Breast Neoplasms
[Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].
Breast Neoplasms
[Corrigendum] Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Breast Neoplasms
[Inhibitory effect of SHP-1 gene transfer on the proliferation of breast cancer cell line MDA-MB-231]
Breast Neoplasms
[Retrovirus-mediated SHP-1 gene expression in human breast cancer MDA-MB-231 cells]
Bronchiolitis
Alveolar Macrophage Phenotype and Compartmentalization Drive Different Pulmonary Changes in Mouse Strains Exposed to Cigarette Smoke.
Bronchiolitis
Smoking p66Shc knocked out mice develop respiratory bronchiolitis with fibrosis but not emphysema.
Bronchitis
Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
Bronchitis, Chronic
[Elastase and acid phosphatase activity in bronchoalveolar lavage fluid during chronic bronchitis]
Bronchopulmonary Dysplasia
Developmental regulation of p66Shc is altered by bronchopulmonary dysplasia in baboons and humans.
Bronchopulmonary Dysplasia
Dual-specificity phosphatase (DUSP) genetic variants predict pulmonary hypertension in patients with bronchopulmonary dysplasia.
Brucellosis
A haplotype at intron 8 of PTPRT gene is associated with resistance to Brucella infection in Argentinian creole goats.
Burkitt Lymphoma
A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.
Burkitt Lymphoma
Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?
Burkitt Lymphoma
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Burkitt Lymphoma
Fcgamma receptor-mediated inhibition of human B cell activation: the role of SHP-2 phosphatase.
Burkitt Lymphoma
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
calpain-2 deficiency
Calpain 2 regulates Akt-FoxO-p27(Kip1) protein signaling pathway in mammary carcinoma.
Candidiasis
Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis.
Candidiasis
DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment.
Candidiasis, Chronic Mucocutaneous
Association of the lymphoid protein tyrosine phosphatase, R620W variant, with chronic mucocutaneous candidiasis.
Carcinogenesis
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
Carcinogenesis
?TrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit.
Carcinogenesis
A brake becomes an accelerator: PTP1B--a new therapeutic target for breast cancer.
Carcinogenesis
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Carcinogenesis
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
Carcinogenesis
A novel function of twins, B subunit of protein phosphatase 2A, in regulating actin polymerization.
Carcinogenesis
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
Carcinogenesis
A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression.
Carcinogenesis
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
Carcinogenesis
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Carcinogenesis
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Carcinogenesis
Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.
Carcinogenesis
Alteration of gene expression during radiation-induced resistance and tumorigenesis in NIH3T3 cells revealed by cDNA microarrays: involvement of MDM2 and CDC25B.
Carcinogenesis
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Carcinogenesis
Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.
Carcinogenesis
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
Carcinogenesis
Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.
Carcinogenesis
CDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell-cycle regulation.
Carcinogenesis
CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability.
Carcinogenesis
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Carcinogenesis
Cdc25A serine 123 phosphorylation couples centrosome duplication with DNA replication and regulates tumorigenesis.
Carcinogenesis
CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.
Carcinogenesis
Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase.
Carcinogenesis
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Carcinogenesis
Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines.
Carcinogenesis
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
Carcinogenesis
Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway.
Carcinogenesis
CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Carcinogenesis
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Carcinogenesis
Clinicopathological significance of PTPN12 expression in human breast cancer.
Carcinogenesis
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Carcinogenesis
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Carcinogenesis
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.
Carcinogenesis
Differential effects of peripheral and transitional prostatic stromal cells on tumorigenesis.
Carcinogenesis
Differential molecular signature alterations of RBSP3, LIMD1 and CDC25A in normal oral epithelium during oral tumorigenesis.
Carcinogenesis
Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.
Carcinogenesis
Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma.
Carcinogenesis
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Carcinogenesis
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Carcinogenesis
Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Carcinogenesis
Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis.
Carcinogenesis
DUSP4 inhibits autophagic cell death in PTC by inhibiting JNK-BCL2-Beclin1 signaling.
Carcinogenesis
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Carcinogenesis
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Carcinogenesis
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Carcinogenesis
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Carcinogenesis
Evaluation of licorice flavonoids as protein tyrosine phosphatase 1B inhibitors.
Carcinogenesis
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Carcinogenesis
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Carcinogenesis
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Carcinogenesis
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Carcinogenesis
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Carcinogenesis
Expression of protein tyrosine phosphatases and its significance in esophageal cancer.
Carcinogenesis
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Carcinogenesis
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Carcinogenesis
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Carcinogenesis
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Carcinogenesis
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Carcinogenesis
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Carcinogenesis
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Carcinogenesis
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Carcinogenesis
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Carcinogenesis
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Carcinogenesis
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Carcinogenesis
Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23.
Carcinogenesis
Ginkgetin Blocks Constitutive STAT3 Activation and Induces Apoptosis through Induction of SHP-1 and PTEN Tyrosine Phosphatases.
Carcinogenesis
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice.
Carcinogenesis
High-resolution crystal structure of the PDZ1 domain of human protein tyrosine phosphatase PTP-Bas.
Carcinogenesis
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Carcinogenesis
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Carcinogenesis
Host genetic factors respond to pathogenic step-specific virulence factors of Helicobacter pylori in gastric carcinogenesis.
Carcinogenesis
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Carcinogenesis
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Carcinogenesis
Identification of differentially expressed genes and functional annotations associated with metastases of the uveal melanoma.
Carcinogenesis
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Carcinogenesis
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Carcinogenesis
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Carcinogenesis
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Carcinogenesis
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Carcinogenesis
In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.
Carcinogenesis
Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.
Carcinogenesis
Increased expression and phosphorylation of sh-ptp2 (syp) in human gastric carcinomas.
Carcinogenesis
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Carcinogenesis
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Carcinogenesis
Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma.
Carcinogenesis
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
Carcinogenesis
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Carcinogenesis
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.
Carcinogenesis
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Carcinogenesis
Involvement of the protein tyrosine phosphatase PTP1C in cellular physiology, autoimmunity and oncogenesis.
Carcinogenesis
Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis.
Carcinogenesis
KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
Carcinogenesis
Kinetic characterization of bovine lung low-molecular-weight protein tyrosine phosphatase.
Carcinogenesis
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Carcinogenesis
LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.
Carcinogenesis
Loss of protein phosphatase 2A regulatory subunit B56? promotes spontaneous tumorigenesis in vivo.
Carcinogenesis
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Carcinogenesis
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Carcinogenesis
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
Carcinogenesis
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Carcinogenesis
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Carcinogenesis
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Carcinogenesis
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.
Carcinogenesis
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Carcinogenesis
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
Carcinogenesis
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.
Carcinogenesis
miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion.
Carcinogenesis
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
Carcinogenesis
miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.
Carcinogenesis
Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.
Carcinogenesis
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Carcinogenesis
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Carcinogenesis
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Carcinogenesis
Murine pancreatic ductal adenocarcinoma produced by in vitro transduction of polyoma middle T oncogene into the islets of Langerhans.
Carcinogenesis
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.
Carcinogenesis
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.
Carcinogenesis
Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Carcinogenesis
Overexpression of TC-PTP in murine epidermis attenuates skin tumor formation.
Carcinogenesis
p27(kip1) Upregulated by hnRNPC1/2 Antagonizes CagA (a Virulence Factor of Helicobacter pylori)-Mediated Pathogenesis.
Carcinogenesis
p38? Mitogen-activated Protein Kinase Signals through Phosphorylating Its Phosphatase PTPH1 in Regulating Ras Protein Oncogenesis and Stress Response.
Carcinogenesis
p63 regulates cell proliferation and cell cycle progression?associated genes in stromal cells of giant cell tumor of the bone.
Carcinogenesis
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Carcinogenesis
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.
Carcinogenesis
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Carcinogenesis
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
Carcinogenesis
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Carcinogenesis
Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis.
Carcinogenesis
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
Carcinogenesis
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Carcinogenesis
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
Carcinogenesis
PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo.
Carcinogenesis
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Carcinogenesis
Prevention of liver carcinogenesis by Amarogentin through modulation of G1/S cell cycle check point and induction of apoptosis.
Carcinogenesis
Primary Epithelioid Angiosarcoma of Finger Masquerading as Epithelioid Hemangioma: Report of a Case and Analysis of Mutational Pattern in Epithelioid Hemangiomas and Angiosarcomas by Next-generation Sequencing.
Carcinogenesis
Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.
Carcinogenesis
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Carcinogenesis
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Carcinogenesis
PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.
Carcinogenesis
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Carcinogenesis
Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibition of p53.
Carcinogenesis
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Carcinogenesis
Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.
Carcinogenesis
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Carcinogenesis
Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
Carcinogenesis
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Carcinogenesis
Protein tyrosine phosphatase Shp2 (Ptpn11) plays an important role in maintenance of chromosome stability.
Carcinogenesis
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Carcinogenesis
Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling.
Carcinogenesis
Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A.
Carcinogenesis
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
Carcinogenesis
PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction.
Carcinogenesis
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
Carcinogenesis
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
Carcinogenesis
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Carcinogenesis
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
Carcinogenesis
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
Carcinogenesis
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
Carcinogenesis
PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.
Carcinogenesis
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Carcinogenesis
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Carcinogenesis
Reciprocal allosteric regulation of p38? and PTPN3 involves a PDZ domain-modulated complex formation.
Carcinogenesis
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Carcinogenesis
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Carcinogenesis
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.
Carcinogenesis
SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis.
Carcinogenesis
Selective elimination of cancer cells by the adenovirus E4orf4 protein in a Drosophila cancer model: a new paradigm for cancer therapy.
Carcinogenesis
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Carcinogenesis
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Carcinogenesis
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Carcinogenesis
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Carcinogenesis
Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.
Carcinogenesis
Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.
Carcinogenesis
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Carcinogenesis
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Carcinogenesis
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Carcinogenesis
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Carcinogenesis
Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus.
Carcinogenesis
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Carcinogenesis
Structure and functions of His domain protein tyrosine phosphatase in receptor trafficking and cancer.
Carcinogenesis
Structure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme.
Carcinogenesis
Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
Carcinogenesis
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Carcinogenesis
Targeted disruption of TC-PTP in the proliferative compartment augments STAT3 and AKT signaling and skin tumor development.
Carcinogenesis
The 48-kDa alternative translation isoform of PP2A:B56epsilon is required for Wnt signaling during midbrain-hindbrain boundary formation.
Carcinogenesis
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
Carcinogenesis
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.
Carcinogenesis
The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity.
Carcinogenesis
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
Carcinogenesis
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Carcinogenesis
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
Carcinogenesis
The gene encoding human nuclear protein tyrosine phosphatase, PRL-1. Cloning, chromosomal localization, and identification of an intron enhancer.
Carcinogenesis
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
Carcinogenesis
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
Carcinogenesis
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
Carcinogenesis
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
Carcinogenesis
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
Carcinogenesis
The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis.
Carcinogenesis
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
Carcinogenesis
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
Carcinogenesis
The receptor-like protein tyrosine phosphatase alpha: a role in cell proliferation and oncogenesis.
Carcinogenesis
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review.
Carcinogenesis
The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.
Carcinogenesis
The role of T-cell protein tyrosine phosphatase in epithelial carcinogenesis.
Carcinogenesis
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
Carcinogenesis
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
Carcinogenesis
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Carcinogenesis
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Carcinogenesis
Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
Carcinogenesis
TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.
Carcinogenesis
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Carcinogenesis
Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells.
Carcinogenesis
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Carcinogenesis
Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.
Carcinogenesis
Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.
Carcinogenesis
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
Carcinogenesis
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Carcinogenesis
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Carcinogenesis
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
Carcinogenesis
[Corrigendum] Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
Carcinogenesis
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
Carcinogenesis
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Carcinogenesis
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
Carcinogenesis
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress].
Carcinogenesis
[Screening and identification of tumor related genes in early stages of transformed NIH3T3 cells associated with overexpressed PTPalpha]
Carcinoid Tumor
Transmembrane protein tyrosine phosphatase IA-2 (ICA512) is expressed in human midgut carcinoids but is not detectable in normal enterochromaffin cells.
Carcinoma
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
Carcinoma
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
Carcinoma
A simple immunohistochemical method for the detection of prostatic acid phosphatase.
Carcinoma
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Carcinoma
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Carcinoma
Accessibility to DNA in carcinoma chromatin is promoted by nanomolar okadaic acid: effect on AT-rich DNA binding proteins.
Carcinoma
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Carcinoma
Acid phosphatase in prostatic tissue homogenates from patients with benign prostatic hyperplasia and prostatic carcinoma.
Carcinoma
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Carcinoma
AlloDriver: a method for the identification and analysis of cancer driver targets.
Carcinoma
Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene.
Carcinoma
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
Carcinoma
An immunological model connecting the pathogenesis of stress, depression and carcinoma.
Carcinoma
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Carcinoma
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Carcinoma
Aqueous extracts of Fructus Ligustri Lucide induce gastric carcinoma cell apoptosis and G2/M cycle arrest.
Carcinoma
Association Between Methylation of SHP-1 Isoform I and SSTR2A Promoter Regions with Breast and Prostate Carcinoma Development.
Carcinoma
Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells.
Carcinoma
Association of human protein-tyrosine phosphatase kappa with members of the armadillo family.
Carcinoma
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Carcinoma
Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.
Carcinoma
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Carcinoma
Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells.
Carcinoma
Beta-catenin interacts with low-molecular-weight protein tyrosine phosphatase leading to cadherin-mediated cell-cell adhesion increase.
Carcinoma
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Carcinoma
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.
Carcinoma
c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.
Carcinoma
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Carcinoma
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
Carcinoma
Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
Carcinoma
Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers.
Carcinoma
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Carcinoma
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Carcinoma
Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR.
Carcinoma
Changes of enzyme activities recognized in lymphocytes from patients with carcinoma of the gastrointestinal tract.
Carcinoma
Chromosomal location of murine protein tyrosine phosphatase (Ptprj and Ptpre) genes.
Carcinoma
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Carcinoma
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Carcinoma
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Carcinoma
Comparative evaluation of serum acid phosphatase, urinary cholesterol, and androgens in diagnosis of prostatic cancer.
Carcinoma
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Carcinoma
Control of acid phosphatase activity in human prostatic carcinoma cell cultures by serum.
Carcinoma
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Carcinoma
Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Carcinoma
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Carcinoma
Decreased acid phosphatase activity in prostate secretion associated with prostatic carcinoma.
Carcinoma
Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.
Carcinoma
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
Carcinoma
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Carcinoma
Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification.
Carcinoma
Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma.
Carcinoma
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Carcinoma
Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles.
Carcinoma
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Carcinoma
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Carcinoma
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
Carcinoma
E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression.
Carcinoma
Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cells.
Carcinoma
Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo.
Carcinoma
Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression.
Carcinoma
Electron microscopic studies on the acid phosphatase activity in rats with transplantable Guerin epithelioma.
Carcinoma
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Carcinoma
Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts.
Carcinoma
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Carcinoma
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Carcinoma
Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Carcinoma
Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression.
Carcinoma
Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane.
Carcinoma
Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.
Carcinoma
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Carcinoma
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Carcinoma
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
Carcinoma
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Carcinoma
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Carcinoma
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.
Carcinoma
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Carcinoma
Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells.
Carcinoma
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Carcinoma
Expression of oxidized protein tyrosine phosphatase and ?H2AX predicts poor survival of gastric carcinoma patients.
Carcinoma
Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy.
Carcinoma
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Carcinoma
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Carcinoma
Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine.
Carcinoma
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Carcinoma
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Carcinoma
Expression of the receptor protein-tyrosine phosphatase, PTPmu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells.
Carcinoma
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
Carcinoma
Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis.
Carcinoma
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Carcinoma
Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence.
Carcinoma
FAP-1 and NF-?B expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.
Carcinoma
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
Carcinoma
Gallic acid induces G2/M phase cell cycle arrest via regulating 14-3-3beta release from Cdc25C and Chk2 activation in human bladder transitional carcinoma cells.
Carcinoma
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
Carcinoma
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Carcinoma
Helicobacter pylori VacA, acting through receptor protein tyrosine phosphatase ?, is crucial for CagA phosphorylation in human duodenum carcinoma cell line AZ-521.
Carcinoma
Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese.
Carcinoma
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
Carcinoma
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
Carcinoma
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Carcinoma
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.
Carcinoma
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
Carcinoma
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Carcinoma
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Carcinoma
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Carcinoma
Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
Carcinoma
Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases.
Carcinoma
Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer.
Carcinoma
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Carcinoma
Identification of Differentially Expressed Genes Involved in the Formation of Multicellular Tumor Spheroids by HT-29 Colon Carcinoma Cells.
Carcinoma
Identification of pivotal cellular factors involved in HPV-induced dysplastic and neoplastic cervical pathologies.
Carcinoma
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Carcinoma
Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.
Carcinoma
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Carcinoma
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Carcinoma
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Carcinoma
Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Carcinoma
Increased expression and phosphorylation of sh-ptp2 (syp) in human gastric carcinomas.
Carcinoma
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Carcinoma
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
Carcinoma
Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas.
Carcinoma
Increased prostate-type acid phosphatase activity in serum and typical bone lesions simulating the presence of prostatic carcinoma.
Carcinoma
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Carcinoma
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Carcinoma
Inhibition of T24 human bladder carcinoma cell migration by RNA interference suppressing the expression of HD-PTP.
Carcinoma
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Carcinoma
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Carcinoma
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Carcinoma
Label-Free Detection of Protein Tyrosine Phosphatase 1B (PTP1B) by Using a Rationally Designed Förster Resonance Energy Transfer (FRET) Probe.
Carcinoma
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
Carcinoma
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Carcinoma
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Carcinoma
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Carcinoma
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Carcinoma
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Carcinoma
Methylaervine as Potential Lead Compound against Cervical Carcinoma: Pharmacologic Mechanism Prediction based on Network Pharmacology.
Carcinoma
Methyllucidone inhibits STAT3 activity by regulating the expression of the protein tyrosine phosphatase MEG2 in DU145 prostate carcinoma cells.
Carcinoma
MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B.
Carcinoma
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Carcinoma
MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12.
Carcinoma
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
Carcinoma
MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B.
Carcinoma
MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma.
Carcinoma
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).
Carcinoma
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
Carcinoma
MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9.
Carcinoma
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Carcinoma
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Carcinoma
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
Carcinoma
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Carcinoma
Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.
Carcinoma
Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta.
Carcinoma
Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584.
Carcinoma
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Carcinoma
Neutrophil acid phosphatase activity in patients with gastric or rectum carcinoma during surgical treatment.
Carcinoma
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Carcinoma
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Carcinoma
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Carcinoma
Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.
Carcinoma
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Carcinoma
Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance.
Carcinoma
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Carcinoma
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
Carcinoma
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
Carcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Carcinoma
p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas.
Carcinoma
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Carcinoma
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Carcinoma
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Carcinoma
PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics.
Carcinoma
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Carcinoma
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Carcinoma
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Carcinoma
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Carcinoma
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Carcinoma
Phosphotyrosine Phosphatase Activity in Ovarian Carcinoma Cells : Stimulation by GnRH in Plasma Membrane.
Carcinoma
Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Carcinoma
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Carcinoma
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Carcinoma
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Carcinoma
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Carcinoma
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Carcinoma
Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells.
Carcinoma
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Carcinoma
Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
Carcinoma
Protein tyrosine phosphatase ? enhances proliferation by increasing ?-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Carcinoma
Protein tyrosine phosphatase alpha regulates cell detachment and cell death profiles induced by nitric oxide donors in the A431 human carcinoma cell line.
Carcinoma
Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses.
Carcinoma
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Carcinoma
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Carcinoma
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Carcinoma
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Carcinoma
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Carcinoma
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
Carcinoma
PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells.
Carcinoma
PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity.
Carcinoma
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
Carcinoma
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
Carcinoma
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
Carcinoma
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
Carcinoma
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Carcinoma
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Carcinoma
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
Carcinoma
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.
Carcinoma
Purification and characterization of a rat liver protein-tyrosine phosphatase with sequence similarity to src-homology region 2.
Carcinoma
Rapid (one-shot) staining method for two-color multiparametric DNA flow cytometric analysis of carcinomas using staining for cytokeratin and leukocyte common antigen.
Carcinoma
Rapid induction of p21WAF1 but delayed down-regulation of Cdc25A in the TGF-beta-induced cell cycle arrest of gastric carcinoma cells.
Carcinoma
Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
Carcinoma
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Carcinoma
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Carcinoma
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Carcinoma
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
Carcinoma
Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells.
Carcinoma
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
Carcinoma
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.
Carcinoma
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP? and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Carcinoma
Retinoic acid induced repression of AP-1 activity is mediated by protein phosphatase 2A in ovarian carcinoma cells.
Carcinoma
Retraction of: Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China; DOI: 10.1089/gtmb.2016.0194.
Carcinoma
Separation and characterization of epithelial cells from prostates and prostatic carcinomas: a review.
Carcinoma
Separation of cells with histochemically demonstrable acid phosphatase activity from suspensions of cells from human prostatic carcinomas in an isokinetic gradient of Ficoll in tissue culture medium.
Carcinoma
Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.
Carcinoma
Simultaneous flow cytometric deoxyribonucleic acid and acid phosphatase analysis of benign and malignant lesions of the prostate.
Carcinoma
Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China.
Carcinoma
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Carcinoma
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Carcinoma
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Carcinoma
Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.
Carcinoma
Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Carcinoma
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
Carcinoma
The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.
Carcinoma
The carboxyl-terminal tyrosine residue of protein-tyrosine phosphatase alpha mediates association with focal adhesion plaques.
Carcinoma
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Carcinoma
The Chalcone Flavokawain B Induces G(2)/M Cell-Cycle Arrest and Apoptosis in Human Oral Carcinoma HSC-3 Cells through the Intracellular ROS Generation and Downregulation of the Akt/p38 MAPK Signaling Pathway.
Carcinoma
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Carcinoma
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
Carcinoma
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
Carcinoma
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
Carcinoma
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Carcinoma
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Carcinoma
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Carcinoma
The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase.
Carcinoma
The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner.
Carcinoma
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Carcinoma
The tyrosine phosphatase, SHP-1, is involved in bronchial mucin production during oxidative stress.
Carcinoma
Theaflavins induce G2/M arrest by modulating expression of p21(waf1/cip1), cdc25C and cyclin B in human prostate carcinoma PC-3 cells.
Carcinoma
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Carcinoma
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Carcinoma
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Carcinoma
Tyrosine phosphorylation translocates beta-catenin from cell-->cell interface to the cytoplasm, but does not significantly enhance the LEF-1-dependent transactivating function.
Carcinoma
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Carcinoma
Tyrosyl kinase activity is inversely related to prostatic acid phosphatase activity in two human prostate carcinoma cell lines.
Carcinoma
Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase.
Carcinoma
[Change of acid phosphatase activity in granulocytes from patients with carcinomas of the gastrointestinal tract]
Carcinoma
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
Carcinoma
[Diurnal variation of the elevated acid phosphatase activity in cases of prostate carcinoma (author's transl)]
Carcinoma
[Electron microscopic studies on the acid phosphatase activity in rats with transplantable Guérin epithelioma]
Carcinoma
[ERK1/2 and p38 kinases are important regulators in P2Y receptor-mediated prostate cancer invasion]
Carcinoma
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Carcinoma
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Carcinoma
[Expression of tyrosine phosphatase containing C-src homology SH-2 in benign prostate hyperplasia]
Carcinoma
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]
Carcinoma
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]
Carcinoma
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
Carcinoma
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Carcinoma
[The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]
Carcinoma
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Adenoid Cystic
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Carcinoma, Adenosquamous
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Ductal
Clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast.
Carcinoma, Ductal
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Carcinoma, Ductal
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Carcinoma, Ductal
Prognostic Significance of Metastatic Lymph Nodes Ratio (MLNR) Combined with Protein-Tyrosine Phosphatase H1 (PTPH1) Expression in Operable Breast Invasive Ductal Carcinoma.
Carcinoma, Ehrlich Tumor
[Inhibition of pinocytosis and of acid phosphatase activity caused by lack of serum in the culture medium of Ehrlich ascites tumor cells (author's transl)]
Carcinoma, Embryonal
Characterization of a protein tyrosine phosphatase (RIP) expressed at a very early stage of differentiation in both mouse erythroleukemia and embryonal carcinoma cells.
Carcinoma, Embryonal
Differential expression of a novel murine non-receptor protein tyrosine phosphatase during differentiation of P19 embryonal carcinoma cells.
Carcinoma, Embryonal
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse embryonal carcinoma (F9) cells.
Carcinoma, Embryonal
Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation.
Carcinoma, Endometrioid
Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway.
Carcinoma, Hepatocellular
A bromopyrrole-containing diterpene alkaloid from the Okinawan marine sponge Agelas nakamurai activates the insulin pathway in Huh-7 human hepatoma cells by inhibiting protein tyrosine phosphatase 1B.
Carcinoma, Hepatocellular
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo.
Carcinoma, Hepatocellular
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Carcinoma, Hepatocellular
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
Carcinoma, Hepatocellular
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Carcinoma, Hepatocellular
Accomplices in Crime: The Diabolical Liaison between PTP1B and Ras in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Aggravated Liver Injury but Attenuated Inflammation in PTPRO-Deficient Mice Following LPS/D-GaIN Induced Fulminant Hepatitis.
Carcinoma, Hepatocellular
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Carcinoma, Hepatocellular
Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A.
Carcinoma, Hepatocellular
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.
Carcinoma, Hepatocellular
Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5.
Carcinoma, Hepatocellular
CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Carcinoma, Hepatocellular
Changes of expressions of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene.
Carcinoma, Hepatocellular
CIP2A Is Highly Expressed in Hepatocellular Carcinoma and Predicts Poor Prognosis.
Carcinoma, Hepatocellular
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Carcinoma, Hepatocellular
Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy.
Carcinoma, Hepatocellular
Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the ?-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.
Carcinoma, Hepatocellular
Development of a time-resolved fluorescent assay for measuring tyrosine-phosphorylated proteins in cells.
Carcinoma, Hepatocellular
Differential regulation of mRNAs encoding three protein-tyrosine phosphatases by insulin and activation of protein kinase C.
Carcinoma, Hepatocellular
Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice
Carcinoma, Hepatocellular
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Carcinoma, Hepatocellular
Dissociation of PTPase levels from their modulation of insulin receptor signal transduction.
Carcinoma, Hepatocellular
Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Carcinoma, Hepatocellular
Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Carcinoma, Hepatocellular
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Carcinoma, Hepatocellular
Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation.
Carcinoma, Hepatocellular
Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
Carcinoma, Hepatocellular
EGF-mediated migration signaling activated by N-acetylglucosaminyltransferase-V via receptor protein tyrosine phosphatase kappa.
Carcinoma, Hepatocellular
Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells.
Carcinoma, Hepatocellular
Enhancement of protein tyrosine phosphatase activity in the proliferation of cloned rat hepatoma H4-II-E cells: suppressive role of endogenous regucalcin.
Carcinoma, Hepatocellular
Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes.
Carcinoma, Hepatocellular
Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine?induced liver cancer via inhibition of cell division cycle 25A.
Carcinoma, Hepatocellular
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Carcinoma, Hepatocellular
Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes.
Carcinoma, Hepatocellular
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Carcinoma, Hepatocellular
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation.
Carcinoma, Hepatocellular
Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues.
Carcinoma, Hepatocellular
Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice.
Carcinoma, Hepatocellular
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Carcinoma, Hepatocellular
Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations.
Carcinoma, Hepatocellular
Gene expressions of protein tyrosine phosphatases in regenerating rat liver and rat ascites hepatoma cells.
Carcinoma, Hepatocellular
Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Carcinoma, Hepatocellular
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hepatitis B virus X protein mutant HBx?127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.
Carcinoma, Hepatocellular
Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
Carcinoma, Hepatocellular
Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Carcinoma, Hepatocellular
Hyperosmotic induction of the mitogen-activated protein kinase phosphatase MKP-1 in H4IIE rat hepatoma cells.
Carcinoma, Hepatocellular
Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.
Carcinoma, Hepatocellular
Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase.
Carcinoma, Hepatocellular
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Carcinoma, Hepatocellular
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Induction of an interferon-gamma Stat3 response in nerve cells by pre-treatment with gp130 cytokines.
Carcinoma, Hepatocellular
Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. Significance of protein tyrosine phosphatase inhibition.
Carcinoma, Hepatocellular
Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas.
Carcinoma, Hepatocellular
Inhibition of the transmembrane protein tyrosine phosphatase lar by 3S-peptide-I enhances insulin receptor phosphorylation in intact cells.
Carcinoma, Hepatocellular
Initiation and maintenance of CNTF-Jak/STAT signaling in neurons is blocked by protein tyrosine phosphatase inhibitors.
Carcinoma, Hepatocellular
Insulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation.
Carcinoma, Hepatocellular
Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells.
Carcinoma, Hepatocellular
Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR.
Carcinoma, Hepatocellular
Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains.
Carcinoma, Hepatocellular
Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade.
Carcinoma, Hepatocellular
Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Carcinoma, Hepatocellular
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in Sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Carcinoma, Hepatocellular
Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
Carcinoma, Hepatocellular
IRE1? links Nck1 deficiency to attenuated PTP1B expression in HepG2 cells.
Carcinoma, Hepatocellular
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Carcinoma, Hepatocellular
Leptin increases hepatic insulin sensitivity and protein tyrosine phosphatase 1B expression.
Carcinoma, Hepatocellular
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment.
Carcinoma, Hepatocellular
Localization of acid phosphatase activity in well-differentiated hepatocellular carcinoma 146.
Carcinoma, Hepatocellular
Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
Carcinoma, Hepatocellular
Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice.
Carcinoma, Hepatocellular
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Carcinoma, Hepatocellular
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
Carcinoma, Hepatocellular
MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
miR-186 Inhibits Liver Cancer Stem Cells Expansion via Targeting PTPN11.
Carcinoma, Hepatocellular
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
Carcinoma, Hepatocellular
miR-206 inhibits cell proliferation, invasion, and migration by down-regulating PTP1B in hepatocellular carcinoma.
Carcinoma, Hepatocellular
miR-532-3p promotes hepatocellular carcinoma progression by targeting PTPRT.
Carcinoma, Hepatocellular
miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.
Carcinoma, Hepatocellular
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
Carcinoma, Hepatocellular
MiR-675 Promotes the Growth of Hepatocellular Carcinoma Cells Through the Cdc25A Pathway.
Carcinoma, Hepatocellular
Mutational analysis of PTPRT phosphatase domains in common human cancers.
Carcinoma, Hepatocellular
NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A.
Carcinoma, Hepatocellular
Okadaic acid promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting protein phosphatase 2A.
Carcinoma, Hepatocellular
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Osmotic loading of neutralizing antibodies demonstrates a role for protein-tyrosine phosphatase 1B in negative regulation of the insulin action pathway.
Carcinoma, Hepatocellular
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells.
Carcinoma, Hepatocellular
Osmotic regulation of MAP-kinase activities and gene expression in H4IIE rat hepatoma cells.
Carcinoma, Hepatocellular
Osmotic regulation of MG-132-induced MAP-kinase phosphatase MKP-1 expression in H4IIE rat hepatoma cells.
Carcinoma, Hepatocellular
Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells.
Carcinoma, Hepatocellular
Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.
Carcinoma, Hepatocellular
Overexpression of regucalcin suppresses cell death and apoptosis in cloned rat hepatoma H4-II-E cells induced by insulin or insulin-like growth factor-I.
Carcinoma, Hepatocellular
p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.
Carcinoma, Hepatocellular
Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes.
Carcinoma, Hepatocellular
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
Carcinoma, Hepatocellular
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth.
Carcinoma, Hepatocellular
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
Carcinoma, Hepatocellular
Protein phosphatase 2A activation mechanism contributes to JS-K induced caspase-dependent apoptosis in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Carcinoma, Hepatocellular
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase receptor type D (PTPRD)-mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review.
Carcinoma, Hepatocellular
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Carcinoma, Hepatocellular
Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition.
Carcinoma, Hepatocellular
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Carcinoma, Hepatocellular
PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
Carcinoma, Hepatocellular
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.
Carcinoma, Hepatocellular
Reduction of PTP1B by RNAi upregulates the activity of insulin controlled fatty acid synthase promoter.
Carcinoma, Hepatocellular
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Rock2 regulates Cdc25A through ubiquitin proteasome system in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Role of endogenous regucalcin in protein tyrosine phosphatase regulation in the cloned rat hepatoma cells (H4-II-E).
Carcinoma, Hepatocellular
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Carcinoma, Hepatocellular
Selective inhibition of protein tyrosine phosphatase activities by H2O2 and vanadate in vitro.
Carcinoma, Hepatocellular
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
Carcinoma, Hepatocellular
SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.
Carcinoma, Hepatocellular
SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.
Carcinoma, Hepatocellular
Suppression of insulin receptor activation by overexpression of the protein-tyrosine phosphatase LAR in hepatoma cells.
Carcinoma, Hepatocellular
Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO.
Carcinoma, Hepatocellular
Suppression of the protein tyrosine phosphatase LAR reduces apolipoprotein B secretion by McA-RH7777 rat hepatoma cells.
Carcinoma, Hepatocellular
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
Carcinoma, Hepatocellular
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Carcinoma, Hepatocellular
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
Carcinoma, Hepatocellular
TGF-?1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.
Carcinoma, Hepatocellular
The characteristic gene expressions of MAPK phosphatases 1 and 2 in hepatocarcinogenesis, rat ascites hepatoma cells, and regenerating rat liver.
Carcinoma, Hepatocellular
The effect of receptor protein tyrosine phosphatase kappa on the change of cell adhesion and proliferation induced by N-acetylglucosaminyltransferase V.
Carcinoma, Hepatocellular
The HNF1?-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
Carcinoma, Hepatocellular
The MAP kinase phosphatase-1 MKP-1/DUSP1 is a regulator of human liver response to transplantation.
Carcinoma, Hepatocellular
The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes.
Carcinoma, Hepatocellular
The protein tyrosine phosphatase LAR has a major impact on insulin receptor dephosphorylation.
Carcinoma, Hepatocellular
The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling.
Carcinoma, Hepatocellular
The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases.
Carcinoma, Hepatocellular
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Transient and sustained ERK phosphorylation and nuclear translocation in growth control.
Carcinoma, Hepatocellular
TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Carcinoma, Hepatocellular
Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Carcinoma, Hepatocellular
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Vanadate inhibits transcription of the rat insulin receptor gene via a proximal sequence of the 5'flanking region.
Carcinoma, Hepatocellular
Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice.
Carcinoma, Hepatocellular
Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo.
Carcinoma, Hepatocellular
[Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway]
Carcinoma, Hepatocellular
[Effect of PTPRD rs2279776 gene and interaction with hepatitis B virus mutations on the risk of hepatocellular carcinoma].
Carcinoma, Hepatocellular
[Effect of ultraviolet radiation on lysosomal acid phosphatase activity Zajdela ascitic hepatoma]
Carcinoma, Hepatocellular
[Gene therapy using a dominant negative form of the protein phosphatase 2A catalytic subunit a driven by a hepatoma tissue-specific promoter achieves effective growth inhibition of hepatoma cells].
Carcinoma, Hepatocellular
[Mechanism of regulation of hepatoma cell cycle by XPD/P44 subcomplex : an in vitro experiment]
Carcinoma, Hepatocellular
[The distribution of acid phosphatase activity in the ultrastructures of liver cells during the development of induced hepatoma]
Carcinoma, Intraductal, Noninfiltrating
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Carcinoma, Lewis Lung
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Carcinoma, Lewis Lung
Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Carcinoma, Mucoepidermoid
Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
Carcinoma, Non-Small-Cell Lung
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Carcinoma, Non-Small-Cell Lung
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Carcinoma, Non-Small-Cell Lung
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Carcinoma, Non-Small-Cell Lung
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Carcinoma, Non-Small-Cell Lung
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Carcinoma, Non-Small-Cell Lung
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Carcinoma, Non-Small-Cell Lung
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.
Carcinoma, Non-Small-Cell Lung
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Carcinoma, Non-Small-Cell Lung
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Carcinoma, Non-Small-Cell Lung
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Carcinoma, Non-Small-Cell Lung
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
Carcinoma, Non-Small-Cell Lung
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Carcinoma, Non-Small-Cell Lung
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
Carcinoma, Non-Small-Cell Lung
MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.
Carcinoma, Non-Small-Cell Lung
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
Carcinoma, Non-Small-Cell Lung
MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A.
Carcinoma, Non-Small-Cell Lung
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Carcinoma, Non-Small-Cell Lung
Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Carcinoma, Non-Small-Cell Lung
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Carcinoma, Non-Small-Cell Lung
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
Carcinoma, Non-Small-Cell Lung
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Carcinoma, Non-Small-Cell Lung
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Carcinoma, Non-Small-Cell Lung
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Carcinoma, Non-Small-Cell Lung
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
Carcinoma, Non-Small-Cell Lung
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Carcinoma, Non-Small-Cell Lung
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Carcinoma, Non-Small-Cell Lung
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
Carcinoma, Non-Small-Cell Lung
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Carcinoma, Non-Small-Cell Lung
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Carcinoma, Non-Small-Cell Lung
[Expressions and significances of PRL-3 and RhoC in A549 cell].
Carcinoma, Ovarian Epithelial
Dual specificity phosphatase 6 as a new therapeutic target candidate for epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
PTN signaling: Components and mechanistic insights in human ovarian cancer.
Carcinoma, Ovarian Epithelial
[Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays]
Carcinoma, Papillary
Induction of thyroid neoplasms in the rat. A histochemical, immunohistochemical, autoradiographic and ultrastructural study.
Carcinoma, Renal Cell
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
Carcinoma, Renal Cell
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Carcinoma, Renal Cell
Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma.
Carcinoma, Renal Cell
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features.
Carcinoma, Renal Cell
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Carcinoma, Renal Cell
Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas.
Carcinoma, Renal Cell
MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B.
Carcinoma, Renal Cell
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
Carcinoma, Renal Cell
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Carcinoma, Renal Cell
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Carcinoma, Renal Cell
Polymorphism in protein tyrosine phosphatase receptor delta is associated with the risk of clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Progress in the correlation between PTPN12 gene expression and human tumors.
Carcinoma, Renal Cell
Protein tyrosine phosphatase ? enhances proliferation by increasing ?-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
Carcinoma, Renal Cell
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Carcinoma, Renal Cell
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Carcinoma, Renal Cell
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Carcinoma, Renal Cell
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Carcinoma, Renal Cell
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTP? and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Carcinoma, Renal Cell
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Carcinoma, Renal Cell
Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation.
Carcinoma, Renal Cell
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
A combined electron-microscope and cytochemical study of acid phosphatase activity in human cervical squamous carcinoma.
Carcinoma, Squamous Cell
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Carcinoma, Squamous Cell
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Carcinoma, Squamous Cell
AlloDriver: a method for the identification and analysis of cancer driver targets.
Carcinoma, Squamous Cell
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
Carcinoma, Squamous Cell
An additional transcript of the cdc25C gene from A431 cells encodes a functional protein.
Carcinoma, Squamous Cell
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Carcinoma, Squamous Cell
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Carcinoma, Squamous Cell
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Carcinoma, Squamous Cell
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Carcinoma, Squamous Cell
Downregulation of cell division cycle 25 homolog C reduces the radiosensitivity and proliferation activity of esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese.
Carcinoma, Squamous Cell
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity.
Carcinoma, Squamous Cell
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy.
Carcinoma, Squamous Cell
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Carcinoma, Squamous Cell
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
Carcinoma, Squamous Cell
High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma.
Carcinoma, Squamous Cell
Imbalanced expression of mitogen-activated protein kinase phosphatase-1 and phosphorylated extracellular signal-regulated kinases in lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Carcinoma, Squamous Cell
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Carcinoma, Squamous Cell
LncRNA HULC promotes lung squamous cell carcinoma by regulating PTPRO via NF-?B.
Carcinoma, Squamous Cell
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Carcinoma, Squamous Cell
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Carcinoma, Squamous Cell
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Carcinoma, Squamous Cell
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Carcinoma, Squamous Cell
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Carcinoma, Squamous Cell
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Carcinoma, Squamous Cell
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
Carcinoma, Squamous Cell
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Carcinoma, Squamous Cell
Partial purification and characterization of phosphotyrosyl-protein phosphatase from Ehrlich ascites tumor cells.
Carcinoma, Squamous Cell
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Carcinoma, Squamous Cell
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Carcinoma, Squamous Cell
Protein-tyrosine phosphatase alpha regulates Src family kinases and alters cell-substratum adhesion.
Carcinoma, Squamous Cell
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
Carcinoma, Squamous Cell
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
Carcinoma, Squamous Cell
Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor.
Carcinoma, Squamous Cell
Significance of PTPRZ1 and CIN85 expression in cervical carcinoma.
Carcinoma, Squamous Cell
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Carcinoma, Squamous Cell
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
Carcinoma, Squamous Cell
The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
Carcinoma, Squamous Cell
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Carcinoma, Squamous Cell
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Carcinoma, Squamous Cell
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Carcinoma, Transitional Cell
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
Carcinosarcoma
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Cardiomegaly
Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.
Cardiomegaly
Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes.
Cardiomegaly
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Cardiomegaly
Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.
Cardiomegaly
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Cardiomegaly
Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Cardiomegaly
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Cardiomegaly
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice.
Cardiomegaly
Growing old, angiotensin II, cardiac hypertrophy, and death: making the connection with p66Shc.
Cardiomegaly
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Cardiomegaly
Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy.
Cardiomegaly
Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes.
Cardiomegaly
mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
Cardiomyopathies
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.
Cardiomyopathies
Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway.
Cardiomyopathies
Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.
Cardiomyopathies
Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation.
Cardiomyopathies
Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival.
Cardiomyopathies
Intravenous Gene Therapy With Pim-1 Via a Cardiotropic Viral Vector Halts the Progression of Diabetic Cardiomyopathy Through Promotion of Prosurvival Signaling.
Cardiomyopathies
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Cardiomyopathies
Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome.
Cardiomyopathies
Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
Cardiomyopathies
Noonan Syndrome Case Report: PTPN11 and Other Potential Genetic Factors Contributing to Lethal Hypertrophic Right Ventricular Cardiomyopathy.
Cardiomyopathies
Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling.
Cardiomyopathy, Dilated
Centrosome-associated CDC25B is a novel disease-causing gene for a syndrome with cataracts, dilated cardiomyopathy, and multiple endocrinopathies.
Cardiomyopathy, Dilated
Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Cardiomyopathy, Dilated
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Cardiomyopathy, Dilated
Dilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A.
Cardiomyopathy, Dilated
No association between transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77C>G) and idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity.
Cardiomyopathy, Hypertrophic
A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.
Cardiomyopathy, Hypertrophic
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
Cardiomyopathy, Hypertrophic
A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.
Cardiomyopathy, Hypertrophic
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Cardiomyopathy, Hypertrophic
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Cardiomyopathy, Hypertrophic
Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Cardiomyopathy, Hypertrophic
Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
Cardiomyopathy, Hypertrophic
Genotype-phenotype correlation analysis in Japanese patients with Noonan syndrome.
Cardiomyopathy, Hypertrophic
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Cardiomyopathy, Hypertrophic
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Cardiomyopathy, Hypertrophic
LEOPARD Syndrome Caused by Tyr279Cys Mutation in the PTPN11 Gene.
Cardiomyopathy, Hypertrophic
LEOPARD syndrome in an infant with severe hypertrophic cardiomyopathy and PTPN11 mutation.
Cardiomyopathy, Hypertrophic
Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy.
Cardiomyopathy, Hypertrophic
New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Cardiomyopathy, Hypertrophic
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
Cardiomyopathy, Hypertrophic
PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Cardiomyopathy, Hypertrophic
PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link?
Cardiomyopathy, Hypertrophic
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".
Cardiomyopathy, Hypertrophic
PTPN11 Mutation Associated with Aortic Dilation and Hypertrophic Cardiomyopathy in a Pediatric Patient with Noonan Syndrome.
Cardiomyopathy, Hypertrophic
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Cardiomyopathy, Hypertrophic
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
Cardiomyopathy, Hypertrophic
PTPN11 mutations play a minor role in isolated congenital heart disease.
Cardiomyopathy, Hypertrophic
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
Cardiomyopathy, Hypertrophic
RAS signaling pathway mutations and hypertrophic cardiomyopathy: getting into and out of the thick of it.
Cardiomyopathy, Hypertrophic
Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.
Cardiomyopathy, Hypertrophic
The PTPN11 gene is not implicated in nonsyndromic hypertrophic cardiomyopathy.
Cardiomyopathy, Hypertrophic
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Cardiomyopathy, Hypertrophic
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
Cardiotoxicity
Calpain-2 promotes MKP-1 expression protecting cardiomyocytes in both in vitro and in vivo mouse models of doxorubicin-induced cardiotoxicity.
Cardiotoxicity
Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein.
Cardiovascular Diseases
Acid phosphatase, genetic polymorphism and cardiovascular risk factors in a pediatric population.
Cardiovascular Diseases
Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm.
Cardiovascular Diseases
Angiotensin (1-7) Inhibits Ang II-mediated ERK1/2 Activation by Stimulating MKP-1 Activation in Vascular Smooth Muscle Cells.
Cardiovascular Diseases
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.
Cardiovascular Diseases
Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation.
Cardiovascular Diseases
Coronary Artery Disease: Evidence of Interaction between PTPN22 and p53 Genetic Polymorphisms.
Cardiovascular Diseases
DNA methylation of the p66Shc promoter is decreased in placental tissue from women delivering intrauterine growth restricted neonates.
Cardiovascular Diseases
Dual role of endothelial nitric oxide synthase in oxidized LDL-induced, p66Shc-mediated oxidative stress in cultured human endothelial cells.
Cardiovascular Diseases
Effect of genetic factors on the association between coronary artery disease and PTPN22 polymorphism.
Cardiovascular Diseases
Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein.
Cardiovascular Diseases
Linking protein to phenotype with Mendelian Randomization detects 38 proteins with causal roles in human diseases and traits.
Cardiovascular Diseases
Mitogen-activated protein kinase phosphatase 1 (MKP-1) in macrophage biology and cardiovascular disease. A redox-regulated master controller of monocyte function and macrophage phenotype.
Cardiovascular Diseases
Mitogen-activated protein kinase phosphatase-1: A critical phosphatase manipulating mitogen-activated protein kinase signaling in cardiovascular disease (Review).
Cardiovascular Diseases
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
Cardiovascular Diseases
Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells.
Cardiovascular Diseases
Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C.
Cardiovascular Diseases
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Cardiovascular Diseases
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Cardiovascular Diseases
Recent advance on PTP1B inhibitors and their biomedical applications.
Cardiovascular Diseases
Role of protein tyrosine phosphatase 1B in cardiovascular diseases.
Cardiovascular Diseases
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
Cardiovascular Diseases
Structure-functional implications of longevity protein p66Shc in health and disease.
Cardiovascular Diseases
The role of p66Shc deletion in age-associated arterial dysfunction and disease states.
Cardiovascular Diseases
The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance.
Carotid Artery Injuries
Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors.
Cataract
Centrosome-associated CDC25B is a novel disease-causing gene for a syndrome with cataracts, dilated cardiomyopathy, and multiple endocrinopathies.
Cataract
Expanding the clinical spectrum of ocular anomalies in Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation.
Cataract
Identification and functional clustering of global gene expression differences between human age-related cataract and clear lenses.
Cataract
Ultrastructural cytochemistry: effect of Sorbinil on arylsulfatases in cataractous lenses.
Celiac Disease
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease.
Celiac Disease
An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.
Celiac Disease
Association of PTPN22 rs2476601 Polymorphism with Rheumatoid Arthritis and Celiac Disease in Khuzestan Province, Southwestern Iran.
Celiac Disease
C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition.
Celiac Disease
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Celiac Disease
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Celiac Disease
Environmental factors related to the induction of beta-cell autoantibodies in 1-yr-old healthy children.
Celiac Disease
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Celiac Disease
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
Celiac Disease
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Cell Transformation, Neoplastic
Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1).
Central Nervous System Diseases
The control of oligodendrocyte bioenergetics by interferon-gamma (IFN-?) and Src homology region 2 domain-containing phosphatase-1 (SHP-1).
Cerebellar Ataxia
Chromosomal localization of an SH2 containing tyrosine phosphatase (SH-PTP3) gene to chromosome 12q24.1.
Cerebellar Ataxia
PTPRR Protein Tyrosine Phosphatase Isoforms and Locomotion of Vesicles and Mice.
Cerebral Hemorrhage
A cannabinoid receptor 2 agonist reduces blood-brain barrier damage via induction of MKP-1 after intracerebral hemorrhage in rats.
Cerebral Hemorrhage
Dauricine alleviated secondary brain injury after intracerebral hemorrhage by upregulating GPX4 expression and inhibiting ferroptosis of nerve cells.
Cerebral Hemorrhage
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Cerebral Hemorrhage
Tristetraprolin attenuates brain edema in a rat model of cerebral hemorrhage.
Cerebral Infarction
Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation.
Cerebral Infarction
PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion.
Cervical Intraepithelial Neoplasia
Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.
Cervical Intraepithelial Neoplasia
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Chagas Disease
Association study of PTPN22 C1858T polymorphism in Trypanosoma cruzi infection.
Chagas Disease
Biochemical characterization of a protein tyrosine phosphatase from Trypanosoma cruzi involved in metacyclogenesis and cell invasion.
Chagas Disease
Structure of the Trypanosoma cruzi protein tyrosine phosphatase TcPTP1, a potential therapeutic target for Chagas' disease.
Chemical and Drug Induced Liver Injury
A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
Chemical and Drug Induced Liver Injury
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Cholangiocarcinoma
Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients.
Cholangiocarcinoma
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Cholangiocarcinoma
Increased expression of CIP2A in cholangiocarcinoma and correlation with poor prognosis.
Cholangiocarcinoma
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
Cholangiocarcinoma
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Cholangiocarcinoma
PTPN3 acts as a tumor suppressor and boosts TGF-? signaling independent of its phosphatase activity.
Cholangiocarcinoma
PTPN3 mutations and HBV may exert synergistic effects in the origin of the intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
The effect of internal biliary drainage on bile pigment accumulation and acid phosphatase activity in human liver during obstructive jaundice.
Cholangiocarcinoma
The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma.
Cholangitis
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Cholangitis, Sclerosing
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Cholangitis, Sclerosing
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
Cholera
Atomic resolution crystal structure of VcLMWPTP-1 from Vibrio cholerae O395: insights into a novel mode of dimerization in the low molecular weight protein tyrosine phosphatase family.
Cholera
Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages.
Cholesteatoma
Alkaline and acid phosphatase activity in postauricular skin and cholesteatoma epithelium.
Cholesteatoma
[Expression and significance of PTEN, P-ERK and P-AKT in the middle ear cholesteatoma].
Cholesteatoma, Middle Ear
[Expression and significance of PTEN, P-ERK and P-AKT in the middle ear cholesteatoma].
Choline Deficiency
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Chondroma
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Chondroma
Intraosseous atypical chondroid tumor or chondrosarcoma grade 1 in patients with multiple osteochondromas.
Chondroma
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Chondroma
SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.
Chondrosarcoma
miRNA-497 Negatively Regulates the Growth and Motility of Chondrosarcoma Cells by Targeting Cdc25A.
Chordoma
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Choriocarcinoma
Dampening of IFN-gamma-inducible gene expression in human choriocarcinoma cells is due to phosphatase-mediated inhibition of the JAK/STAT-1 pathway.
Choriocarcinoma
The protein-tyrosine phosphatase, SRC homology-2 domain containing protein tyrosine phosphatase-2, is a crucial mediator of exogenous insulin-like growth factor signaling to human trophoblast.
Choriocarcinoma
Vanadate regulates the insulin mitogenic effect by modulating SHP-2 association with insulin receptor substrate 1 in JAr human choriocarcinoma cells.
Choroid Plexus Neoplasms
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity.
Choroid Plexus Neoplasms
Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors.
Chronic Kidney Disease-Mineral and Bone Disorder
Nature of mononuclear cells positive for acid phosphatase activity in bone marrow of patients with renal osteodystrophy.
Chronic Urticaria
Association Between PTPN22 Polymorphisms and IgE Responses to Staphylococcal Superantigens in Chronic Urticaria.
Chronic Urticaria
Association of PTPN22 single nucleotide polymorphisms with chronic spontaneous urticaria.
Cleft Palate
Inactivation of LAR family phosphatase genes Ptprs and Ptprf causes craniofacial malformations resembling Pierre-Robin sequence.
Cleft Palate
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Coinfection
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Coinfection
Evaluation of Primitive Murine Hematopoietic Stem and Progenitor Cell Transduction In Vitro and In Vivo by Recombinant Adeno-Associated Virus Vector Serotypes 1 Through 5.
Coinfection
Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5.
Coinfection
Expression of Toll-like receptor signaling-related genes in pigs co-infected with porcine reproductive and respiratory syndrome virus and porcine circovirus type 2.
Coinfection
Mitogen Activated Protein Kinase Phosphatase 2, MKP-2, regulates the Inflammatory Response in Sepsis.
Coinfection
Signal transduction-mediated adherence and entry of Helicobacter pylori into cultured cells.
Coinfection
Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction.
Colitis
Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis.
Colitis
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Colitis
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Colitis
Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.
Colitis
Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice.
Colitis
Genetic analysis of the Trichuris muris-induced model of colitis reveals QTL overlap and a novel gene cluster for establishing colonic inflammation: Trichuris muris-induced colitis genetic study.
Colitis
Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis.
Colitis
Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats.
Colitis
Increased expression of midkine in the rat colon during healing of experimental colitis.
Colitis
Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse.
Colitis
Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.
Colitis
Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.
Colitis
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia.
Colitis
Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis.
Colitis
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Colitis
Network pharmacology-based identification of the protective mechanisms of taraxasterol in experimental colitis.
Colitis
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Colitis
Nitric Oxide Is Involved in Activation of Toll-Like Receptor 4 Signaling through Tyrosine Nitration of Src Homology Protein Tyrosine Phosphatase 2 in Murine Dextran Sulfate-Induced Colitis.
Colitis
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
Colitis
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
Colitis
Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner.
Colitis
Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic Cells.
Colitis
Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium.
Colitis
PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis.
Colitis
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Colitis
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
Colitis
Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.
Colitis
Selective Sequestration of STAT1 in the Cytoplasm via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis.
Colitis
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Colitis
SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis.
Colitis
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
Colitis
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
Colitis
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Colitis
Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene Ptpn2 in Myeloid Cells.
Colitis
[Free Radical Production and Production Mechanism in the Early and Advanced Stages of Gastrointestinal Lesions].
Colitis
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Colitis, Ulcerative
Apical junction complex proteins and ulcerative colitis: a focus on the PTPRS gene.
Colitis, Ulcerative
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Colitis, Ulcerative
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Colitis, Ulcerative
Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.
Colitis, Ulcerative
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Colitis, Ulcerative
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.
Colitis, Ulcerative
Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis.
Colitis, Ulcerative
Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice.
Colitis, Ulcerative
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Colitis, Ulcerative
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Colitis, Ulcerative
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Colitis, Ulcerative
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Colitis, Ulcerative
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
Colitis, Ulcerative
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Colitis, Ulcerative
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Colitis, Ulcerative
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Colitis, Ulcerative
Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population.
Colitis, Ulcerative
Protein-tyrosine phosphatase sigma is associated with ulcerative colitis.
Colitis, Ulcerative
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
Colitis, Ulcerative
PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3.
Colitis, Ulcerative
PTPRO exaggerates inflammation in ulcerative colitis through TLR4/NF-?B pathway.
Colitis, Ulcerative
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
Colitis, Ulcerative
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
Colitis, Ulcerative
SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis.
Colitis, Ulcerative
Single Nucleotide Polymorphisms of PTPN22 Gene in Iranian Patients with Ulcerative Colitis.
Colitis, Ulcerative
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
Colitis, Ulcerative
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Colitis, Ulcerative
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Colitis-Associated Neoplasms
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Colitis-Associated Neoplasms
The tyrosine phosphatase Shp-2 confers resistance to colonic inflammation by driving goblet cell function and crypt regeneration.
Colonic Neoplasms
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
Colonic Neoplasms
5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells.
Colonic Neoplasms
A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism.
Colonic Neoplasms
Activation of PERK Contributes to Apoptosis and G2/M Arrest by Microtubule Disruptors in Human Colorectal Carcinoma Cells .
Colonic Neoplasms
Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation.
Colonic Neoplasms
Can dehydroepiandrostenedione (DHEA) target PRL-3 to prevent colon cancer metastasis?
Colonic Neoplasms
Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3? pathway in colon cancer.
Colonic Neoplasms
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
Colonic Neoplasms
Combined Phenotype of 4 Markers Improves Prognostic Value of Patients With Colon Cancer.
Colonic Neoplasms
Comparative quantitation of aberrant glycoforms by lectin-based glycoprotein enrichment coupled with multiple-reaction monitoring mass spectrometry.
Colonic Neoplasms
Cordyceps militaris Grown on Germinated Soybean Induces G2/M Cell Cycle Arrest through Downregulation of Cyclin B1 and Cdc25c in Human Colon Cancer HT-29 Cells.
Colonic Neoplasms
Cytokine associated sensitivity of colon carcinoma cells to FasR-mediated cytotoxicity of CTL.
Colonic Neoplasms
Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins.
Colonic Neoplasms
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Colonic Neoplasms
Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells.
Colonic Neoplasms
DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells.
Colonic Neoplasms
Down-regulation of Cdc25c, CDK1 and Cyclin B1 and Up-regulation of Wee1 by Curcumin Promotes Human Colon Cancer Colo 205 Cell Entry into G2/M-phase of Cell Cycle.
Colonic Neoplasms
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Colonic Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Colonic Neoplasms
Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Colonic Neoplasms
Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3.
Colonic Neoplasms
Fas-associated phosphatase-1 promotes Fas-mediated apoptosis in human colon cancer cells: novel function of FAP-1.
Colonic Neoplasms
Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5.
Colonic Neoplasms
Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD.
Colonic Neoplasms
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Colonic Neoplasms
HOXD13 promotes the malignant progression of colon cancer by upregulating PTPRN2.
Colonic Neoplasms
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
Colonic Neoplasms
Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration.
Colonic Neoplasms
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Colonic Neoplasms
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Colonic Neoplasms
Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin.
Colonic Neoplasms
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Colonic Neoplasms
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Colonic Neoplasms
Interleukin-2 enhances susceptibility of colon cancer cells to FasR mediated apoptosis by up-regulating Fas receptor level and down-regulating FAP-1 expression.
Colonic Neoplasms
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
Colonic Neoplasms
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Colonic Neoplasms
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Colonic Neoplasms
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase.
Colonic Neoplasms
microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells.
Colonic Neoplasms
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
Colonic Neoplasms
Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.
Colonic Neoplasms
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Colonic Neoplasms
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Colonic Neoplasms
Mutational analysis of PTPRT phosphatase domains in common human cancers.
Colonic Neoplasms
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Colonic Neoplasms
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
Colonic Neoplasms
NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway.
Colonic Neoplasms
Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.
Colonic Neoplasms
Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells.
Colonic Neoplasms
Preferential requirement for protein tyrosine phosphatase activity in the 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of human colon cancer cells.
Colonic Neoplasms
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
Colonic Neoplasms
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Colonic Neoplasms
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.
Colonic Neoplasms
Protein phosphatase 2A is essential to maintain active Wnt signaling and its A? tumor suppressor subunit is not expressed in colon cancer cells.
Colonic Neoplasms
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Colonic Neoplasms
PTP-PEST controls motility, adherens junction assembly, and Rho GTPase activity in colon cancer cells.
Colonic Neoplasms
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
Colonic Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Colonic Neoplasms
PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ-mediated interaction.
Colonic Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Colonic Neoplasms
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Colonic Neoplasms
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
Colonic Neoplasms
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Colonic Neoplasms
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
Colonic Neoplasms
PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
Colonic Neoplasms
pTyr(421) Cortactin Is Overexpressed in Colon Cancer and Is Dephosphorylated by Curcumin: Involvement of Non-Receptor Type 1 Protein Tyrosine Phosphatase (PTPN1).
Colonic Neoplasms
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Colonic Neoplasms
Receptor-type protein tyrosine phosphatase ? directly dephosphorylates CD133 and regulates downstream AKT activation.
Colonic Neoplasms
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Colonic Neoplasms
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
Colonic Neoplasms
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Colonic Neoplasms
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells.
Colonic Neoplasms
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
Colonic Neoplasms
Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding.
Colonic Neoplasms
Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility.
Colonic Neoplasms
Sulforaphene suppresses growth of colon cancer-derived tumors via induction of glutathione depletion and microtubule depolymerization.
Colonic Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Colonic Neoplasms
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Colonic Neoplasms
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
Colonic Neoplasms
The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis.
Colonic Neoplasms
The mycotoxin patulin decreases expression of density-enhanced phosphatase-1 by down-regulating PPAR? in human colon cancer cells.
Colonic Neoplasms
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
Colonic Neoplasms
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Colonic Neoplasms
The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Colonic Neoplasms
Tumour suppressor function of protein tyrosine phosphatase receptor-T.
Colonic Neoplasms
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Colonic Neoplasms
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Colonic Neoplasms
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Colonic Neoplasms
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Colonic Neoplasms
WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability.
Colonic Neoplasms
[Development of anti cancer drugs targeted on Fas-mediated apoptosis signal]
Colonic Neoplasms
[Effects of phosphatase of regenerating liver cell-3 gene silence by RNA interference on the expression of matrix metalloproteinases-2,-9 in human colon cancer cells]
Colonic Neoplasms
[P66shc action on resistance of colon carcinoma RKO cells to oxidative stress].
Colorectal Neoplasms
3'-hydroxy-4'-methoxy-?-methyl-?-nitrostyrene inhibits tumorigenesis in colorectal cancer cells through ROS-mediated DNA damage and mitochondrial dysfunction.
Colorectal Neoplasms
A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.
Colorectal Neoplasms
A missense variant in PTPN12 associated with the risk of colorectal cancer by modifying Ras/MEK/ERK signaling.
Colorectal Neoplasms
A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.
Colorectal Neoplasms
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Colorectal Neoplasms
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Colorectal Neoplasms
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Colorectal Neoplasms
B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A.
Colorectal Neoplasms
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
Colorectal Neoplasms
Candidate genes for hereditary colorectal cancer: Mutational screening and systematic review.
Colorectal Neoplasms
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
Colorectal Neoplasms
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
Colorectal Neoplasms
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Colorectal Neoplasms
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
Colorectal Neoplasms
Circular RNA circ_0007142 Facilitates Colorectal Cancer Progression by Modulating CDC25A Expression via miR-122-5p.
Colorectal Neoplasms
Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
Colorectal Neoplasms
Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer.
Colorectal Neoplasms
Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Colorectal Neoplasms
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Colorectal Neoplasms
Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
Colorectal Neoplasms
Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Colorectal Neoplasms
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Colorectal Neoplasms
Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
Colorectal Neoplasms
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Colorectal Neoplasms
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
Colorectal Neoplasms
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Colorectal Neoplasms
Engineering non-natural inhibitor sensitivity in protein tyrosine phosphatase H1.
Colorectal Neoplasms
Erratum: B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A: Erratum.
Colorectal Neoplasms
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Colorectal Neoplasms
Expression levels and associations of five long non-coding RNAs in gastric cancer and their clinical significance.
Colorectal Neoplasms
Expression of Concern: Upregulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
Colorectal Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Colorectal Neoplasms
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Colorectal Neoplasms
Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Colorectal Neoplasms
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Colorectal Neoplasms
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Colorectal Neoplasms
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Colorectal Neoplasms
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Colorectal Neoplasms
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
Colorectal Neoplasms
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer.
Colorectal Neoplasms
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
Colorectal Neoplasms
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Colorectal Neoplasms
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Colorectal Neoplasms
Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells.
Colorectal Neoplasms
Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.
Colorectal Neoplasms
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14.
Colorectal Neoplasms
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.
Colorectal Neoplasms
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.
Colorectal Neoplasms
Immunohistochemical and Western blot analysis of two protein tyrosine phosphatase receptors, R and Z1, in colorectal carcinoma, colon adenoma and normal colon tissues.
Colorectal Neoplasms
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Colorectal Neoplasms
Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas.
Colorectal Neoplasms
Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
Colorectal Neoplasms
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.
Colorectal Neoplasms
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Colorectal Neoplasms
Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue.
Colorectal Neoplasms
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
Colorectal Neoplasms
Knockdown of PRL-3 increases mitochondrial superoxide anion production through transcriptional regulation of RAP1.
Colorectal Neoplasms
Levels of expression of pleiotrophin and protein tyrosine phosphatase zeta are decreased in human colorectal cancers.
Colorectal Neoplasms
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Colorectal Neoplasms
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Colorectal Neoplasms
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Colorectal Neoplasms
Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells.
Colorectal Neoplasms
Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
Colorectal Neoplasms
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Colorectal Neoplasms
Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
Colorectal Neoplasms
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Colorectal Neoplasms
Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk.
Colorectal Neoplasms
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
Colorectal Neoplasms
MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
Colorectal Neoplasms
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
Colorectal Neoplasms
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
Colorectal Neoplasms
MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
Colorectal Neoplasms
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Colorectal Neoplasms
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Colorectal Neoplasms
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Colorectal Neoplasms
Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Colorectal Neoplasms
Mutational analysis of FLASH and PTPN13 genes in colorectal carcinomas.
Colorectal Neoplasms
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Colorectal Neoplasms
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
Colorectal Neoplasms
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Colorectal Neoplasms
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Colorectal Neoplasms
Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers.
Colorectal Neoplasms
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Colorectal Neoplasms
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Colorectal Neoplasms
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Colorectal Neoplasms
Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.
Colorectal Neoplasms
Polypyrimidine tract-binding protein 1-mediated down-regulation of ATG10 facilitates metastasis of colorectal cancer cells.
Colorectal Neoplasms
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
Colorectal Neoplasms
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Colorectal Neoplasms
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
Colorectal Neoplasms
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
Colorectal Neoplasms
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Colorectal Neoplasms
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
Colorectal Neoplasms
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
Colorectal Neoplasms
PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.
Colorectal Neoplasms
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Colorectal Neoplasms
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Colorectal Neoplasms
Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.
Colorectal Neoplasms
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Colorectal Neoplasms
Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer.
Colorectal Neoplasms
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
Colorectal Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Colorectal Neoplasms
PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis.
Colorectal Neoplasms
PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation.
Colorectal Neoplasms
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
Colorectal Neoplasms
PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway.
Colorectal Neoplasms
PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer.
Colorectal Neoplasms
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
Colorectal Neoplasms
PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.
Colorectal Neoplasms
PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients.
Colorectal Neoplasms
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Colorectal Neoplasms
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Colorectal Neoplasms
Retraction: Upregulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
Colorectal Neoplasms
RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer.
Colorectal Neoplasms
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases.
Colorectal Neoplasms
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
Colorectal Neoplasms
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Colorectal Neoplasms
SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A.
Colorectal Neoplasms
Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer.
Colorectal Neoplasms
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
Colorectal Neoplasms
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
Colorectal Neoplasms
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Colorectal Neoplasms
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
Colorectal Neoplasms
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Colorectal Neoplasms
The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Colorectal Neoplasms
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
Colorectal Neoplasms
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.
Colorectal Neoplasms
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
Colorectal Neoplasms
The PTPN13 Y2081D (T>G) (rs989902) polymorphism is associated with an increased risk of sporadic colorectal cancer.
Colorectal Neoplasms
The Suppressing Effects of Dkk3 Expression on Aggressiveness and Tumorigenesis of Colorectal Cancer.
Colorectal Neoplasms
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Colorectal Neoplasms
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Colorectal Neoplasms
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Colorectal Neoplasms
Tumor-associated macrophages (TAMs) depend on Shp2 for their anti-tumor roles in colorectal cancer.
Colorectal Neoplasms
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Colorectal Neoplasms
Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells.
Colorectal Neoplasms
Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis.
Colorectal Neoplasms
Up-regulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3.
Colorectal Neoplasms
Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review.
Colorectal Neoplasms
Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor ? (TGF?).
Colorectal Neoplasms
[Cloning of human PRL-3 gene and construction of its prokaryotic expression vector]
Colorectal Neoplasms
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
Colorectal Neoplasms
[Construction of the life cycle of Angiostrongylus cantonensis in laboratory]
Colorectal Neoplasms
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
Colorectal Neoplasms
[Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance].
Colorectal Neoplasms
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
Colorectal Neoplasms
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Colorectal Neoplasms
[Expression of the zinc finger transcriptional factor Snail in colorectal carcinoma and its significance]
Colorectal Neoplasms, Hereditary Nonpolyposis
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Communicable Diseases
The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.
Congenital Abnormalities
Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity and calvarial defects in mice.
Congenital Abnormalities
Effects of mechanical loading on the expression of pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in a rat spinal deformity model.
Congenital Abnormalities
Pathogenesis of adolescent idiopathic scoliosis in girls - a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy.
Congenital Abnormalities
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
Congenital Abnormalities
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Congenital Disorders of Glycosylation
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shp2 function in hematopoietic stem cell biology and leukemogenesis.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Connective Tissue Diseases
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Corneal Dystrophies, Hereditary
Association of common variants in TCF4 and PTPRG with Fuchs' corneal dystrophy: a systematic review and meta-analysis.
Corneal Dystrophies, Hereditary
Association of Transcription Factor 4 (TCF4) and Protein Tyrosine Phosphatase, Receptor Type G (PTPRG) with Corneal Dystrophies in Southern Chinese.
Coronary Artery Disease
Coronary Artery Disease: Evidence of Interaction between PTPN22 and p53 Genetic Polymorphisms.
Coronary Artery Disease
Effect of genetic factors on the association between coronary artery disease and PTPN22 polymorphism.
Coronary Artery Disease
Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease.
Coronary Artery Disease
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Coronary Artery Disease
Modulation of bone marrow-derived endothelial progenitor cell activity by protein tyrosine phosphatases.
Coronary Artery Disease
Search for genetic variants in the p66Shc longevity gene by PCR-single strand conformational polymorphism in patients with early-onset cardiovascular disease.
Coronary Artery Disease
The 981C>T polymorphism in protein tyrosine phosphatase 1B is associated with decreased risk of coronary artery disease in Chinese Han population.
Coronary Artery Disease
The p66shc gene expression in peripheral blood monocytes is increased in patients with coronary artery disease.
Coronary Artery Disease
The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.
Coronary Disease
The expression of p66shc in peripheral blood monocytes is increased in patients with coronary heart disease and correlated with endothelium-dependent vasodilatation.
Costello Syndrome
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Costello Syndrome
Exclusion of PTPN11 mutations in Costello syndrome: further evidence for distinct genetic etiologies for Noonan, cardio-facio-cutaneous and Costello syndromes.
Costello Syndrome
Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Costello Syndrome
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
Costello Syndrome
No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome.
Costello Syndrome
Spectrum of Mutations in Noonan Syndrome and Their Correlation with Phenotypes.
Craniofacial Abnormalities
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Craniosynostoses
A de novo balanced translocation t(7;12)(p21.2;p12.3) in a patient with Saethre-Chotzen-like phenotype downregulates TWIST and an osteoclastic protein-tyrosine phosphatase, PTP-oc.
Craniosynostoses
Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Craniosynostoses
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Crohn Disease
A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease.
Crohn Disease
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution.
Crohn Disease
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease.
Crohn Disease
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Crohn Disease
Association Between the PTPN2 Gene and Crohn's Disease: Dissection of Potential Causal Variants.
Crohn Disease
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Crohn Disease
Associations between PTPN2 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.
Crohn Disease
Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy.
Crohn Disease
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.
Crohn Disease
Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis.
Crohn Disease
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Crohn Disease
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Crohn Disease
Expression of the membrane protein tyrosine phosphatase CD148 in human tissues.
Crohn Disease
Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn's Disease: On the Way to Personalized Medicine?
Crohn Disease
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Crohn Disease
Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease.
Crohn Disease
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
Crohn Disease
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Crohn Disease
Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion.
Crohn Disease
Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-?-Induced Signaling in Human Monocytes.
Crohn Disease
Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.
Crohn Disease
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Crohn Disease
Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
Crohn Disease
Modulation of PTPN2/22 Function by Spermidine in CRISPR-Cas9-Edited T-Cells Associated with Crohn's Disease and Rheumatoid Arthritis.
Crohn Disease
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Crohn Disease
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Crohn Disease
Protection of epithelial barrier function by the Crohn's disease associated gene, protein tyrosine phosphatase N2.
Crohn Disease
Protein tyrosine phosphatase N2 regulates TNF?-induced signalling and cytokine secretion in human intestinal epithelial cells.
Crohn Disease
Protein Tyrosine Phosphatase non-Receptor Type 2 regulates IFN-?-induced cytokine signaling in THP-1 monocytes.
Crohn Disease
Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.
Crohn Disease
PTPN2 but not PTPN22 is associated with Crohn's disease in a New Zealand population.
Crohn Disease
PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis.
Crohn Disease
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
Crohn Disease
PTPN2 is associated with Crohn's disease and its expression is regulated by NKX2-3.
Crohn Disease
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
Crohn Disease
PTPN22 Modulates Macrophage Polarization and Susceptibility to Dextran Sulfate Sodium-Induced Colitis.
Crohn Disease
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Crohn Disease
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
Crohn Disease
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
Crohn Disease
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
Crohn Disease
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Crohn Disease
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Crohn Disease
Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs.
Cross Infection
A Potential Mechanism for Immune Suppression by Beta-Adrenergic Receptor Stimulation following Traumatic Injury.
Cryptorchidism
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Cryptorchidism
New Mutations Associated with Rasopathies in a Central European Population and Genotype-Phenotype Correlations.
Cutis Laxa
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Cystadenoma
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Cystic Fibrosis
Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein.
Cystic Fibrosis
Cysteine string protein interacts with and modulates the maturation of the cystic fibrosis transmembrane conductance regulator.
Cystic Fibrosis
Cysteine string protein monitors late steps in cystic fibrosis transmembrane conductance regulator biogenesis.
Cystic Fibrosis
Cysteine string protein promotes proteasomal degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) by increasing its interaction with the C terminus of Hsp70-interacting protein and promoting CFTR ubiquitylation.
Cystic Fibrosis
Expression and regulation of chloride channels in neonatal rat cardiomyocytes.
Cystic Fibrosis
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin.
Cystic Fibrosis
Interaction of the protein phosphatase 2A with the regulatory domain of the cystic fibrosis transmembrane conductance regulator channel.
Cystic Fibrosis
Parallel single nucleotide polymorphism genotyping by surface invasive cleavage with universal detection.
Cystic Fibrosis
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
Cystic Fibrosis
The cystic fibrosis transmembrane conductance regulator is regulated by a direct interaction with the protein phosphatase 2A.
Cystic Fibrosis
The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.
Cystic Fibrosis
The +1858 C/T Polymorphism in the PTPN22 Gene Is Associated with Cystic Fibrosis Patients in Northeast Mexico.
Cystic Fibrosis
ZnT8 antibodies in patients with cystic fibrosis: An expression of secondary beta-cell damage?
Cysts
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Cysts
Characterization of low molecular weight protein tyrosine phosphatases of Entamoeba histolytica.
Cysts
Excystation of Giardia muris induced by a phosphate-bicarbonate medium: localization of acid phosphatase.
Cysts
Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.
Cysts
Histochemistry and ultrastructure of the metacercarial cyst of Bolbogonotylus corkumi (Trematoda: Cryptogonimidae).
Cysts
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Cysts
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
Cysts
[The characteristics of chemical composition of content of unicameral bone cysts depending on their growth stage].
Dandy-Walker Syndrome
Array-based molecular karyotyping in fetuses with isolated brain malformations identifies disease-causing CNVs.
Deafness
A C-terminal nonsense mutation links PTPRQ with autosomal-dominant hearing loss, DFNA73.
Deafness
A reduction in Ptprq associated with specific features of the deafness phenotype of the miR-96 mutant mouse diminuendo.
Deafness
Deafness and vestibular dysfunction in a Doberman Pinscher puppy associated with a mutation in the PTPRQ gene.
Deafness
Hair Bundle Defects and Loss of Function in the Vestibular End Organs of Mice Lacking the Receptor-Like Inositol Lipid Phosphatase PTPRQ.
Deafness
Identification of a novel compound heterozygous mutation in PTPRQ in a DFNB84 family with prelingual sensorineural hearing impairment.
Deafness
Identification of Novel PTPRQ and MYO1A Mutations in An Iranian Pedigree with Autosomal Recessive Hearing Loss.
Deafness
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
Deafness
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Deafness
Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction.
Deafness
Proband Whole-Exome Sequencing Identified Genes Responsible for Autosomal Recessive Non-Syndromic Hearing Loss in 33 Chinese Nuclear Families.
Deafness
PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.
Dehydration
Glucagon-induced expression of the MAP kinase phosphatase MKP-1 in rat hepatocytes.
Dehydration
Importance of inositols and their derivatives in cowpea under root dehydration: An omics perspective.
Dementia
Anti-CD45RO suppresses human immunodeficiency virus type 1 replication in microglia: role of Hck tyrosine kinase and implications for AIDS dementia.
Dementia
Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats.
Dementia
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Dementia
Expression changes of growth-associated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats.
Dementia
Intracerebroventricular administration of okadaic acid induces hippocampal glucose uptake dysfunction and tau phosphorylation.
Dementia
Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats.
Dementia
The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer's Disease and Other Neurological Disorders.
Dementia, Vascular
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes.
Dementia, Vascular
Beneficial Effect of Protein Tyrosine Phosphatase Inhibitor and Phytoestrogen in Dyslipidemia-Induced Vascular Dementia in Ovariectomized Rats.
Demyelinating Diseases
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Demyelinating Diseases
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
Demyelinating Diseases
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Demyelinating Diseases
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Demyelinating Diseases
Developmental expression and function analysis of protein tyrosine phosphatase receptor type D in oligodendrocyte myelination.
Demyelinating Diseases
Exosomal Circular RNA as a Biomarker Platform for the Early Diagnosis of Immune-Mediated Demyelinating Disease.
Demyelinating Diseases
Inactivation of Protein Tyrosine Phosphatase Receptor Type Z by Pleiotrophin Promotes Remyelination through Activation of Differentiation of Oligodendrocyte Precursor Cells.
Demyelinating Diseases
Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
Demyelinating Diseases
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
Demyelinating Diseases
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
Demyelinating Diseases
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Demyelinating Diseases
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Demyelinating Diseases
Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination.
Demyelinating Diseases
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
Demyelinating Diseases
The control of reactive oxygen species production by SHP-1 in oligodendrocytes.
Dengue
Protein tyrosine phosphatase, opisthorchiasis and dengue: A proteomics interrelationship.
Dengue
Tyrosine kinase/phosphatase inhibitors decrease dengue virus production in HepG2 cells.
Dental Calculus
[Deposition of tartar in human teeth and acid phosphatase activity in saliva]
Dental Caries
[The correlation between salivary acid phosphatase activity and dental caries]
Dental Plaque
The effect of dental plaque grown in the presence of xylitol or sucrose on bone resorption in vitro.
Dermatitis
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Dermatitis
Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis.
Dermatitis, Atopic
Genetic control of serum IgE levels: a study of low molecular weight protein tyrosine phosphatase.
Dermatitis, Atopic
Licoricidin Abrogates T-Cell Activation by Modulating PTPN1 Activity and Attenuates Atopic Dermatitis In Vivo.
Dermatitis, Atopic
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Dermatitis, Atopic
PTPN22 polymorphisms may indicate a role for this gene in atopic dermatitis in West Highland white terriers.
Dermatitis, Contact
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Dermatitis, Contact
Machine-learning-driven biomarker discovery for the discrimination between allergic and irritant contact dermatitis.
Dermatitis, Phototoxic
Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Dermatomyositis
Concomitance of basophilia, ribonucleic acid and acid phosphatase activity in regenerating muscle fibres.
Dermatomyositis
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Diabetes Complications
Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms.
Diabetes Complications
Inhibitory activity of Aralia continentalis roots on protein tyrosine phosphatase 1B and rat lens aldose reductase.
Diabetes Complications
Marine algae as a prospective source for antidiabetic compounds - A brief review.
Diabetes Complications
p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications.
Diabetes Complications
Protein Tyrosine Phosphatase 1B and ?-Glucosidase Inhibitory Phlorotannins from Edible Brown Algae, Ecklonia stolonifera and Eisenia bicyclis.
Diabetes Complications
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Diabetes Complications
The redox enzyme p66Shc contributes to diabetes and ischemia-induced delay in cutaneous wound healing.
Diabetes Insipidus
Acid phosphatase activity in the rat neurohypophysis during increased levels of gonadothrophic hormones, in diabetes insipidus (Bratteboro strain) and after water loading.
Diabetes Mellitus
A Computer-Driven Scaffold-Hopping Approach Generating New PTP1B Inhibitors from the Pyrrolo[1,2-a]quinoxaline Core.
Diabetes Mellitus
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
Diabetes Mellitus
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Diabetes Mellitus
A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population.
Diabetes Mellitus
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adults.
Diabetes Mellitus
Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Diabetes Mellitus
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Diabetes Mellitus
An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors.
Diabetes Mellitus
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Diabetes Mellitus
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Diabetes Mellitus
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Diabetes Mellitus
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Diabetes Mellitus
Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.
Diabetes Mellitus
Association of protein tyrosine phosphatase non-receptor type 22 gene functional variant C1858T, HLA-DQ/DR genotypes and autoantibodies with susceptibility to type-1 diabetes mellitus in Kuwaiti Arabs.
Diabetes Mellitus
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Diabetes Mellitus
Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents.
Diabetes Mellitus
Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Diabetes Mellitus
Bioactivity-guided isolation of 1,2,3,4,6-Penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor.
Diabetes Mellitus
Carbazole alkaloids from the fruits of Clausena anisum-olens with potential PTP1B and ?-glucosidase inhibitory activities.
Diabetes Mellitus
Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus.
Diabetes Mellitus
Characteristics of the interaction mechanisms of procyanidin B1 and procyanidin B2 with protein tyrosine phosphatase-1B: Analysis by kinetics, spectroscopy methods and molecular docking.
Diabetes Mellitus
Concurrent extrahepatic autoimmune disorders: unexplored dimension of autoimmune liver disease in children.
Diabetes Mellitus
Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC?/p66Shc axis and activation of FOXO-3a.
Diabetes Mellitus
Cytosolic Low Molecular Weight Protein-Tyrosine Phosphatase Activity and Clinical Manifestations of Diabetes.
Diabetes Mellitus
Deletion of AT2 Receptor Prevents SHP-1-Induced VEGF Inhibition and Improves Blood Flow Reperfusion in Diabetic Ischemic Hindlimb.
Diabetes Mellitus
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Diabetes Mellitus
Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Diabetes Mellitus
Detection of proteolytic cleavages of diabetes-associated protein IA-2 beta in the pancreas and the brain using novel anti-IA-2 beta monoclonal antibodies.
Diabetes Mellitus
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Diabetes Mellitus
Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties.
Diabetes Mellitus
Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent.
Diabetes Mellitus
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Diabetes Mellitus
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Diabetes Mellitus
Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents.
Diabetes Mellitus
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Diabetes Mellitus
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Diabetes Mellitus
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Diabetes Mellitus
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Diabetes Mellitus
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Diabetes Mellitus
Genetic Variants of PTPN2 Gene in Chinese Children with Type 1 Diabetes Mellitus.
Diabetes Mellitus
Genistein-derivatives from Tetracera scandens stimulate glucose-uptake in L6 myotubes.
Diabetes Mellitus
Glucose Uptake Activities of Bis (2, 3-Dibromo-4, 5-Dihydroxybenzyl) Ether, a Novel Marine Natural Product from Red Alga Odonthaliacorymbifera with Protein Tyrosine Phosphatase 1B Inhibition, In Vitro and In Vivo.
Diabetes Mellitus
Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.
Diabetes Mellitus
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Diabetes Mellitus
Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation.
Diabetes Mellitus
Humoral autoreactivity to an alternatively spliced variant of ICA512/IA-2 in Type I diabetes.
Diabetes Mellitus
IA-2A positivity rate at manifestation of type 1 diabetes mellitus in Slovak children culminates in September.
Diabetes Mellitus
Identification and evaluation of magnolol and chrysophanol as the principle protein tyrosine phosphatase-1B inhibitory compounds in a Kampo medicine, Masiningan.
Diabetes Mellitus
Identification of lipid-like salicylic acid-based derivatives as potent and membrane-permeable PTP1B inhibitors.
Diabetes Mellitus
Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation.
Diabetes Mellitus
Identification of PTP1B regulators from Cymbopogon citratus and its enrichment analysis for diabetes mellitus.
Diabetes Mellitus
In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B.
Diabetes Mellitus
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Diabetes Mellitus
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
Diabetes Mellitus
In vitro effects of cinnamic acid derivatives on protein tyrosine phosphatase 1B.
Diabetes Mellitus
Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
Diabetes Mellitus
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Diabetes Mellitus
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Diabetes Mellitus
Inhibitors of Protein Tyrosine Phosphatase 1B from Marine Natural Products.
Diabetes Mellitus
Inhibitory Effects of Secondary Metabolites from the Lichen Stereocaulon evolutum on Protein Tyrosine Phosphatase 1B.
Diabetes Mellitus
Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese.
Diabetes Mellitus
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Diabetes Mellitus
Integration of network and experimental pharmacology to decipher the antidiabetic action of Duranta repens L.
Diabetes Mellitus
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Diabetes Mellitus
Isolation and Characterization of Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitory Polyphenolic Compounds From
Diabetes Mellitus
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Diabetes Mellitus
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Diabetes Mellitus
Mechanism of attenuation of diabetes mellitus and hypercholesterolemia induced vascular endothelial dysfunction by protein tyrosine phosphatase inhibition.
Diabetes Mellitus
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Diabetes Mellitus
Methylation pattern variation between goats and rats during the onset of puberty.
Diabetes Mellitus
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Diabetes Mellitus
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Diabetes Mellitus
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
Diabetes Mellitus
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Diabetes Mellitus
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Diabetes Mellitus
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
Diabetes Mellitus
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Diabetes Mellitus
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Diabetes Mellitus
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Diabetes Mellitus
Potential Inhibitors of Protein Tyrosine Phosphatase (PTP1B) Enzyme: Promising Target for Type-II Diabetes Mellitus.
Diabetes Mellitus
Potential Utility of Sodium Selenate as an Adjunct to Metformin in Treating Type II Diabetes Mellitus in Rats: A Perspective on Protein Tyrosine Phosphatase.
Diabetes Mellitus
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Diabetes Mellitus
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Diabetes Mellitus
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Diabetes Mellitus
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Diabetes Mellitus
Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function.
Diabetes Mellitus
Protein tyrosine phosphatase activity in insulin-resistant rodent Psammomys obesus.
Diabetes Mellitus
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Diabetes Mellitus
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Diabetes Mellitus
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
Diabetes Mellitus
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Diabetes Mellitus
Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction.
Diabetes Mellitus
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Diabetes Mellitus
PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?
Diabetes Mellitus
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
Diabetes Mellitus
Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G. Don.
Diabetes Mellitus
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Diabetes Mellitus
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
Diabetes Mellitus
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Diabetes Mellitus
Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Diabetes Mellitus
Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.
Diabetes Mellitus
Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
Diabetes Mellitus
T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus.
Diabetes Mellitus
The -1123G>C Variant of PTPN22 Gene Promoter is Associated with Latent Autoimmune Diabetes in Adult Chinese Hans.
Diabetes Mellitus
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
Diabetes Mellitus
The IA-2 gene family: homologs in Caenorhabditis elegans, Drosophila and zebrafish.
Diabetes Mellitus
The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population.
Diabetes Mellitus
The Role of PTPN22 C1858T Gene Polymorphism in Diabetes Mellitus Type 1: First Evaluation in Greek Children and Adolescents.
Diabetes Mellitus
The rs1893217 (T/C) polymorphism in PTPN2 gene is not associated with type 1 diabetes mellitus in subjects from Southern Brazil.
Diabetes Mellitus
Thyroid autoimmunity in 72 children with type 1 diabetes mellitus: relationship with pancreatic autoimmunity and child growth.
Diabetes Mellitus
Type 1 diabetes mellitus. Comparison between the association with PTPN22 genotype and the association with ACP1-ADA1 joint genotype.
Diabetes Mellitus
Validation Of Formylchromane Derivatives As Ptp 1b Inhibitors By Pharmacophore Modeling, Atom Based 3d-Qsar And Docking Studies.
Diabetes Mellitus
Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
Diabetes Mellitus
[Association of -6735T-->C variant of glucokinase-associated dual-specificity phosphatase 12 gene with type 2 diabetes in Chinese]
Diabetes Mellitus
[Association of the C1858T polymorphism of the PTPN22 gene with type 1 diabetes]
Diabetes Mellitus
[Content of different cytokines in the blood of healthy children and their siblings who are either.positive or negative for diabetes-associated autoantibodies (GADA, 1A-2A, IAA)]
Diabetes Mellitus
[Effects of rare islet autoantibodies on islet function in patients with latent autoimmune diabetes in adults].
Diabetes Mellitus
[STUDY OF THE PTPN22 GENE IN CHILDREN WITH TYPE 1 DIABETES MELLITUS IN THE AZERBAIJANI POPULATION].
Diabetes Mellitus, Experimental
Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats.
Diabetes Mellitus, Type 1
A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits.
Diabetes Mellitus, Type 1
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
Diabetes Mellitus, Type 1
A functional polymorphism of Ptpn22 is associated with type 1 diabetes in the BioBreeding rat.
Diabetes Mellitus, Type 1
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.
Diabetes Mellitus, Type 1
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Diabetes Mellitus, Type 1
A Haplotype-Based Analysis of the PTPN22 Locus in Type 1 Diabetes.
Diabetes Mellitus, Type 1
A novel single nucleotide polymorphism in the protein tyrosine phosphatase N22 gene (PTPN22) is associated with Type 1 diabetes in a Chinese population.
Diabetes Mellitus, Type 1
A polymorphism in PTPN2 gene is associated with an earlier onset of type 1 diabetes.
Diabetes Mellitus, Type 1
A radioligand-binding assay for detecting antibodies specific for proinsulin and insulin using 35S-proinsulin.
Diabetes Mellitus, Type 1
A Simple Screening Method for Individuals at Risk of Developing Type 1 Diabetes: Measurement of Islet Cell Autoantibodies (GADA, IA-2A, and IAA) on Dried Capillary Blood Spots Collected on Filter Paper.
Diabetes Mellitus, Type 1
A strategy for combining minor genetic susceptibility genes to improve prediction of disease in type 1 diabetes.
Diabetes Mellitus, Type 1
A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion.
Diabetes Mellitus, Type 1
A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population.
Diabetes Mellitus, Type 1
A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene.
Diabetes Mellitus, Type 1
A variable degree of autoimmunity in the pedigree of a patient with type 1 diabetes homozygous for the PTPN22 1858T variant.
Diabetes Mellitus, Type 1
Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes.
Diabetes Mellitus, Type 1
Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adults.
Diabetes Mellitus, Type 1
Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis.
Diabetes Mellitus, Type 1
An inverse association between history of childhood eczema and subsequent risk of type 1 diabetes that is not likely to be explained by HLA-DQ, PTPN22, or CTLA4 polymorphisms.
Diabetes Mellitus, Type 1
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Diabetes Mellitus, Type 1
An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies.
Diabetes Mellitus, Type 1
Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases.
Diabetes Mellitus, Type 1
Analysis of PTPN22 C1858T gene polymorphism in cases with type 1 diabetes of Azerbaijan, Northwest Iran.
Diabetes Mellitus, Type 1
Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality.
Diabetes Mellitus, Type 1
Antibodies to the protein tyrosine phosphatases IAR and IA-2 are associated with progression to insulin-dependent diabetes (IDDM) in first-degree relatives at-risk for IDDM.
Diabetes Mellitus, Type 1
Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome.
Diabetes Mellitus, Type 1
Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?
Diabetes Mellitus, Type 1
Assessment of type 1 diabetes risk conferred by HLA-DRB1, INS-VNTR and PTPN22 genes using the Bayesian network approach.
Diabetes Mellitus, Type 1
Assignment of Ptprn2, the gene encoding receptor-type protein tyrosine phosphatase IA-2beta, a major autoantigen in insulin-dependent diabetes mellitus, to mouse chromosome region 12F.
Diabetes Mellitus, Type 1
Association analysis of PTPN22, CTLA4 and IFIH1 genes with type 1 diabetes in Colombian families.
Diabetes Mellitus, Type 1
Association between IA-2 autoantibody epitope specificities and age of onset in Japanese patients with autoimmune diabetes.
Diabetes Mellitus, Type 1
Association between PTPN22 C1858T and type 1 diabetes: a replication in continental Italy.
Diabetes Mellitus, Type 1
Association between the 1858T allele of the protein tyrosine phosphatase nonreceptor type 22 and type 1 diabetes in a Brazilian population.
Diabetes Mellitus, Type 1
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Diabetes Mellitus, Type 1
Association of IL-2RA/CD25 with type 1 diabetes in the Belgian population.
Diabetes Mellitus, Type 1
Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes.
Diabetes Mellitus, Type 1
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Diabetes Mellitus, Type 1
Association of PTPN22 C1858T and CTLA-4 A49G polymorphisms with type 1 diabetes in Croatians.
Diabetes Mellitus, Type 1
Association of PTPN22 C1858T polymorphism and type 1 diabetes: a meta-analysis.
Diabetes Mellitus, Type 1
Association of PTPN22 gene polymorphism with type 1 diabetes mellitus in Chinese children and adolescents.
Diabetes Mellitus, Type 1
Association of PTPN22 haplotypes with type 1 diabetes in the Japanese population.
Diabetes Mellitus, Type 1
Association of PTPN22+1858C/T polymorphism with Type 1 diabetes in the North Indian population.
Diabetes Mellitus, Type 1
Association of TCR/CD3, PTPN22, CD28 and ZAP70 gene polymorphisms with type 1 diabetes risk in Tunisian population: family based association study.
Diabetes Mellitus, Type 1
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Diabetes Mellitus, Type 1
Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Mellitus, Type 1
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Diabetes Mellitus, Type 1
Association of TNF-?, CTLA4, and PTPN22 polymorphisms with type 1 diabetes and other autoimmune diseases in Brazil.
Diabetes Mellitus, Type 1
Association of variants in PTPN22, CTLA-4, IL2-RA, and INS genes with type 1 diabetes in Emiratis.
Diabetes Mellitus, Type 1
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Diabetes Mellitus, Type 1
Associations of GWAS-Supported Non-MHC Genes with Autoimmune Thyroiditis in Patients with Type 1 Diabetes.
Diabetes Mellitus, Type 1
Autoantibodies and HLA susceptibility markers in Canadian first-degree relatives of patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies.
Diabetes Mellitus, Type 1
Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2.
Diabetes Mellitus, Type 1
Autoantibodies to multiple islet autoantigens in patients with abrupt onset type 1 diabetes and diabetes diagnosed with urinary glucose screening.
Diabetes Mellitus, Type 1
Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based cardiac autonomic neuropathy.
Diabetes Mellitus, Type 1
Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of "A+" Subtypes of Ketosis-Prone Diabetes.
Diabetes Mellitus, Type 1
Autoantibodies to tissue transglutaminase in patients from eastern India with malnutrition-modulated diabetes mellitus, insulin-dependent diabetes mellitus, and non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Diabetes Mellitus, Type 1
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Diabetes Mellitus, Type 1
Autonomic function and autoantibodies to autonomic nervous structures, glutamic acid decarboxylase and islet tyrosine phosphatase in adolescent patients with IDDM.
Diabetes Mellitus, Type 1
Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility.
Diabetes Mellitus, Type 1
BACH2, a candidate risk gene for type 1 diabetes, regulates apoptosis in pancreatic ?-cells via JNK1 modulation and crosstalk with the candidate gene PTPN2.
Diabetes Mellitus, Type 1
BLOCK-BASED BAYESIAN EPISTASIS ASSOCIATION MAPPING WITH APPLICATION TO WTCCC TYPE 1 DIABETES DATA.
Diabetes Mellitus, Type 1
Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.
Diabetes Mellitus, Type 1
CD11a expression and soluble ICAM-1 levels in peripheral blood in high-risk and overt type 1 diabetes subjects.
Diabetes Mellitus, Type 1
Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children.
Diabetes Mellitus, Type 1
Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes.
Diabetes Mellitus, Type 1
Characterization of the humoral immune response to islet antigen 2 in children with newly diagnosed type 1 diabetes.
Diabetes Mellitus, Type 1
Cloning of candidate autoantigen carboxypeptidase H from a human islet library: sequence identity with human brain CPH.
Diabetes Mellitus, Type 1
Coincidence of PTPN22 c.1858CC and FCRL3 -169CC genotypes as a biomarker of preserved residual ?-cell function in children with type 1 diabetes.
Diabetes Mellitus, Type 1
Combined measurement of diabetes mellitus immunological markers: an assessment of its benefits in adult-onset patients.
Diabetes Mellitus, Type 1
Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. The DENIS Study Group. Deutsche Nikotinamid Interventions-Studie.
Diabetes Mellitus, Type 1
Comparison of IA-2 with IA-2beta and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera.
Diabetes Mellitus, Type 1
Confirmation of the association of the R620W polymorphism in the protein tyrosine phosphatase PTPN22 with type 1 diabetes in a family based study.
Diabetes Mellitus, Type 1
Conjugation of Antisense Oligonucleotides to PEGylated Carbon Nanotubes Enables Efficient Knockdown of PTPN22 in T Lymphocytes.
Diabetes Mellitus, Type 1
Conserved epitopes in the protein tyrosine phosphatase family of diabetes autoantigens.
Diabetes Mellitus, Type 1
Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians.
Diabetes Mellitus, Type 1
Cord blood insulinoma-associated protein 2 autoantibodies are associated with increased risk of type 1 diabetes in the population-based Diabetes Prediction in Skåne study.
Diabetes Mellitus, Type 1
Course of islet autoantibody titers during Ig-immunoadsorption in a patient with newly diagnosed type 1 diabetes.
Diabetes Mellitus, Type 1
COVID-19 infection as a trigger for new-onset type 1 diabetes in a susceptible individual - or just coincidence?
Diabetes Mellitus, Type 1
CRISPR-Cas9-Mediated Modification of the NOD Mouse Genome With Ptpn22R619W Mutation Increases Autoimmune Diabetes.
Diabetes Mellitus, Type 1
Cross reactivity between IA-2 and phogrin/IA-2beta in binding of autoantibodies in IDDM.
Diabetes Mellitus, Type 1
CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry.
Diabetes Mellitus, Type 1
Curcumin reverses diabetic nephropathy in streptozotocin-induced diabetes in rats by inhibition of PKC?/p66Shc axis and activation of FOXO-3a.
Diabetes Mellitus, Type 1
Daily vegetable intake during pregnancy negatively associated to islet autoimmunity in the offspring-The ABIS study.
Diabetes Mellitus, Type 1
Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Deletion of the secretory vesicle proteins IA-2 and IA-2{beta} disrupts circadian rhythms of cardiovascular and physical activity.
Diabetes Mellitus, Type 1
Dense-core vesicle proteins IA-2 and IA-2{beta} affect renin synthesis and secretion through the {beta}-adrenergic pathway.
Diabetes Mellitus, Type 1
Detection of autoantibodies to the diabetes-associated antigen IA-2 by a sensitive enzyme-linked immunosorbent assay.
Diabetes Mellitus, Type 1
Developmental expression and localization of IA-2 mRNA in mouse neuroendocrine tissues.
Diabetes Mellitus, Type 1
Dietary risk factors for the emergence of type 1 diabetes-related autoantibodies in 21/2 year-old Swedish children.
Diabetes Mellitus, Type 1
Differences in prevalence of antibodies to GAD and IA-2 and their titers at diagnosis in children with slowly and rapidly progressive forms of type 1 diabetes.
Diabetes Mellitus, Type 1
Different modulation of Ptpn22 in effector and regulatory T cells leads to attenuation of autoimmune diabetes in transgenic nonobese diabetic mice.
Diabetes Mellitus, Type 1
Differential association of the PTPN22 coding variant with autoimmune diseases in a Dutch population.
Diabetes Mellitus, Type 1
Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies.
Diabetes Mellitus, Type 1
Disease-associated autoantibodies during pregnancy and at birth in families affected by type 1 diabetes.
Diabetes Mellitus, Type 1
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Diabetes Mellitus, Type 1
Distinct genetic and immunological features in patients with onset of IDDM before and after age 40.
Diabetes Mellitus, Type 1
Disturbances in the secretion of neurotransmitters in IA-2/IA-2beta null mice: changes in behavior, learning and lifespan.
Diabetes Mellitus, Type 1
Do non-HLA genes influence development of persistent islet autoimmunity and type 1 diabetes in children with high-risk HLA-DR,DQ genotypes?
Diabetes Mellitus, Type 1
Does the relative risk for type 1 diabetes conferred by HLA-DQ, INS, and PTPN22 polymorphisms vary with maternal age, birth weight, or cesarean section?
Diabetes Mellitus, Type 1
Dual Role of PTPN22 but Not NLRP3 Inflammasome Polymorphisms in Type 1 Diabetes and Celiac Disease in Children.
Diabetes Mellitus, Type 1
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes.
Diabetes Mellitus, Type 1
Effect of the PTPN22 and INS Risk Genotypes on the Progression to Clinical Type 1 Diabetes After the Initiation of ?-cell Autoimmunity.
Diabetes Mellitus, Type 1
Effects of Non-HLA Gene Polymorphisms on Development of Islet Autoimmunity and Type 1 Diabetes in a Population With High-Risk HLA-DR,DQ Genotypes.
Diabetes Mellitus, Type 1
Engineering and expression of the intracellular domain of insulinoma-associated tyrosine phosphatase (IA-2ic), a type 1 diabetes autoantigen, in plants.
Diabetes Mellitus, Type 1
Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis.
Diabetes Mellitus, Type 1
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Diabetes Mellitus, Type 1
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Diabetes Mellitus, Type 1
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Diabetes Mellitus, Type 1
Evidence That HLA Class I and II Associations With Type 1 Diabetes, Autoantibodies to GAD and Autoantibodies to IA-2, Are Distinct.
Diabetes Mellitus, Type 1
Exploiting novel tailored immunotherapies of type 1 diabetes: Short interfering RNA delivered by cationic liposomes enables efficient down-regulation of variant PTPN22 gene in T lymphocytes.
Diabetes Mellitus, Type 1
Expression and function of IA-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases.
Diabetes Mellitus, Type 1
Expression, characterization, processing and immunogenicity of an insulin-dependent diabetes mellitus autoantigen, IA-2, in Sf-9 cells.
Diabetes Mellitus, Type 1
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Diabetes Mellitus, Type 1
Fine mapping of diabetes-associated IA-2 specific autoantibodies.
Diabetes Mellitus, Type 1
Frequency of islet cell autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes patients.
Diabetes Mellitus, Type 1
Further evidence of a primary, causal association of the PTPN22 620W variant with type 1 diabetes.
Diabetes Mellitus, Type 1
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
Diabetes Mellitus, Type 1
GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.
Diabetes Mellitus, Type 1
Gammadelta T-cells alterations in the peripheral blood of high risk diabetes type 1 subjects with subclinical pancreatic B-cells impairment.
Diabetes Mellitus, Type 1
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Diabetes Mellitus, Type 1
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
Diabetes Mellitus, Type 1
Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West.
Diabetes Mellitus, Type 1
Genetic developments in autoimmune thyroid disease: an evolutionary process.
Diabetes Mellitus, Type 1
Genetic differences between type 1 diabetes with and without other autoimmune diseases.
Diabetes Mellitus, Type 1
Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes.
Diabetes Mellitus, Type 1
Genetic Variants of PTPN2 Gene in Chinese Children with Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease.
Diabetes Mellitus, Type 1
Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations.
Diabetes Mellitus, Type 1
Genomic structure and promoter sequence of the insulin-dependent diabetes mellitus autoantigen, IA-2 (PTPRN).
Diabetes Mellitus, Type 1
Genotypes of cytosolic low-molecular-weight protein-tyrosine-phosphatase correlate with age at onset of type 1 diabetes in a sex-specific manner.
Diabetes Mellitus, Type 1
Glutamic acid decarboxylase and ICA512/IA-2 autoantibodies as disease markers and relationship to residual beta-cell function and glycemic control in young type 1 diabetic patients.
Diabetes Mellitus, Type 1
Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.
Diabetes Mellitus, Type 1
High frequency of diabetes-specific autoantibodies in parents of children with type 1 diabetes. DENIS study group.
Diabetes Mellitus, Type 1
High T cell responses to the glutamic acid decarboxylase (GAD) isoform 67 reflect a hyperimmune state that precedes the onset of insulin-dependent diabetes.
Diabetes Mellitus, Type 1
HLA-DR, HLA-DQB1 and PTPN22 gene polymorphism: association with age at onset for autoimmune diabetes.
Diabetes Mellitus, Type 1
Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes.
Diabetes Mellitus, Type 1
Humoral immune response to islet autoantigens in Japanese patients with type 1 diabetes.
Diabetes Mellitus, Type 1
IA-2 antibodies--a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group.
Diabetes Mellitus, Type 1
IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes.
Diabetes Mellitus, Type 1
IA-2 autoantibodies restricted to the IgG4 subclass are associated with protection from type 1 diabetes.
Diabetes Mellitus, Type 1
IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes.
Diabetes Mellitus, Type 1
IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
IA-2A positivity rate at manifestation of type 1 diabetes mellitus in Slovak children culminates in September.
Diabetes Mellitus, Type 1
IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.
Diabetes Mellitus, Type 1
Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.
Diabetes Mellitus, Type 1
Identification and functional analysis of mutations in the hepatocyte nuclear factor-1alpha gene in anti-islet autoantibody-negative Japanese patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Diabetes Mellitus, Type 1
Identification of monogenic gene mutations in Japanese subjects diagnosed with type 1B diabetes between >5 and 15.1 years of age.
Diabetes Mellitus, Type 1
Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2.
Diabetes Mellitus, Type 1
Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2.
Diabetes Mellitus, Type 1
In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation.
Diabetes Mellitus, Type 1
Increased Plasma Soluble Interleukin-2 Receptor Alpha Levels in Patients With Long-Term Type 1 Diabetes With Vascular Complications Associated With IL2RA and PTPN2 Gene Polymorphisms.
Diabetes Mellitus, Type 1
Influence of PTPN22 Allotypes on Innate and Adaptive Immune Function in Health and Disease.
Diabetes Mellitus, Type 1
Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
Diabetes Mellitus, Type 1
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Diabetes Mellitus, Type 1
Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese.
Diabetes Mellitus, Type 1
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Diabetes Mellitus, Type 1
Insulin secretion in islets from mice with a double knockout for the dense core vesicle proteins islet antigen-2 (IA-2) and IA-2beta.
Diabetes Mellitus, Type 1
Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes.
Diabetes Mellitus, Type 1
Investigation of the vitamin D receptor gene (VDR) and its interaction with protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) on risk of islet autoimmunity and type 1 diabetes: The Diabetes Autoimmunity Study in the Young (DAISY).
Diabetes Mellitus, Type 1
Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?
Diabetes Mellitus, Type 1
Islet cell related antibodies and type 1 diabetes associated with echovirus 30 epidemic: a case report.
Diabetes Mellitus, Type 1
Joint effects of HLA, INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes.
Diabetes Mellitus, Type 1
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Diabetes Mellitus, Type 1
Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice.
Diabetes Mellitus, Type 1
Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years.
Diabetes Mellitus, Type 1
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
Diabetes Mellitus, Type 1
Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes.
Diabetes Mellitus, Type 1
Lymphoid-specific tyrosine phosphatase (Lyp): a potential drug target for treatment of autoimmune diseases.
Diabetes Mellitus, Type 1
Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2.
Diabetes Mellitus, Type 1
MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic {beta}-cell responses to the viral by-product double stranded RNA.
Diabetes Mellitus, Type 1
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories.
Diabetes Mellitus, Type 1
Meta-analysis of the family-based association between the PTPN22 C1858T polymorphism and type 1 diabetes.
Diabetes Mellitus, Type 1
Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes.
Diabetes Mellitus, Type 1
Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitope.
Diabetes Mellitus, Type 1
Multimerization of the protein-tyrosine phosphatase (PTP)-like insulin-dependent diabetes mellitus autoantigens IA-2 and IA-2beta with receptor PTPs (RPTPs). Inhibition of RPTPalpha enzymatic activity.
Diabetes Mellitus, Type 1
Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population.
Diabetes Mellitus, Type 1
No evidence for association of PTPN22 R620W functional variant C1858T with type 1 diabetes in Asian Indians.
Diabetes Mellitus, Type 1
No evidence of autoimmunity in 6-year-old children immunized at birth with recombinant hepatitis B vaccine.
Diabetes Mellitus, Type 1
No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
Diabetes Mellitus, Type 1
Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies.
Diabetes Mellitus, Type 1
Novel homozygous AIRE mutation in a German patient with severe APECED.
Diabetes Mellitus, Type 1
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Diabetes Mellitus, Type 1
Overexpression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T Cell Activation.
Diabetes Mellitus, Type 1
Pancreatic autoantibodies, HLA DR and PTPN22 polymorphisms in first degree relatives of patients with type 1 diabetes and multiethnic background.
Diabetes Mellitus, Type 1
Pancreatic T cell protein-tyrosine phosphatase deficiency affects beta cell function in mice.
Diabetes Mellitus, Type 1
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Diabetes Mellitus, Type 1
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood.
Diabetes Mellitus, Type 1
Polymorphism rs2476601 in the PTPN22 gene is associated with type 1 diabetes in children from the South Region of Brazil.
Diabetes Mellitus, Type 1
Population-based and family-based studies on the protein tyrosine phosphatase non-receptor 22 gene polymorphism and type 1 diabetes: a meta-analysis.
Diabetes Mellitus, Type 1
Predicting progression to diabetes in islet autoantibody positive children.
Diabetes Mellitus, Type 1
Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.
Diabetes Mellitus, Type 1
Prediction of type 1 diabetes among siblings of affected children and in the general population.
Diabetes Mellitus, Type 1
Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study.
Diabetes Mellitus, Type 1
Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes.
Diabetes Mellitus, Type 1
Preserved Proinsulin Production in Homozygous PTPN 22 C1858T Variant Type 1 Diabetes: A Possible Explanation for Absence of Overt Ketoacidosis Despite Omission of Exogenous Insulin.
Diabetes Mellitus, Type 1
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Diabetes Mellitus, Type 1
Prevalence of ZnT8 antibody in relation to phenotype and SLC30A8 polymorphism in adult autoimmune diabetes: results from the HUNT study, Norway.
Diabetes Mellitus, Type 1
Prevalence, characteristics and diabetes risk associated with transient maternally acquired islet antibodies and persistent islet antibodies in offspring of parents with type 1 diabetes.
Diabetes Mellitus, Type 1
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk.
Diabetes Mellitus, Type 1
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Diabetes Mellitus, Type 1
Protein tyrosine phosphatases and type 1 diabetes: genetic and functional implications of PTPN2 and PTPN22.
Diabetes Mellitus, Type 1
PTPN2 gene polymorphisms are associated with type 1 diabetes mellitus in Brazilian subjects?
Diabetes Mellitus, Type 1
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Diabetes Mellitus, Type 1
PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis.
Diabetes Mellitus, Type 1
PTPN2, a candidate gene for type 1 diabetes, modulates pancreatic ?-cell apoptosis via regulation of the BH3-only protein Bim.
Diabetes Mellitus, Type 1
PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity.
Diabetes Mellitus, Type 1
PTPN22 1858T Allele is Associated with Younger Age at Onset of Type 1 Diabetes and Unrelated to Subsequent Thyroid Autoimmunity.
Diabetes Mellitus, Type 1
Ptpn22 and Cd2 Variations Are Associated with Altered Protein Expression and Susceptibility to Type 1 Diabetes in Nonobese Diabetic Mice.
Diabetes Mellitus, Type 1
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
Diabetes Mellitus, Type 1
PTPN22 and islet-specific autoimmunity: What have the mouse models taught us?
Diabetes Mellitus, Type 1
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
Diabetes Mellitus, Type 1
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Diabetes Mellitus, Type 1
PTPN22 Gene Polymorphism (C1858T) Is Associated with Susceptibility to Type 1 Diabetes: A Meta-Analysis of 19,495 Cases and 25,341 Controls.
Diabetes Mellitus, Type 1
Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.
Diabetes Mellitus, Type 1
PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits.
Diabetes Mellitus, Type 1
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Diabetes Mellitus, Type 1
PTPN22 Silencing in the NOD Model Indicates the Type 1 Diabetes-Associated Allele Is Not a Loss-of-Function Variant.
Diabetes Mellitus, Type 1
PTPN22 Single-Nucleotide Polymorphisms in Iranian Patients with Type 1 Diabetes Mellitus.
Diabetes Mellitus, Type 1
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
Diabetes Mellitus, Type 1
PTPN22, PDCD1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Polish patients.
Diabetes Mellitus, Type 1
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Diabetes Mellitus, Type 1
Regulation of B cell homeostasis by Ptpn22 contributes to type 1 diabetes in NOD mice.
Diabetes Mellitus, Type 1
Regulation of the diabetes-associated autoantigen IA-2 in INS-1 pancreatic beta-cells.
Diabetes Mellitus, Type 1
Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes.
Diabetes Mellitus, Type 1
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus.
Diabetes Mellitus, Type 1
Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis.
Diabetes Mellitus, Type 1
Risk genes and autoantibodies in Egyptian children with type 1 diabetes - low frequency of autoantibodies in carriers of the HLA-DRB1*04:05-DQA1*03-DQB1*02 risk haplotype.
Diabetes Mellitus, Type 1
Role of C1858T polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian children and adolescents with type 1 diabetes.
Diabetes Mellitus, Type 1
Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes.
Diabetes Mellitus, Type 1
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Diabetes Mellitus, Type 1
Screening for preclinical type 1 diabetes in a discrete population with an apparent increased disease incidence.
Diabetes Mellitus, Type 1
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Diabetes Mellitus, Type 1
Sex-specific association of the human PTPN22 1858T-allele with type 1 diabetes.
Diabetes Mellitus, Type 1
Shared and distinct genetic variants in type 1 diabetes and celiac disease.
Diabetes Mellitus, Type 1
Significance of IA-2 antibody in Japanese type 1 diabetes: its association with GAD antibody.
Diabetes Mellitus, Type 1
Single-cell profiling reveals dendritic cell signatures associated with autoimmune inflammation.
Diabetes Mellitus, Type 1
Soluble adhesion molecules in Finnish schoolchildren with signs of preclinical type 1 diabetes.
Diabetes Mellitus, Type 1
Spontaneous peripheral T-cell responses to the IA-2beta (phogrin) autoantigen in young nonobese diabetic mice.
Diabetes Mellitus, Type 1
Stability of proICA512/IA-2 and Its Targeting to Insulin Secretory Granules Require ?4-Sheet-Mediated Dimerization of Its Ectodomain in the Endoplasmic Reticulum.
Diabetes Mellitus, Type 1
Strategies for identifying and predicting islet autoantigen T-cell epitopes in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
Diabetes Mellitus, Type 1
Susceptibility to type 1 diabetes conferred by the PTPN22 C1858T polymorphism in the Spanish population.
Diabetes Mellitus, Type 1
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): Association between a promoter polymorphism and type 1 diabetes in Asian populations.
Diabetes Mellitus, Type 1
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): Association between a promoter polymorphism and type 1 diabetes in Asian populations. American Journal of Medical Genetics 140A:586-593 (2006).
Diabetes Mellitus, Type 1
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
Diabetes Mellitus, Type 1
T cell reactivity to DR*0401- and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes.
Diabetes Mellitus, Type 1
T-cell epitope analysis on the autoantigen phogrin (IA-2beta) in the nonobese diabetic mouse.
Diabetes Mellitus, Type 1
T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents.
Diabetes Mellitus, Type 1
T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
Diabetes Mellitus, Type 1
Targeted Deep Sequencing in Multiple-Affected Sibships of European Ancestry Identifies Rare Deleterious Variants in PTPN22 That Confer Risk for Type 1 Diabetes.
Diabetes Mellitus, Type 1
Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice.
Diabetes Mellitus, Type 1
Temporal trends of HLA, CTLA-4 and PTPN22 genotype frequencies among type 1 diabetes in Continental Italy.
Diabetes Mellitus, Type 1
Testing for linkage and association with rheumatoid arthritis a ptpn22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population.
Diabetes Mellitus, Type 1
The -1123G>C Variant of PTPN22 Gene Promoter is Associated with Latent Autoimmune Diabetes in Adult Chinese Hans.
Diabetes Mellitus, Type 1
The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population.
Diabetes Mellitus, Type 1
The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2.
Diabetes Mellitus, Type 1
The association between rs1893217, rs478582 in PTPN2 and T1D risk with different diagnosed age, and related clinical characteristics in Chinese Han population.
Diabetes Mellitus, Type 1
The association between the PTPN22 1858C>T variant and type 1 diabetes depends on HLA risk and GAD65 autoantibodies.
Diabetes Mellitus, Type 1
The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis.
Diabetes Mellitus, Type 1
The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females.
Diabetes Mellitus, Type 1
The Core Cysteines, (C909) of Islet Antigen-2 and (C945) of Islet Antigen-2?, Are Crucial to Autoantibody Binding in Type 1 Diabetes.
Diabetes Mellitus, Type 1
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
Diabetes Mellitus, Type 1
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes.
Diabetes Mellitus, Type 1
The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing.
Diabetes Mellitus, Type 1
The Potential Role of PTPN-22 C1858T Gene Polymorphism in the Pathogenesis of Type 1 Diabetes in Saudi Population.
Diabetes Mellitus, Type 1
The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes.
Diabetes Mellitus, Type 1
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
Diabetes Mellitus, Type 1
The protein tyrosine phosphatase PTPN22 negatively regulates presentation of immune complex derived antigens.
Diabetes Mellitus, Type 1
The PTPN22 1858T allele but not variants in the proximal promoter region of IL-21 gene is associated with the susceptibility to type 1 diabetes and the presence of autoantibodies in a Brazilian cohort.
Diabetes Mellitus, Type 1
The PTPN22 1858T gene variant in type 1 diabetes is associated with reduced residual beta-cell function and worse metabolic control.
Diabetes Mellitus, Type 1
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Diabetes Mellitus, Type 1
The PTPN22 C1858T gene variant is associated with proinsulin in new-onset type 1 diabetes.
Diabetes Mellitus, Type 1
The PTPN22 promoter polymorphism -1123G>C association cannot be distinguished from the 1858C>T association in a Norwegian rheumatoid arthritis material.
Diabetes Mellitus, Type 1
The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity.
Diabetes Mellitus, Type 1
The relationship between humoral and cellular immunity to IA-2 in IDDM.
Diabetes Mellitus, Type 1
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.
Diabetes Mellitus, Type 1
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
Diabetes Mellitus, Type 1
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
Diabetes Mellitus, Type 1
The rs1893217 (T/C) polymorphism in PTPN2 gene is not associated with type 1 diabetes mellitus in subjects from Southern Brazil.
Diabetes Mellitus, Type 1
Thyroid autoimmunity in 72 children with type 1 diabetes mellitus: relationship with pancreatic autoimmunity and child growth.
Diabetes Mellitus, Type 1
Time-resolved fluorescence imaging in islet cell autoantibody quantitation.
Diabetes Mellitus, Type 1
Time-resolved immunofluorometric dual-label assay for simultaneous detection of autoantibodies to GAD65 and IA-2 in children with type 1 diabetes.
Diabetes Mellitus, Type 1
Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes.
Diabetes Mellitus, Type 1
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Diabetes Mellitus, Type 1
Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens.
Diabetes Mellitus, Type 1
Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives.
Diabetes Mellitus, Type 1
Type 1 diabetes linked PTPN22 gene polymorphism is associated with the frequency of circulating regulatory T cells.
Diabetes Mellitus, Type 1
Type 1 diabetes mellitus. Comparison between the association with PTPN22 genotype and the association with ACP1-ADA1 joint genotype.
Diabetes Mellitus, Type 1
Type 1 diabetes-related antibodies in the fetal circulation: prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes.
Diabetes Mellitus, Type 1
Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease.
Diabetes Mellitus, Type 1
Vaccinations may induce diabetes-related autoantibodies in one-year-old children.
Diabetes Mellitus, Type 1
Women diagnosed with gestational diabetes mellitus do not carry antibodies against minor islet cell antigens.
Diabetes Mellitus, Type 1
Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children.
Diabetes Mellitus, Type 1
[Association of the C1858T polymorphism of the PTPN22 gene with type 1 diabetes]
Diabetes Mellitus, Type 1
[Content of different cytokines in the blood of healthy children and their siblings who are either.positive or negative for diabetes-associated autoantibodies (GADA, 1A-2A, IAA)]
Diabetes Mellitus, Type 1
[IA-2 and anti-GAD antibodies in patients with newly diagnosed type 1 diabetes and their first degree relatives]
Diabetes Mellitus, Type 1
[Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies]
Diabetes Mellitus, Type 1
[Research progress of several protein tyrosine phosphatases in diabetes.]
Diabetes Mellitus, Type 1
[STUDY OF THE PTPN22 GENE IN CHILDREN WITH TYPE 1 DIABETES MELLITUS IN THE AZERBAIJANI POPULATION].
Diabetes Mellitus, Type 2
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
Diabetes Mellitus, Type 2
3D-QSAR Studies on a Series of 2,4-Thiazolidinedione Derivatives: A Self-Organizing Molecular Field Analysis Approach to Design Novel PTP 1B Inhibitors.
Diabetes Mellitus, Type 2
4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.
Diabetes Mellitus, Type 2
A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.
Diabetes Mellitus, Type 2
A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway.
Diabetes Mellitus, Type 2
A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro.
Diabetes Mellitus, Type 2
A polysaccharide extract of mulberry leaf ameliorates hepatic glucose metabolism and insulin signaling in rats with type 2 diabetes induced by high fat-diet and streptozotocin.
Diabetes Mellitus, Type 2
A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice.
Diabetes Mellitus, Type 2
A simple and visible colorimetric method through Zr(4+)-phosphate coordination for the assay of protein tyrosine phosphatase 1B and screening of its inhibitors.
Diabetes Mellitus, Type 2
Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans.
Diabetes Mellitus, Type 2
Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes.
Diabetes Mellitus, Type 2
Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Diabetes Mellitus, Type 2
Altered basal and insulin-stimulated phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects.
Diabetes Mellitus, Type 2
Altered PTPRD DNA methylation associates with restricted adipogenesis in healthy first-degree relatives of Type 2 diabetes subjects.
Diabetes Mellitus, Type 2
Amelioration of insulin resistance in diabetic ob/ob mice by a new type of orally active insulin-mimetic vanadyl complex: bis(1-oxy-2-pyridinethiolato)oxovanadium(IV) with VO(S(2)O(2)) coordination mode.
Diabetes Mellitus, Type 2
An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors.
Diabetes Mellitus, Type 2
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Diabetes Mellitus, Type 2
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Diabetes Mellitus, Type 2
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Diabetes Mellitus, Type 2
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Diabetes Mellitus, Type 2
Antidiabetic and Antioxidant Properties of Alkaloids from Catharanthus roseus (L.) G. Don.
Diabetes Mellitus, Type 2
Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice.
Diabetes Mellitus, Type 2
Antihyperglycemic effect of Annona squamosa hexane extract in type 2 diabetes animal model: PTP1B inhibition, a possible mechanism of action?
Diabetes Mellitus, Type 2
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Diabetes Mellitus, Type 2
Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies.
Diabetes Mellitus, Type 2
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Diabetes Mellitus, Type 2
Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes.
Diabetes Mellitus, Type 2
Association of the PTPN1 gene with type 2 diabetes and insulin resistance.
Diabetes Mellitus, Type 2
Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people.
Diabetes Mellitus, Type 2
Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes.
Diabetes Mellitus, Type 2
Autoimmunity-Associated PTPN22 Polymorphisms in Latent Autoimmune Diabetes of the Adult Differ from Those of Type 1 Diabetes Patients.
Diabetes Mellitus, Type 2
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Diabetes Mellitus, Type 2
Cellular effects of small molecule PTP1B inhibitors on insulin signaling.
Diabetes Mellitus, Type 2
Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update.
Diabetes Mellitus, Type 2
Characteristics of the interaction mechanisms of procyanidin B1 and procyanidin B2 with protein tyrosine phosphatase-1B: Analysis by kinetics, spectroscopy methods and molecular docking.
Diabetes Mellitus, Type 2
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Diabetes Mellitus, Type 2
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
Diabetes Mellitus, Type 2
CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors.
Diabetes Mellitus, Type 2
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Diabetes Mellitus, Type 2
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
Diabetes Mellitus, Type 2
Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP.
Diabetes Mellitus, Type 2
Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
Diabetes Mellitus, Type 2
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase.
Diabetes Mellitus, Type 2
Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy.
Diabetes Mellitus, Type 2
Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Diabetes Mellitus, Type 2
Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes.
Diabetes Mellitus, Type 2
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
Diabetes Mellitus, Type 2
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Diabetes Mellitus, Type 2
Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties.
Diabetes Mellitus, Type 2
Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent.
Diabetes Mellitus, Type 2
Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site.
Diabetes Mellitus, Type 2
Discovery of novel inhibitor of human leukocyte common antigen-related phosphatase.
Diabetes Mellitus, Type 2
Discovery of Novel PTP1B Inhibitors Derived from the BH3 Domain of Proapoptotic Bcl-2 Proteins with Antidiabetic Potency.
Diabetes Mellitus, Type 2
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Diabetes Mellitus, Type 2
Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
Diabetes Mellitus, Type 2
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Diabetes Mellitus, Type 2
Dual targeting of PTP1B and glucosidases with new bifunctional iminosugar inhibitors to address type 2 diabetes.
Diabetes Mellitus, Type 2
Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Diabetes Mellitus, Type 2
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Diabetes Mellitus, Type 2
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Diabetes Mellitus, Type 2
Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression.
Diabetes Mellitus, Type 2
Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents.
Diabetes Mellitus, Type 2
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Diabetes Mellitus, Type 2
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Diabetes Mellitus, Type 2
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Diabetes Mellitus, Type 2
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Diabetes Mellitus, Type 2
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Diabetes Mellitus, Type 2
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
Diabetes Mellitus, Type 2
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
Diabetes Mellitus, Type 2
Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes.
Diabetes Mellitus, Type 2
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Diabetes Mellitus, Type 2
Genetic variants in PTPRD and risk of gestational diabetes mellitus.
Diabetes Mellitus, Type 2
Genetic variation in receptor protein tyrosine phosphatase {sigma} is associated with type 2 diabetes in Swedish Caucasians.
Diabetes Mellitus, Type 2
Genistein-derivatives from Tetracera scandens stimulate glucose-uptake in L6 myotubes.
Diabetes Mellitus, Type 2
Haplo-Insufficiency of the Insulin Receptor in the presence of a splice-site mutation in Ppp2r2a results in a novel di-genic mouse model of type 2 diabetes.
Diabetes Mellitus, Type 2
High-Resolution PTP1B Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Miconia albicans.
Diabetes Mellitus, Type 2
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Diabetes Mellitus, Type 2
Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes.
Diabetes Mellitus, Type 2
Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
Diabetes Mellitus, Type 2
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).
Diabetes Mellitus, Type 2
Identification and characterization of potent and selective inhibitors targeting protein tyrosine phosphatase 1B (PTP1B).
Diabetes Mellitus, Type 2
Identification of Autoantibody Negative Autoimmune Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Identification of Cyanidin-3-arabinoside Extracted from Blueberry as a Selective Protein Tyrosine Phosphatase 1B Inhibitor.
Diabetes Mellitus, Type 2
Identification of lipid-like salicylic acid-based derivatives as potent and membrane-permeable PTP1B inhibitors.
Diabetes Mellitus, Type 2
Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Diabetes Mellitus, Type 2
Improved glucose-stimulated insulin secretion by intra-islet inhibition of protein-tyrosine phosphatase 1B expression in rats fed a high-fat diet.
Diabetes Mellitus, Type 2
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
Diabetes Mellitus, Type 2
In silico modeling of protein tyrosine phosphatase 1B inhibitors with cellular activity.
Diabetes Mellitus, Type 2
In silico modelling and molecular dynamics simulation studies of thiazolidine based PTP1B inhibitors.
Diabetes Mellitus, Type 2
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Diabetes Mellitus, Type 2
In vitro anti-diabetic effect of flavonoids and pheophytins from Allophylus cominia Sw. on the glucose uptake assays by HepG2, L6, 3T3-L1 and fat accumulation in 3T3-L1 adipocytes.
Diabetes Mellitus, Type 2
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Diabetes Mellitus, Type 2
Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum.
Diabetes Mellitus, Type 2
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Diabetes Mellitus, Type 2
Inhibition of protein tyrosine phosphatase 1B by lignans from Myristica fragrans.
Diabetes Mellitus, Type 2
Inhibition of protein tyrosine phosphatase 1B by lupeol and lupenone isolated from Sorbus commixta.
Diabetes Mellitus, Type 2
Inhibition of Protein Tyrosine Phosphatase 1B by Prenylated Isoflavonoids Isolated from the Stem Bark of Erythrina addisoniae1.
Diabetes Mellitus, Type 2
Inhibition of Protein Tyrosine Phosphatase 1B by Ursane-Type Triterpenes Isolated from Symplocos paniculata.
Diabetes Mellitus, Type 2
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Diabetes Mellitus, Type 2
Inhibitors for proteins endowed with catalytic and non-catalytic activity which recognize pTyr.
Diabetes Mellitus, Type 2
Inhibitory Effects of Secondary Metabolites from the Lichen Stereocaulon evolutum on Protein Tyrosine Phosphatase 1B.
Diabetes Mellitus, Type 2
Insight into the PTP1B Inhibitory Activity of Arylbenzofurans: An In Vitro and In Silico Study.
Diabetes Mellitus, Type 2
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity.
Diabetes Mellitus, Type 2
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Diabetes Mellitus, Type 2
Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?
Diabetes Mellitus, Type 2
Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes.
Diabetes Mellitus, Type 2
Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots.
Diabetes Mellitus, Type 2
Lack of association between polymorphisms in the gene encoding protein tyrosine phosphatase 1B (PTPN1) and risk of Type 2 diabetes.
Diabetes Mellitus, Type 2
Lack of association of PTPN1 gene polymorphisms with type 2 diabetes in south Indians.
Diabetes Mellitus, Type 2
Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years.
Diabetes Mellitus, Type 2
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
Diabetes Mellitus, Type 2
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Diabetes Mellitus, Type 2
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Measuring gene-gene interaction using Kullback-Leibler divergence.
Diabetes Mellitus, Type 2
Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
Diabetes Mellitus, Type 2
Missense mutation of Pro387Leu in protein tyrosine phosphatase-1B (PTP-1B) is not associated with type 2 diabetes in a Chinese Han population.
Diabetes Mellitus, Type 2
New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting ?-glucosidase and the PTP-1B signaling pathway.
Diabetes Mellitus, Type 2
New prenylated flavanones from Erythrina abyssinica with Protein tyrosine phosphatase 1B (PTP1B) inhibitory activity.
Diabetes Mellitus, Type 2
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
Diabetes Mellitus, Type 2
Novel heteroaryl phosphonicdiamides PTPs inhibitors as anti-hyperglycemic agents.
Diabetes Mellitus, Type 2
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Diabetes Mellitus, Type 2
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Diabetes Mellitus, Type 2
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
Diabetes Mellitus, Type 2
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Diabetes Mellitus, Type 2
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Diabetes Mellitus, Type 2
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
Diabetes Mellitus, Type 2
p66Shc, a multifaceted protein linking Erk signalling, glucose metabolism, and oxidative stress.
Diabetes Mellitus, Type 2
Palmitate action to inhibit glycogen synthase and stimulate protein phosphatase 2A increases with risk factors for type 2 diabetes.
Diabetes Mellitus, Type 2
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Diabetes Mellitus, Type 2
Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance.
Diabetes Mellitus, Type 2
Polymorphisms in the glucokinase-associated, dual-specificity phosphatase 12 (DUSP12) gene under chromosome 1q21 linkage peak are associated with type 2 diabetes.
Diabetes Mellitus, Type 2
Polymorphisms within the protein tyrosine phosphatase 1B (PTPN1) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits.
Diabetes Mellitus, Type 2
Positive Association Between Type 2 Diabetes Risk Alleles Near CDKAL1 and Reduced Birthweight in Chinese Han Individuals.
Diabetes Mellitus, Type 2
PPAR-?2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B (PTP1B) inhibitory constituents from the aerial parts of Tradescantia spathacea Sw.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Diabetes Mellitus, Type 2
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B inhibitory activity of amentoflavone and its cellular effect on tyrosine phosphorylation of insulin receptors.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity.
Diabetes Mellitus, Type 2
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatase-1B modulates pancreatic ?-cell mass.
Diabetes Mellitus, Type 2
Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling.
Diabetes Mellitus, Type 2
Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Diabetes Mellitus, Type 2
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Diabetes Mellitus, Type 2
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Diabetes Mellitus, Type 2
Protein-tyrosine phosphatase 1B substrates and metabolic regulation.
Diabetes Mellitus, Type 2
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Diabetes Mellitus, Type 2
PTP1B and TC-PTP: regulators of transformation and tumorigenesis.
Diabetes Mellitus, Type 2
PTP1B and TCPTP: Non-redundant phosphatases in insulin signaling and glucose homeostasis.
Diabetes Mellitus, Type 2
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.
Diabetes Mellitus, Type 2
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.
Diabetes Mellitus, Type 2
PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta).
Diabetes Mellitus, Type 2
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
Diabetes Mellitus, Type 2
PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014).
Diabetes Mellitus, Type 2
PTP1B inhibitory effect of abietane diterpenes isolated from Salvia miltiorrhiza.
Diabetes Mellitus, Type 2
PTP1B inhibitory effects of tridepside and related metabolites isolated from the Antarctic lichen Umbilicaria antarctica.
Diabetes Mellitus, Type 2
PTP1B Inhibitory Secondary Metabolites from Marine-Derived Fungal Strains Penicillium spp. and Eurotium sp.
Diabetes Mellitus, Type 2
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes.
Diabetes Mellitus, Type 2
QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives.
Diabetes Mellitus, Type 2
Quantitative evaluation of PTPN22 copy number variation by digital droplet PCR and association with type 2 diabetes risk.
Diabetes Mellitus, Type 2
Reactions of 1,3-Diketones with a Dipeptide Isothiazolidin-3-one: Toward Agents That Covalently Capture Oxidized Protein Tyrosine Phosphatase 1B.
Diabetes Mellitus, Type 2
Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes.
Diabetes Mellitus, Type 2
Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Diabetes Mellitus, Type 2
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Diabetes Mellitus, Type 2
Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice.
Diabetes Mellitus, Type 2
Replication study for the association of rs391300 in SRR and rs17584499 in PTPRD with susceptibility to type 2 diabetes in a Japanese population.
Diabetes Mellitus, Type 2
Rhododendric acid A, a new ursane-type PTP1B inhibitor from the endangered plant Rhododendron brachycarpum G. Don.
Diabetes Mellitus, Type 2
Screening and identification of potential PTP1B allosteric inhibitors using in silico and in vitro approaches.
Diabetes Mellitus, Type 2
Sensitivity of protein tyrosine phosphatase activity to the redox environment, cytochrome C, and microperoxidase.
Diabetes Mellitus, Type 2
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
Diabetes Mellitus, Type 2
SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes.
Diabetes Mellitus, Type 2
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Diabetes Mellitus, Type 2
Steroidal Alkaloids from Veratrum nigrum Enhance Glucose Uptake in Skeletal Muscle Cells.
Diabetes Mellitus, Type 2
Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.
Diabetes Mellitus, Type 2
Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.
Diabetes Mellitus, Type 2
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.
Diabetes Mellitus, Type 2
Synthesis and biological evaluation of novel N-aryl-?-(benzoazol-2-yl)-sulfanylalkanamides as dual inhibitors of ?-glucosidase and protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Synthesis of triazole-linked beta-C-glycosyl dimers as inhibitors of PTP1B.
Diabetes Mellitus, Type 2
Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Diabetes Mellitus, Type 2
Synthesis, In Vitro Evaluation and Molecular Docking of the 5-Acetyl-2-aryl-6-hydroxybenzo[b]furans against Multiple Targets Linked to Type 2 Diabetes.
Diabetes Mellitus, Type 2
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.
Diabetes Mellitus, Type 2
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
Diabetes Mellitus, Type 2
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
Diabetes Mellitus, Type 2
The mechanism of allosteric inhibition of protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.
Diabetes Mellitus, Type 2
The Role of MKP-5 in Adipocyte-Macrophage Interactions during Obesity.
Diabetes Mellitus, Type 2
The role of protein-tyrosine phosphatase 1B in integrin signaling.
Diabetes Mellitus, Type 2
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
Diabetes Mellitus, Type 2
The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.
Diabetes Mellitus, Type 2
The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates.
Diabetes Mellitus, Type 2
Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors.
Diabetes Mellitus, Type 2
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Diabetes Mellitus, Type 2
Type 2 diabetes risk gene Dusp8 regulates hypothalamic Jnk signaling and insulin sensitivity.
Diabetes Mellitus, Type 2
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
Diabetes Mellitus, Type 2
Ursolic acid derivatives as potential antidiabetic agents: In vitro, in vivo, and in silico studies.
Diabetes Mellitus, Type 2
Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Validation Of Formylchromane Derivatives As Ptp 1b Inhibitors By Pharmacophore Modeling, Atom Based 3d-Qsar And Docking Studies.
Diabetes Mellitus, Type 2
Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Vindogentianine, a hypoglycemic alkaloid from Catharanthus roseus (L.) G. Don (Apocynaceae).
Diabetes Mellitus, Type 2
Virtual screening, optimization, and identification of a novel specific PTP-MEG2 inhibitor with potential therapy for T2DM.
Diabetes Mellitus, Type 2
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B.
Diabetes Mellitus, Type 2
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
Diabetes Mellitus, Type 2
[Association of -6735T-->C variant of glucokinase-associated dual-specificity phosphatase 12 gene with type 2 diabetes in Chinese]
Diabetes Mellitus, Type 2
[Effects of rare islet autoantibodies on islet function in patients with latent autoimmune diabetes in adults].
Diabetes Mellitus, Type 2
[Multivariate logistic regression analysis on the risk factors of type 2 diabetes mellitus]
Diabetes Mellitus, Type 2
[PTP1B inhibitory activities of bromophenol derivatives from algae]
Diabetes Mellitus, Type 2
[Research progress of several protein tyrosine phosphatases in diabetes.]
Diabetes Mellitus, Type 2
[Role of protein tyrosine phosphatase 1B in the type 2 diabetes and obesity]
Diabetes Mellitus, Type 2
[Search for Protein Tyrosine Phosphatase 1B Inhibitors from Marine Organisms and Induced Production of New Fungal Metabolites by Modulating Culture Methods].
Diabetes Mellitus, Type 2
[Single nucleotide polymorphism of protein tyrosine phosphatase 1B (PTP-1B) gene. Clinical implications in type 2 diabetes]
Diabetes, Gestational
Expression of Dual-Specificity Phosphatase 9 in Placenta and Its Relationship with Gestational Diabetes Mellitus.
Diabetes, Gestational
Functional genetic variants in the 3'UTR of PTPRD associated with the risk of gestational diabetes mellitus.
Diabetes, Gestational
MiR-6869-5p Induces M2 Polarization by Regulating PTPRO in Gestational Diabetes Mellitus.
Diabetes, Gestational
Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood.
Diabetes, Gestational
[Association of DUSP9 gene polymorphisms with gestational diabetes mellitus].
Diabetic Angiopathies
N?-carboxymethyllysine-mediated endoplasmic reticulum stress promotes endothelial cell injury through Nox4/MKP-3 interaction.
Diabetic Cardiomyopathies
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.
Diabetic Cardiomyopathies
Diabetic cardiomyopathy: a "cardiac stem cell disease" involving p66Shc, an attractive novel molecular target for heart failure therapy.
Diabetic Cardiomyopathies
Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats.
Diabetic Ketoacidosis
Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual ?-cell function 1 year after diagnosis of type 1 diabetes.
Diabetic Nephropathies
A novel biphenyl compound, VMNS2e, ameliorates streptozotocin induced diabetic nephropathy in rats.
Diabetic Nephropathies
Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.
Diabetic Nephropathies
Author Correction: p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy.
Diabetic Nephropathies
Diabetic nephropathy: Role of podocyte SHP-1 in hyperglycaemic memory.
Diabetic Nephropathies
Dioscorea zingiberensis ameliorates diabetic nephropathy by inhibiting NLRP3 inflammasome and curbing the expression of p66Shc in high-fat diet/streptozotocin-induced diabetic mice.
Diabetic Nephropathies
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Diabetic Nephropathies
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Diabetic Nephropathies
Hyperglycaemia Stress-Induced Renal Injury is Caused by Extensive Mitochondrial Fragmentation, Attenuated MKP1 Signalling, and Activated JNK-CaMKII-Fis1 Biological Axis.
Diabetic Nephropathies
Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats.
Diabetic Nephropathies
Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes.
Diabetic Nephropathies
Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients.
Diabetic Nephropathies
p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway.
Diabetic Nephropathies
p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
Diabetic Nephropathies
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
Diabetic Nephropathies
p66Shc: A novel biomarker of tubular oxidative injury in patients with diabetic nephropathy.
Diabetic Nephropathies
Perturbations in mitochondrial dynamics by p66Shc lead to renal tubular oxidative injury in human diabetic nephropathy.
Diabetic Nephropathies
PKC? promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc.
Diabetic Nephropathies
Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.
Diabetic Nephropathies
PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
Diabetic Nephropathies
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
Diabetic Nephropathies
Targeting VE-PTP phosphatase protects the kidney from diabetic injury.
Diabetic Nephropathies
The CREB/KMT5A complex regulates PTP1B to modulate high glucose-induced endothelial inflammatory factor levels in diabetic nephropathy.
Diabetic Nephropathies
The PKC?-p66shc-NADPH oxidase pathway plays a crucial role in diabetic nephropathy.
Diabetic Nephropathies
TRIM18-Regulated STAT3 Signaling Pathway via PTP1B Promotes Renal Epithelial-Mesenchymal Transition, Inflammation, and Fibrosis in Diabetic Kidney Disease.
Diabetic Nephropathies
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Diabetic Neuropathies
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Diabetic Retinopathy
9-cis-retinoic acid improves sensitivity to platelet-derived growth factor-BB via RXR? and SHP-1 in diabetic retinopathy.
Diabetic Retinopathy
?A1-crystallin regulates glucose metabolism and mitochondrial function in mouse retinal astrocytes by modulating PTP1B activity.
Diabetic Retinopathy
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.
Diabetic Retinopathy
Adaptor Protein p66Shc: A Link Between Cytosolic and Mitochondrial Dysfunction in the Development of Diabetic Retinopathy.
Diabetic Retinopathy
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]
Digestive System Neoplasms
[Acid phosphatase activity and non-specific esterase D of alpha-naphthyl acetate in the lymphocytes of patients with digestive system neoplasms after surgical treatment]
Distemper
Accumulation of Extracellular Matrix in Advanced Lesions of Canine Distemper Demyelinating Encephalitis.
Diverticulitis
RNA-seq implicates deregulation of the immune system in the pathogenesis of diverticulitis.
Down Syndrome
CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21).
Down Syndrome
Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.
Down Syndrome
Phosphotyrosine phosphatase activity and haematologic changes in Down's syndrome patients.
Ductus Arteriosus, Patent
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Duodenal Ulcer
[CagA tyrosine phosphorylation motif structure and SHP-2 binding ability of Helicobacter pylori studied in stomach cancer and duodenal ulcer cell lines]
Duodenal Ulcer
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Dysentery, Amebic
Acid phosphatase activity in the intestinal wall in experimental amebic colitis.
Dyskinesias
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Dyskinesias
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Dyslipidemias
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese.
Dyslipidemias
Cyclocarya paliurus Leaves Tea Improves Dyslipidemia in Diabetic Mice: A Lipidomics-Based Network Pharmacology Study.
Dyslipidemias
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Dyslipidemias
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Dyslipidemias
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Dyslipidemias
Increased hepatic FAT/CD36, PTP1B and decreased HNF4A expression contributes to dyslipidemia associated with ethanol-induced liver dysfunction: Rescue effect of ginger extract.
Dyslipidemias
Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
Dyslipidemias
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Eczema
An inverse association between history of childhood eczema and subsequent risk of type 1 diabetes that is not likely to be explained by HLA-DQ, PTPN22, or CTLA4 polymorphisms.
Ellis-Van Creveld Syndrome
Genomic structure and localization of the human protein phosphatase 2A BRgamma regulatory subunit.
Encephalitis
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
Encephalomyelitis
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Encephalomyelitis
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Encephalomyelitis
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Encephalomyelitis
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Encephalomyelitis
Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis.
Encephalomyelitis
MAP kinase phosphatase 2 deficient mice develop attenuated experimental autoimmune encephalomyelitis through regulating dendritic cells and T cells.
Encephalomyelitis
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Encephalomyelitis
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Encephalomyelitis
Protein tyrosine phosphatase ? regulates autoimmune encephalomyelitis development.
Encephalomyelitis
Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice.
Encephalomyelitis
The P66Shc/mitochondrial permeability transition pore pathway determines neurodegeneration.
Encephalomyelitis, Autoimmune, Experimental
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Encephalomyelitis, Autoimmune, Experimental
Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice.
Encephalomyelitis, Autoimmune, Experimental
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Encephalomyelitis, Autoimmune, Experimental
Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
MAP kinase phosphatase 2 deficient mice develop attenuated experimental autoimmune encephalomyelitis through regulating dendritic cells and T cells.
Encephalomyelitis, Autoimmune, Experimental
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Encephalomyelitis, Autoimmune, Experimental
Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice.
Encephalomyelitis, Autoimmune, Experimental
The P66Shc/mitochondrial permeability transition pore pathway determines neurodegeneration.
Encephalomyelitis, Venezuelan Equine
Acid phosphatase activity in mouse brain infected with Venezuelan equine encephalomyelitis virus.
Enchondromatosis
Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
Endocrine System Diseases
[Latent forms of adult-onset autoimmune polyglandular syndrome: diagnosis and management of patients].
Endometrial Hyperplasia
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Endometrial Hyperplasia
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Endometrial Hyperplasia
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.
Endometrial Neoplasms
Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer.
Endometrial Neoplasms
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Endometrial Neoplasms
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Endometrial Neoplasms
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Endometrial Neoplasms
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Endometrial Neoplasms
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Endometrial Neoplasms
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Endometrial Neoplasms
Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.
Endometrial Neoplasms
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Endometrial Neoplasms
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Endometrial Neoplasms
Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Endometrial Neoplasms
miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression.
Endometrial Neoplasms
MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
Endometrial Neoplasms
Phosphotyrosine phosphatase-activity in membranes from endometrial carcinoma.
Endometrial Neoplasms
PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells.
Endometrial Neoplasms
Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
Endometrial Neoplasms
Prolactin receptor-linked tyrosine-phosphorylation of membrane-proteins is mediated by GTP-binding protein in endometrial carcinoma and endometrium.
Endometrial Neoplasms
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Endometrial Neoplasms
Regulation of PTP1D mRNA by peptide growth factors in the human endometrial cell line HEC-1-A.
Endometrial Neoplasms
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Endometrial Neoplasms
The Highly Recurrent PP2A A?-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.
Endometrial Neoplasms
TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Endometriosis
An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression.
Endometriosis
Association of the protein tyrosine phosphatase non-receptor 22 polymorphism (PTPN22) with endometriosis: a meta-analysis.
Endometriosis
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Endometriosis
Identification of global transcriptome abnormalities and potential biomarkers in eutopic endometria of women with endometriosis: A preliminary study.
Endometriosis
Phosphatase of regenerating liver-3: a novel and promising marker in human endometriosis.
Endometriosis
PRL-3 Is Involved in Estrogen- and IL-6-Induced Migration of Endometrial Stromal Cells From Ectopic Endometrium.
Endometriosis
SMURF1-mediated ubiquitylation of SHP-1 promotes cell proliferation and invasion of endometrial stromal cells in endometriosis.
Endometriosis
The association of PTPN22 polymorphism with endometriosis: effect of genetic and clinical factors.
Endometriosis
The effect of ACP1, ADA6 and PTPN22 genetic polymorphisms on the association between p53 codon 72 polymorphism and endometriosis.
Endotoxemia
Mitogen-activated protein kinase phosphatase-1 expression in macrophages is controlled by lymphocytes during macrophage activation.
Endotoxemia
Mitogen-activated protein kinase phosphatase-1 inhibits myocardial TNF-? expression and improves cardiac function during endotoxemia.
Endotoxemia
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Endotoxemia
Protein phosphatase 2A contributes to the cardiac dysfunction induced by endotoxemia.
Enteritis
Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-?B activation.
Enteritis
Supplementation exogenous bile acid improved growth and intestinal immune function associated with NF-?B and TOR signalling pathways in on-growing grass carp (Ctenopharyngodon idella): Enhancement the effect of protein-sparing by dietary lipid.
Enteritis
Vitamin A deficiency suppresses fish immune function with differences in different intestinal segments: the role of transcriptional factor NF-?B and p38 mitogen-activated protein kinase signalling pathways.
Enterocolitis, Necrotizing
Single nucleotide polymorphisms in the dual specificity phosphatase genes and risk of necrotizing enterocolitis in premature infant.
Enterotoxemia
[Activity of various enzymes of the intestinal mucosa in spontaneous colibacteriosis in pigs]
Enterovirus Infections
Enterovirus infection can induce immune responses that cross-react with beta-cell autoantigen tyrosine phosphatase IA-2/IAR.
Enterovirus Infections
Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans.
Enzootic Bovine Leukosis
Bovine leukemia virus transmembrane protein gp30 physically associates with the down-regulatory phosphatase SHP-1.
Eosinophilia
Endothelial cell PTP1B regulates leukocyte recruitment during allergic inflammation.
Eosinophilia
Expression on human eosinophils of CD148: a membrane tyrosine phosphatase. Implications in the effector function of eosinophils.
Eosinophilia
Histological and histochemical examinations of the myocardium of rats kept on low-magnesium diet and treated with cyclophosphamide.
Eosinophilia
The expression of cancerous inhibitor protein phosphatase 2A in chronic rhinosinusitis with nasal polyps.
Ependymoma
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Epidermodysplasia Verruciformis
The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.
Epilepsies, Myoclonic
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.
Epilepsy
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Epilepsy
Genetic diagnoses in epilepsy: The impact of dynamic exome analysis in a pediatric cohort.
Epilepsy
Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an animal model for Lafora disease.
Epilepsy
Large De Novo Microdeletion in Epilepsy with Intellectual and Developmental Disabilities, with a Systems Biology Analysis.
Epilepsy
Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of serine 89.
Epilepsy
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Epilepsy
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Epilepsy
Transient expression of the mitogen-activated protein kinase phosphatase MKP-1 (3CH134/ERP1) in the rat brain after limbic epilepsy.
Epilepsy
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Epilepsy
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
Epilepsy, Post-Traumatic
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Epilepsy, Temporal Lobe
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
Epstein-Barr Virus Infections
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Erectile Dysfunction
Argirein alleviates corpus cavernosum dysfunction by suppressing pro-inflammatory factors p66Shc and ER stress chaperone Bip in diabetic rats.
Escherichia coli Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Escherichia coli Infections
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Esophageal Achalasia
Gender-specific association of the PTPN22 C1858T polymorphism with achalasia.
Esophageal Neoplasms
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Esophageal Neoplasms
Artesunate induces apoptosis and inhibits growth of Eca109 and Ec9706 human esophageal cancer cell lines in vitro and in vivo.
Esophageal Neoplasms
CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers.
Esophageal Neoplasms
Expression and significance of CDC25B, PED/PEA-15 in esophageal carcinoma.
Esophageal Neoplasms
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Esophageal Neoplasms
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Esophageal Neoplasms
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.
Esophageal Neoplasms
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Esophageal Neoplasms
Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis.
Esophageal Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Esophageal Neoplasms
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Esophageal Squamous Cell Carcinoma
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Esophageal Squamous Cell Carcinoma
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Esophageal Squamous Cell Carcinoma
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Methylation and expression of PTPN22 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
MiR-214 inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by targeting CDC25B.
Esophageal Squamous Cell Carcinoma
MiR-450a-5p inhibits autophagy and enhances radiosensitivity by targeting dual-specificity phosphatase 10 in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Esophageal Squamous Cell Carcinoma
p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy.
Esophageal Squamous Cell Carcinoma
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Esophageal Squamous Cell Carcinoma
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Esophageal Squamous Cell Carcinoma
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
Esophageal Squamous Cell Carcinoma
Retraction of: Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China; DOI: 10.1089/gtmb.2016.0194.
Esophageal Squamous Cell Carcinoma
Single Nucleotide Polymorphisms in the PTPN1 Gene Are Associated with Susceptibility to Esophageal Squamous Cell Carcinoma: A Case-Control Study in Inner Mongolia, China.
Esophageal Squamous Cell Carcinoma
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
Esophageal Squamous Cell Carcinoma
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Essential Hypertension
Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension.
Essential Hypertension
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Essential Hypertension
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Essential Hypertension
Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity.
Exanthema
Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children.
Exostoses
SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.
Exostoses, Multiple Hereditary
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Extranodal Extension
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Eye Burns
[Changes in the acid phosphatase activity of the cornea in the dynamics of a chemical eye burn]
Eye Diseases
Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation.
Familial Mediterranean Fever
Lack of the Association of the PTPN22 C1858T Gene Polymorphism With Susceptibility to Familial Mediterranean Fever.
Fanconi Anemia
Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.
Fasciculation
Chondroitin sulfate proteoglycan phosphacan associates with parallel fibers and modulates axonal extension and fasciculation of cerebellar granule cells.
Fasciculation
Receptor tyrosine phosphatases guide vertebrate motor axons during development.
Fatty Liver
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Fatty Liver
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Fatty Liver
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Fatty Liver
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Fatty Liver
Protective Function of Mitogen-Activated Protein Kinase Phosphatase 5 in Aging- and Diet-Induced Hepatic Steatosis and Steatohepatitis.
Fatty Liver
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Fatty Liver
Structure-functional implications of longevity protein p66Shc in health and disease.
Fatty Liver, Alcoholic
The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells.
Fatty Liver, Alcoholic
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Favism
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
Fetal Death
Early fetal death associated with compound heterozygosity for Noonan syndrome-causative PTPN11 mutations.
Fetal Diseases
Activation of oxidative stress signaling that is implicated in apoptosis with a mouse model of diabetic embryopathy.
Fetal Growth Retardation
Intrauterine Growth Restriction Affects Hippocampal Dual Specificity Phosphatase 5 Gene Expression and Epigenetic Characteristics.
Fetal Growth Retardation
Intrauterine growth restriction alters T-lymphocyte cell number and dual specificity phosphatase 1 levels in the thymus of newborn and juvenile rats.
Fibroma
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Fibromatosis, Gingival
Association of mutation in PTPN14 gene and gingival fibromatosis with distinctive facies: a novel finding in whole exome sequencing.
Fibrosarcoma
The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta.
Filariasis
Study of human and parasitic factors in relation to bancroftian filariasis in Egypt.
Fluorosis, Dental
MAP kinase phosphatase MKP-1 regulates p-ERK1/2 signaling pathway with fluoride treatment.
Fluorosis, Dental
Moderating Role of TSHR and PTPN22 Gene Polymorphisms in Effects of Excessive Fluoride on Thyroid: a School-Based Cross-Sectional Study.
Food Hypersensitivity
Asthma and allergic symptoms and type 1 diabetes-related autoantibodies in 2.5-yr-old children.
Fractures, Spontaneous
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Fragile X Syndrome
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Fragile X Syndrome
The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.
Frontotemporal Dementia
Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family.
Frontotemporal Dementia
Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations.
Funnel Chest
Giant Cell Lesions in Noonan Syndrome: Case Report and Review of The Literature.
Ganglion Cysts
Induction of protein tyrosine phosphatase epsilon transcripts during NGF-induced neuronal differentiation of PC12D cells and during the development of the cerebellum.
Ganglioneuroma
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Gastritis
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Gastritis
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
Gastritis
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Gastritis, Atrophic
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Gastritis, Atrophic
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
Gastritis, Atrophic
The effects of cure of Helicobacter pylori infection on the signal transduction of gastric epithelial cells.
Gastroenteritis
Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes.
Gastrointestinal Diseases
Cytotoxicity and recognition of receptor-like protein tyrosine phosphatases, RPTPalpha and RPTPbeta, by Helicobacter pylori m2VacA.
Gastrointestinal Diseases
Dynamics of the WPD loop of the Yersinia protein tyrosine phosphatase.
Gastrointestinal Diseases
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Gastrointestinal Diseases
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Gastrointestinal Neoplasms
Molecular cloning of a human transmembrane-type protein tyrosine phosphatase and its expression in gastrointestinal cancers.
Gastrointestinal Stromal Tumors
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Gaucher Disease
ACID PHOSPHATASE ACTIVITY OF SERUM, THROMBOCYTES AND ERYTHROCYTES IN A JUVENILE FORM OF GAUCHER'S DISEASE.
Gaucher Disease
Biochemical properties of the tartrate-resistant acid phosphatase activity in Gaucher disease.
Gaucher Disease
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
Gaucher Disease
Gaucher disease: comparative study of acid phosphatase and glucocerebrosidase in normal and type-1 Gaucher tissues.
Gaucher Disease
Sodium taurocholate effect on beta-glucosidase activity: a new approach for identification of Gaucher disease using the synthetic substrate and leucocytes.
Gaucher Disease
The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis.
Genetic Diseases, Inborn
Clinical exome sequencing: results from 2819 samples reflecting 1000 families.
Genetic Diseases, Inborn
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Genetic Diseases, Inborn
Engineering Cell-Permeable Proteins through Insertion of Cell-Penetrating Motifs into Surface Loops.
Genetic Diseases, Inborn
Fetal hydrops and the Incremental yield of Next generation sequencing over standard prenatal Diagnostic testing (FIND) study: prospective cohort study and meta-analysis.
Genetic Diseases, Inborn
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
Genetic Diseases, Inborn
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
Genetic Diseases, Inborn
Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene.
Genetic Diseases, Inborn
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Genetic Diseases, Inborn
The regulation of male fertility by the PTPN11 tyrosine phosphatase.
Giant Cell Arteritis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Giant Cell Arteritis
Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.
Giant Cell Arteritis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Giant Cell Arteritis
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
Giant Cell Arteritis
PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis.
Giant Cell Tumor of Bone
Localization of acid phosphatase activity in a giant cell tumor of bone.
Giant Cell Tumors
New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone.
Glaucoma
Early remodelling of the extracellular matrix proteins tenascin-C and phosphacan in retina and optic nerve of an experimental autoimmune glaucoma model.
Glaucoma
Loss of Shp2 Rescues BDNF/TrkB Signaling and Contributes to Improved Retinal Ganglion Cell Neuroprotection.
Glaucoma
Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma.
Glaucoma, Open-Angle
Extracellular Matrix Remodeling in the Retina and Optic Nerve of a Novel Glaucoma Mouse Model.
Glioblastoma
A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells.
Glioblastoma
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase micro.
Glioblastoma
ceRNA Network Analysis Shows That lncRNA CRNDE Promotes Progression of Glioblastoma Through Sponge mir-9-5p.
Glioblastoma
Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.
Glioblastoma
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Glioblastoma
Contactin is expressed in human astrocytic gliomas and mediates repulsive effects.
Glioblastoma
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies.
Glioblastoma
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Glioblastoma
Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
Glioblastoma
Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?
Glioblastoma
Dual-specificity phosphatase (DUSP6) in human glioblastoma: epithelial-to-mesenchymal transition (EMT) involvement.
Glioblastoma
Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.
Glioblastoma
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Glioblastoma
Euxanthone represses the proliferation, migration, and invasion of glioblastoma cells by modulating STAT3/SHP-1 signaling.
Glioblastoma
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas.
Glioblastoma
Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.
Glioblastoma
Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment.
Glioblastoma
Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway.
Glioblastoma
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Glioblastoma
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Glioblastoma
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Glioblastoma
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Glioblastoma
Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines.
Glioblastoma
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Glioblastoma
Mesenchymal glioblastoma constitutes a major ceRNA signature in the TGF-? pathway.
Glioblastoma
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma.
Glioblastoma
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Glioblastoma
Molecular Basis of the Interaction of the Human Protein Tyrosine Phosphatase Non-receptor Type 4 (PTPN4) with the Mitogen-activated Protein Kinase p38?.
Glioblastoma
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Glioblastoma
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
Glioblastoma
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Glioblastoma
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Glioblastoma
Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C.
Glioblastoma
Ouabain elicits human glioblastoma cells apoptosis by generating reactive oxygen species in ERK-p66SHC-dependent pathway.
Glioblastoma
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
Glioblastoma
Peptides targeting the PDZ domain of PTPN4 are efficient inducers of glioblastoma cell death.
Glioblastoma
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.
Glioblastoma
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis.
Glioblastoma
PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
Glioblastoma
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Glioblastoma
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Glioblastoma
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.
Glioblastoma
Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo.
Glioblastoma
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Glioblastoma
Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration.
Glioblastoma
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Glioblastoma
PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
Glioblastoma
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
Glioblastoma
PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling.
Glioblastoma
Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy.
Glioblastoma
RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo.
Glioblastoma
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.
Glioblastoma
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Glioblastoma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Glioblastoma
Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Glioblastoma
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Glioblastoma
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
Glioblastoma
The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.
Glioblastoma
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
Glioblastoma
The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Glioblastoma
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Glioblastoma
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Glioblastoma
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Glioblastoma
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Glioblastoma
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Glioma
?1,6 GlcNAc branches-modified protein tyrosine phosphatase Mu attenuates its tyrosine phosphatase activity and promotes glioma cell migration through PLC?-PKC pathways.
Glioma
A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells.
Glioma
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Glioma
Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
Glioma
An alternative role for the src-homology-domain-containing phosphotyrosine phosphatase (SH-PTP2) in regulating epidermal-growth-factor-dependent cell growth.
Glioma
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
Glioma
Cadmium specifically induces MKP-1 expression via the glutathione depletion-mediated p38 MAPK activation in C6 glioma cells.
Glioma
CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples.
Glioma
Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma.
Glioma
Constitutive CHK1 expression drives a pSTAT3-CIP2A circuit that promotes glioblastoma cell survival and growth.
Glioma
Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism.
Glioma
Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Glioma
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Glioma
Gossypin Induces G2/M Arrest in Human Malignant Glioma U251 Cells by the Activation of Chk1/Cdc25C Pathway.
Glioma
High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response.
Glioma
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Glioma
Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules.
Glioma
Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue.
Glioma
Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility.
Glioma
Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway.
Glioma
LncRNA TCONS_00004099-derived microRNA regulates oncogenesis through PTPRF in gliomas.
Glioma
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Glioma
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Glioma
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Glioma
MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation.
Glioma
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Glioma
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Glioma
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Glioma
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Glioma
Novel LncRNA OXCT1-AS1 indicates poor prognosis and contributes to tumorigenesis by regulating miR-195/CDC25A axis in glioblastoma.
Glioma
Potent and selective inhibition of T-cell protein tyrosine phosphatase (TCPTP) by a dinuclear copper(II) complex.
Glioma
Pristimerin inhibits glioma progression by targeting AGO2 and PTPN1 expression via miR-542-5p.
Glioma
Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest.
Glioma
Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
Glioma
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Glioma
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Glioma
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
Glioma
PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Glioma
PTPN2 induced by inflammatory response and oxidative stress contributed to glioma progression.
Glioma
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas.
Glioma
Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Glioma
Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes.
Glioma
Reduced phosphorylation of Stat3 at Ser-727 mediated by Casein Kinase 2 - Protein Phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells.
Glioma
Roles and potential clinical applications of intermediate filament proteins in brain tumors.
Glioma
Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells.
Glioma
SHP-2-upregulated ZEB1 is important for PDGFR?-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Glioma
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Glioma
Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Glioma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Glioma
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Glioma
The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation.
Glioma
The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2.
Glioma
The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas.
Glioma
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Glioma
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Glioma
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Glioma
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Glioma
UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway.
Glioma
Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.
Glioma, Subependymal
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Glomerulonephritis
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Glomerulonephritis
Expression of B cell receptor-associated signaling molecules in human lupus.
Glomerulonephritis
Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis.
Glomerulonephritis
Oxidative stress-inducible protein tyrosine phosphatase in glomerulonephritis.
Glomerulonephritis
Proliferating and migrating mesangial cells responding to injury express a novel receptor protein-tyrosine phosphatase in experimental mesangial proliferative glomerulonephritis.
Glomerulonephritis
PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein.
Glomerulonephritis, IGA
Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy.
Glomerulosclerosis, Focal Segmental
Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis.
Glucagonoma
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Glucagonoma
Profile and differential expression of protein tyrosine phosphatases in mouse pancreatic islet tumor cell lines.
Glucose Intolerance
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
Glucose Intolerance
Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action.
Glucose Intolerance
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
Glucose Intolerance
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Glucose Intolerance
Effects of vitamin D and resveratrol on metabolic associated markers in liver and adipose tissue from SAMP8 mice.
Glucose Intolerance
Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats.
Glucose Intolerance
Frequency of latent autoimmune diabetes in adults in Asian patients diagnosed as type 2 diabetes in Birmingham, United Kingdom.
Glucose Intolerance
Genetic variation in receptor protein tyrosine phosphatase {sigma} is associated with type 2 diabetes in Swedish Caucasians.
Glucose Intolerance
Insulin secretion in islets from mice with a double knockout for the dense core vesicle proteins islet antigen-2 (IA-2) and IA-2beta.
Glucose Intolerance
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Glucose Intolerance
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.
Glucose Intolerance
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Glucose Intolerance
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Glucose Intolerance
Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B axis.
Glucose Intolerance
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Glucose Intolerance
Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice.
Glucose Intolerance
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Glucose Intolerance
Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice.
Glucose Intolerance
To binge or not to binge: Binge drinking disrupts glucose homeostasis by impairing hypothalamic but not liver insulin signaling.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
Glucosephosphate Dehydrogenase Deficiency
Red cell acid phosphatase activity in carriers of beta-thalassemia trait and glucose-6-phosphate dehydrogenase deficiency.
glutamate-5-semialdehyde dehydrogenase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Glycogen Storage Disease
Centronuclear myopathy: histochemistry and electron microscopy. Report of two cases.
Glycogen Storage Disease Type II
Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology.
Goiter
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Goiter
Moderating Role of TSHR and PTPN22 Gene Polymorphisms in Effects of Excessive Fluoride on Thyroid: a School-Based Cross-Sectional Study.
Goiter
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Goiter
[Changes in the lactate dehydrogenase and alkaline and acid phosphatase activity in the arterial and venous blood serum and thyroid tissue in different forms of goiter]
Goiter
[Histochemical characteristics of some oxidation-reduction hydrolytic enzymes in different forms of goiter]
Graft vs Host Disease
Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
Graft vs Host Disease
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Gram-Negative Bacterial Infections
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Gram-Positive Bacterial Infections
Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria.
Gram-Positive Bacterial Infections
The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages.
Granular Cell Tumor
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
Granular Cell Tumor
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Granuloma
A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1.
Granulomatosis with Polyangiitis
PTPN22 R620W polymorphism in the ANCA-associated vasculitides.
Granulomatosis with Polyangiitis
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Graves Disease
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
Graves Disease
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Graves Disease
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Graves Disease
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Graves Disease
Association of PTPN22 1858T/T genotype with type 1 diabetes, Graves' disease but not with rheumatoid arthritis in Russian population.
Graves Disease
Association of PTPN22 polymorphism and its correlation with Graves' disease susceptibility in Polish adult population-A preliminary study.
Graves Disease
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Graves Disease
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Graves Disease
Associations of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms with susceptibility to Graves' disease in a Japanese population.
Graves Disease
Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves' disease.
Graves Disease
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Graves Disease
Genetic developments in autoimmune thyroid disease: an evolutionary process.
Graves Disease
Genetic heterogeneity of susceptibility gene in different ethnic populations: refining association study of PTPN22 for Graves' disease in a Chinese Han population.
Graves Disease
Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset.
Graves Disease
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Graves Disease
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Graves Disease
Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves' disease: susceptibility and clinical features.
Graves Disease
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy.
Graves Disease
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Graves Disease
PTPN22 1858 C/T Exon Polymorphism is not Associated with Graves' Disease in Kashmiri population.
Graves Disease
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
Graves Disease
PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes.
Graves Disease
RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.
Graves Disease
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Graves Disease
The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease.
Graves Disease
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
Graves Disease
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
Graves Disease
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
Graves Disease
Use of Tag single nucleotide polymorphisms (SNPs) to screen PTPN21: no association with Graves' disease.
Hamartoma
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Hamartoma
Pathogenic variants of DYNC2H1, KIAA0556, and PTPN11 associated with hypothalamic hamartoma.
Hamartoma Syndrome, Multiple
Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas.
Hamartoma Syndrome, Multiple
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Hamartoma Syndrome, Multiple
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.
Hamartoma Syndrome, Multiple
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Hamartoma Syndrome, Multiple
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
Hamartoma Syndrome, Multiple
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.
Hamartoma Syndrome, Multiple
Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome.
Hamartoma Syndrome, Multiple
The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Hashimoto Disease
Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.
Hashimoto Disease
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Hashimoto Disease
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Hashimoto Disease
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
Head and Neck Neoplasms
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Head and Neck Neoplasms
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Head and Neck Neoplasms
Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy.
Head and Neck Neoplasms
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Head and Neck Neoplasms
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Head and Neck Neoplasms
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Head and Neck Neoplasms
S-Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses radiation-induced apoptosis.
Hearing Loss
A C-terminal nonsense mutation links PTPRQ with autosomal-dominant hearing loss, DFNA73.
Hearing Loss
Autosomal Recessive Congenital Sensorineural Hearing Loss due to a Novel Compound Heterozygous PTPRQ Mutation in a Chinese Family.
Hearing Loss
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Hearing Loss
Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss.
Hearing Loss
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Hearing Loss
Expression of ERK signaling inhibitors Dusp6, Dusp7, and Dusp9 during mouse ear development.
Hearing Loss
First confirmatory study on PTPRQ as an autosomal dominant non-syndromic hearing loss gene.
Hearing Loss
Hair Bundle Defects and Loss of Function in the Vestibular End Organs of Mice Lacking the Receptor-Like Inositol Lipid Phosphatase PTPRQ.
Hearing Loss
Identification of a novel compound heterozygous mutation in PTPRQ in a DFNB84 family with prelingual sensorineural hearing impairment.
Hearing Loss
Identification of Novel PTPRQ and MYO1A Mutations in An Iranian Pedigree with Autosomal Recessive Hearing Loss.
Hearing Loss
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
Hearing Loss
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
Hearing Loss
Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction.
Hearing Loss
Nonsense mutation of the stereociliar membrane protein gene PTPRQ in human hearing loss DFNB84.
Hearing Loss
Novel PTPRQ mutations identified in three congenital hearing loss patients with various types of hearing loss.
Hearing Loss
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Hearing Loss
Rosiglitazone Improves Glucocorticoid Resistance in a Sudden Sensorineural Hearing Loss by Promoting MAP Kinase Phosphatase-1 Expression.
Hearing Loss
Spectrum and frequencies of non GJB2 gene mutations in Czech patients with early non-syndromic hearing loss detected by gene panel NGS and whole-exome sequencing.
Hearing Loss
When transcripts matter: delineating between non-syndromic hearing loss DFNB32 and hearing impairment infertile male syndrome (HIIMS).
Hearing Loss
Whole-exome sequencing identified a novel heterozygous mutation of SALL1 and a new homozygous mutation of PTPRQ in a Chinese family with Townes-Brocks syndrome and hearing loss.
Hearing Loss
[Case report and diagnosis of Noonan syndrome with multiple lentigines with deafness as its main clinical feature].
Hearing Loss, Sensorineural
A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population.
Hearing Loss, Sensorineural
Autosomal Recessive Congenital Sensorineural Hearing Loss due to a Novel Compound Heterozygous PTPRQ Mutation in a Chinese Family.
Hearing Loss, Sensorineural
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Hearing Loss, Sensorineural
Identification of Two Novel Compound Heterozygous PTPRQ Mutations Associated with Autosomal Recessive Hearing Loss in a Chinese Family.
Hearing Loss, Sensorineural
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Hearing Loss, Sensorineural
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Hearing Loss, Sensorineural
Novel PTPRQ mutations identified in three congenital hearing loss patients with various types of hearing loss.
Heart Arrest
Early glycogen synthase kinase-3? and protein phosphatase 2A independent tau dephosphorylation during global brain ischaemia and reperfusion following cardiac arrest and the role of the adenosine monophosphate kinase pathway.
Heart Defects, Congenital
A novel heterozygous MAP2K1 mutation in a patient with Noonan syndrome with multiple lentigines.
Heart Defects, Congenital
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Heart Defects, Congenital
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.
Heart Defects, Congenital
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Heart Defects, Congenital
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Heart Defects, Congenital
Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Heart Defects, Congenital
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Heart Defects, Congenital
Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.
Heart Defects, Congenital
PTPN11 mutations play a minor role in isolated congenital heart disease.
Heart Defects, Congenital
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Heart Defects, Congenital
Search for Rare Copy-Number Variants in Congenital Heart Defects Identifies Novel Candidate Genes and a Potential Role for FOXC1 in Patients With Coarctation of the Aorta.
Heart Defects, Congenital
SHP-2 regulates growth factor dependent vascular signalling and function.
Heart Defects, Congenital
The genetics of congenital heart disease: a review of recent developments.
Heart Defects, Congenital
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Heart Diseases
Association study of PTPN22 C1858T polymorphism in Trypanosoma cruzi infection.
Heart Diseases
Deletion of low molecular weight protein tyrosine phosphatase (Acp1) protects against stress-induced cardiomyopathy.
Heart Diseases
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Heart Diseases
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Heart Diseases
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Heart Failure
Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
Heart Failure
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Heart Failure
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene.
Heart Failure
Diabetic cardiomyopathy: a "cardiac stem cell disease" involving p66Shc, an attractive novel molecular target for heart failure therapy.
Heart Failure
Differential gene expression in skeletal muscle after induction of heart failure: impact of cytokines on protein phosphatase 2A expression.
Heart Failure
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice.
Heart Failure
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
Heart Failure
Exploration the Mechanism of Doxorubicin-Induced Heart Failure in Rats by Integration of Proteomics and Metabolomics Data.
Heart Failure
Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality.
Heart Failure
Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure.
Heart Failure
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Heart Failure
Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure.
Heart Failure
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
Heart Failure
P66Shc deletion ameliorates oxidative stress and cardiac dysfunction in pressure overload-induced heart failure.
Heart Failure
p66Shc links alpha1-adrenergic receptors to a reactive oxygen species-dependent AKT-FOXO3A phosphorylation pathway in cardiomyocytes.
Heart Failure
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Heart Failure
Protein Tyrosine Phosphatase-1B inactivation limits aging-associated heart failure in mice.
Heart Failure
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Heart Failure
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Heart Failure
The NF-kB regulates the SHP-1 expression in monocytes in congestive heart failure.
Heart Failure
[New pharmacological approaches in heart failure: should we treat the endothelium?]
Heart Septal Defects, Atrial
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Heart Septal Defects, Atrial
Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.
Heart Septal Defects, Atrial
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Heart Septal Defects, Atrial
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
Heart Septal Defects, Ventricular
Mosaic partial deletion of PTPN12 in a child with interrupted aortic arch type A.
Hemangioblastoma
Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.
Hemangioma
Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.
Hemangioma
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Hemangioma, Cavernous, Central Nervous System
Association of Variants in FCGR2A, PTPN2 and GM-CSF with Cerebral Cavernous Malformation: Potential Biomarkers for Symptomatic Disease.
Hemangioma, Cavernous, Central Nervous System
Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3.
Hemangiosarcoma
Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma.
Hematologic Neoplasms
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.
Hematologic Neoplasms
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Hematologic Neoplasms
Aberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia.
Hematologic Neoplasms
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Hematologic Neoplasms
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Hematologic Neoplasms
Deficiency in hematopoietic phosphatase ptpn6/Shp1 hyperactivates the innate immune system and impairs control of bacterial infections in zebrafish embryos.
Hematologic Neoplasms
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Hematologic Neoplasms
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
Hematologic Neoplasms
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
Hematologic Neoplasms
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Hematologic Neoplasms
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
Hematologic Neoplasms
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Hematologic Neoplasms
Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells.
Hematologic Neoplasms
Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Hematologic Neoplasms
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Hematologic Neoplasms
Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.
Hematologic Neoplasms
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Hematologic Neoplasms
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b.
Hematologic Neoplasms
Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
Hematologic Neoplasms
SHP-1 Protein Tyrosine Phosphatase Associates with the Adaptor Protein CrkL.
Hematologic Neoplasms
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
Hematologic Neoplasms
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Hematologic Neoplasms
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
Hematologic Neoplasms
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Hematologic Neoplasms
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
Hematologic Neoplasms
The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/?-catenin signaling pathway.
Hematologic Neoplasms
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
Hematologic Neoplasms
The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.
Hematologic Neoplasms
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Hematologic Neoplasms
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Hematologic Neoplasms
[Expression and Significance of PTPL1 in Hematological Malignan-cies].
Hemochromatosis
Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.
Hemochromatosis
Iron content and acid phosphatase activity in hepatic parenchymal lysosomes of patients with hemochromatosis before and after phlebotomy treatment.
Hemorrhagic Fever, Ebola
Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.
Hepatitis
Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A.
Hepatitis
Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice.
Hepatitis
[The morphologic basis for the mechanism of increased serum acid phosphatase activity in patients with viral hepatitis]
Hepatitis B
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Hepatitis B
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Hepatitis B
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Hepatitis B
Hepatitis B virus X protein impairs ?-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
Hepatitis B
Hepatitis B virus X protein mutant HBx?127 promotes proliferation of hepatoma cells through up-regulating miR-215 targeting PTPRT.
Hepatitis B
Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein.
Hepatitis B
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Hepatitis B
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Hepatitis B
Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.
Hepatitis B
[Effect of PTPRD rs2279776 gene and interaction with hepatitis B virus mutations on the risk of hepatocellular carcinoma].
Hepatitis B
[Functional-metabolic activity of the mononuclear phagocyte system of the blood, liver, spleen and skin in children with hepatitis B]
Hepatitis B, Chronic
Association of PTPN22 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.
Hepatitis C
Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.
Hepatitis C
Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line.
Hepatitis C
Hepatitis C Virus Induced miR200c Down Modulates FAP-1, a Negative Regulator of Src Signaling and Promotes Hepatic Fibrosis.
Hepatitis C
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.
Hepatitis C
Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-{gamma} production.
Hepatitis C
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Hepatitis C
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
Hepatitis C
Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.
Hepatitis C
Protein phosphatase 2A impairs IFN?-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.
Hepatitis C
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Hepatitis C
Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
Hepatitis C
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Hepatitis C
The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein.
Hepatitis C, Chronic
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A.
Hepatitis C, Chronic
Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair.
Hepatitis C, Chronic
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
Hepatitis C, Chronic
PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.
Hepatitis C, Chronic
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.
Hepatitis, Alcoholic
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
Hepatitis, Autoimmune
77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link.
Hepatitis, Autoimmune
Association of STAT4, TGF?1, SH2B3 and PTPN22 polymorphisms with autoimmune hepatitis.
Hepatitis, Autoimmune
C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis.
Hepatitis, Autoimmune
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Hepatoblastoma
In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
Hepatoblastoma
The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Hepatolenticular Degeneration
Electron probe microanalysis of liver in Wilson's disease. Simultaneous assay for copper and for lead deposited by acid phosphatase activity in lysosomes.
Hepatolenticular Degeneration
LIVER CELL LYSOSOMES IN WILSON'S DISEASE: ACID PHOSPHATASE ACTIVITY BY LIGHT AND ELECTRON MICROSCOPY.
Hepatolenticular Degeneration
Studies on the pathogenesis of hepatolenticular degeneration. I. Acid phosphatase activity in copper-loaded rat livers.
Hepatomegaly
Biological action of lantadene C, a new hepatotoxicant from Lantana camara var. aculeata.
Hepatomegaly
Effect of polymorphic crystal forms of lantana toxins on icterogenic action in guinea pigs.
Hepatomegaly
Molecular structure, polymorphism, and toxicity of lantadene A, the pentacyclic triterpenoid from the hepatotoxic plant Lantana camara.
Hernias, Diaphragmatic, Congenital
Exome sequencing of fetuses with congenital diaphragmatic hernia supports a causal role for NR2F2, PTPN11, and WT1 variants.
Herpes Simplex
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Herpes Simplex
Search for varicella zoster virus and herpes simplex virus-1 in normal human cerebral arteries.
Herpes Simplex
The ESCRT-II Subunit EAP20/VPS25 and the Bro1 Domain Proteins HD-PTP and BROX Are Individually Dispensable for Herpes Simplex Virus 1 Replication.
Herpes Simplex
The Interaction of Herpes Simplex Virus 1 Regulatory Protein ICP22 with the cdc25C Phosphatase Is Enabled In Vitro by Viral Protein Kinases US3 and UL13.
Herpes Zoster
The localisation of acid phosphatase activity changes in lysosomes in the adrenal zona fasciculata of intact and hypophysectomized rats following ACTH administration.
Hirschsprung Disease
Downregulation of Protein Tyrosine Phosphatase Receptor Type R Accounts for the Progression of Hirschsprung Disease.
Histiocytic Sarcoma
Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas.
Histiocytic Sarcoma
Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Histiocytic Sarcoma
Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Histiocytic Sarcoma
Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Histiocytosis
an aggressive multifocal primary CNS histiocytosis with PTPN11 (Shp2) mutation.
Histiocytosis
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Histiocytosis, Langerhans-Cell
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
histone deacetylase deficiency
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Hodgkin Disease
A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.
Hodgkin Disease
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Hodgkin Disease
Acid phosphatase activity in monocytes and sera of patients with Hodgkin's disease.
Hodgkin Disease
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Hodgkin Disease
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Hodgkin Disease
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Hodgkin Disease
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
Hodgkin Disease
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Hodgkin Disease
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Hodgkin Disease
[Granulocyte acid phosphatase activity during the course of chronic myeloid leukemia and Hodgkin's disease]
HTLV-I Infections
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
HTLV-I Infections
Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells.
Huntington Disease
Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
Huntington Disease
Calpain and STriatal-Enriched protein tyrosine Phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model.
Huntington Disease
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.
Huntington Disease
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Huntington Disease
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Hydrocephalus
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Hydrocephalus
Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Hydrocephalus
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
Hydrocephalus, Normal Pressure
PTPRQ as a potential biomarker for idiopathic normal pressure hydrocephalus.
Hydrops Fetalis
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
Hydrops Fetalis
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Hydrothorax
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Hyperalgesia
BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation.
Hyperalgesia
CSF-CN contributes to cancer-induced bone pain via the MKP-1-mediated MAPK pathway.
Hyperalgesia
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Hyperalgesia
Mitogen-activated protein kinase phosphatase-3 (MKP-3) in the surgical wound is necessary for the resolution of postoperative pain in mice.
Hyperalgesia
Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.
Hyperalgesia
Propentofylline reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatase-1: An experimental study in a rat model of acute incisional pain.
Hyperalgesia
Shp-1 dephosphorylates TRPV1 in dorsal root ganglion neurons and alleviates CFA-induced inflammatory pain in rats.
Hyperalgesia
Spinal mitogen-activated protein kinase phosphatase-3 (MKP-3) is necessary for the normal resolution of mechanical allodynia in a mouse model of acute postoperative pain.
Hyperalgesia
Spinal SHP2 Contributes to Exaggerated Incisional Pain in Adult Rats Subjected to Neonatal and Adult Incisions via PI3K.
Hypercholesterolemia
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
Hypercholesterolemia
Epigenetic upregulation of p66shc mediates low-density lipoprotein cholesterol-induced endothelial cell dysfunction.
Hypercholesterolemia
Mechanism of attenuation of diabetes mellitus and hypercholesterolemia induced vascular endothelial dysfunction by protein tyrosine phosphatase inhibition.
Hypercholesterolemia
P66Shc mediates increased platelet activation and aggregation in hypercholesterolemia.
Hypercholesterolemia
Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models.
Hyperglycemia
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.
Hyperglycemia
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Hyperglycemia
Antidiabetic property of Symplocos cochinchinensis is mediated by inhibition of alpha glucosidase and enhanced insulin sensitivity.
Hyperglycemia
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Hyperglycemia
Cardiac mitochondrial dysfunction during hyperglycemia-The role of oxidative stress and p66Shc signaling.
Hyperglycemia
Diterpenes from seeds of Phalaris canariensis and their PTP1B inhibitory activity and hypoglycemic effects in streptozotocin-induced diabetic mice.
Hyperglycemia
Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats.
Hyperglycemia
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Hyperglycemia
Glomerular VEGF resistance induced by PKC?/SHP-1 activation and contribution to diabetic nephropathy.
Hyperglycemia
Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.
Hyperglycemia
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
Hyperglycemia
Highly Selective Protein Tyrosine Phosphatase Inhibitor, 2,2',3,3'-Tetrabromo-4,4',5,5'-tetrahydroxydiphenylmethane, Ameliorates Type 2 Diabetes Mellitus in BKS db Mice.
Hyperglycemia
Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction.
Hyperglycemia
Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.
Hyperglycemia
Hypomethylation of the promoter of the catalytic subunit of protein phosphatase 2A in response to hyperglycemia.
Hyperglycemia
Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition.
Hyperglycemia
Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Hyperglycemia
Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice.
Hyperglycemia
Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates igf-I signaling in vivo.
Hyperglycemia
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
Hyperglycemia
Leptin Signaling in the Arcuate Nucleus Reduces Insulin's Capacity to Suppress Hepatic Glucose Production in Obese Mice.
Hyperglycemia
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Hyperglycemia
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
Hyperglycemia
MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
Hyperglycemia
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
Hyperglycemia
P66Shc-Induced MicroRNA-34a Causes Diabetic Endothelial Dysfunction by Downregulating Sirtuin1.
Hyperglycemia
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Hyperglycemia
Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats.
Hyperglycemia
Protein tyrosine phosphatase 1B is impaired in skeletal muscle of diabetic Psammomys obesus.
Hyperglycemia
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Hyperglycemia
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Hyperglycemia
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat.
Hyperglycemia
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Hyperglycemia
Regulation of malonyl-CoA-acyl carrier protein transacylase network in umbilical cord blood affected by intrauterine hyperglycemia.
Hyperglycemia
Somatostatin protects photoreceptor cells against high glucose-induced apoptosis.
Hyperhomocysteinemia
Attenuation of hyperhomocysteinemia induced vascular dementia by sodium orthovanadate perhaps via PTP1B: Pertinent downstream outcomes.
Hyperinsulinism
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Hyperinsulinism
Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery.
Hyperinsulinism
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease.
Hyperinsulinism
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Hyperinsulinism
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
Hyperinsulinism
Hyperinsulinemia induces insulin resistance and immune suppression via Ptpn6/Shp1 in zebrafish.
Hyperinsulinism
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Hyperinsulinism
Type 1 diabetes-related antibodies in the fetal circulation: prevalence and influence on cord insulin and birth weight in offspring of mothers with type 1 diabetes.
Hyperostosis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Hyperparathyroidism
[Blood serum alkaline and acid phosphatase activity in different forms of hyperparathyroidism]
Hypersensitivity
A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development.
Hypersensitivity
A putative P-type ATPase, Apt1, is involved in stress tolerance and virulence in Cryptococcus neoformans.
Hypersensitivity
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Hypersensitivity
Arabidopsis MAP kinase phosphatase 1 and its target MAP kinases 3 and 6 antagonistically determine UV-B stress tolerance, independent of the UVR8 photoreceptor pathway.
Hypersensitivity
Atf1 is a target of the mitogen-activated protein kinase Pmk1 and regulates cell integrity in fission yeast.
Hypersensitivity
Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation.
Hypersensitivity
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Hypersensitivity
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Hypersensitivity
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Hypersensitivity
Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K.
Hypersensitivity
Human Leukocyte Antigen (DR1)-DQB1*0501 and (DR15)-DQB1*0602 Haplotypes Are Associated with Humoral Responses to Early Food Allergens in Children.
Hypersensitivity
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
Hypersensitivity
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Hypersensitivity
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.
Hypersensitivity
Loss of STEP61 couples disinhibition to N-methyl-d-aspartate receptor potentiation in rodent and human spinal pain processing.
Hypersensitivity
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Hypersensitivity
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
Hypersensitivity
Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain.
Hypersensitivity
Mitogen-activated protein kinase phosphatase-3 (MKP-3) in the surgical wound is necessary for the resolution of postoperative pain in mice.
Hypersensitivity
Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4.
Hypersensitivity
Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells.
Hypersensitivity
SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.
Hypersensitivity
Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.
Hypersensitivity
Spontaneous eosinophilic nasal inflammation in a genetically-mutant mouse: comparative study with an allergic inflammation model.
Hypersensitivity
Striatal-enriched phosphatase 61 inhibited the nociceptive plasticity in spinal cord dorsal horn of rats.
Hypersensitivity
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Hypersensitivity
Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice.
Hypersensitivity
[Acid phosphatase activity in peripheral blood cells in streptococcal allergy of the immediate type]
Hypertelorism
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Hypertelorism
Giant Cell Lesions in Noonan Syndrome: Case Report and Review of The Literature.
Hypertelorism
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Hypertelorism
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Hypertension
Activity of two enzymes associated with apoptosis and cell aging in arterial hypertension.
Hypertension
Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate.
Hypertension
Aortic cholesterol esterase and other lysosomal enzyme activities in DOCA-salt, renal and spontaneous hypertension in the rat.
Hypertension
Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.
Hypertension
Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.
Hypertension
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension.
Hypertension
Differences in Oxidative Stress Status and Expression of MKP-1 in Dorsal Medulla of Transgenic Rats with Altered Brain Renin-Angiotensin System.
Hypertension
Distribution of the number of false discoveries in large-scale family-based association testing with application to the association between PTPN1 and hypertension and obesity.
Hypertension
Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity.
Hypertension
In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes.
Hypertension
Induction of mitogen-activated protein kinase phosphatase-1 during acute hypertension.
Hypertension
MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation.
Hypertension
Naringenin prevents pregnancy-induced hypertension via suppression of JAK/STAT3 signalling pathway in mice.
Hypertension
p53 impairs endothelium-dependent vasomotor function through transcriptional upregulation of p66shc.
Hypertension
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
Hypertension
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Hypertension
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Hypertension
Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension.
Hypertension
Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure.
Hypertension
Replication of Genome-Wide Association Signals of Type 2 Diabetes in Han Chinese in a Prospective Cohort.
Hypertension
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Hypertension
Trichostatin A Modulates Angiotensin II-induced Vasoconstriction and Blood Pressure Via Inhibition of p66shc Activation.
Hypertension
Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes.
Hypertension
VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes.
Hypertension
VE-PTP inhibition: a novel therapeutic target for hypertension in diabetic patients.
Hypertension
[Determination of dehydrogenase and acid phosphatase activity in the lymphocytes in hypertension and vasorenal hypertension]
Hypertension, Portal
Defective mitogen-activated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications.
Hypertension, Pulmonary
Dual-specificity phosphatase (DUSP) genetic variants predict pulmonary hypertension in patients with bronchopulmonary dysplasia.
Hypertension, Pulmonary
Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.
Hypertension, Pulmonary
MKP-1 is a target of miR-210 and mediate the negative regulation of miR-210 inhibitor on hypoxic hPASMC proliferation.
Hypertension, Pulmonary
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Hyperthyroidism
Genotypes in relation to phenotypic appearance and exposure to environmental factors in Graves hyperthyroidism.
Hyperthyroidism
RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.
Hyperthyroidism
Specific activities of seminal vesicular phosphomonoesterases and Mg2+-,Ca2+- and Na+/K(+)-adenosine triphosphatases in hypo- and hyperthyroid albino rats.
Hyperthyroidism
[Cytochemical properties of peripheral blood neutrophils in patients with hyperthyroidism]
Hypertriglyceridemia
Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats.
Hypertriglyceridemia
Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression.
Hypocalcemia
Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Hypoglycemia
Acute induction of gene expression in brain and liver by insulin-induced hypoglycemia.
Hypoglycemia
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Hypogonadism
Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3?-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes.
Hypoparathyroidism
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Hypophosphatasia
Persistently raised serum acid phosphatase activity in a patient with hypophosphatasia: electrophoretic and molecular weight characterisation as type 5.
Hypopigmentation
PP2A and DUSP6 are involved in sphingosylphosphorylcholine-induced hypopigmentation.
Hypoproteinemia
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Hypotension
Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin.
Hypotension
Differences in Oxidative Stress Status and Expression of MKP-1 in Dorsal Medulla of Transgenic Rats with Altered Brain Renin-Angiotensin System.
Hypotension
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.
Hypotension
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Hypothyroidism
A phenome-wide association study of 26 mendelian genes reveals phenotypic expressivity of common and rare variants within the general population.
Hypoxia, Brain
Effect of hypoxia on the expression and activity of mitogen-activated protein (MAP) kinase-phosphatase-1 (MKP-1) and MKP-3 in neuronal nuclei of newborn piglets: the role of nitric oxide.
Hypoxia, Brain
Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.
Hypoxia, Brain
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Hypoxia-Ischemia, Brain
The cytochemistry of anoxic and anoxic-ischemic encephalopathy in rats. I. Alterations in neuronal lysosomes identified by acid phosphatase activity.
Idiopathic Pulmonary Fibrosis
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
Role of Mitogen activated-kinase (MAPK)-phosphatase (MKP)-5 in pulmonary fibrosis.
IgA Deficiency
A functional PTPN22 polymorphism associated with several autoimmune diseases is not associated with IgA deficiency in the Spanish population.
IgA Vasculitis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Immune System Diseases
CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry.
Immune System Diseases
Genetic determinants of diabetes are similarly associated with other immune-mediated diseases.
Immune System Diseases
Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models.
Immune System Diseases
Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Infarction, Middle Cerebral Artery
Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat.
Infarction, Middle Cerebral Artery
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Infections
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.
Infections
A haplotype at intron 8 of PTPRT gene is associated with resistance to Brucella infection in Argentinian creole goats.
Infections
A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1.
Infections
A translocated protein tyrosine phosphatase of Pseudomonas syringae pv. tomato DC3000 modulates plant defence response to infection.
Infections
Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages.
Infections
Acid phosphatase activity in hemolymph of the migratory grasshopper, Melanoplus sanguinipes, during Beauveria bassiana infection.
Infections
Adenovirus sequesters phosphorylated STAT1 at viral replication centers and inhibits STAT dephosphorylation.
Infections
An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells.
Infections
Anaplasma phagocytophilum AnkA is tyrosine-phosphorylated at EPIYA motifs and recruits SHP-1 during early infection.
Infections
Anti-tumor necrosis factor ? treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.
Infections
Association between diversity in the Src homology 2 domain--containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer.
Infections
Association of PTPN22 gene polymorphisms with chronic hepatitis B virus infection in Chinese Han population.
Infections
Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese.
Infections
Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence.
Infections
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
Infections
B Cell-Intrinsic Expression of Interferon Regulatory Factor 1 Supports Chronic Murine Gammaherpesvirus 68 Infection.
Infections
CD40-Modulated Dual-Specificity Phosphatases MAPK Phosphatase (MKP)-1 and MKP-3 Reciprocally Regulate Leishmania major Infection.
Infections
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Infections
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Infections
Change in the isoenzyme composition of acid phosphatase in murine peritoneal macrophages exposed to or infected with Trypanosoma cruzi.
Infections
Characterization and kinetic analysis of protein tyrosine phosphatase-H2 from Microplitis demolitor bracovirus.
Infections
Characterization of a protein tyrosine phosphatase as a host factor promoting baculovirus replication in silkworm, Bombyx mori.
Infections
Characterization of myeloid-specific peroxidase, keratin 8, and dual specificity phosphatase 1 as innate immune genes involved in the resistance of crucian carp (Carassius auratus gibelio) to Cyprinid herpesvirus 2 infection.
Infections
Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth.
Infections
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Infections
Comparative Study of the Ability of Leishmania mexicana Promastigotes and Amastigotes to Alter Macrophage Signalling and Functions.
Infections
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Infections
Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major.
Infections
Decrease of acid phosphatase activity in murine peritoneal macrophages infected with Leishmania donovani.
Infections
Deficiency in hematopoietic phosphatase ptpn6/Shp1 hyperactivates the innate immune system and impairs control of bacterial infections in zebrafish embryos.
Infections
Deletion of the Dual Specific Phosphatase-4 (DUSP-4) Gene Reveals an Essential Non-redundant Role for MAP Kinase Phosphatase-2 (MKP-2) in Proliferation and Cell Survival.
Infections
Differential gene expression of ASUN, NEMF, PTPRC and DHX29: Candidate biomarkers for diagnosis of active and latent tuberculosis.
Infections
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Infections
Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.
Infections
Downmodulation of Effector Functions in NK Cells upon Toxoplasma gondii Infection.
Infections
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Infections
Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.
Infections
Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.
Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Infections
Effect of virulent and less virulent strains of Nocardia asteroides on acid-phosphatase activity in alveolar and peritoneal macrophages maintained in vitro.
Infections
Endophyte-mediated effects on the growth and physiology of Achnatherum sibiricum are conditional on both N and P availability.
Infections
Environmental factors related to the induction of beta-cell autoantibodies in 1-yr-old healthy children.
Infections
Enzymatic changes in serum and tissues in fowl infected with a neurotropic-mesogenic strain of Newcastle disease virus.
Infections
Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway.
Infections
Evidence for inhibition of fusion of lysosomal and prelysosomal compartments with phagosomes in macrophages infected with pathogenic Mycobacterium avium.
Infections
Exploitation of host cell signaling machinery: activation of macrophage phosphotyrosine phosphatases as a novel mechanism of molecular microbial pathogenesis.
Infections
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Infections
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.
Infections
Expression of the A subunit of protein phosphatase 2A and characterization of its interactions with the catalytic and regulatory subunits.
Infections
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Infections
First genome-wide association study of non-severe malaria in two birth cohorts in Benin.
Infections
Gene expression profiling identifies candidate biomarkers for active and latent tuberculosis.
Infections
Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions.
Infections
Genome-wide survey for baculoviral host homologs using the Bombyx genome sequence.
Infections
Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
Infections
Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Infections
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.
Infections
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Infections
Histochemical differentiation of filarial larvae found in Simulium damnosum s.l. in West Africa.
Infections
Homophilic binding of PTP mu, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation.
Infections
Host cell responses to Listeria monocytogenes infection include differential transcription of host stress genes involved in signal transduction.
Infections
Human Cytomegalovirus miR-UL148D Facilitates Latent Viral Infection by Targeting Host Cell Immediate Early Response Gene 5.
Infections
Hydrolytic enzyme activity in rhesus monkey placenta during early gestational malaria: histochemical studies.
Infections
Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway.
Infections
Identification of a PP2A gene in Bombyx mori with antiviral function against B. mori nucleopolyhedrovirus.
Infections
Identification of leishmania fructose-1,6-bisphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1.
Infections
Identification of lncRNA-155 encoded by MIR155HG as a novel regulator of innate immunity against influenza A virus infection.
Infections
Identification of replication-competent HSV-1 Cgal+ strain signaling targets in human hepatoma cells by functional organelle proteomics.
Infections
IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis.
Infections
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Infections
Immunological consequences of intestinal helminth infections: antigen presentation and immunosuppression by peritoneal cells.
Infections
Impaired CD45-associated tyrosine phosphatase activity during HIV-1 infection: implications for CD3 and CD4 receptor signalling.
Infections
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro.
Infections
Insulin gene profile cycles with season of birth of future diabetic children and their relatives.
Infections
Insulin inhibits PDGF-directed VSMC migration via NO/ cGMP increase of MKP-1 and its inactivation of MAPKs.
Infections
Intracellular acid phosphatase content and ability of different macrophage populations to kill Nocardia asteroides.
Infections
Involvement of MAP-kinases and -phosphatases in uptake and intracellular replication of Listeria monocytogenes in J774 macrophage cells.
Infections
Involvement of protein tyrosine kinases and phosphatases in uptake and intracellular replication of virulent and avirulent Leishmania donovani promastigotes in mouse macrophage cells.
Infections
Isolation of two Locust protein targets of a protein tyrosine phosphatase from Metarhizium anisopliae strain CQMa102.
Infections
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
Infections
Legionella pneumophila major acid phosphatase and its role in intracellular infection.
Infections
Leishmania major intracellular survival is not altered in SHP-1 deficient mev or CD45-/- mice.
Infections
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.
Infections
Leishmania-Induced IRAK-1 Inactivation Is Mediated by SHP-1 Interacting with an Evolutionarily Conserved KTIM Motif.
Infections
Malabsorption syndrome observed in the common octopus Octopus vulgaris infected with Aggregata octopiana (Protista: Apicomplexa).
Infections
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Infections
MAP kinase phosphatase-2 plays a critical role in response to infection by Leishmania mexicana.
Infections
MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages.
Infections
MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a.
Infections
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
Infections
Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein.
Infections
MptpB Promotes Mycobacteria Survival by Inhibiting the Expression of Inflammatory Mediators and Cell Apoptosis in Macrophages.
Infections
Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection.
Infections
Mycobacterium avium Subspecies paratuberculosis Infects and Replicates within Human Monocyte-Derived Dendritic Cells.
Infections
New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB.
Infections
Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects.
Infections
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Infections
Parvovirus-induced depletion of cyclin B1 prevents mitotic entry of infected cells.
Infections
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
Infections
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Infections
Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain.
Infections
Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway.
Infections
Phosphorylation control of protein tyrosine phosphatase A activity in Mycobacterium tuberculosis.
Infections
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Infections
Poliovirus entry into human brain microvascular cells requires receptor-induced activation of SHP-2.
Infections
PP2A-dependent control of transcriptionally active FOXO3a in CD8(+) central memory lymphocyte survival requires p47(phox).
Infections
Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae.
Infections
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Infections
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Infections
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
Infections
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Infections
Protein tyrosine phosphatase PTPN22 has dual roles in promoting pathogen versus homeostatic-driven CD8 T-cell responses.
Infections
Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Infections
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
Infections
Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection.
Infections
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages.
Infections
PtpA, a secreted tyrosine phosphatase from Staphylococcus aureus, contributes to virulence and interacts with coronin-1A during infection.
Infections
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Infections
Reactive oxygen species mediate virus-induced STAT activation: role of tyrosine phosphatases.
Infections
Receptor-like tyrosine phosphatases CD45 and CD148 have distinct functions in chemoattractant-mediated neutrophil migration and response to S. aureus.
Infections
Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.
Infections
Reduced pathogenicity of a Candida albicans MAP kinase phosphatase (CPP1) mutant in the murine mastitis model.
Infections
Relationship between the diversity of the cagA gene of Helicobacter pylori and gastric cancer in Okinawa, Japan.
Infections
Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Infections
Role of SHP2 Protein Tyrosine Phosphatase in SERT Inhibition by Enteropathogenic E. coli (EPEC).
Infections
Runx proteins mediate protective immunity against Leishmania donovani infection by promoting CD40 expression on dendritic cells.
Infections
SHP-1 As a Critical Regulator of Mycoplasma pneumoniae-Induced Inflammation in Human Asthmatic Airway Epithelial Cells.
Infections
Shp-2 contributes to anti-RSV activity in human pulmonary alveolar epithelial cells by interfering with the IFN-?-induced Jak/Stat1 pathway.
Infections
SHP-2 Mediates Cryptosporidium parvum Infectivity in Human Intestinal Epithelial Cells.
Infections
SHP1 tyrosine phosphatase gets involved in host defense against Streptococcus agalactiae infection and BCR signaling pathway in Nile tilapia (Oreochromis niloticus).
Infections
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
Infections
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Infections
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Infections
Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication.
Infections
Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole: Role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NF?B.
Infections
Susceptibility of naïve and differentiated PC12 cells to Japanese encephalitis virus infection.
Infections
T Cell Hypo-Responsiveness against Leishmania major in MAP Kinase Phosphatase (MKP) 2 Deficient C57BL/6 Mice Does Not Alter the Healer Disease Phenotype.
Infections
TGF-?(1) re-programs TLR4 signaling in L. donovani infection: enhancement of SHP-1 and ubiquitin-editing enzyme A20.
Infections
The apo-structure of the low-molecular-weight protein tyrosine phosphatase A (MptpA) from Mycobacterium tuberculosis allows for better target-specific drug development.
Infections
The Aspergillus flavus Phosphatase CDC14 Regulates Development, Aflatoxin Biosynthesis and Pathogenicity.
Infections
The effect of intracellular Chlamydia psittaci on lysosomal enzyme activities in mouse peritoneal macrophages.
Infections
The effects of cure of Helicobacter pylori infection on the signal transduction of gastric epithelial cells.
Infections
The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.
Infections
The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation.
Infections
The modulation of phosphatase expression impacts the proliferation efficiency of HSV-1 in infected astrocytes.
Infections
The p66Shc protein controls redox signaling and oxidation-dependent DNA damage in human liver cells.
Infections
The tyrosine phosphatase SHP-2 dephosphorylated by ALV-J via its Env efficiently promotes ALV-J replication.
Infections
Theoretical studies on the interaction of biphenyl inhibitors with Mycobacterium tuberculosis protein tyrosine phosphatase MptpB.
Infections
Therapeutic Targeting of Protein Tyrosine Phosphatases from Mycobacterium tuberculosis.
Infections
TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice.
Infections
Transformation of mouse peritoneal macrophages and bone marrow cells by simian virus 40.
Infections
Tyrosine phosphatase MptpA of Mycobacterium tuberculosis inhibits phagocytosis and increases actin polymerization in macrophages.
Infections
Tyrosine Phosphatase PTPN22: Multifunctional Regulator of Immune Signaling, Development, and Disease.
Infections
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
Infections
Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant.
Infections
Tyrosine Phosphorylation and Dephosphorylation in Burkholderia cenocepacia Affect Biofilm Formation, Growth under Nutritional Deprivation, and Pathogenicity.
Infections
Weighted gene co-expression network analysis and drug-gene interaction bioinformatics uncover key genes associated with various presentations of malaria infection in African children and major drug candidates.
Infections
Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.
Infections
[Network pharmacology study of Yi medicine Jinweitai Capsules in treating gastrointestinal diseases].
Infertility
Deletion of the tyrosine phosphatase Shp2 in Sertoli cells causes infertility in mice.
Infertility
Lack of the protein tyrosine phosphatase SHP-1 results in decreased numbers of glia within the motheaten (me/me) mouse brain.
Infertility
P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan.
Infertility
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
Infertility
When transcripts matter: delineating between non-syndromic hearing loss DFNB32 and hearing impairment infertile male syndrome (HIIMS).
Infertility
[Clinical and experimental studies on male infertility. 2. Experimental studies. Histochemical demonstration of acid phosphatase activity in the testes of mice and their responce to the drugs for the male infertility (author's transl)]
Infertility
[Expression levels of Cdc2 and Cdc25A mRNA in cattle, yak, and cattle-yak testis]
Infertility, Female
Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility.
Infertility, Male
Inhibition of CDC2/Cyclin B1 in response to selenium-induced oxidative stress during spermatogenesis: potential role of Cdc25c and p21.
Infertility, Male
Integrated Analysis of DNA Methylation and mRNA Expression Profiles to Identify Key Genes in Severe Oligozoospermia.
Infertility, Male
Post-transcriptional regulation of CDC25A by BOLL is a conserved fertility mechanism essential for human spermatogenesis.
Infertility, Male
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
Infertility, Male
[Clinical and experimental studies on male infertility. 2. Experimental studies. Histochemical demonstration of acid phosphatase activity in the testes of mice and their responce to the drugs for the male infertility (author's transl)]
Inflammatory Bowel Diseases
A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
Inflammatory Bowel Diseases
Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis.
Inflammatory Bowel Diseases
An integrated in silico approach to understand protein-protein interactions: human meprin-? with fetuin-A.
Inflammatory Bowel Diseases
Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease.
Inflammatory Bowel Diseases
Association of ZAP70 and PTPN6, but Not BANK1 or CLEC2D, with Inflammatory Bowel Disease in the Tunisian Population.
Inflammatory Bowel Diseases
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
Inflammatory Bowel Diseases
Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: a meta-analysis.
Inflammatory Bowel Diseases
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
Inflammatory Bowel Diseases
GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis.
Inflammatory Bowel Diseases
Inflammatory bowel disease: Are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase.
Inflammatory Bowel Diseases
Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-?-Induced Signaling in Human Monocytes.
Inflammatory Bowel Diseases
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia.
Inflammatory Bowel Diseases
Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis.
Inflammatory Bowel Diseases
Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis.
Inflammatory Bowel Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Inflammatory Bowel Diseases
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
Inflammatory Bowel Diseases
PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.
Inflammatory Bowel Diseases
Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.
Inflammatory Bowel Diseases
Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population.
Inflammatory Bowel Diseases
Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine.
Inflammatory Bowel Diseases
Protein tyrosine phosphatase ? targets apical junction complex proteins in the intestine and regulates epithelial permeability.
Inflammatory Bowel Diseases
Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease.
Inflammatory Bowel Diseases
Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy.
Inflammatory Bowel Diseases
PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background.
Inflammatory Bowel Diseases
PTPN2 links colonic and joint inflammation in experimental autoimmune arthritis.
Inflammatory Bowel Diseases
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Inflammatory Bowel Diseases
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Inflammatory Bowel Diseases
Regulation of epithelial barrier function by the inflammatory bowel disease candidate gene, PTPN2.
Inflammatory Bowel Diseases
rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls.
Inflammatory Bowel Diseases
Spermidine stimulates T-cell protein tyrosine phosphatase-mediated protection of intestinal epithelial barrier function.
Inflammatory Bowel Diseases
T cell protein tyrosine phosphatase prevents STAT1 induction of claudin-2 expression in intestinal epithelial cells.
Inflammatory Bowel Diseases
T cells are influenced by a long non-coding RNA in the autoimmune associated PTPN2 locus.
Inflammatory Bowel Diseases
The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.
Inflammatory Bowel Diseases
The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease.
Inflammatory Bowel Diseases
The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions.
Inflammatory Bowel Diseases
The PTPN22 C1858T (R620W) functional polymorphism in inflammatory bowel disease.
Inflammatory Bowel Diseases
The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis.
Inflammatory Bowel Diseases
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation.
Inflammatory Bowel Diseases
VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-?-induced Intestinal Epithelial Barrier Defects.
Influenza, Human
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Influenza, Human
Autoimmune variant PTPN22 C1858T is associated with impaired responses to influenza virus vaccination.
Influenza, Human
CDC25B promotes influenza A virus replication by regulating the phosphorylation of nucleoprotein.
Influenza, Human
Immunologic response to vaccine challenge in pregnant PTPN22 R620W carriers and non-carriers.
Influenza, Human
Protein Tyrosine Phosphatase SHP2 Suppresses Host Innate Immunity against Influenza A Virus by Regulating EGFR-Mediated Signaling.
Influenza, Human
Targeting cell division cycle 25 homolog B to regulate influenza virus replication.
Influenza, Human
Vaccinations may induce diabetes-related autoantibodies in one-year-old children.
Influenza, Human
[Biological properties of live and inactivated influenza vaccines under experimental conditions]
Influenza, Human
[Change in the acid phosphatase activity of susceptible cells at the early stages of their interaction with Sendai and influenza A2 (Hong Kong) 68 viruses]
Insulin Resistance
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
Insulin Resistance
A comprehensive review on the antidiabetic activity of flavonoids targeting PTP1B and DPP-4: a structure-activity relationship analysis.
Insulin Resistance
A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.
Insulin Resistance
A Novel Protein Tyrosine Phosphatase 1B inhibitor with Therapeutic Potential for Insulin Resistance.
Insulin Resistance
A novel PTP1B inhibitor extracted from Ganoderma lucidum ameliorates insulin resistance by regulating IRS1-GLUT4 cascades in the insulin signaling pathway.
Insulin Resistance
A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells.
Insulin Resistance
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
Insulin Resistance
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance.
Insulin Resistance
Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans.
Insulin Resistance
Accumulation of ceramide in slow-twitch muscle contributes to the development of insulin resistance in the obese JCR:LA-cp rat.
Insulin Resistance
Acute exercise decreases PTP-1B protein level and improves insulin signaling in the liver of old rats.
Insulin Resistance
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis.
Insulin Resistance
Alteration of phosphotyrosine phosphatase activity in tissues from diabetic and pregnant rats.
Insulin Resistance
Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes.
Insulin Resistance
Alternative translation initiation of Caveolin-2 desensitizes insulin signaling through dephosphorylation of insulin receptor by PTP1B and causes insulin resistance.
Insulin Resistance
Amorphastilbol exerts beneficial effects on glucose and lipid metabolism in mice consuming a high-fat-diet.
Insulin Resistance
An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A).
Insulin Resistance
Angiotensin II-induced insulin resistance and protein tyrosine phosphatases.
Insulin Resistance
Ankaflavin: a natural novel PPAR? agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo.
Insulin Resistance
Anti-Diabetic Activity of 2,3,6-Tribromo-4,5-Dihydroxybenzyl Derivatives from Symphyocladia latiuscula through PTP1B Downregulation and ?-Glucosidase Inhibition.
Insulin Resistance
Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms.
Insulin Resistance
Anti-obesity and hypolipidemic effects of Rheum undulatum in high-fat diet-fed C57BL/6 mice through protein tyrosine phosphatase 1B inhibition.
Insulin Resistance
Antidiabetic effects of bitter gourd extracts in insulin-resistant db/db mice.
Insulin Resistance
Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice.
Insulin Resistance
Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.
Insulin Resistance
Association Between First Episode Schizophrenia, Metabolic Syndrome and Insulin Resistance-Related Proteins in Female Balb/C Mice.
Insulin Resistance
Association of protein tyrosine phosphatase 1B gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the insulin resistance atherosclerosis study (IRAS) family study.
Insulin Resistance
Association of the PTPN1 gene with type 2 diabetes and insulin resistance.
Insulin Resistance
Association testing of the protein tyrosine phosphatase 1B gene (PTPN1) with type 2 diabetes in 7,883 people.
Insulin Resistance
Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells.
Insulin Resistance
Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-?B in C2C12 myotubes.
Insulin Resistance
Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes.
Insulin Resistance
Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet.
Insulin Resistance
Basal activation of p70S6K results in adipose-specific insulin resistance in protein-tyrosine phosphatase 1B -/- mice.
Insulin Resistance
Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats.
Insulin Resistance
BH3 mimetics derived from Bim-BH3 domain core region show PTP1B inhibitory activity.
Insulin Resistance
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Insulin Resistance
Binge drinking induces whole-body insulin resistance by impairing hypothalamic insulin action.
Insulin Resistance
Bis(ethylmaltolato)oxidovanadium(iv) inhibited the pathogenesis of Alzheimer's disease in triple transgenic model mice.
Insulin Resistance
Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
Insulin Resistance
BPN, a marine-derived PTP1B inhibitor, activates insulin signaling and improves insulin resistance in C2C12 myotubes.
Insulin Resistance
Characterization of the inhibitory activity of natural tanshinones from Salvia miltiorrhiza roots on protein tyrosine phosphatase 1B.
Insulin Resistance
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Insulin Resistance
Combination of the anthocyanidins malvidin and peonidin attenuates lipopolysaccharide-mediated inflammatory gene expression in primary human adipocytes.
Insulin Resistance
Cyanidin and delphinidin modulate inflammation and altered redox signaling improving insulin resistance in high fat-fed mice.
Insulin Resistance
CYC31, A Natural Bromophenol PTP1B Inhibitor, Activates Insulin Signaling and Improves Long Chain-Fatty Acid Oxidation in C2C12 Myotubes.
Insulin Resistance
Cyclosporine A enhances gluconeogenesis while sirolimus impairs insulin signaling in peripheral tissues after 3 weeks of treatment.
Insulin Resistance
Cysteine string protein 1 (CSP1) modulates insulin sensitivity by attenuating glucose transporter 4 (GLUT4) vesicle docking with the plasma membrane.
Insulin Resistance
Data in support of fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.
Insulin Resistance
Decrease of miR-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid.
Insulin Resistance
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Insulin Resistance
Deletion of Shp2 tyrosine phosphatase in muscle leads to dilated cardiomyopathy, insulin resistance, and premature death.
Insulin Resistance
Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity.
Insulin Resistance
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy.
Insulin Resistance
Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes.
Insulin Resistance
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
Insulin Resistance
Differential regulation of multiple hepatic protein tyrosine phosphatases in alloxan diabetic rats.
Insulin Resistance
Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Insulin Resistance
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Insulin Resistance
Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
Insulin Resistance
Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells.
Insulin Resistance
Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance.
Insulin Resistance
Early growth response-1 negative feedback regulates skeletal muscle postprandial insulin sensitivity via activating Ptp1b transcription.
Insulin Resistance
Early obesity and age-related mimicry of metabolic syndrome in female mice with sex hormonal imbalances.
Insulin Resistance
Early overnutrition impairs insulin signaling in the heart of adult Swiss mice.
Insulin Resistance
Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice.
Insulin Resistance
Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance.
Insulin Resistance
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Insulin Resistance
Effects of hepatic protein tyrosine phosphatase 1B and methionine restriction on hepatic and whole-body glucose and lipid metabolism in mice.
Insulin Resistance
EGCG evokes Nrf2 nuclear translocation and dampens PTP1B expression to ameliorate metabolic misalignment under insulin resistance condition.
Insulin Resistance
Egr-1 transcriptionally activates protein phosphatase PTP1B to facilitate hyperinsulinemia-induced insulin resistance in the liver in type 2 diabetes.
Insulin Resistance
Electroacupuncture Improves Insulin Resistance by Reducing Neuroprotein Y/Agouti-Related Protein Levels and Inhibiting Expression of Protein Tyrosine Phosphatase 1B in Diet-induced Obese Rats.
Insulin Resistance
Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats.
Insulin Resistance
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Insulin Resistance
Establishment of a cell-based drug screening model for identifying down-regulators of Protein Tyrosine Phosphatase 1B expression.
Insulin Resistance
Estradiol Protects Neuropeptide Y/Agouti-related Peptide Neurons against Insulin Resistance in Females.
Insulin Resistance
Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures in type 2 diabetic rats.
Insulin Resistance
Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice.
Insulin Resistance
Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance.
Insulin Resistance
Expression of SHP-1 Induced by Hyperglycemia Prevents Insulin Actions in Podocytes.
Insulin Resistance
Fanconi anemia links reactive oxygen species to insulin resistance and obesity.
Insulin Resistance
Ficus deltoidea extract down-regulates protein tyrosine phosphatase 1B expression in a rat model of type 2 diabetes mellitus: a new insight into its antidiabetic mechanism.
Insulin Resistance
Flavonoids from Sophora alopecuroides L. improve palmitate-induced insulin resistance by inhibiting PTP1B activity in vitro.
Insulin Resistance
FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice.
Insulin Resistance
Fucosterol activates the insulin signaling pathway in insulin resistant HepG2 cells via inhibiting PTP1B.
Insulin Resistance
Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice.
Insulin Resistance
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Insulin Resistance
Gene Expression of Protein Tyrosine Phosphatase 1B and Endoplasmic Reticulum Stress During Septic Shock.
Insulin Resistance
Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes.
Insulin Resistance
Gestational Protein Restriction impairs Glucose Disposal in the Gastrocnemius muscles of Female Rats.
Insulin Resistance
Grape powder extract attenuates tumor necrosis factor alpha-mediated inflammation and insulin resistance in primary cultures of human adipocytes.
Insulin Resistance
Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.
Insulin Resistance
Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance.
Insulin Resistance
Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
Insulin Resistance
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
Insulin Resistance
Hepatic PTP1B Expression Involvement in the Effects of Chinese Medicine Formula Xiao-Gao-Jiang-Zhuo Using an Obese Rat Model.
Insulin Resistance
Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
Insulin Resistance
Hepatocyte-specific ptpn6 deletion protects from obesity-linked hepatic insulin resistance.
Insulin Resistance
High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation.
Insulin Resistance
High-Resolution Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Vietnamese Plants.
Insulin Resistance
High-Resolution PTP1B Inhibition Profiling Combined with HPLC-HRMS-SPE-NMR for Identification of PTP1B Inhibitors from Miconia albicans.
Insulin Resistance
Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B.
Insulin Resistance
Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats.
Insulin Resistance
Hypoglycemic mechanism of a novel proteoglycan, extracted from Ganoderma lucidum, in hepatocytes.
Insulin Resistance
Identification of Cyanidin-3-arabinoside Extracted from Blueberry as a Selective Protein Tyrosine Phosphatase 1B Inhibitor.
Insulin Resistance
Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evoluton, synthesis, biological evaluation and molecular dynamics simulation.
Insulin Resistance
Impaired insulin signaling and spatial learning in middle-aged rats: The role of PTP1B.
Insulin Resistance
Improved adipose tissue function with initiation of protease inhibitor-only ART.
Insulin Resistance
Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B.
Insulin Resistance
Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue.
Insulin Resistance
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1.
Insulin Resistance
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
Insulin Resistance
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Insulin Resistance
In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
Insulin Resistance
In vivo vascular rarefaction and hypertension induced by dexamethasone are related to phosphatase PTP1B activation not endothelial metabolic changes.
Insulin Resistance
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.
Insulin Resistance
Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice.
Insulin Resistance
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.
Insulin Resistance
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Insulin Resistance
Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.
Insulin Resistance
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.
Insulin Resistance
Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice.
Insulin Resistance
Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro.
Insulin Resistance
Inhibiting protein tyrosine phosphatase 1B to improve regenerative functions of endothelial cells.
Insulin Resistance
Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways.
Insulin Resistance
Inhibition of protein tyrosine phosphatase 1B by flavonoids: A structure - activity relationship study.
Insulin Resistance
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Insulin Resistance
Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice.
Insulin Resistance
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Insulin Resistance
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Insulin Resistance
Insulin receptor dephosphorylation by phosphotyrosine phosphatases obtained from insulin-resistant obese mice.
Insulin Resistance
Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression.
Insulin Resistance
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Insulin Resistance
Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90.
Insulin Resistance
Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes.
Insulin Resistance
Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance.
Insulin Resistance
Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
Insulin Resistance
Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity.
Insulin Resistance
Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity.
Insulin Resistance
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Insulin Resistance
Kinetics and molecular docking studies of pimarane-type diterpenes as protein tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots.
Insulin Resistance
Knock-down of LAR protein tyrosine phosphatase induces insulin resistance.
Insulin Resistance
Knocking down amygdalar PTP1B in diet-induced obese rats improves insulin signaling/action, decreases adiposity and may alter anxiety behavior.
Insulin Resistance
Leptin increases hepatic insulin sensitivity and protein tyrosine phosphatase 1B expression.
Insulin Resistance
Leukocyte antigen-related inhibition attenuates palmitate-induced insulin resistance in muscle cells.
Insulin Resistance
Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression.
Insulin Resistance
Liver-specific deletion of protein tyrosine phosphatase (PTP) 1B improves obesity- and pharmacologically induced endoplasmic reticulum stress.
Insulin Resistance
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
Insulin Resistance
Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors.
Insulin Resistance
Loss of protein tyrosine phosphatase 1B increases IGF-I receptor tyrosine phosphorylation but does not rescue retinal defects in IRS2-deficient mice.
Insulin Resistance
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Insulin Resistance
Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance.
Insulin Resistance
Marine Bromophenol Derivative 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-isopropoxymethyl benzyl)benzene-1,2-diol Protects Hepatocytes from Lipid-Induced Cell Damage and Insulin Resistance via PTP1B Inhibition.
Insulin Resistance
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Insulin Resistance
Maternal insulin resistance multigenerationally impairs synaptic plasticity and memory via gametic mechanisms.
Insulin Resistance
Membrane localization of protein-tyrosine phosphatase 1B is essential for its activation of sterol regulatory element-binding protein-1 gene expression and consequent hypertriglyceridaemia.
Insulin Resistance
Metabolic diseases drug discovery world summit. July 28-29, 2003, San Diego, CA, USA.
Insulin Resistance
Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis.
Insulin Resistance
Modulation of cellular insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells.
Insulin Resistance
Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66Shc.
Insulin Resistance
Molecular and cellular mechanisms linking inflammation to insulin resistance and ?-cell dysfunction.
Insulin Resistance
Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of Protein Tyrosine Phosphatase-1B.
Insulin Resistance
Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic PTP1b deletion mice.
Insulin Resistance
Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions.
Insulin Resistance
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
Insulin Resistance
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Insulin Resistance
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-?B-mediated PTP1B expression.
Insulin Resistance
New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting ?-glucosidase and the PTP-1B signaling pathway.
Insulin Resistance
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
Insulin Resistance
Novel idebenone analogs block Shc's access to insulin receptor to improve insulin sensitivity.
Insulin Resistance
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Insulin Resistance
Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies.
Insulin Resistance
Novel Protein Tyrosine Phosphatase 1B Inhibitor-Geranylated Flavonoid from Mulberry Leaves Ameliorates Insulin Resistance.
Insulin Resistance
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness.
Insulin Resistance
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
Insulin Resistance
Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B.
Insulin Resistance
Osmotic regulation of insulin-induced mitogen-activated protein kinase phosphatase (MKP-1) expression in H4IIE rat hepatoma cells.
Insulin Resistance
Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt/Protein kinase B activation.
Insulin Resistance
Overexpression of PTPN2 in Visceral Adipose Tissue Ameliorated Atherosclerosis via T Cells Polarization Shift in Diabetic Apoe-/- Mice.
Insulin Resistance
Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.
Insulin Resistance
Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance.
Insulin Resistance
p66(ShcA): linking mammalian longevity with obesity-induced insulin resistance.
Insulin Resistance
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Insulin Resistance
Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells.
Insulin Resistance
Peroxiredoxin 2 mediates insulin sensitivity of skeletal muscles through regulation of protein tyrosine phosphatase oxidation.
Insulin Resistance
Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring.
Insulin Resistance
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Insulin Resistance
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Insulin Resistance
Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance.
Insulin Resistance
Phosphatase activity in rat adipocytes: effects of insulin and insulin resistance.
Insulin Resistance
Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to dephosphorylate the insulin receptor.
Insulin Resistance
Pimarane Diterpenoids from the Seeds of Caesalpinia minax as PTP1B Inhibitors and Insulin Sensitizers.
Insulin Resistance
Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge.
Insulin Resistance
Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis.
Insulin Resistance
PP2A inhibition results in hepatic insulin resistance despite Akt2 activation.
Insulin Resistance
Probing the relationship between insulin sensitivity and longevity using genetically modified mice.
Insulin Resistance
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Insulin Resistance
Protein tyrosine phosphatase 1B and insulin resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B axis.
Insulin Resistance
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Insulin Resistance
Protein tyrosine phosphatase 1B inhibition: opportunities and challenges.
Insulin Resistance
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Insulin Resistance
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Insulin Resistance
Protein Tyrosine Phosphatase 1B inhibitors: a novel therapeutic strategy for the management of type 2 diabetes mellitus.
Insulin Resistance
Protein tyrosine phosphatase 1B inhibitory activities of ursane- and lupane-type triterpenes from Sorbus pohuashanensis.
Insulin Resistance
Protein tyrosine phosphatase 1B is impaired in skeletal muscle of diabetic Psammomys obesus.
Insulin Resistance
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Insulin Resistance
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Insulin Resistance
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism.
Insulin Resistance
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Insulin Resistance
Protein tyrosine phosphatase activity in insulin-resistant rodent Psammomys obesus.
Insulin Resistance
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Insulin Resistance
Protein tyrosine phosphatase regulation in fibroblasts from patients with an insulin receptor gene mutation.
Insulin Resistance
Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells.
Insulin Resistance
Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population.
Insulin Resistance
Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants.
Insulin Resistance
Protein Tyrosine Phosphatases: Potential Role in beta-Cell Insulin Signal Transduction.
Insulin Resistance
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Insulin Resistance
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
Insulin Resistance
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
Insulin Resistance
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.
Insulin Resistance
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Insulin Resistance
Protein-Tyrosine Phosphatase-1B Mediates Sleep Fragmentation-Induced Insulin Resistance and Visceral Adipose Tissue Inflammation in Mice.
Insulin Resistance
Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in l6 myocytes and Fao hepatoma cells.
Insulin Resistance
Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.
Insulin Resistance
Protein-tyrosine-phosphatase 1B activation is regulated developmentally in muscle of neonatal pigs.
Insulin Resistance
PTP1B and TCPTP: Non-redundant phosphatases in insulin signaling and glucose homeostasis.
Insulin Resistance
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice.
Insulin Resistance
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat.
Insulin Resistance
PTP1B deficiency improves hypothalamic insulin sensitivity resulting in the attenuation of AgRP mRNA expression under high-fat diet conditions.
Insulin Resistance
PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro.
Insulin Resistance
PTPIP51 interaction with PTP1B and 14-3-3? in adipose tissue of insulin-resistant mice.
Insulin Resistance
PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol.
Insulin Resistance
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
Insulin Resistance
Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice.
Insulin Resistance
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media.
Insulin Resistance
Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.
Insulin Resistance
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.
Insulin Resistance
Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes.
Insulin Resistance
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Insulin Resistance
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
Insulin Resistance
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice.
Insulin Resistance
Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice.
Insulin Resistance
Reduction of protein-tyrosine phosphatase-1B increases insulin signaling in FAO hepatoma cells.
Insulin Resistance
Reduction of PTP1B induces differential expression of PI3-kinase (p85alpha) isoforms.
Insulin Resistance
Replication of Genome-Wide Association Signals of Type 2 Diabetes in Han Chinese in a Prospective Cohort.
Insulin Resistance
Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner.
Insulin Resistance
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation.
Insulin Resistance
RNA sequencing of the human milk fat layer transcriptome reveals distinct gene expression profiles at three stages of lactation.
Insulin Resistance
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Insulin Resistance
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
Insulin Resistance
Safranal, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves glucose tolerance in diabetic KK-A(y) mice.
Insulin Resistance
Scopoletin Protects against Methylglyoxal-Induced Hyperglycemia and Insulin Resistance Mediated by Suppression of Advanced Glycation Endproducts (AGEs) Generation and Anti-Glycation.
Insulin Resistance
SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits.
Insulin Resistance
Selective hepatic insulin resistance in mice heterozygous for a mitochondrial trifunctional protein defect.
Insulin Resistance
Selective inhibition of PTP1B by Vitalboside A from Syzygium cumini enhances insulin sensitivity and attenuates lipid accumulation via partial agonism to PPAR?: In Vitro and In Silico investigation.
Insulin Resistance
Serum Ceramide Reduction by Blueberry Anthocyanin-Rich Extract Alleviates Insulin Resistance in Hyperlipidemia Mice.
Insulin Resistance
Serum protein signature of coronary artery disease in type 2 diabetes mellitus.
Insulin Resistance
Short-Term Strength Exercise Reduces Hepatic Insulin Resistance in Obese Mice by Reducing PTP1B Content, Regardless of Changes in Body Weight.
Insulin Resistance
SHP-1 activation inhibits vascular smooth muscle cell proliferation and intimal hyperplasia in a rodent model of insulin resistance and diabetes.
Insulin Resistance
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Insulin Resistance
SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B.
Insulin Resistance
Skeletal muscle protein tyrosine phosphatase 1B regulates insulin sensitivity in African Americans.
Insulin Resistance
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Insulin Resistance
Skeletal Muscle-Specific Deletion of MKP-1 Reveals a p38 MAPK/JNK/Akt Signaling Node That Regulates Obesity-Induced Insulin Resistance.
Insulin Resistance
Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.
Insulin Resistance
Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, Cristina M. Rondinone, Angela M. Valverde, and Margarita Lorenzo. Protein-Tyrosine Phosphatase 1B-Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-?-Induced Insulin Resistance. Diabetes 2007;56:404-413. https://doi.org/10.2337/db06-0989.
Insulin Resistance
Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet.
Insulin Resistance
Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics.
Insulin Resistance
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
Insulin Resistance
Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Insulin Resistance
Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.
Insulin Resistance
Synthesis and biological evaluation of novel N-aryl-?-(benzoazol-2-yl)-sulfanylalkanamides as dual inhibitors of ?-glucosidase and protein tyrosine phosphatase 1B.
Insulin Resistance
Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.
Insulin Resistance
Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells.
Insulin Resistance
Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Insulin Resistance
Synthesis, molecular docking and PTP1B inhibitory activity of functionalized 4,5-dihydronaphthofurans and dibenzofurans.
Insulin Resistance
T cell protein tyrosine phosphatase (TCPTP) deficiency in muscle does not alter insulin signalling and glucose homeostasis in mice.
Insulin Resistance
T-Cell Protein Tyrosine Phosphatase Regulates Bone Resorption and Whole-Body Insulin Sensitivity through Its Expression in Osteoblasts.
Insulin Resistance
Targeted SHP-1 Silencing Modulates the Macrophage Phenotype, Leading to Metabolic Improvement in Dietary Obese Mice.
Insulin Resistance
Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice.
Insulin Resistance
Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.
Insulin Resistance
TCPTP Regulates Insulin Signaling in AgRP Neurons to Coordinate Glucose Metabolism With Feeding.
Insulin Resistance
The allelic variant of LAR gene promoter -127 bp T-->A is associated with reduced risk of obesity and other features related to insulin resistance.
Insulin Resistance
The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity.
Insulin Resistance
The dual-specificity phosphatase 2 (DUSP2) does not regulate obesity-associated inflammation or insulin resistance in mice.
Insulin Resistance
The Effects of Total Flavonoids from Buckwheat Flowers and Leaves on Renal Damage and PTP1B Expression in Type 2 Diabetic Rats.
Insulin Resistance
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
Insulin Resistance
The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance.
Insulin Resistance
The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.
Insulin Resistance
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Insulin Resistance
Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities.
Insulin Resistance
TISSUE-SPECIFICITY ON INSULIN ACTION AND RESISTANCE. PAST TO RECENT MECHANISMS.
Insulin Resistance
TNF? increases hypothalamic PTP1B activity via the NF?B pathway in rat hypothalamic organotypic cultures.
Insulin Resistance
To binge or not to binge: Binge drinking disrupts glucose homeostasis by impairing hypothalamic but not liver insulin signaling.
Insulin Resistance
Toward a treatment of diabesity: Rational design, synthesis and biological evaluation of benzene-sulfonamide derivatives as a new class of PTP-1B inhibitors.
Insulin Resistance
Transcriptional response of porcine skeletal muscle to feeding a linseed-enriched diet to growing pigs.
Insulin Resistance
Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action.
Insulin Resistance
Treatment of type 2 diabetes mellitus via reversing insulin resistance and regulating lipid homeostasis in vitro and in vivo using cajanonic acid A.
Insulin Resistance
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
Insulin Resistance
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Insulin Resistance
Tumor necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review).
Insulin Resistance
Vanadate enhances but does not normalize glucose transport and insulin receptor phosphorylation in skeletal muscle from obese women with gestational diabetes mellitus.
Insulin Resistance
Vitamin A improves insulin sensitivity by increasing insulin receptor phosphorylation through protein tyrosine phosphatase1B regulation at early age in obese rats of WNIN/Ob strain.
Insulin Resistance
Water Extract of Mungbean (Vigna radiata L.) Inhibits Protein Tyrosine Phosphatase-1B in Insulin-Resistant HepG2 Cells.
Insulin Resistance
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
Insulin Resistance
[Effects of candesartan on expressions of JAK2 and PTP-1B in adipose tissue of high-fat diet-fed rats].
Insulin Resistance
[Effects of flavones of buckwheat flower and leaf on insulin resistance and liver PTP1B in type 2 diabetic rats]
Insulin Resistance
[Free fatty acids promoting PTP1B expression in rat skeletal muscle and hepatic cells]
Insulin Resistance
[Investigating the effects of compound WS090152 on non-alcoholic fatty liver in mice].
Insulin Resistance
[Investigation of a compound, compatibility of Rhodiola crenulata, Cordyceps militaris, and Rheum palmatum, on metabolic syndrome treatment I--improving insulin resistance].
Insulin Resistance
[Molecular mechanism and clinical impact of insulin resistance in type 2 diabetes mellitus]
Insulin Resistance
[Study on the mechanism of action of total flavonoids of Litsea coreana for reducing blood glucose level in rat with type 2 diabetes mellitus]
Insulin Resistance
[The effect of different types of bariatric surgery on the metabolic and hormonal parameters in rats with decompensed form of type 2 diabetes mellitus.]
Insulin Resistance
[The protein expression of insulin receptor substrate-1 and protein tyrosine phosphatase with two src-homology II in the adipose tissue from type II diabetic patients]
Insulin Resistance
[The role of protein tyrosine phosphatase (PTP-1B) in insulin resistance]
Insulinoma
Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes. Overlapping specificities to phogrin and ICA512/IA-2.
Insulinoma
Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults.
Insulinoma
Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase.
Insulinoma
Evaluating the Prognostic Value of Islet Autoantibody Monitoring in Islet Transplant Recipients with Long-Standing Type 1 Diabetes Mellitus.
Insulinoma
IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype.
Insulinoma
IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.
Insulinoma
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment.
Insulinoma
Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2.
Insulinoma
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma.
Insulinoma
Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes.
Insulinoma
Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application.
Insulinoma
Profile and differential expression of protein tyrosine phosphatases in mouse pancreatic islet tumor cell lines.
Insulinoma
Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients.
Insulinoma
Secretory-granule dynamics visualized in vivo with a phogrin-green fluorescent protein chimaera.
Insulinoma
Splice variant 3, but not 2 of receptor protein-tyrosine phosphatase sigma can mediate stimulation of insulin-secretion by alpha-latrotoxin.
Intellectual Disability
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Intellectual Disability
Clinical and Molecular Analysis of Patients with RASopathies in Turkish Patients.
Intellectual Disability
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Intellectual Disability
Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability.
Intellectual Disability
Hyperactivated PTP1B phosphatase in parvalbumin neurons alters anterior cingulate inhibitory circuits and induces autism-like behaviors.
Intellectual Disability
IL-1 receptor accessory protein-like 1 associated with mental retardation and autism mediates synapse formation by trans-synaptic interaction with protein tyrosine phosphatase ?.
Intellectual Disability
Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex.
Intellectual Disability
PTPN4 germline variants result in aberrant neurodevelopment and growth.
Intestinal Neoplasms
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Intestinal Volvulus
Acid phosphatase activity in the larval stages of Onchocerca volvulus developing in the vector Simulium damnosum.
Intestinal Volvulus
Some observations on onchocerciasis including sowda in the Yemen Arab Republic.
Invasive Fungal Infections
Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication.
Iron Overload
Iron content and acid phosphatase activity in hepatic parenchymal lysosomes of patients with hemochromatosis before and after phlebotomy treatment.
Iron Overload
Iron overload threatens the growth of osteoblast cells via inhibiting the PI3K/AKT/FOXO3a/DUSP14 signaling pathway.
Ischemic Attack, Transient
Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase.
Ischemic Stroke
A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.
Ischemic Stroke
Motheaten (me/me) mice deficient in SHP-1 are less susceptible to focal cerebral ischemia.
Ischemic Stroke
Neuronal protein-tyrosine phosphatase 1B hinders sensory-motor functional recovery and causes affective disorders in two different focal ischemic stroke models.
Ischemic Stroke
PTP1B inhibitor alleviates deleterious microglial activation and neuronal injury after ischemic stroke by modulating the ER stress-autophagy axis via PERK signaling in microglia.
Ischemic Stroke
PTPN21 protects PC12 cell against oxygen-glucose deprivation by activating cdk5 through ERK1/2 signaling pathway.
Ischemic Stroke
Regulation of post-ischemic inflammatory response: A novel function of the neuronal tyrosine phosphatase STEP.
Ischemic Stroke
S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke.
Ischemic Stroke
Upregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats.
Joint Diseases
Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.
Joint Diseases
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Keloid
Multifaceted array-based keloidal gene expression profiling reveals specific MDFI upregulation in keloid lesions.
Keloid
Protein tyrosine phosphatase 1B regulates fibroblasts proliferation, motility and extracellular matrix synthesis via the MAPK/ERK signalling pathway in keloid.
Keratitis, Herpetic
[Alkaline and acid phosphatase activity and localization in the eye tissues and fluids in herpetic keratitis]
Keratoacanthoma
An ultrastructural study of the localization of acid phosphatase activity in the untreated and vitamin A acid treated keratoacanthoma.
Keratoconjunctivitis
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
Keratoconus
Enhanced expression of a transmembrane phosphotyrosine phosphatase (LAR) in keratoconus cultures and corneas.
Keratoconus
Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients.
Keratoconus
[Study on enhanced leukocyte antigen-related tyrosine phosphatase in keratoconus]
Keratosis
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Keratosis
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
Ketosis
Preserved Proinsulin Production in Homozygous PTPN 22 C1858T Variant Type 1 Diabetes: A Possible Explanation for Absence of Overt Ketoacidosis Despite Omission of Exogenous Insulin.
Kidney Diseases
Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice.
Kidney Diseases
Hippocampal mitogen-activated protein kinase phosphatase-1 regulates behavioral and systemic effects of chronic corticosterone administration.
Kidney Diseases
Oxidative stress, a common molecular pathway for kidney disease: role of the redox enzyme p66Shc.
Kidney Diseases
p66Shc-mediated hydrogen peroxide production impairs nephrogenesis causing reduction of number of glomeruli.
Kidney Diseases, Cystic
Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2 -/- mice.
Kidney Failure, Chronic
Decreased p66Shc promoter methylation in patients with end-stage renal disease.
Kidney Failure, Chronic
Lower p66Shc promoter methylation in subjects with chronic renal failure.
Kidney Neoplasms
Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O.
Kidney Neoplasms
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Kidney Neoplasms
Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells.
Kidney Neoplasms
microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells.
Kidney Neoplasms
Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells.
Kidney Neoplasms
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Kidney Neoplasms
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Kidney Neoplasms
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Kidney Neoplasms
The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Klatskin Tumor
Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
Klatskin Tumor
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Lafora Disease
A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).
Lafora Disease
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Lafora Disease
Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.
Lafora Disease
Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli.
Lafora Disease
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Lafora Disease
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Lafora Disease
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Lafora Disease
Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.
Lafora Disease
Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity.
Lafora Disease
Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.
Lafora Disease
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Lafora Disease
Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.
Lafora Disease
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Lafora Disease
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Lafora Disease
Molecular characterization of laforin, a dual-specificity protein phosphatase implicated in Lafora disease.
Lafora Disease
Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions.
Lafora Disease
Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.
Lafora Disease
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
Lafora Disease
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
Lafora Disease
Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex.
Lambert-Eaton Myasthenic Syndrome
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Latent Autoimmune Diabetes in Adults
Association of common type 1 and type 2 diabetes gene variants with latent autoimmune diabetes in adults: A meta-analysis.
Latent Autoimmune Diabetes in Adults
Low Frequencies of Autoimmunity-Associated PTPN22 Polymorphisms in MODY Patients, Including Those Transiently Expressing Islet Cell Autoantibodies.
Latent Autoimmune Diabetes in Adults
The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis.
Latent Autoimmune Diabetes in Adults
The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.
Latent Tuberculosis
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Latent Tuberculosis
Differential gene expression of ASUN, NEMF, PTPRC and DHX29: Candidate biomarkers for diagnosis of active and latent tuberculosis.
Learning Disabilities
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Legionnaires' Disease
Identification of putative cytoskeletal protein homologues in the protozoan host Hartmannella vermiformis as substrates for induced tyrosine phosphatase activity upon attachment to the Legionnaires' disease bacterium, Legionella pneumophila.
Leigh Disease
Modulation of mitochondrial dysfunction-related oxidative stress in fibroblasts of patients with Leigh syndrome by inhibition of prooxidative p66Shc pathway.
Leiomyoma
Significant relationship of combined ACP1/PTPN22 genotype variants with the growth of uterine leiomyomas.
Leiomyomatosis
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Leiomyosarcoma
Leiomyosarcoma of the heart and its pulmonary metastasis, both with prominent osteoclast-like multinucleated giant cells expressing tartrate-resistant acid phosphatase activity.
Leishmaniasis
Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major.
Leishmaniasis
Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases.
Leishmaniasis
Leishmania major intracellular survival is not altered in SHP-1 deficient mev or CD45-/- mice.
Leishmaniasis
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.
Leishmaniasis
Peroxovanadium-mediated protection against murine leishmaniasis: role of the modulation of nitric oxide.
Leishmaniasis
Proteases and phosphatases during Leishmania-macrophage interaction: paving the road for pathogenesis.
Leishmaniasis
Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis.
Leishmaniasis
Role of host protein tyrosine phosphatase SHP-1 in Leishmania donovani-induced inhibition of nitric oxide production.
Leishmaniasis
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines.
Leishmaniasis, Visceral
Immunomodulation of dual specificity phosphatase 4 during visceral leishmaniasis.
Leishmaniasis, Visceral
Leishmania infantum-chagasi activates SHP-1 and reduces NFAT5/TonEBP activity in the mouse kidney inner medulla.
Lentigo
Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
Lentigo
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Lentigo
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
Lentigo
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Lentigo
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Lentigo
Dermatological manifestations in Noonan syndrome: a prospective multicentric study of 129 patients positive for mutation.
Lentigo
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Lentigo
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Lentigo
Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Lentigo
Extensive abdominal lipomatosis in a patient with Noonan/LEOPARD syndrome (Noonan syndrome-Multiple Lentigines).
Lentigo
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Lentigo
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Lentigo
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Lentigo
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Lentigo
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
Lentigo
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".
Lentigo
Sporadic case of eruptive lentiginosis caused by Thr468Met missense mutation in the PTPN11 gene in a Han Chinese patient: first report and systematic literature review.
Lentigo
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
Lentigo
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
Lentigo
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
LEOPARD Syndrome
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive).
LEOPARD Syndrome
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
LEOPARD Syndrome
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
LEOPARD Syndrome
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
LEOPARD Syndrome
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
LEOPARD Syndrome
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
LEOPARD Syndrome
Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.
LEOPARD Syndrome
Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
LEOPARD Syndrome
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.
LEOPARD Syndrome
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
LEOPARD Syndrome
Distinct and overlapping functions of ptpn11 genes in Zebrafish development.
LEOPARD Syndrome
Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
LEOPARD Syndrome
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
LEOPARD Syndrome
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
LEOPARD Syndrome
Familial aggregation of genetically heterogeneous hypertrophic cardiomyopathy: a boy with LEOPARD syndrome due to PTPN11 mutation and his nonsyndromic father lacking PTPN11 mutations.
LEOPARD Syndrome
Familial cases of atypical clinical features genetically diagnosed as LEOPARD syndrome (multiple lentigines syndrome).
LEOPARD Syndrome
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling.
LEOPARD Syndrome
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
LEOPARD Syndrome
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
LEOPARD Syndrome
Genetic heterogeneity in LEOPARD syndrome: two families with no mutations in PTPN11.
LEOPARD Syndrome
Germline PTPN11 and somatic PIK3CA variant in a boy with megalencephaly-capillary malformation syndrome (MCAP) - pure coincidence?
LEOPARD Syndrome
Identification of a PTPN11 hot spot mutation in a child with atypical LEOPARD syndrome.
LEOPARD Syndrome
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
LEOPARD Syndrome
Leopard syndrome caused by heterozygous missense mutation of Tyr 279 Cys in the PTPN11 gene in a sporadic case of Chinese Han.
LEOPARD Syndrome
LEOPARD syndrome in an infant with severe hypertrophic cardiomyopathy and PTPN11 mutation.
LEOPARD Syndrome
LEOPARD Syndrome with PTPN11 Gene Mutation in Three Family Members Presenting with Different Phenotypes.
LEOPARD Syndrome
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
LEOPARD Syndrome
LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature.
LEOPARD Syndrome
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
LEOPARD Syndrome
LEOPARD Syndrome: A Variant of Noonan Syndrome Strongly Associated With Hypertrophic Cardiomyopathy.
LEOPARD Syndrome
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
LEOPARD Syndrome
Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
LEOPARD Syndrome
mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
LEOPARD Syndrome
Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.
LEOPARD Syndrome
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
LEOPARD Syndrome
New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
LEOPARD Syndrome
Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
LEOPARD Syndrome
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
LEOPARD Syndrome
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
LEOPARD Syndrome
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
LEOPARD Syndrome
P0-Related Protein Accelerates Human Mesenchymal Stromal Cell Migration by Modulating VLA-5 Interactions with Fibronectin.
LEOPARD Syndrome
Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
LEOPARD Syndrome
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
LEOPARD Syndrome
Phenotype-genotype correlation in a patient with co-occurrence of Marfan and LEOPARD syndromes.
LEOPARD Syndrome
Phenotypical diversity of patients with LEOPARD syndrome carrying the worldwide recurrent p.Tyr279Cys PTPN11 mutation.
LEOPARD Syndrome
Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.
LEOPARD Syndrome
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
LEOPARD Syndrome
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
LEOPARD Syndrome
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
LEOPARD Syndrome
PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype.
LEOPARD Syndrome
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.
LEOPARD Syndrome
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
LEOPARD Syndrome
PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience.
LEOPARD Syndrome
PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?
LEOPARD Syndrome
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
LEOPARD Syndrome
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.
LEOPARD Syndrome
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
LEOPARD Syndrome
Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesis.
LEOPARD Syndrome
Shp2 in myocytes is essential for cardiovascular and neointima development.
LEOPARD Syndrome
Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2-Induced Gastrulation Defects.
LEOPARD Syndrome
Spectrum of Mutations in Noonan Syndrome and Their Correlation with Phenotypes.
LEOPARD Syndrome
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
LEOPARD Syndrome
Syndromic Hearing Loss in Association with PTPN11-Related Disorder: The Experience of Cochlear Implantation in a Child with LEOPARD Syndrome.
LEOPARD Syndrome
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
LEOPARD Syndrome
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
LEOPARD Syndrome
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
LEOPARD Syndrome
[Noonan syndrome and Leopard syndrome linked to mutation of the gene PTPN11]
Leprosy
Analysis of the rs2476601 polymorphism of PTPN22 in Mexican mestizo patients with leprosy.
Leprosy
Protein tyrosine phosphatase non-receptor type 22 gene polymorphism C1858T is not associated with leprosy in Azerbaijan, Northwest Iran.
Leprosy
The role of polymorphic protein tyrosine phosphatase non-receptor type 22 in leprosy.
Leukemia
(1)H, (15)N and (13)C sequence specific backbone assignment of the vanadate inhibited hematopoietic tyrosine phosphatase.
Leukemia
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Leukemia
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
Leukemia
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Leukemia
A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis.
Leukemia
A gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Leukemia
A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival.
Leukemia
A toxicogenomic approach for identifying biomarkers for myelosuppressive anemia in rats.
Leukemia
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Leukemia
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Leukemia
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
Leukemia
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Leukemia
Aggregation of IgE receptors in rat basophilic leukemia 2H3 cells induces tyrosine phosphorylation of the cytosolic protein-tyrosine phosphatase HePTP.
Leukemia
Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells.
Leukemia
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.
Leukemia
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Leukemia
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
Leukemia
Apoptosis and mitotic arrest are two independent effects of the protein phosphatases inhibitor okadaic acid in K562 leukemia cells.
Leukemia
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase.
Leukemia
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
Leukemia
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Leukemia
Biochemical characterization of tyrosine kinase and phosphotyrosine phosphatase activities of HL-60 leukemia cells.
Leukemia
Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.
Leukemia
Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation.
Leukemia
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Leukemia
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Leukemia
Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone.
Leukemia
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Leukemia
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Leukemia
Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit ? and MAPK phosphatase-1 expression in human leukemia U937 cells.
Leukemia
Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2.
Leukemia
De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Leukemia
Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation.
Leukemia
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.
Leukemia
Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia.
Leukemia
Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia.
Leukemia
Differential expression of protein tyrosine phosphatase genes during phorbol ester-induced differentiation of human leukemia U937 cells.
Leukemia
Differential regulation of leukemia inhibitory factor-stimulated neuronal gene expression by protein phosphatases SHP-1 and SHP-2 through mitogen-activated protein kinase-dependent and -independent pathways.
Leukemia
Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines.
Leukemia
Distinct promoters control transmembrane and cytosolic protein tyrosine phosphatase epsilon expression during macrophage differentiation.
Leukemia
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
Leukemia
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Leukemia
Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.
Leukemia
Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle.
Leukemia
Down-regulation of telomerase activity via protein phosphatase 2A activation in salvicine-induced human leukemia HL-60 cell apoptosis.
Leukemia
DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118.
Leukemia
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Leukemia
Effects of extremely low frequency magnetic fields on NGF induced neuronal differentiation of PC12 cells.
Leukemia
Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro.
Leukemia
Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells.
Leukemia
Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells.
Leukemia
Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1.
Leukemia
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Leukemia
Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play.
Leukemia
Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia.
Leukemia
Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Leukemia
Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis.
Leukemia
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Leukemia
Expression changes of ERK1/2, STAT3 and SHP-2 in bone marrow cells from gamma-ray induced leukemia mice.
Leukemia
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Leukemia
Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication.
Leukemia
Factors affecting acid phosphatase activity in exponential and synchronized L5178Y mouse leukemia cells.
Leukemia
Four-year remission despite umbilical cord graft rejection in juvenile myelomonocytic leukemia with PTPN11 mutations.
Leukemia
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Leukemia
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
Leukemia
Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells.
Leukemia
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Leukemia
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Leukemia
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.
Leukemia
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Leukemia
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Leukemia
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Leukemia
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Leukemia
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Leukemia
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Leukemia
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia.
Leukemia
Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.
Leukemia
HOXA11 plays critical roles in disease progression and response to cytarabine in AML.
Leukemia
Hypophosphorylation of pRB and repression of cyclin D3 and cdc25A during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells.
Leukemia
Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.
Leukemia
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Leukemia
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Leukemia
Increased prostate-type acid phosphatase activity in serum and typical bone lesions simulating the presence of prostatic carcinoma.
Leukemia
Independent roles of SOCS-3 and SHP-2 in the regulation of neuronal gene expression by leukemia inhibitory factor.
Leukemia
Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence.
Leukemia
Inhibition of ATRA-induced myeloid differentiation in acute promyelocytic leukemia by a new protein tyrosine phosphatase inhibitor, 3,4-dephostatin.
Leukemia
Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B.
Leukemia
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Leukemia
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Leukemia
Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor.
Leukemia
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
Leukemia
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Leukemia
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Leukemia
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Leukemia
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Leukemia
LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.
Leukemia
Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Leukemia
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Leukemia
Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.
Leukemia
Malignant lymphoma of pre-T-cell type terminating in acute myelocytic leukemia. A case report with enzymic and immunologic marker studies.
Leukemia
Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells.
Leukemia
Mechanistic insights explain the transforming potential of the T507K substitution in the protein tyrosine phosphatase SHP2.
Leukemia
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Leukemia
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Leukemia
Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4.
Leukemia
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Leukemia
Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor.
Leukemia
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Leukemia
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Leukemia
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Leukemia
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Leukemia
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Leukemia
Myricetin prevents thapsigargin-induced CDK5-P66Shc signalosome mediated pancreatic ?-cell dysfunction.
Leukemia
Negative autoregulation of Src homology region 2-domain-containing phosphatase-1 in rat basophilic leukemia-2H3 cells.
Leukemia
Negative regulation of immunoreceptor signaling by protein adapters: Shc proteins join the club.
Leukemia
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Leukemia
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Leukemia
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Leukemia
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Leukemia
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
Leukemia
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Leukemia
Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Leukemia
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Leukemia
Oncophosphosignaling Favors a Glycolytic Phenotype in Human Drug Resistant Leukemia.
Leukemia
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Leukemia
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Leukemia
Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.
Leukemia
Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome.
Leukemia
Phorbol ester stimulates the activity of a protein tyrosine phosphatase containing SH2 domains (PTP1C) in HL-60 leukemia cells by increasing gene expression.
Leukemia
Phorbol ester-induced expression, phosphorylation, and translocation of protein-tyrosine-phosphatase 1C in HL-60 cells.
Leukemia
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
Leukemia
Positive regulation of c-Jun N-terminal kinase and TNF-alpha production but not histamine release by SHP-1 in RBL-2H3 mast cells.
Leukemia
Potent activation of phospholipase D by phenylarsine oxide in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
Leukemia
Preferential requirement for protein tyrosine phosphatase activity in the 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of human colon cancer cells.
Leukemia
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Leukemia
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
Leukemia
Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling.
Leukemia
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Leukemia
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Leukemia
Protein tyrosine phosphatase-PEST (PTP-PEST) regulates mast cell-activating signals in PTP activity-dependent and -independent manners.
Leukemia
Protein-tyrosine phosphatase activity maintains the viability of hairy cells and modulates their response to interferon-alpha.
Leukemia
Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells.
Leukemia
Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells.
Leukemia
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
Leukemia
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Leukemia
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Leukemia
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Leukemia
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Leukemia
PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Leukemia
Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias.
Leukemia
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Leukemia
Regulation of protein phosphotyrosine content by changes in tyrosine kinase and protein phosphotyrosine phosphatase activities during induced granulocytic and monocytic differentiation of HL-60 leukemia cells.
Leukemia
Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3.
Leukemia
Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
Leukemia
Reversible phosphorylation in haematological malignancies: Potential role for protein tyrosine phosphatases in treatment?
Leukemia
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Leukemia
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Leukemia
Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation.
Leukemia
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
Leukemia
Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal.
Leukemia
Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.
Leukemia
Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
Leukemia
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Leukemia
Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia.
Leukemia
Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants.
Leukemia
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
Leukemia
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
Leukemia
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Leukemia
TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses.
Leukemia
TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells.
Leukemia
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Leukemia
The oncoprotein I-2PP2A/SET negatively regulates the MEK/ERK pathway and cell proliferation.
Leukemia
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.
Leukemia
The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.
Leukemia
Thymoquinone Suppresses Cell Proliferation and Enhances Apoptosis of HL60 Leukemia Cells through Re-Expression of JAK/STAT Negative Regulators.
Leukemia
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
Leukemia
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Leukemia
Two bcr/abl fusion gene products, P210bcr/abl and P190bcr/abl, are equally sensitive to the protein tyrosine phosphatase of mature granulocytes.
Leukemia
Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.
Leukemia
Tyrosine kinase and phosphotyrosine phosphatase activity in human promyelocytic leukemia cells and human polymorphonuclear leukocytes.
Leukemia
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Leukemia
[Beta-glucuronidase and acid phosphatase activity in the blast cells of acute lymphoblastic and undifferentiated leukemia patients]
Leukemia
[Characteristics of the diagnosis and treatment of secondary pneumonia in acute leukemia]
Leukemia
[Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells].
Leukemia
[Effect of 5-aza-CdR Demethylation on Expression of SHP-1 and C-kit Genes in Leukemia HL-60 Cells].
Leukemia
[Effect of A Methylation Inhibitor 5-aza-2'-deoxycytidine on SHP-1 Gene Expression, Proliferation and Apoptosis in K562 Cells.]
Leukemia
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Leukemia
[Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons]
Leukemia
[Involvement of PTP-U2 in terminal differentiation and apoptosis of leukemia cells]
Leukemia
[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]
Leukemia
[Recent progress in the protein-tyrosine phosphatase SHP1 gene: the significant correlation of the SHP1 gene silencing with the onset of lymphomas/leukemias]
Leukemia
[The expression and clinical significance of hematopoietic cell phosphatase and cysteinyl aspartate-specific proteinase in leukemia]
Leukemia, Erythroblastic, Acute
Characterization of a protein tyrosine phosphatase (RIP) expressed at a very early stage of differentiation in both mouse erythroleukemia and embryonal carcinoma cells.
Leukemia, Erythroblastic, Acute
Chromosomal location of murine protein tyrosine phosphatase (Ptprj and Ptpre) genes.
Leukemia, Erythroblastic, Acute
Evidence for a novel antioxidant function and isoform-specific regulation of the human p66Shc gene.
Leukemia, Erythroblastic, Acute
Expression of the protein tyrosine phosphatase beta2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation.
Leukemia, Erythroblastic, Acute
Induction of IW32 erythroleukemia cell differentiation by p53 is dependent on protein tyrosine phosphatase.
Leukemia, Erythroblastic, Acute
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse embryonal carcinoma (F9) cells.
Leukemia, Erythroblastic, Acute
Induction of specific protein tyrosine phosphatase transcripts during differentiation of mouse erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.
Leukemia, Hairy Cell
The cytochemistry of tartrate-resistant acid phosphatase. Technical considerations.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of Protein Tyrosine Phosphatase Receptor Type ? Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Leukemia, Lymphocytic, Chronic, B-Cell
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.
Leukemia, Lymphocytic, Chronic, B-Cell
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Leukemia, Lymphocytic, Chronic, B-Cell
Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Leukemia, Lymphocytic, Chronic, B-Cell
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Leukemia, Lymphocytic, Chronic, B-Cell
p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
Leukemia, Lymphocytic, Chronic, B-Cell
PRL-2 increases Epo and IL-3 responses in hematopoietic cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC.
Leukemia, Lymphocytic, Chronic, B-Cell
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
Leukemia, Lymphocytic, Chronic, B-Cell
The cytokine midkine and its receptor RPTP? regulate B cell survival in a pathway induced by CD74.
Leukemia, Lymphocytic, Chronic, B-Cell
The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
Leukemia, Lymphoid
Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies.
Leukemia, Lymphoid
[Blood immunoglobulin level and acid phosphatase activity in the lymphocytes in different stages of lymphocytic leukemia according to the Rai classification]
Leukemia, Lymphoid
[Lymphocyte acid phosphatase activity in lymphocytic leukemia studied in tissue culture with the use of diffusion chambers]
Leukemia, Monocytic, Acute
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
Leukemia, Monocytic, Acute
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type ? in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Characterization of a membrane-associated phosphotyrosyl protein phosphatase from the A431 human epidermoid carcinoma cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differential expression of SHP-1 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Eupolyphaga sinensis Walker inhibits human chronic myeloid leukemia cell K562 growth by inducing G2-M phase cell cycle arrest and targeting EGFR signaling pathway and in S180 tumor-bearing mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein tyrosine phosphatase 1B negatively regulates macrophage development through CSF-1 signaling.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein Tyrosine Phosphatase Receptor Type {gamma} Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Redirecting traffic using the XPO1 police.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Regulative Loop between ?-catenin and Protein Tyrosine Receptor Type ? in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Granulocyte acid phosphatase activity during the course of chronic myeloid leukemia and Hodgkin's disease]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[SHP-1 gene in the disease progression of chronic myeloid leukemia].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[The expression and clinical significance of hematopoietic cell phosphatase and cysteinyl aspartate-specific proteinase in leukemia]
Leukemia, Myeloid
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells.
Leukemia, Myeloid
Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro.
Leukemia, Myeloid
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Leukemia, Myeloid
Phorbol ester-resistant monoblastoid leukemia cells with a functional mitogen-activated protein kinase cascade but without responsive protein tyrosine phosphatases.
Leukemia, Myeloid
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
Leukemia, Myeloid
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
Leukemia, Myeloid
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Leukemia, Myeloid
Triphenyltin enhances the neutrophilic differentiation of promyelocytic HL-60 cells.
Leukemia, Myeloid
Up-regulation of I-2(PP2A)/SET gene expression in rat primary hepatomas and regenerating livers.
Leukemia, Myeloid
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Leukemia, Myeloid, Acute
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.
Leukemia, Myeloid, Acute
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Leukemia, Myeloid, Acute
Acute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation.
Leukemia, Myeloid, Acute
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Leukemia, Myeloid, Acute
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Leukemia, Myeloid, Acute
Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Leukemia, Myeloid, Acute
Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD.
Leukemia, Myeloid, Acute
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Leukemia, Myeloid, Acute
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.
Leukemia, Myeloid, Acute
Deficiency in Protein Tyrosine Phosphatase PTP1B Shortens Lifespan and Leads to Development of Acute Leukemia.
Leukemia, Myeloid, Acute
Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2.
Leukemia, Myeloid, Acute
Dual-specificity phosphatase 10 is fused to MDS1/EVI1-like gene 1 in a case of acute myelogenous leukemia with der1t1;1(p36.3;q21).
Leukemia, Myeloid, Acute
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Leukemia, Myeloid, Acute
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Leukemia, Myeloid, Acute
Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.
Leukemia, Myeloid, Acute
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia.
Leukemia, Myeloid, Acute
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Leukemia, Myeloid, Acute
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
Leukemia, Myeloid, Acute
KIAA1524: A novel MLL translocation partner in acute myeloid leukemia.
Leukemia, Myeloid, Acute
LEO1 is regulated by PRL-3 and mediates its oncogenic properties in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML.
Leukemia, Myeloid, Acute
Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.
Leukemia, Myeloid, Acute
Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients.
Leukemia, Myeloid, Acute
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Leukemia, Myeloid, Acute
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.
Leukemia, Myeloid, Acute
Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Leukemia, Myeloid, Acute
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Leukemia, Myeloid, Acute
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Leukemia, Myeloid, Acute
Non-canonical activation of ?-catenin by PRL-3 phosphatase in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Overexpression of SET is a recurrent event associated with poor outcome that contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling.
Leukemia, Myeloid, Acute
Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
PTPIP51 is phosphorylated by Lyn and c-Src kinases lacking dephosphorylation by PTP1B in acute myeloid leukemia.
Leukemia, Myeloid, Acute
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Leukemia, Myeloid, Acute
RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia.
Leukemia, Myeloid, Acute
SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Leukemia, Myeloid, Acute
STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
Leukemia, Myeloid, Acute
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
Leukemia, Myeloid, Acute
The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP.
Leukemia, Myeloid, Acute
The protein phosphatase 2A regulatory subunit B55? is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Leukemia, Myeloid, Acute
Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Leukemia, Myeloid, Acute
[Effects of PTPN11 on the Biological Characteristics of AML Cells].
Leukemia, Myeloid, Acute
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Leukemia, Myelomonocytic, Chronic
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Leukemia, Myelomonocytic, Juvenile
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
A gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
Leukemia, Myelomonocytic, Juvenile
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Leukemia, Myelomonocytic, Juvenile
Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.
Leukemia, Myelomonocytic, Juvenile
CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Leukemia, Myelomonocytic, Juvenile
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Leukemia, Myelomonocytic, Juvenile
Complete Resolution of Lymphoid Interstitial Pneumonia in a Patient With Juvenile Myelomonocytic Leukemia Treated With Allogeneic Bone Marrow Transplant: Killing 2 Birds With 1 Stone.
Leukemia, Myelomonocytic, Juvenile
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Effects of a Leukemia-associated Gain-of-Function Mutation of SHP-2 Phosphatase on Interleukin-3 Signaling.
Leukemia, Myelomonocytic, Juvenile
Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Expanding the SHOC2 mutation associated phenotype of noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis.
Leukemia, Myelomonocytic, Juvenile
Four-year remission despite umbilical cord graft rejection in juvenile myelomonocytic leukemia with PTPN11 mutations.
Leukemia, Myelomonocytic, Juvenile
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Leukemia, Myelomonocytic, Juvenile
Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Leukemia, Myelomonocytic, Juvenile
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Leukemia, Myelomonocytic, Juvenile
Genetic disruption of the PI3K regulatory subunits, p85?, p55?, and p50?, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Leukemia, Myelomonocytic, Juvenile
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Leukemia, Myelomonocytic, Juvenile
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Leukemia, Myelomonocytic, Juvenile
Germline PTPN11 mutation affecting exon 8 in a case of syndromic juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Leukemia, Myelomonocytic, Juvenile
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Leukemia, Myelomonocytic, Juvenile
Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Leukemia, Myelomonocytic, Juvenile
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Leukemia, Myelomonocytic, Juvenile
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Leukemia, Myelomonocytic, Juvenile
Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Leukemia, Myelomonocytic, Juvenile
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Leukemia, Myelomonocytic, Juvenile
Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations.
Leukemia, Myelomonocytic, Juvenile
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Leukemia, Myelomonocytic, Juvenile
Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Leukemia, Myelomonocytic, Juvenile
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Leukemia, Myelomonocytic, Juvenile
Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
Leukemia, Myelomonocytic, Juvenile
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Leukemia, Myelomonocytic, Juvenile
Osteopetrosis mimicking juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Pediatric myelodysplastic syndrome with inflammatory manifestations: Diagnosis, genetics, treatment, and outcome.
Leukemia, Myelomonocytic, Juvenile
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Leukemia, Myelomonocytic, Juvenile
PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Leukemia, Myelomonocytic, Juvenile
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Leukemia, Myelomonocytic, Juvenile
Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
Leukemia, Myelomonocytic, Juvenile
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Role of protein phosphatases in the cancer microenvironment.
Leukemia, Myelomonocytic, Juvenile
Serial investigation of PTPN11 mutation in nonhematopoietic tissues in a patient with juvenile myelomonocytic leukemia who was treated with unrelated cord blood transplantation.
Leukemia, Myelomonocytic, Juvenile
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Leukemia, Myelomonocytic, Juvenile
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Leukemia, Myelomonocytic, Juvenile
Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Leukemia, Myelomonocytic, Juvenile
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.
Leukemia, Myelomonocytic, Juvenile
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
Leukemia, Myelomonocytic, Juvenile
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Leukemia, Myelomonocytic, Juvenile
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Leukemia, Prolymphocytic
Alkaline phosphatase and tartrate resistant acid phosphatase activity in cells of prolymphocytic leukemia.
Leukemia, Prolymphocytic, T-Cell
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Leukemia, Promyelocytic, Acute
Inhibition of ATRA-induced myeloid differentiation in acute promyelocytic leukemia by a new protein tyrosine phosphatase inhibitor, 3,4-dephostatin.
Leukemia, Promyelocytic, Acute
Involvement of SHP-1, a phosphotyrosine phosphatase, during myeloid cell differentiation in acute promyelocytic leukemia cell lines.
Leukemia, T-Cell
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Leukemia, T-Cell
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Leukemia, T-Cell
Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate.
Leukemia, T-Cell
Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia.
Leukemia, T-Cell
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
Leukemia-Lymphoma, Adult T-Cell
Comprehensive high-throughput meta-analysis of differentially expressed microRNAs in transcriptomic datasets reveals significant disruption of MAPK/JNK signal transduction pathway in Adult T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Leukemia-Lymphoma, Adult T-Cell
KU70 Inhibition Impairs Both Non-Homologous End Joining and Homologous Recombination DNA Damage Repair Through SHP-1 Induced Dephosphorylation of SIRT1 in Adult T-Cell Leukemia-Lymphoma Cells.
Leukemia-Lymphoma, Adult T-Cell
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Leukocytosis
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Leukocytosis
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Leukocytosis
[Changes in the functional state of the lysosomal apparatus of the peripheral blood neutrophilic leukocytes in rabbits under the action of immobilization with thyroid hormone deficiency]
Leukocytosis
[Effect of beta receptor blockaders on the status of the lysosomal system of peripheral blood neutrophils in rabbits with immobilization stress]
Leukomalacia, Periventricular
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
Li-Fraumeni Syndrome
Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Lichen Planus, Oral
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
Lipoma
PP2A binds the LIM-domains of Lipoma Preferred Partner via its PR130/B" subunit to regulate cell adhesion and migration.
Liposarcoma
Characterization of a human cell line stably over-expressing the candidate oncogene, dual specificity phosphatase 12.
Liver Abscess, Amebic
Characterization of the protein tyrosine phosphatase PRL from Entamoeba histolytica.
Liver Cirrhosis
Computational identification of microRNAs and their targets in liver cirrhosis.
Liver Cirrhosis
Inhibition of p66Shc Oxidative Signaling via CA-Induced Upregulation of miR-203a-3p Alleviates Liver Fibrosis Progression.
Liver Cirrhosis
Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone.
Liver Cirrhosis
LncRNA Mical2/miR-203a-3p sponge participates in epithelial-mesenchymal transition by targeting p66Shc in liver fibrosis.
Liver Cirrhosis
p66Shc Contributes to Liver Fibrosis through the Regulation of Mitochondrial Reactive Oxygen Species.
Liver Cirrhosis
Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases.
Liver Cirrhosis
PTP1B confers liver fibrosis by regulating the activation of hepatic stellate cells.
Liver Cirrhosis
PTP1B promotes macrophage activation by regulating the NF-?B pathway in alcoholic liver injury.
Liver Cirrhosis
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
Liver Cirrhosis
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Liver Cirrhosis, Biliary
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Liver Cirrhosis, Biliary
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Liver Cirrhosis, Biliary
The PTPN22 1858T variant is not associated with primary biliary cirrhosis.
Liver Cirrhosis, Biliary
Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22.
Liver Diseases
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.
Liver Diseases
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
Liver Diseases
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Liver Diseases
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression.
Liver Diseases
Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan.
Liver Diseases
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Liver Diseases
Increased hepatic FAT/CD36, PTP1B and decreased HNF4A expression contributes to dyslipidemia associated with ethanol-induced liver dysfunction: Rescue effect of ginger extract.
Liver Diseases
Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.
Liver Diseases
Interrogating Endogenous Protein Phosphatase Activity with Rationally Designed Chemosensors.
Liver Diseases
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.
Liver Diseases
Perturbation of Specific Signaling Pathways Is Involved in Initiation of Mouse Liver Fibrosis.
Liver Diseases
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Liver Diseases
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Liver Diseases
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Liver Diseases
Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients.
Liver Diseases
PTPROt aggravates inflammation by enhancing NF-?B activation in liver macrophages during nonalcoholic steatohepatitis.
Liver Diseases
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
Liver Diseases, Alcoholic
Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease.
Liver Diseases, Alcoholic
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
Liver Diseases, Alcoholic
Reduced methylation of PP2Ac promotes ethanol-induced lipid accumulation through FOXO1 phosphorylation in vitro and in vivo.
Liver Failure
Protein tyrosine phosphatase 1B modulates GSK3?/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity.
Liver Failure
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
Liver Failure
Signalling pathways involved in paracetamol-induced hepatotoxicity: new insights on the role of protein tyrosine phosphatase 1B.
Liver Failure, Acute
Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.
Liver Failure, Acute
PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure.
Liver Neoplasms
Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
Liver Neoplasms
Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A.
Liver Neoplasms
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Liver Neoplasms
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Liver Neoplasms
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
Liver Neoplasms
Shp2 Deletion in Hepatocytes Suppresses Hepatocarcinogenesis Driven by Oncogenic ?-Catenin, PIK3CA and MET.
Liver Neoplasms
Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL?6 in vitro and in vivo.
Liver Neoplasms
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
Liver Neoplasms
[Inhibiting effects of RNA interference PRL-3 on the invasion of human hepatocellular cancer cells.]
Lung Diseases
Circulating levels of tartrate-resistant acid phosphatase in macrophage-activated lung disease.
Lung Diseases
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
Lung Diseases
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Lung Diseases
Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells.
Lung Diseases
The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38.
Lung Diseases
[Comparative data of a study of the alkaline and acid phosphatase activity of blood serum and of neutrophils in patients with nonspecific inflammatory lung diseases]
Lung Diseases
[Determination of alveolar macrophage function in nonspecific lung diseases by the simultaneous estimation of phagocytosis and acid phosphatase activity]
Lung Injury
Loss of myeloid-specific protein phosphatase 2A enhances lung injury and fibrosis and results in IL-10-dependent sensitization of epithelial cell apoptosis.
Lung Injury
Phosphotyrosine phosphatase and tyrosine kinase inhibition modulate airway pressure-induced lung injury.
Lung Injury
Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A.
Lung Injury
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
Lung Injury
Suppression of the p66shc adapter protein by protocatechuic acid prevents the development of lung injury induced by intestinal ischemia reperfusion in mice.
Lung Neoplasms
A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A.
Lung Neoplasms
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
Lung Neoplasms
A superoxide-mediated MKP-1 Degradation and JNK Activation Pathway for Luteolin-induced Lung Cancer Cytotoxicity.
Lung Neoplasms
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Lung Neoplasms
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Lung Neoplasms
Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells.
Lung Neoplasms
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Lung Neoplasms
Association of Topoisomerase II (TOP2A) and Dual-Specificity Phosphatase 6 (DUSP6) Single Nucleotide Polymorphisms with Radiation Treatment Response and Prognosis of Lung Cancer in Han Chinese.
Lung Neoplasms
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Lung Neoplasms
CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner.
Lung Neoplasms
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Lung Neoplasms
Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture.
Lung Neoplasms
Coexisting amplifications of the chromosome 1p32 genes (PTPRF and MYCL1) encoding protein tyrosine phosphatase LAR and L-myc in a small cell lung cancer line.
Lung Neoplasms
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Lung Neoplasms
Copy number variations of chromosome 17p13.1 might be linked to high risk of lung cancer in heavy smokers.
Lung Neoplasms
DDIAS promotes STAT3 activation by preventing STAT3 recruitment to PTPRM in lung cancer cells.
Lung Neoplasms
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Lung Neoplasms
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Lung Neoplasms
Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Lung Neoplasms
Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1.
Lung Neoplasms
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.
Lung Neoplasms
Dual Specificity Phosphatase 6 (DUSP6) Polymorphism Predicts Prognosis of Inoperable Non-Small Cell Lung Cancer after Chemoradiotherapy.
Lung Neoplasms
Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells.
Lung Neoplasms
Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer.
Lung Neoplasms
Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Lung Neoplasms
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Lung Neoplasms
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Lung Neoplasms
Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.
Lung Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Lung Neoplasms
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Lung Neoplasms
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Lung Neoplasms
Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium.
Lung Neoplasms
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Lung Neoplasms
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Lung Neoplasms
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Lung Neoplasms
High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis.
Lung Neoplasms
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Lung Neoplasms
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.
Lung Neoplasms
Human Cancer-Associated Mutations in the A{alpha} Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in A{alpha} Knock-In and Knockout Mice.
Lung Neoplasms
IA-2, a transmembrane protein tyrosine phosphatase, is expressed in human lung cancer cell lines with neuroendocrine phenotype.
Lung Neoplasms
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Lung Neoplasms
Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Lung Neoplasms
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Lung Neoplasms
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Lung Neoplasms
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Lung Neoplasms
Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation.
Lung Neoplasms
Involvement of MAPK phosphatase-1 in dexamethasone-induced chemoresistance in lung cancer.
Lung Neoplasms
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Lung Neoplasms
Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP ?/? signaling by menin.
Lung Neoplasms
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Lung Neoplasms
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
Lung Neoplasms
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Lung Neoplasms
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
Lung Neoplasms
MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK.
Lung Neoplasms
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
Lung Neoplasms
miR-339-5p Increases Radiosensitivity of Lung Cancer Cells by Targeting Phosphatases of Regenerating Liver-1 (PRL-1).
Lung Neoplasms
MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A.
Lung Neoplasms
Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients.
Lung Neoplasms
Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance.
Lung Neoplasms
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Lung Neoplasms
Molecular Nodal Restaging Based on CEACAM5, FGFR2b and PTPN11 Expression Adds No Relevant Clinical Information in Resected Non-Small Cell Lung Cancer.
Lung Neoplasms
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Lung Neoplasms
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
Lung Neoplasms
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Lung Neoplasms
p53 regulates cellular responses to environmental carcinogen benzo[a]pyrene-7,8-diol-9,10-epoxide in human lung cancer cells.
Lung Neoplasms
Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
Lung Neoplasms
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Lung Neoplasms
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Lung Neoplasms
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Lung Neoplasms
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
Lung Neoplasms
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Lung Neoplasms
Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.
Lung Neoplasms
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Lung Neoplasms
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Lung Neoplasms
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Lung Neoplasms
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.
Lung Neoplasms
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Lung Neoplasms
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Lung Neoplasms
Protein tyrosine phosphatase receptor-type O targeted by methylation in lung cancer.
Lung Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Lung Neoplasms
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
Lung Neoplasms
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Lung Neoplasms
PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.
Lung Neoplasms
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
Lung Neoplasms
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
Lung Neoplasms
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Lung Neoplasms
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Lung Neoplasms
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Lung Neoplasms
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Lung Neoplasms
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Lung Neoplasms
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Lung Neoplasms
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Lung Neoplasms
Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients.
Lung Neoplasms
Statistical completion of a partially identified graph with applications for the estimation of gene regulatory networks.
Lung Neoplasms
Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.
Lung Neoplasms
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
Lung Neoplasms
The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells.
Lung Neoplasms
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Lung Neoplasms
The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
Lung Neoplasms
The Lysyl Oxidase Propeptide Interacts with the Receptor-Type Protein Tyrosine Phosphatase Kappa and Inhibits {beta}-Catenin Transcriptional Activity in Lung Cancer Cells.
Lung Neoplasms
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
Lung Neoplasms
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.
Lung Neoplasms
The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo.
Lung Neoplasms
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Lung Neoplasms
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Lung Neoplasms
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
Lung Neoplasms
Tripartite motif protein 11 (TRIM11), an oncogene for human lung cancer via the DUSP6-mediated ERK1/2 signaling pathway.
Lung Neoplasms
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Lung Neoplasms
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Lung Neoplasms
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Lung Neoplasms
Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
Lung Neoplasms
YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Lung Neoplasms
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
Lung Neoplasms
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Lung Neoplasms
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Lung Neoplasms
[Expression of protein-tyrosine-phosphatase 1B in non-small-cell lung cancer and its prognostic significance].
Lung Neoplasms
[The relationship between histological classification of lung cancer and protein tyrosine phosphatase.]
Lupus Erythematosus, Systemic
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models.
Lupus Erythematosus, Systemic
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Lupus Erythematosus, Systemic
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Altered expression of protein tyrosine phosphatase, non-receptor type 22 isoforms in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population.
Lupus Erythematosus, Systemic
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Lupus Erythematosus, Systemic
Association between PPP2CA polymorphisms and clinical features in southwest Chinese systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Association of PTPN22 gene polymorphism and systemic lupus erythematosus in a cohort of Egyptian patients: impact on clinical and laboratory results.
Lupus Erythematosus, Systemic
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Lupus Erythematosus, Systemic
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.
Lupus Erythematosus, Systemic
Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes.
Lupus Erythematosus, Systemic
Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.
Lupus Erythematosus, Systemic
Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-? receptor signaling.
Lupus Erythematosus, Systemic
Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.
Lupus Erythematosus, Systemic
Contribution of the R620W polymorphism of protein tyrosine phosphatase non-receptor 22 to systemic lupus erythematosus in Poland.
Lupus Erythematosus, Systemic
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Lupus Erythematosus, Systemic
Ethnic differences in allele frequency of autoimmune-disease-associated SNPs.
Lupus Erythematosus, Systemic
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Lupus Erythematosus, Systemic
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Expression of the sialosyl-Tn epitope on CD45 derived from activated peripheral blood T cells.
Lupus Erythematosus, Systemic
Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.
Lupus Erythematosus, Systemic
Genetic association between a lymphoid tyrosine phosphatase (PTPN22) and type 1 diabetes.
Lupus Erythematosus, Systemic
Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE.
Lupus Erythematosus, Systemic
High prevalence of protein tyrosine phosphatase non-receptor N22 gene functional variant R620W in systemic lupus erythematosus patients from Kuwait: implications for disease susceptibility.
Lupus Erythematosus, Systemic
Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.
Lupus Erythematosus, Systemic
JAK2 and PTPRC mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Lupus Erythematosus, Systemic
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Lupus Erythematosus, Systemic
Meta-Analysis of the Correlation Between PTPN22 Gene Polymorphisms and Susceptibility to Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Lupus Erythematosus, Systemic
Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele.
Lupus Erythematosus, Systemic
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Promoter Hypomethylation Results in Increased Expression of Protein Phosphatase 2A in T Cells from Patients with Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Lupus Erythematosus, Systemic
PTPN22 1858C>T gene polymorphism in patients with SLE: association with serological and clinical results.
Lupus Erythematosus, Systemic
PTPN22 1858C?>?T polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis update.
Lupus Erythematosus, Systemic
PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
Lupus Erythematosus, Systemic
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
Lupus Erythematosus, Systemic
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
Lupus Erythematosus, Systemic
PTPN22 Gene Polymorphisms in Pediatric Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
PTPN22 polymorphisms, but not R620W, were associated with the genetic susceptibility of systemic lupus erythematosus and rheumatoid arthritis in a Chinese Han population.
Lupus Erythematosus, Systemic
PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner.
Lupus Erythematosus, Systemic
PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Lupus Erythematosus, Systemic
Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE).
Lupus Erythematosus, Systemic
Regulation of autoimmune and anti-tumour T cell responses by PTPN22.
Lupus Erythematosus, Systemic
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.
Lupus Erythematosus, Systemic
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
Lupus Erythematosus, Systemic
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Lupus Erythematosus, Systemic
Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases.
Lupus Erythematosus, Systemic
The association between the PTPN22 C1858T polymorphism and systemic lupus erythematosus: a meta-analysis update.
Lupus Erythematosus, Systemic
The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients.
Lupus Erythematosus, Systemic
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
Lupus Erythematosus, Systemic
The functional R620W variant of the PTPN22 gene is associated with celiac disease.
Lupus Erythematosus, Systemic
The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility.
Lupus Erythematosus, Systemic
The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.
Lupus Erythematosus, Systemic
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
Lupus Erythematosus, Systemic
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
Lupus Erythematosus, Systemic
The PTPN22 R263Q polymorphism confers protection against systemic lupus erythematosus and rheumatoid arthritis, while PTPN22 R620W confers susceptibility to Graves' disease in a Mexican population.
Lupus Erythematosus, Systemic
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in caucasian case-control samples.
Lupus Erythematosus, Systemic
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples.
Lupus Erythematosus, Systemic
The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review.
Lupus Erythematosus, Systemic
TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey.
Lupus Erythematosus, Systemic
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
Lupus Erythematosus, Systemic
[Correlation between PTPN22 gene polymorphism and systemic lupus erythematosus in Chinese Han patients.]
Lupus Erythematosus, Systemic
[Genetic polymorphisms of low molecular weight protein tyrosine phosphatase (LMW-PTP): relationship with erythrocyte enzymatic phenotype in patients with Systemic Lupus Erythematosus]
Lupus Nephritis
Association of polymorphic variants of PTPN22, TNF and VDR genes in children with lupus nephritis: A study in Colombian family triads.
Lupus Nephritis
IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice.
Lymphadenopathy
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Lymphangioma, Cystic
How necessary is to analyze PTPN11 gene in fetuses with first trimester cystic hygroma and normal karyotype?
Lymphangioma, Cystic
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Lymphangioma, Cystic
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
Lymphangioma, Cystic
PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings.
Lymphatic Metastasis
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Lymphatic Metastasis
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Lymphatic Metastasis
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Lymphatic Metastasis
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Lymphatic Metastasis
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Lymphatic Metastasis
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Lymphatic Metastasis
Clinicopathological significance of PTPN12 expression in human breast cancer.
Lymphatic Metastasis
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Lymphatic Metastasis
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Lymphatic Metastasis
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Lymphatic Metastasis
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Lymphatic Metastasis
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Lymphatic Metastasis
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Lymphatic Metastasis
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Lymphatic Metastasis
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Lymphatic Metastasis
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Lymphatic Metastasis
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Lymphatic Metastasis
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Lymphatic Metastasis
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Lymphatic Metastasis
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Lymphatic Metastasis
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Lymphatic Metastasis
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Lymphatic Metastasis
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
Lymphatic Metastasis
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Lymphatic Metastasis
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
Lymphatic Metastasis
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
Lymphatic Metastasis
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Lymphatic Metastasis
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Lymphatic Metastasis
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
Lymphatic Metastasis
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Lymphatic Metastasis
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Lymphatic Metastasis
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Lymphatic Metastasis
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Lymphatic Metastasis
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Lymphatic Metastasis
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Lymphatic Metastasis
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Lymphatic Metastasis
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Lymphatic Metastasis
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Lymphatic Metastasis
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Lymphatic Metastasis
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Lymphatic Metastasis
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Lymphatic Metastasis
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Lymphatic Metastasis
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Lymphatic Metastasis
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Lymphatic Metastasis
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Lymphatic Metastasis
Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Lymphatic Metastasis
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Lymphatic Metastasis
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Lymphatic Metastasis
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
Lymphatic Metastasis
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
Lymphatic Metastasis
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Lymphatic Metastasis
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Lymphatic Metastasis
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Lymphatic Metastasis
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
Lymphatic Metastasis
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Lymphatic Metastasis
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Lymphatic Metastasis
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Lymphatic Metastasis
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Lymphatic Metastasis
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Lymphatic Metastasis
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
Lymphatic Metastasis
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Lymphedema
Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.
Lymphocytic Choriomeningitis
CD8+ T cell responses to a viral escape mutant epitope: active suppression via altered SHP-1 activity.
Lymphocytic Choriomeningitis
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Lymphocytic Choriomeningitis
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Lymphocytic Choriomeningitis
PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection.
Lymphocytic Choriomeningitis
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Lymphohistiocytosis, Hemophagocytic
Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis.
Lymphoma
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Lymphoma
Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases.
Lymphoma
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
Lymphoma
alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor.
Lymphoma
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Lymphoma
Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation.
Lymphoma
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.
Lymphoma
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Lymphoma
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Lymphoma
c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma.
Lymphoma
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma
cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.
Lymphoma
Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.
Lymphoma
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
Lymphoma
Comparative quantitative analysis of cluster of differentiation 45 antigen expression on lymphocyte subsets.
Lymphoma
Correction: The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration.
Lymphoma
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Lymphoma
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Lymphoma
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Lymphoma
Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes.
Lymphoma
Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.
Lymphoma
Effects of pleiotrophin, a heparin-binding growth factor, on human primary and immortalized chondrocytes.
Lymphoma
Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation.
Lymphoma
Expression of pleiotrophin and its receptors in human placenta suggests roles in trophoblast life cycle and angiogenesis.
Lymphoma
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Lymphoma
Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma.
Lymphoma
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas.
Lymphoma
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Lymphoma
Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Lymphoma
Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
Lymphoma
High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity.
Lymphoma
High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.
Lymphoma
Identification of pleiotrophin in conditioned medium secreted from neural stem cells by SELDI-TOF and SELDI-tandem mass spectrometry.
Lymphoma
Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.
Lymphoma
Inhibition of Receptor Protein Tyrosine Phosphatase ?/? reduces alcohol intake in rats.
Lymphoma
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Lymphoma
Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells.
Lymphoma
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Lymphoma
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Lymphoma
MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway.
Lymphoma
Molecular cloning and characterization of a novel human receptor protein tyrosine phosphatase gene, hPTP-J: down-regulation of gene expression by PMA and calcium ionophore in Jurkat T lymphoma cells.
Lymphoma
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Lymphoma
No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis.
Lymphoma
Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc.
Lymphoma
Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins.
Lymphoma
Pleiotrophin increases neurite length and number of spiral ganglion neurons in vitro.
Lymphoma
Pleiotrophin induces neurite outgrowth and up-regulates growth-associated protein (GAP-43) mRNA through the ALK/GSK3beta/beta-catenin signaling in developing mouse neurons.
Lymphoma
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Lymphoma
Potential biomarkers screening to predict side effects of dexamethasone in different cancers.
Lymphoma
Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.
Lymphoma
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Lymphoma
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.
Lymphoma
Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis.
Lymphoma
PTN-PTPRZ signalling is involved in deer antler stem cell regulation during tissue regeneration.
Lymphoma
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Lymphoma
Receptor-type tyrosine-protein phosphatase ? directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Lymphoma
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Lymphoma
Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray.
Lymphoma
Regulation of BCR- and PKC/Ca(2+)-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and -tyrosine phosphatase activities.
Lymphoma
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
Lymphoma
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
Lymphoma
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.
Lymphoma
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Lymphoma
The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2.
Lymphoma
The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2.
Lymphoma
The heparin-binding growth factor midkine: the biological activities and candidate receptors.
Lymphoma
The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
Lymphoma
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.
Lymphoma
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Lymphoma
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Lymphoma
Transcriptional regulation of a receptor protein tyrosine phosphatase gene hPTP-J by PKC-mediated signaling pathways in Jurkat and Molt-4 T lymphoma cells.
Lymphoma
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Lymphoma
Tumor-associated macrophages increase the proportion of cancer stem cells in lymphoma by secreting pleiotrophin.
Lymphoma
Tyrosine kinase and CD45 tyrosine phosphatase activity mediate p21ras activation in B cells stimulated through the antigen receptor.
Lymphoma
Tyrosine phosphatase activity of lymphoma CD45 (GP180) is regulated by a direct interaction with the cytoskeleton.
Lymphoma
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Lymphoma
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Lymphoma
Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies.
Lymphoma
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
Lymphoma
[Effect of Bortezomib on Proliferation, Apoptosis and SHP-2 Gene Expression of Lymphoma Cells].
Lymphoma
[Effects of sodium orthovanadate on proliferation and apoptosis in raji cells and its mechanism]
Lymphoma
[Evaluation of tartrate-resistant acid phosphatase activity in lymphoma cells of the bone marrow]
Lymphoma
[Recent progress in the protein-tyrosine phosphatase SHP1 gene: the significant correlation of the SHP1 gene silencing with the onset of lymphomas/leukemias]
Lymphoma
[SHP-1 gene's methylation status of Daudi lymphoma cell and the demethylation effect of 5-aza-2'-deoxycytidine]
Lymphoma, B-Cell
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Lymphoma, B-Cell
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Lymphoma, B-Cell
BCL6 regulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Lymphoma, B-Cell
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, B-Cell
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Lymphoma, B-Cell
Effect of Huaier on the proliferation and apoptosis of human gastric cancer cells through modulation of the PI3K/AKT signaling pathway.
Lymphoma, B-Cell
Effect of Jianpi Bushen prescription on the expression of SHP-1 and apoptosis-related genes in chemically damaged model mice.
Lymphoma, B-Cell
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Lymphoma, B-Cell
Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation.
Lymphoma, B-Cell
Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls.
Lymphoma, B-Cell
In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
Lymphoma, B-Cell
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway.
Lymphoma, B-Cell
PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis.
Lymphoma, B-Cell
Protective effect of zinc on N-methyl-N-nitrosourea and testosterone-induced prostatic intraepithelial neoplasia in the dorsolateral prostate of Sprague Dawley rats.
Lymphoma, B-Cell
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest.
Lymphoma, B-Cell
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Lymphoma, B-Cell
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
Lymphoma, B-Cell
SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
Lymphoma, B-Cell
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Lymphoma, B-Cell
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Lymphoma, B-Cell
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Lymphoma, B-Cell, Marginal Zone
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Follicular
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Follicular
Histochemical and immunohistochemical study of diffuse large-cell lymphomas.
Lymphoma, Large B-Cell, Diffuse
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Lymphoma, Large B-Cell, Diffuse
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Lymphoma, Large B-Cell, Diffuse
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Large B-Cell, Diffuse
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Lymphoma, Large B-Cell, Diffuse
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
Lymphoma, Large-Cell, Anaplastic
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
Lymphoma, Mantle-Cell
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Mantle-Cell
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Lymphoma, Mantle-Cell
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.
Lymphoma, Mantle-Cell
Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis.
Lymphoma, Mantle-Cell
SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts.
Lymphoma, Non-Hodgkin
5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells.
Lymphoma, Non-Hodgkin
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Lymphoma, Non-Hodgkin
Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.
Lymphoma, Non-Hodgkin
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma: a predictor of aggressive disease and new treatment target.
Lymphoma, Primary Effusion
Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Lymphoma, T-Cell
Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1 depleted cancers.
Lymphoma, T-Cell
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Lymphoma, T-Cell, Cutaneous
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
Lymphoma, T-Cell, Cutaneous
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Lymphoma, T-Cell, Cutaneous
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
Lymphoma, T-Cell, Peripheral
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Lymphopenia
PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.
Lymphopenia
The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals.
Lymphoproliferative Disorders
CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A.
Lymphoproliferative Disorders
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders.
Lymphoproliferative Disorders
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Lymphoproliferative Disorders
Isoenzymatic study of leucocytic acid phosphatase in haematologic diagnosis.
Lymphoproliferative Disorders
Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7.
Lysosomal Storage Diseases
[Decrease in the rats of intraliposomal proteolysis and labilization of rat liver lysosomes following suramin administration]
Macular Degeneration
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Macular Edema
Exploring the effect of inhibitor AKB-9778 on VE-PTP by molecular docking and molecular dynamics simulation.
Macular Edema
Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates tie2.
Malabsorption Syndromes
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
Malaria
A Bacterial Phosphatase-Like Enzyme of the Malaria Parasite Plasmodium falciparum Possesses Tyrosine Phosphatase Activity and Is Implicated in the Regulation of Band 3 Dynamics during Parasite Invasion.
Malaria
Characterization of a unique aspartate-rich protein of the SET/TAF-family in the human malaria parasite, Plasmodium falciparum, which inhibits protein phosphatase 2A.
Malaria
First genome-wide association study of non-severe malaria in two birth cohorts in Benin.
Malaria
[Acid phosphatase activity of circulating leukocytes in mice in experimental malaria]
Malaria, Cerebral
Protein Tyrosine Phosphatase Inhibition Prevents Experimental Cerebral Malaria by Precluding CXCR3 Expression on T Cells.
Malnutrition
Maternal food restriction enhances insulin-induced GLUT-4 translocation and insulin signaling pathway in skeletal muscle from suckling rats.
Massive Hepatic Necrosis
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
Mastitis
GWAS and gene networks for milk-related traits from test-day multiple lactations in Portuguese Holstein cattle.
Mastitis
Reduced pathogenicity of a Candida albicans MAP kinase phosphatase (CPP1) mutant in the murine mastitis model.
Mastocytoma
The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.
Mastocytosis
Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently.
Mastocytosis
SLAM family member 8 is involved in oncogenic KIT-mediated signaling in human mastocytosis.
Medulloblastoma
Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Medulloblastoma
p53 Function is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Megalencephaly
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Melanoma
67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A) activation elicits melanoma-specific antitumor activity overcoming drug resistance.
Melanoma
A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis.
Melanoma
A receptor-type protein tyrosine phosphatase PTP zeta is expressed in human cutaneous melanomas.
Melanoma
Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood.
Melanoma
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Melanoma
An Anticancer Effect of Curcumin Mediated by Down-regulating PRL-3 Expression on Highly Metastatic Melanoma Cells.
Melanoma
Cantharidin induces G2/M phase arrest by inhibition of Cdc25c and Cyclin A and triggers apoptosis through reactive oxygen species and the mitochondria?dependent pathways of A375.S2 human melanoma cells.
Melanoma
CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation.
Melanoma
Comparative proteomic analysis of mouse melanoma cell line B16, a metastatic descendant B16F10, and B16 overexpressing the metastasis-associated tyrosine phosphatase PRL-3.
Melanoma
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
Melanoma
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Melanoma
Endothelial Phosphatase VE-PTP Participates in Vasculogenic Mimicry by Preventing Autophagic Degradation of VE-Cadherin.
Melanoma
Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Melanoma
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Melanoma
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Melanoma
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.
Melanoma
Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells.
Melanoma
Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome.
Melanoma
Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
Melanoma
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Melanoma
Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation.
Melanoma
MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.
Melanoma
Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Melanoma
Microarray analysis of differentially expressed genes regulating lipid metabolism during melanoma progression.
Melanoma
miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF?R1, GNAQ, WASL, and RAC1.
Melanoma
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Melanoma
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Melanoma
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.
Melanoma
Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
Melanoma
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Melanoma
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Melanoma
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Melanoma
PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
Melanoma
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
Melanoma
PRL-3/PTP4A3 phosphatase regulates integrin ?1 in adhesion structures during migration of human ocular melanoma cells.
Melanoma
Protein tyrosine phosphatase 4A3 (PTP4A3) is required for Xenopus laevis cranial neural crest migration in vivo.
Melanoma
Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14).
Melanoma
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2.
Melanoma
Proteomic analysis and the antimetastatic effect of N-(4-methyl)phenyl-O-(4-methoxy) phenyl-thionocarbamate-induced apoptosis in human melanoma SK-MEL-28 cells.
Melanoma
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Melanoma
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
Melanoma
RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
Melanoma
Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesis.
Melanoma
Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Melanoma
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Melanoma
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
Melanoma
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
Melanoma
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Melanoma
The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function.
Melanoma
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
Melanoma
The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization.
Melanoma
Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells.
Melanoma
Tubeimoside I Inhibits Cell Proliferation and Induces a Partly Disrupted and Cytoprotective Autophagy Through Rapidly Hyperactivation of MEK1/2-ERK1/2 Cascade via Promoting PTP1B in Melanoma.
Melanoma
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Melanoma
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Melanoma, Experimental
Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity.
Melioidosis
Demonstration of acid phosphatase activity in antigenic glycoprotein fractions obtained from the culture filtrate of Pseudomonas pseudomallei.
Memory Disorders
A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease.
Memory Disorders
Alzheimer's Disease Drug Discovery--11th international conference--Promising new therapeutic approaches. 27-28 September 2010, Jersey City, NJ, USA.
Memory Disorders
Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid ?-Associated Alzheimer's Disease in Mice.
Memory Disorders
Phenotypically distinct subtypes of psychosis accompany novel or rare variants in four different signaling genes.
Memory Disorders
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Memory Disorders
Se-Methylselenocysteine Ameliorates Neuropathology and Cognitive Deficits by Attenuating Oxidative Stress and Metal Dyshomeostasis in Alzheimer Model Mice.
Memory Disorders
Trillium tschonoskii maxim extract attenuates abnormal Tau phosphorylation.
Meniere Disease
Association of a functional polymorphism of PTPN22 encoding a lymphoid protein phosphatase in bilateral Meniere's disease.
Meningioma
Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.
Meningioma
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies.
Meningioma
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Meningioma
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
Meningioma
Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.
Meningitis
Acid phosphatase activity of cerebrospinal fluid cells in bacterial and abacterial meningitis.
Meningitis
[Acid phosphatase activity of the cerebrospinal fluid in various types of meningitis.]
Meningitis, Pneumococcal
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Menkes Kinky Hair Syndrome
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Mesothelioma, Malignant
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Metabolic Diseases
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Metabolic Diseases
Anti-obesity and hypolipidemic effects of Rheum undulatum in high-fat diet-fed C57BL/6 mice through protein tyrosine phosphatase 1B inhibition.
Metabolic Diseases
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Metabolic Diseases
Important roles of protein tyrosine phosphatase PTPN12 in tumor progression.
Metabolic Diseases
Improving Obesity and Insulin Resistance by Targeting Skeletal Muscle MKP-1.
Metabolic Diseases
Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.
Metabolic Diseases
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Metabolic Diseases
Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes.
Metabolic Diseases
Mitogen-activated protein kinase phosphatase-1 - a potential therapeutic target in metabolic disease.
Metabolic Diseases
Prenatal Growth Patterns and Birthweight Are Associated With Differential DNA Methylation and Gene Expression of Cardiometabolic Risk Genes in Human Placentas: A Discovery-Based Approach.
Metabolic Diseases
Role of Receptor Protein Tyrosine Phosphatases (RPTPs) in Insulin Signaling and Secretion.
Metabolic Diseases
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
Metabolic Diseases
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
Metabolic Syndrome
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
Metabolic Syndrome
At the Crossroads of Longevity and Metabolism: The Metabolic Syndrome and Life-Span Determinant Pathways.
Metabolic Syndrome
Cellular effects of small molecule PTP1B inhibitors on insulin signaling.
Metabolic Syndrome
DUSP1 Gene Polymorphisms Are Associated with Obesity-Related Metabolic Complications among Severely Obese Patients and Impact on Gene Methylation and Expression.
Metabolic Syndrome
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
Metabolic Syndrome
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.
Metabolic Syndrome
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress.
Metabolic Syndrome
MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice.
Metabolic Syndrome
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
Metabolic Syndrome
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
Metabolic Syndrome
No association of reported functional protein tyrosine phosphatase 1B 3' UTR gene polymorphism with features of the metabolic syndrome in a Swedish population.
Metabolic Syndrome
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Metabolic Syndrome
Penostatin derivatives, a novel kind of protein phosphatase 1b inhibitors isolated from solid cultures of the entomogenous fungus Isaria tenuipes.
Metabolic Syndrome
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Metabolic Syndrome
Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders.
Metabolic Syndrome
Protein tyrosine phosphatase-1B gene PTPN1: selection of tagging single nucleotide polymorphisms and association with body fat, insulin sensitivity, and the metabolic syndrome in a normal female population.
Metabolic Syndrome
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Metabolic Syndrome
Reply to Dahlman et al. No association of reported functional protein tyrosine phosphatase 1B 3'UTR gene polymorphism with features of the metabolic syndrome in a Swedish population. J Int Med 2004; 255: 694-5.
Metabolic Syndrome
Single nucleotide polymorphisms of protein tyrosine phosphatase 1B gene are associated with obesity in morbidly obese French subjects.
Metabolic Syndrome
Structure and biosynthesis of fumosorinone, a new protein tyrosine phosphatase 1B inhibitor firstly isolated from the entomogenous fungus Isaria fumosorosea.
Metabolic Syndrome
The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy.
Metabolic Syndrome
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Metabolic Syndrome
Upregulation of lipogenesis and protein tyrosine phosphatase-1B expression in the liver of Wistar rats with metabolic syndrome chronically induced by drinking sucrose water.
methylenetetrahydrofolate dehydrogenase (nad+) deficiency
Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice.
Metrorrhagia
Automated MALDI Target Preparation Concept: Providing Ultra-High-Throughput Mass Spectrometry-Based Screening for Drug Discovery.
Metrorrhagia
Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1.
Microcephaly
Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia.
Micrognathism
Inactivation of LAR family phosphatase genes Ptprs and Ptprf causes craniofacial malformations resembling Pierre-Robin sequence.
Micrognathism
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Microphthalmos
Rapamycin prevents spontaneous abortion by triggering decidual stromal cell autophagy-mediated NK cell residence.
Mitochondrial Diseases
Oxidative stress-dependent p66Shc phosphorylation in skin fibroblasts of children with mitochondrial disorders.
Monoclonal Gammopathy of Undetermined Significance
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Mouth Neoplasms
Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis.
Mouth Neoplasms
Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo.
Mouth Neoplasms
Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer.
Mouth Neoplasms
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
Mouth Neoplasms
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Mouth Neoplasms
p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression.
Mouth Neoplasms
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Mouth Neoplasms
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Movement Disorders
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Moyamoya Disease
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Moyamoya Disease
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Mucocutaneous Lymph Node Syndrome
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Mucopolysaccharidoses
[Changes in acid phosphatase activity induced by vitamin A in cultures of fibroblasts from a patient with mucopolysaccharidosis]
Multiple Endocrine Neoplasia
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
Multiple Endocrine Neoplasia
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
Multiple Endocrine Neoplasia Type 1
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
Multiple Endocrine Neoplasia Type 2a
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
Multiple Endocrine Neoplasia Type 2a
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Multiple Endocrine Neoplasia Type 2b
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
Multiple Endocrine Neoplasia Type 2b
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Multiple Myeloma
Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Multiple Myeloma
Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma.
Multiple Myeloma
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Multiple Myeloma
Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1.
Multiple Myeloma
Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN.
Multiple Myeloma
Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission.
Multiple Myeloma
Histochemical and immunohistochemical techniques on acrylate embedded bone biopsies.
Multiple Myeloma
IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Multiple Myeloma
Phosphatase of regenerating liver-3 regulates cancer cell metabolism in multiple myeloma.
Multiple Myeloma
Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.
Multiple Myeloma
PRL-3 promotes a positive feedback loop between STAT1/2-induced gene expression and glycolysis in multiple myeloma.
Multiple Myeloma
Protein phosphatase 2A modulates the proliferation of human multiple myeloma cells via regulation of the production of reactive oxygen intermediates and anti-apoptotic factors.
Multiple Myeloma
Retraction: Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1.
Multiple Myeloma
Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
Multiple Myeloma
The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling.
Multiple Myeloma
Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells.
Multiple Myeloma
Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.
Multiple Myeloma
[Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
Multiple Myeloma
[Usefulness of plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
Multiple Sclerosis
A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions.
Multiple Sclerosis
A point mutation in PTPRC is associated with the development of multiple sclerosis.
Multiple Sclerosis
Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z.
Multiple Sclerosis
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population.
Multiple Sclerosis
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Multiple Sclerosis
Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.
Multiple Sclerosis
Could ?-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson's Disease and Diabetes as Well as Potential Therapies?
Multiple Sclerosis
CYBB/NOX2 in conventional DCs controls T cell encephalitogenicity during neuroinflammation.
Multiple Sclerosis
Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?
Multiple Sclerosis
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
Multiple Sclerosis
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Multiple Sclerosis
Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome.
Multiple Sclerosis
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Multiple Sclerosis
Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
Multiple Sclerosis
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
Multiple Sclerosis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Multiple Sclerosis
MicroRNA-448 promotes multiple sclerosis development through induction of Th17 response through targeting protein tyrosine phosphatase non-receptor type 2 (PTPN2).
Multiple Sclerosis
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Multiple Sclerosis
Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 in Nervous System Development and Disease.
Multiple Sclerosis
Protein tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis.
Multiple Sclerosis
Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population.
Multiple Sclerosis
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Multiple Sclerosis
PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients.
Multiple Sclerosis
PTPRC (CD45) is not associated with multiple sclerosis in a large cohort of German patients.
Multiple Sclerosis
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients.
Multiple Sclerosis
Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes.
Multiple Sclerosis
RXR? Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc.
Multiple Sclerosis
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
Multiple Sclerosis
Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
Multiple Sclerosis
The control of reactive oxygen species production by SHP-1 in oligodendrocytes.
Multiple Sclerosis
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Multiple Sclerosis
The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis.
Multiple Sclerosis
The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom.
Muscle Hypotonia
B56?-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
Muscle Hypotonia
Neurodevelopmental phenotype caused by a de novo PTPN4 single nucleotide variant disrupting protein localization in neuronal dendritic spines.
Muscle Spasticity
Activity of smooth muscle phosphatases 1 and 2A in rabbit basilar artery in vasospasm.
Muscle Spasticity
Morphological and functional effects of altered cysteine string protein at the Drosophila larval neuromuscular junction.
Muscle Spasticity
Recombinant osteopontin attenuates experimental cerebral vasospasm following subarachnoid hemorrhage in rats through an anti-apoptotic mechanism.
Muscle Spasticity
Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage.
Muscle Weakness
Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome.
Muscular Atrophy
C1-Ten Is a Protein Tyrosine Phosphatase of Insulin Receptor Substrate 1 (IRS-1), Regulating IRS-1 Stability and Muscle Atrophy.
Muscular Atrophy
Dietary supplementation with ketoacids protects against CKD-induced oxidative damage and mitochondrial dysfunction in skeletal muscle of 5/6 nephrectomised rats.
Muscular Atrophy
Dual-specificity phosphatase 29 is induced during neurogenic skeletal muscle atrophy and attenuates glucocorticoid receptor activity in muscle cell culture.
Muscular Atrophy
Dual-Specificity Phosphatase 4 (Dusp4) is Upregulated During Skeletal Muscle Atrophy and Modulates Extracellular Signal-Regulated Kinase (ERK) Activity.
Muscular Atrophy
Inhibition of C1-Ten PTPase activity reduces insulin resistance through IRS-1 and AMPK pathways.
Muscular Atrophy
The lysosomal enzymes acid phosphatase and cathepsin D in rats intoxicated with Senna occidentalis seeds.
Muscular Diseases
Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1.
Muscular Diseases
Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
Muscular Diseases
SHP-1-Dependent Macrophage Differentiation Exacerbates Virus-Induced Myositis.
Muscular Dystrophies
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Muscular Dystrophy, Duchenne
Concomitance of basophilia, ribonucleic acid and acid phosphatase activity in regenerating muscle fibres.
Musculoskeletal Abnormalities
P0-Related Protein Accelerates Human Mesenchymal Stromal Cell Migration by Modulating VLA-5 Interactions with Fibronectin.
Myasthenia Gravis
Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis.
Myasthenia Gravis
Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.
Myasthenia Gravis
Expression and clinical significance of protein tyrosine phosphatase nonreceptor 22 in resected thymoma.
Myasthenia Gravis
Lack of association of the CIITA -168A?G promoter SNP with myasthenia gravis and its role in autoimmunity.
Myasthenia Gravis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Myasthenia Gravis
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
Myasthenia Gravis
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data.
Myasthenia Gravis
PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysis.
Myasthenia Gravis
PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis.
Myasthenia Gravis
The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
Myasthenia Gravis
The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis.
Mycobacterium Infections
Systematic Analysis of Mycobacterial Acylation Reveals First Example of Acylation-mediated Regulation of Enzyme Activity of a Bacterial Phosphatase.
Mycoses
The PTPN22 R620W polymorphism is associated with severe bacterial infections after human leukocyte antigen geno-identical haematopoietic stem-cell transplantations.
Mycoses
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
Myelodysplastic Syndromes
A case of Behcet's disease associated with myelodysplastic syndrome involving trisomy 8 and a gain-of-function mutation in SHP-2.
Myelodysplastic Syndromes
A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1.
Myelodysplastic Syndromes
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Myelodysplastic Syndromes
Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.
Myelodysplastic Syndromes
Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Myelodysplastic Syndromes
Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome.
Myelodysplastic Syndromes
Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis.
Myelodysplastic Syndromes
Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.
Myelodysplastic Syndromes
Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Myelodysplastic Syndromes
Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia.
Myelodysplastic Syndromes
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Myelodysplastic Syndromes
Novel oncogenic PTPN11 mutations in myelodysplastic syndrome in Korean patients.
Myelodysplastic Syndromes
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Myelodysplastic Syndromes
[Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
Myelodysplastic Syndromes
[Relationship between SHP-1 gene methylation and STAT3 phosphorylation and prognosis in patients with myelodysplastic syndrome].
Myeloproliferative Disorders
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Myeloproliferative Disorders
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Myeloproliferative Disorders
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Myeloproliferative Disorders
Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Myeloproliferative Disorders
Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.
Myeloproliferative Disorders
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Myeloproliferative Disorders
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Myeloproliferative Disorders
Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal.
Myeloproliferative Disorders
The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling.
Myeloproliferative Disorders
Transient myeloproliferative disorder in an infant with PTPN11 mutation.
Myocardial Infarction
Cardiac alkaline and acid phosphatase activity and potassium concentration in dogs with acute myocardial infarction.
Myocardial Infarction
Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein.
Myocardial Infarction
Crucial lncRNAs associated with adipocyte differentiation from human adipose-derived stem cells based on co-expression and ceRNA network analyses.
Myocardial Infarction
Disrupting protein tyrosine phosphatase ? does not prevent sympathetic axonal dieback following myocardial infarction.
Myocardial Infarction
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
Myocardial Infarction
Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating ?-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting ?-Catenin.
Myocardial Infarction
Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
Myocardial Infarction
Overexpression of protein phosphatase 2A in a murine model of chronic myocardial infarction leads to increased adverse remodeling but restores the regulation of ?-catenin by glycogen synthase kinase 3?
Myocardial Infarction
PTPRG is an ischemia risk locus essential for HCO3--dependent regulation of endothelial function and tissue perfusion.
Myocardial Infarction
RNA interference targeting SHP-1 attenuates myocardial infarction in rats.
Myocardial Infarction
Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure.
Myocardial Infarction
SH2 domain-containing protein tyrosine phosphatase-2 (SHP-2) prevents cardiac remodeling after myocardial infarction through ERK/SMAD signaling pathway.
Myocardial Infarction
Simultaneous regulation of apoptotic gene silencing and angiogenic gene expression for myocardial infarction therapy: Single-carrier delivery of SHP-1 siRNA and VEGF-expressing pDNA.
Myocardial Infarction
Survival pathways in hypertrophy and heart failure: the gp130-STAT axis.
Myocardial Infarction
Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis.
Myocardial Infarction
Targeting protein tyrosine phosphatase ? after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias.
Myocardial Infarction
Targeting Protein Tyrosine Phosphatase PTP-PEST for Therapeutic Intervention in Acute Myocardial Infarction.
Myocardial Infarction
Up-regulating microRNA-203 alleviates myocardial remodeling and cell apoptosis through down-regulating PTP1B in rats with myocardial infarction.
Myocardial Infarction
Upregulating MicroRNA-203 Alleviates Myocardial Remodeling and Cell Apoptosis Through Downregulating Protein Tyrosine Phosphatase 1B in Rats With Myocardial Infarction.
Myocardial Infarction
[Acid phosphatase activity of the leukocytes of patients with myocardial infarct]
Myocardial Ischemia
Coronary artery dilatation in LEOPARD syndrome. A child case and literature review.
Myocardial Ischemia
Electron microscopic cytochemical studies on acid phosphatase activity in acute myocardial ischemia.
Myocardial Ischemia
Overexpression of miR-210 promotes the potential of cardiac stem cells against hypoxia.
Myocardial Ischemia
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Myocardial Reperfusion Injury
The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
Myoclonic Epilepsies, Progressive
A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).
Myoclonic Epilepsies, Progressive
Alternative splicing modulates subcellular localization of laforin.
Myoclonic Epilepsies, Progressive
Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase.
Myoclonic Epilepsies, Progressive
Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.
Myoclonic Epilepsies, Progressive
Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice.
Myoclonic Epilepsies, Progressive
Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.
Myoclonic Epilepsies, Progressive
Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.
Myoclonic Epilepsies, Progressive
Regional and developmental expression of Epm2a gene and its evolutionary conservation.
Myoclonus
Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling.
Myoma
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Myopathies, Structural, Congenital
A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast.
Myopathies, Structural, Congenital
Centronuclear myopathy: histochemistry and electron microscopy. Report of two cases.
Myopathies, Structural, Congenital
ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins.
Myopathies, Structural, Congenital
Inaugural article: myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate.
Myopathies, Structural, Congenital
MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy.
Myopathies, Structural, Congenital
Rat testicular myotubularin, a protein tyrosine phosphatase expressed by Sertoli and germ cells, is a potential marker for studying cell-cell interactions in the rat testis.
Myopia
Association Mapping of the High-Grade Myopia MYP3 Locus Reveals Novel Candidates UHRF1BP1L, PTPRR, and PPFIA2.
Myopia
Association of Extracellular Signal-Regulated Kinase Genes With Myopia: A Longitudinal Study of Chinese Children.
Myositis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Myositis
Regulation of the chikungunya-virus-induced innate inflammatory response by protein tyrosine phosphatase non-receptor 6 in muscle cells.
Myositis
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Myotoxicity
The lysosomal enzymes acid phosphatase and cathepsin D in rats intoxicated with Senna occidentalis seeds.
Myxoma
Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.
Nasal Polyps
The expression of cancerous inhibitor protein phosphatase 2A in chronic rhinosinusitis with nasal polyps.
Nasal Polyps
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Nasopharyngeal Carcinoma
DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.
Nasopharyngeal Carcinoma
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Increased SHP-1 expression results in radioresistance, inhibition of cellular senescence, and cell cycle redistribution in nasopharyngeal carcinoma cells.
Nasopharyngeal Carcinoma
Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Nasopharyngeal Carcinoma
MicroRNA-378g enhanced radiosensitivity of NPC cells partially by targeting protein tyrosine phosphatase SHP-1.
Nasopharyngeal Carcinoma
MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells.
Nasopharyngeal Carcinoma
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
Nasopharyngeal Carcinoma
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Quinalizarin enhances radiosensitivity of nasopharyngeal carcinoma cells partially by suppressing SHP-1 expression.
Nasopharyngeal Carcinoma
SHP-1 overexpression increases the radioresistance of NPC cells by enhancing DSB repair, increasing S phase arrest and decreasing cell apoptosis.
Nasopharyngeal Carcinoma
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
Neoplasm Metastasis
1H, 15N, 13C resonance assignments of the reduced and active form of human Protein Tyrosine Phosphatase, PRL-1.
Neoplasm Metastasis
1HN, 13C, and 15N backbone resonance assignments of the SET/TAF-1?/I2PP2A oncoprotein (residues 23-225).
Neoplasm Metastasis
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
Neoplasm Metastasis
A novel binding factor of 14-3-3beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasis.
Neoplasm Metastasis
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Neoplasm Metastasis
Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.
Neoplasm Metastasis
Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Neoplasm Metastasis
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Neoplasm Metastasis
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Neoplasm Metastasis
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Neoplasm Metastasis
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Neoplasm Metastasis
Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition.
Neoplasm Metastasis
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Neoplasm Metastasis
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Neoplasm Metastasis
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Neoplasm Metastasis
Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
Neoplasm Metastasis
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.
Neoplasm Metastasis
Can dehydroepiandrostenedione (DHEA) target PRL-3 to prevent colon cancer metastasis?
Neoplasm Metastasis
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Neoplasm Metastasis
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
Neoplasm Metastasis
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
Neoplasm Metastasis
CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma.
Neoplasm Metastasis
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
Neoplasm Metastasis
CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Neoplasm Metastasis
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Neoplasm Metastasis
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Neoplasm Metastasis
Clinicopathological significance of PTPN12 expression in human breast cancer.
Neoplasm Metastasis
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Neoplasm Metastasis
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Neoplasm Metastasis
Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Neoplasm Metastasis
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Neoplasm Metastasis
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Neoplasm Metastasis
Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer.
Neoplasm Metastasis
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Neoplasm Metastasis
Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
Neoplasm Metastasis
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Neoplasm Metastasis
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Neoplasm Metastasis
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Neoplasm Metastasis
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Neoplasm Metastasis
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Neoplasm Metastasis
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Neoplasm Metastasis
Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo.
Neoplasm Metastasis
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Neoplasm Metastasis
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Neoplasm Metastasis
Epithelial-Mesenchymal Transition in Colorectal Carcinoma: Comparison Between Primary Tumor, Lymph Node and Liver Metastases.
Neoplasm Metastasis
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Neoplasm Metastasis
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Neoplasm Metastasis
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Neoplasm Metastasis
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Neoplasm Metastasis
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Neoplasm Metastasis
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Neoplasm Metastasis
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Neoplasm Metastasis
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Neoplasm Metastasis
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Neoplasm Metastasis
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Neoplasm Metastasis
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Neoplasm Metastasis
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Neoplasm Metastasis
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Neoplasm Metastasis
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Neoplasm Metastasis
Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma.
Neoplasm Metastasis
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Neoplasm Metastasis
Gene expression profiles in cells transformed by overexpression of the IGF-I receptor.
Neoplasm Metastasis
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Neoplasm Metastasis
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
Neoplasm Metastasis
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
Neoplasm Metastasis
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Neoplasm Metastasis
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Neoplasm Metastasis
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
Neoplasm Metastasis
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
Neoplasm Metastasis
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
Neoplasm Metastasis
High Migration and Invasion Ability of PGCCs and Their Daughter Cells Associated With the Nuclear Localization of S100A10 Modified by SUMOylation.
Neoplasm Metastasis
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Neoplasm Metastasis
High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients.
Neoplasm Metastasis
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Neoplasm Metastasis
Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.
Neoplasm Metastasis
Hypocalcemia associated with estrogen therapy for metastatic adenocarcinoma of the prostate.
Neoplasm Metastasis
Identification of genes that may play critical roles in phenobarbital (PB)-induced liver tumorigenesis due to altered DNA methylation.
Neoplasm Metastasis
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Neoplasm Metastasis
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Neoplasm Metastasis
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
Neoplasm Metastasis
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Neoplasm Metastasis
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Neoplasm Metastasis
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Neoplasm Metastasis
Increase in CIP2A expression is associated with doxorubicin resistance.
Neoplasm Metastasis
Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome.
Neoplasm Metastasis
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Neoplasm Metastasis
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Neoplasm Metastasis
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Neoplasm Metastasis
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Neoplasm Metastasis
Integrated Analysis of Global mRNA and Protein Expression Data in HEK293 Cells Overexpressing PRL-1.
Neoplasm Metastasis
KCNN4 channels participate in the EMT induced by PRL-3 in colorectal cancer.
Neoplasm Metastasis
Leiomyosarcoma of the heart and its pulmonary metastasis, both with prominent osteoclast-like multinucleated giant cells expressing tartrate-resistant acid phosphatase activity.
Neoplasm Metastasis
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Neoplasm Metastasis
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Neoplasm Metastasis
Loss of receptor protein tyrosine phosphatase ?/? (RPTP?/?) promotes prostate cancer metastasis.
Neoplasm Metastasis
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Neoplasm Metastasis
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Neoplasm Metastasis
Low molecular weight protein tyrosine phosphatase as signaling hub of cancer hallmarks.
Neoplasm Metastasis
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Neoplasm Metastasis
Measuring p66Shc Signaling Pathway Activation and Mitochondrial Translocation in Cultured Cells.
Neoplasm Metastasis
MenaINV mediates synergistic crosstalk between signaling pathways driving chemotaxis and haptotaxis.
Neoplasm Metastasis
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Neoplasm Metastasis
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Neoplasm Metastasis
Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
Neoplasm Metastasis
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
Neoplasm Metastasis
MicroRNA-217 suppressed epithelial-to-mesenchymal transition in gastric cancer metastasis through targeting PTPN14.
Neoplasm Metastasis
microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
Neoplasm Metastasis
MicroRNA-378g enhanced radiosensitivity of NPC cells partially by targeting protein tyrosine phosphatase SHP-1.
Neoplasm Metastasis
MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU.
Neoplasm Metastasis
MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta.
Neoplasm Metastasis
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
Neoplasm Metastasis
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
Neoplasm Metastasis
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
Neoplasm Metastasis
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
Neoplasm Metastasis
miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE.
Neoplasm Metastasis
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
Neoplasm Metastasis
miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
Neoplasm Metastasis
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Neoplasm Metastasis
Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma.
Neoplasm Metastasis
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Neoplasm Metastasis
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Neoplasm Metastasis
New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.
Neoplasm Metastasis
Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Neoplasm Metastasis
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Neoplasm Metastasis
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Neoplasm Metastasis
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Neoplasm Metastasis
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Neoplasm Metastasis
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Neoplasm Metastasis
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Neoplasm Metastasis
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Neoplasm Metastasis
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
Neoplasm Metastasis
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Neoplasm Metastasis
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 directly interacts with integrin ?1 and regulates its phosphorylation at tyrosine 783.
Neoplasm Metastasis
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Neoplasm Metastasis
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Neoplasm Metastasis
Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.
Neoplasm Metastasis
Polyphyllin I and VII potentiate the chemosensitivity of A549/DDP cells to cisplatin by enhancing apoptosis, reversing EMT and suppressing the CIP2A/AKT/mTOR signaling axis.
Neoplasm Metastasis
Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Neoplasm Metastasis
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
Neoplasm Metastasis
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
Neoplasm Metastasis
Presence of creatine kinase BB isoenzyme in some patients with prostatic carcinoma.
Neoplasm Metastasis
Primary pineal tumors - Unraveling histological challenges and certain clinical myths.
Neoplasm Metastasis
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Neoplasm Metastasis
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
Neoplasm Metastasis
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Neoplasm Metastasis
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasm Metastasis
PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer.
Neoplasm Metastasis
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
Neoplasm Metastasis
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Neoplasm Metastasis
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
Neoplasm Metastasis
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
Neoplasm Metastasis
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
Neoplasm Metastasis
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Neoplasm Metastasis
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
Neoplasm Metastasis
PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.
Neoplasm Metastasis
PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels.
Neoplasm Metastasis
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
Neoplasm Metastasis
PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells.
Neoplasm Metastasis
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.
Neoplasm Metastasis
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Neoplasm Metastasis
PRL-3/PTP4A3 phosphatase regulates integrin ?1 in adhesion structures during migration of human ocular melanoma cells.
Neoplasm Metastasis
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Neoplasm Metastasis
Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Neoplasm Metastasis
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Neoplasm Metastasis
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Neoplasm Metastasis
Prognostic value of PRL-3 overexpression in early stages of colonic cancer.
Neoplasm Metastasis
Protein phosphatase 2A C? regulates proliferation, migration, and metastasis of osteosarcoma cells.
Neoplasm Metastasis
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Neoplasm Metastasis
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Neoplasm Metastasis
Protein tyrosine phosphatase 4A3 (PTP4A3) is required for Xenopus laevis cranial neural crest migration in vivo.
Neoplasm Metastasis
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Neoplasm Metastasis
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Neoplasm Metastasis
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Neoplasm Metastasis
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Neoplasm Metastasis
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Neoplasm Metastasis
Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Neoplasm Metastasis
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Neoplasm Metastasis
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Neoplasm Metastasis
Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
Neoplasm Metastasis
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
Neoplasm Metastasis
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Neoplasm Metastasis
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Neoplasm Metastasis
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.
Neoplasm Metastasis
Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells.
Neoplasm Metastasis
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.
Neoplasm Metastasis
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Neoplasm Metastasis
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
Neoplasm Metastasis
PTP1B up-regulates EGFR expression by dephosphorylating MYH9 at Y1408 to promote cell migration and invasion in esophageal squamous cell carcinoma.
Neoplasm Metastasis
PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer.
Neoplasm Metastasis
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma.
Neoplasm Metastasis
PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization.
Neoplasm Metastasis
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
Neoplasm Metastasis
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Neoplasm Metastasis
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Neoplasm Metastasis
PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization.
Neoplasm Metastasis
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
Neoplasm Metastasis
PTPR? Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-? Receptor 1.
Neoplasm Metastasis
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
Neoplasm Metastasis
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
Neoplasm Metastasis
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.
Neoplasm Metastasis
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Neoplasm Metastasis
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Neoplasm Metastasis
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Neoplasm Metastasis
Ras-induced and ERK1/2 Phosphorylation-Dependent Isomerization of PTP-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST.
Neoplasm Metastasis
Regulation of the Src Kinase-associated Phosphoprotein 55 Homologue by the Protein Tyrosine Phosphatase PTP-PEST in the Control of Cell Motility.
Neoplasm Metastasis
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Neoplasm Metastasis
Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma.
Neoplasm Metastasis
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms.
Neoplasm Metastasis
Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model.
Neoplasm Metastasis
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Neoplasm Metastasis
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Neoplasm Metastasis
RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis.
Neoplasm Metastasis
Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti- Cancer Drug Target.
Neoplasm Metastasis
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Neoplasm Metastasis
Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
Neoplasm Metastasis
SHP-1 Acts as a Tumor Suppressor in Hepatocarcinogenesis and HCC Progression.
Neoplasm Metastasis
SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasm Metastasis
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
Neoplasm Metastasis
Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells.
Neoplasm Metastasis
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Neoplasm Metastasis
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Neoplasm Metastasis
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Neoplasm Metastasis
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
Neoplasm Metastasis
Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer.
Neoplasm Metastasis
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
Neoplasm Metastasis
Structure and backbone dynamics of vanadate-bound PRL-3: comparison of 15N nuclear magnetic resonance relaxation profiles of free and vanadate-bound PRL-3.
Neoplasm Metastasis
Structure of human PRL-3, the phosphatase associated with cancer metastasis.
Neoplasm Metastasis
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
Neoplasm Metastasis
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Neoplasm Metastasis
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Neoplasm Metastasis
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
Neoplasm Metastasis
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
Neoplasm Metastasis
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Neoplasm Metastasis
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
Neoplasm Metastasis
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Neoplasm Metastasis
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
Neoplasm Metastasis
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
Neoplasm Metastasis
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
Neoplasm Metastasis
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
Neoplasm Metastasis
The mechanisms of colorectal cancer cell mesenchymal-epithelial transition induced by hepatocyte exosome-derived miR-203a-3p.
Neoplasm Metastasis
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
Neoplasm Metastasis
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
Neoplasm Metastasis
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
Neoplasm Metastasis
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
Neoplasm Metastasis
The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
Neoplasm Metastasis
The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Neoplasm Metastasis
The SIX1-EYA transcriptional complex as a therapeutic target in cancer.
Neoplasm Metastasis
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
Neoplasm Metastasis
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
Neoplasm Metastasis
The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas.
Neoplasm Metastasis
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Neoplasm Metastasis
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Neoplasm Metastasis
Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.
Neoplasm Metastasis
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Neoplasm Metastasis
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Neoplasm Metastasis
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Neoplasm Metastasis
Vemurafenib downmodulates aggressiveness mediators of colorectal cancer (CRC): Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP), Protein Tyrosine Phosphatase 1B (PTP1B) and Transforming Growth Factor ? (TGF?).
Neoplasm Metastasis
Whole-exome sequencing identifies prognostic mutational signatures in gastric cancer.
Neoplasm Metastasis
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Neoplasm Metastasis
[Construction of a lentiviral vector for RNA interference of PRL-3 gene and its stable expression in SW480 cells]
Neoplasm Metastasis
[Construction of the life cycle of Angiostrongylus cantonensis in laboratory]
Neoplasm Metastasis
[Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]
Neoplasm Metastasis
[Establishment of a colorectal cancer cell line with PRL-3 and CDH22 gene knock-down by lentivirus-mediated RNA interference.]
Neoplasm Metastasis
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Neoplasm Metastasis
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Neoplasm Metastasis
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
Neoplasm Metastasis
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
Neoplasm Metastasis
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Neoplasm Metastasis
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Neoplasm Metastasis
[Histochemical study of the immune response of the regional lymph nodes in breast and stomach cancer]
Neoplasm Metastasis
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
Neoplasm Metastasis
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Neoplasm Micrometastasis
Erratum to: The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Neoplasm Micrometastasis
The role of SHP-1 promoter 2 hypermethylation detection of lymph node micrometastasis in resectable stage I non-small cell lung cancer as a prognostic marker of disease recurrence.
Neoplasm, Residual
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Neoplasm, Residual
Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
Neoplasms
(-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
Neoplasms
17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells.
Neoplasms
1alpha,25-dihydroxyvitamin D3 activates T cells of tumor bearers through protein phosphatase 2A.
Neoplasms
1H, 13C and 15N NMR chemical shift assignments of cAMP-regulated phosphoprotein-19 and -16 (ARPP-19 and ARPP-16).
Neoplasms
1H, 15N, 13C resonance assignments of the reduced and active form of human Protein Tyrosine Phosphatase, PRL-1.
Neoplasms
1HN, 13C, and 15N backbone resonance assignments of the SET/TAF-1?/I2PP2A oncoprotein (residues 23-225).
Neoplasms
2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets.
Neoplasms
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Neoplasms
5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization.
Neoplasms
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
Neoplasms
?-Caryophyllene attenuates lipopolysaccharide-induced acute lung injury via inhibition of the MAPK signalling pathway.
Neoplasms
?-Tocotrienol but not ?-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Neoplasms
A 100-kb physical and transcriptional map around the EDH17B2 gene: identification of three novel genes and a pseudogene of a human homologue of the rat PRL-1 tyrosine phosphatase.
Neoplasms
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.
Neoplasms
A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
Neoplasms
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.
Neoplasms
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Neoplasms
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Neoplasms
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
Neoplasms
A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.
Neoplasms
A dimeric urea of the bisabolene sesquiterpene from the Okinawan marine sponge Axinyssa sp. inhibits protein tyrosine phosphatase 1B activity in Huh-7 human hepatoma cells.
Neoplasms
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Neoplasms
A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1.
Neoplasms
A high-molecular weight complex with acid phosphatase activity in human breast cancer.
Neoplasms
A Highly Sensitive Electrochemiluminescence Biosensor for Pyrophosphatase Detection Based on Click Chemistry-Triggered Hybridization Chain Reaction in Homogeneous Solution.
Neoplasms
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
Neoplasms
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Neoplasms
A new abietane diterpenoid from Ajuga ovalifolia var. calantha induces human lung epithelial A549 cell apoptosis by inhibiting SHP2.
Neoplasms
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type ? in chronic myeloid leukemia patients.
Neoplasms
A nonhomologous end-joining pathway is required for protein phosphatase 2A promotion of DNA double-strand break repair.
Neoplasms
A Nonsynonymous/Synonymous Substitution Analysis of the B56 Gene Family Aids in Understanding B56 Isoform Diversity.
Neoplasms
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Neoplasms
A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.
Neoplasms
A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.
Neoplasms
A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
Neoplasms
A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
Neoplasms
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Neoplasms
A novel splice variant of the protein tyrosine phosphatase PTPRJ that encodes for a soluble protein involved in angiogenesis.
Neoplasms
A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis.
Neoplasms
A polar extract of the Maya healing plant Anthurium schlechtendalii (Aracea) exhibits strong in vitro anticancer activity.
Neoplasms
A polybromodiphenyl ether from an Indonesian marine sponge Lamellodysidea herbacea and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment.
Neoplasms
A Potential Therapeutic Application of SET/I2PP2A Inhibitor OP449 for Canine T-Cell Lymphoma.
Neoplasms
A preliminary study of elevated alkaline phosphatase and cathepsin in bronchial aspirates of patients with lung cancer and bronchitis.
Neoplasms
A retrospective cohort study of clinical value of PRL-3 in stage III human colorectal cancer.
Neoplasms
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Neoplasms
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).
Neoplasms
A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Neoplasms
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Neoplasms
A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites.
Neoplasms
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Neoplasms
A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.
Neoplasms
A squalamine derivative, NV669, as a novel PTP1B inhibitor: in vitro and in vivo effects on pancreatic and hepatic tumor growth.
Neoplasms
A synthetic biotinylated peptide, BP21, inhibits the induction of mRNA expression of inflammatory substances by oxidized- and lyso-phosphatidylcholine.
Neoplasms
A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma.
Neoplasms
A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles.
Neoplasms
A transgenic Drosophila model demonstrates that the Helicobacter pylori CagA protein functions as a eukaryotic Gab adaptor.
Neoplasms
A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression.
Neoplasms
A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
Neoplasms
A unique and rapid approach toward the efficient development of novel protein tyrosine phosphatase (PTP) inhibitors based on 'clicked' pseudo-glycopeptides.
Neoplasms
Aberrant activation of the CD45-Wnt signaling axis promotes stemness and therapy resistance in colorectal cancer cells.
Neoplasms
Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Neoplasms
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.
Neoplasms
Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.
Neoplasms
Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Neoplasms
Aberrant promoter 2 methylation?mediated downregulation of protein tyrosine phosphatase, non?receptor type 6, is associated with progression of esophageal squamous cell carcinoma.
Neoplasms
Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.
Neoplasms
Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas.
Neoplasms
Abnormal splicing of SHP-1 protein tyrosine phosphatase in human T cells. Implications for lymphomagenesis.
Neoplasms
Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo.
Neoplasms
Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors.
Neoplasms
Absence of PTEN/MMAC1 germ-line mutations in sporadic Bannayan-Riley-Ruvalcaba syndrome.
Neoplasms
Absolute configuration and protein tyrosine phosphatase 1B inhibitory activity of xanthoepocin, a dimeric naphtopyrone from Penicillium sp. IQ-429.
Neoplasms
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Neoplasms
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Neoplasms
Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.
Neoplasms
Acid Phosphatase Activity of Normal and Tumor Tissue of Tobacco Grown in Vitro and in Vivo.
Neoplasms
Acid phosphatase and non-specific alpha-naphthol acetate esterase activities of monocytes in patients with cancer of the digestive tract during surgical treatment.
Neoplasms
Acid phosphatase in prostatic tissue homogenates from patients with benign prostatic hyperplasia and prostatic carcinoma.
Neoplasms
Acid phosphatase response in murine rhabdomyosarcoma for various tumour volumes and after different doses of neutron irradiation, alone or combined with exogenous ATP.
Neoplasms
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
Neoplasms
Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure.
Neoplasms
Actinomycetes for marine drug discovery isolated from mangrove soils and plants in China.
Neoplasms
Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood.
Neoplasms
Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
Neoplasms
Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients.
Neoplasms
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Neoplasms
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Neoplasms
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase.
Neoplasms
Activation of oncogenic tyrosine kinase signaling promotes insulin receptor-mediated cone photoreceptor survival.
Neoplasms
Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Neoplasms
Activation of protein kinases and the inactivation of protein phosphatase 2A in tumour necrosis factor and interleukin-1 signal-transduction pathways.
Neoplasms
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Neoplasms
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.
Neoplasms
Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
Neoplasms
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Neoplasms
Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells.
Neoplasms
Activity of some lysosomal enzymes in serum and in tumors of patients with squamous cell lung carcinoma.
Neoplasms
Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity.
Neoplasms
Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B.
Neoplasms
Adrenocorticotropin induces mitogen-activated protein kinase phosphatase 1 in Y1 mouse adrenocortical tumor cells.
Neoplasms
Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells.
Neoplasms
ALK receptor activation, ligands and therapeutic targeting in glioblastoma and in other cancers.
Neoplasms
Alkaline phosphatase and phosphoamino acid phosphatases in normal and cancerous tissues of the human larynx.
Neoplasms
Alkaloids from the nearly ripe fruits of Evodia rutaecarpa and their bioactivities.
Neoplasms
Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.
Neoplasms
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Neoplasms
Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma.
Neoplasms
AlloDriver: a method for the identification and analysis of cancer driver targets.
Neoplasms
Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.
Neoplasms
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Neoplasms
Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo.
Neoplasms
Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.
Neoplasms
Altered distribution and expression of protein tyrosine phosphatases in normal human skin as compared to squamous cell carcinomas.
Neoplasms
Altered expression of phosphatase of regenerating liver gene family in non-small cell lung cancer.
Neoplasms
Altered response of a human squamous cell carcinoma cell line to 1, 25-dihydroxyvitamin D(3) after transfer of a normal chromosome 11.
Neoplasms
An acid phosphatase in the plasma membranes of human astrocytoma showing marked specificity toward phosphotyrosine protein.
Neoplasms
An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.
Neoplasms
An Adamantyl-Substituted Retinoid-Derived Molecule That Inhibits Cancer Cell Growth and Angiogenesis by Inducing Apoptosis and Binds to Small Heterodimer Partner Nuclear Receptor: Effects of Modifying Its Carboxylate Group on Apoptosis, Proliferation, and Protein-Tyrosine Phosphatase Activity.
Neoplasms
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
Neoplasms
An Anticancer Effect of Curcumin Mediated by Down-regulating PRL-3 Expression on Highly Metastatic Melanoma Cells.
Neoplasms
An integrated in silico approach to understand protein-protein interactions: human meprin-? with fetuin-A.
Neoplasms
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis.
Neoplasms
An unexpected new role of mutant Ras: perturbation of human embryonic development.
Neoplasms
An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond.
Neoplasms
Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer.
Neoplasms
Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
Neoplasms
Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.
Neoplasms
Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
Neoplasms
Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
Neoplasms
Anti-Alzheimer's Disease Molecular Mechanism of Acori Tatarinowii Rhizoma Based on Network Pharmacology.
Neoplasms
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
Neoplasms
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Neoplasms
Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Neoplasms
Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells.
Neoplasms
Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Neoplasms
Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition.
Neoplasms
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.
Neoplasms
APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.
Neoplasms
Apigetrin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell.
Neoplasms
Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
Neoplasms
Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Neoplasms
Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia.
Neoplasms
Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas.
Neoplasms
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
Neoplasms
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-X(L) and survivin.
Neoplasms
Assessment of biochemical parameters and characterization of TNF? -308G/A and PTPN22 +1858C/T gene polymorphisms in the risk of obesity in adolescents.
Neoplasms
Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Neoplasms
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Neoplasms
Association between diversity in the Src homology 2 domain--containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer.
Neoplasms
Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese.
Neoplasms
Association of 3BP2 with SHP-1 regulates SHP-1-mediated production of TNF-? in RBL-2H3 cells.
Neoplasms
Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation.
Neoplasms
Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.
Neoplasms
Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C.
Neoplasms
Association of the protein-tyrosine phosphatase DEP-1 with its substrate FLT3 visualized by in situ proximity ligation assay.
Neoplasms
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Neoplasms
AT2 Receptor Mediated Activation of the Tyrosine Phosphatase PTP1B Blocks Caveolin-1 Enhanced Migration, Invasion and Metastasis of Cancer Cells.
Neoplasms
Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
Neoplasms
Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.
Neoplasms
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Neoplasms
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Neoplasms
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.
Neoplasms
Autoimmunity-Related Risk Variants in PTPN22 and CTLA4 Are Associated With ME/CFS With Infectious Onset.
Neoplasms
Azide-alkyne cycloaddition-mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools.
Neoplasms
B Cell-Intrinsic SHP1 Expression Promotes the Gammaherpesvirus-Driven Germinal Center Response and the Establishment of Chronic Infection.
Neoplasms
B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.
Neoplasms
B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A.
Neoplasms
Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Neoplasms
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Neoplasms
Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
Neoplasms
Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.
Neoplasms
Biochemical evaluation of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting phosphatases of regenerating liver.
Neoplasms
Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors.
Neoplasms
Biological function of protein tyrosine phosphatase H-type receptor and its progress in tumor.
Neoplasms
Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.
Neoplasms
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Neoplasms
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels.
Neoplasms
Both HPV and carcinogen contribute to the development of resistance to apoptosis during oral carcinogenesis.
Neoplasms
BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
Neoplasms
c-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer.
Neoplasms
c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.
Neoplasms
Caged xanthones displaying protein tyrosine phosphatase 1B (PTP1B) inhibition from Cratoxylum cochinchinense.
Neoplasms
Calpain 2 regulates Akt-FoxO-p27(Kip1) protein signaling pathway in mammary carcinoma.
Neoplasms
Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.
Neoplasms
Cancer-associated fibroblasts promote bone invasion in oral squamous cell carcinoma.
Neoplasms
Cancer-derived mutations in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation.
Neoplasms
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.
Neoplasms
Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
Neoplasms
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
Neoplasms
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Neoplasms
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Neoplasms
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Neoplasms
Carcinoma of the prostate in childhood and adolescence: report of a case and review of the literature.
Neoplasms
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition.
Neoplasms
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
Neoplasms
Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp60(c-src).
Neoplasms
CCL26 Participates in the PRL-3-Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration.
Neoplasms
CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR.
Neoplasms
CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.
Neoplasms
cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.
Neoplasms
cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas.
Neoplasms
CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells.
Neoplasms
Cdc25A promotes cell survival by stimulating NF-?B activity through I?B-? phosphorylation and destabilization.
Neoplasms
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment.
Neoplasms
Cdc25A Regulates Matrix Metalloprotease 1 through Foxo1 and Mediates Metastasis of Breast Cancer Cells.
Neoplasms
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Neoplasms
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Neoplasms
CDC25B induces cellular senescence and correlates with tumor suppression in a p53-dependent manner.
Neoplasms
CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation.
Neoplasms
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Neoplasms
Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors.
Neoplasms
CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.
Neoplasms
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Neoplasms
Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Neoplasms
CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma.
Neoplasms
CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual specificity phosphatase 1.
Neoplasms
cDNA microarray analysis of differential gene expression in gastric cancer cells sensitive and resistant to 5-Fluorouracil and Cisplatin.
Neoplasms
Cell cycle dysregulation influences survival in high risk breast cancer patients.
Neoplasms
Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Neoplasms
Cell Transformation by PTP1B Truncated Mutants Found in Human Colon and Thyroid Tumors.
Neoplasms
Cell Type-Specific and Inducible PTEN Gene Silencing by a Tetracycline Transcriptional Activator-Regulated Short Hairpin RNA.
Neoplasms
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.
Neoplasms
Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac.
Neoplasms
Changes of expressions of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3'-methyl-4-dimethylamino-azobenzene.
Neoplasms
Characterization of gene rearrangements resulted from genomic structural aberrations in human esophageal squamous cell carcinoma KYSE150 cells.
Neoplasms
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array.
Neoplasms
Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells.
Neoplasms
Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha.
Neoplasms
Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas.
Neoplasms
Characterization of the submicroscopic deletion in the small-cell lung carcinoma (SCLC) cell line U2020.
Neoplasms
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Neoplasms
Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-?B pathway in breast cancer cells.
Neoplasms
Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Neoplasms
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Neoplasms
Chlorin e6 and CRISPR-Cas9 dual-loading system with deep penetration for a synergistic tumoral photodynamic-immunotherapy.
Neoplasms
Chondroitin Sulfate Proteoglycans Potently Inhibit Invasion and Serve as a Central Organizer of the Brain Tumor Microenvironment.
Neoplasms
Chrodrimanins O-S from the fungus Penicillium sp. SCS-KFD09 isolated from a marine worm, Sipunculusnudus.
Neoplasms
Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells.
Neoplasms
CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Neoplasms
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Neoplasms
CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis.
Neoplasms
CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Neoplasms
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Neoplasms
CIP2A Is Highly Expressed in Hepatocellular Carcinoma and Predicts Poor Prognosis.
Neoplasms
CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
Neoplasms
CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing ?-catenin.
Neoplasms
Cip2A modulates osteogenic differentiation via the ERK-Runx2 pathway in MG63 cells.
Neoplasms
Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Neoplasms
CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection.
Neoplasms
CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
Neoplasms
CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
Neoplasms
CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.
Neoplasms
CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells.
Neoplasms
Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.
Neoplasms
Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner.
Neoplasms
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Neoplasms
Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer.
Neoplasms
Clinical relevance of protein-tyrosine (de-)phosphorylation in head and neck cancer.
Neoplasms
Clinical significance of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in human cancers.
Neoplasms
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
Neoplasms
Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma.
Neoplasms
Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Neoplasms
Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.
Neoplasms
Cluster of differentiation 45 activation is crucial in interleukin-10-dependent tumor-associated dendritic cell differentiation.
Neoplasms
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.
Neoplasms
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.
Neoplasms
Combination of Sodium Cantharidinate with Cisplatin Synergistically Hampers Growth of Cervical Cancer.
Neoplasms
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
Neoplasms
Combined expression of metastasis related markers Naa10p, SNCG and PRL-3 and its prognostic value in breast cancer patients.
Neoplasms
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Neoplasms
Comments on: "Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk".
Neoplasms
Common molecular cytogenetic pathway in papillary tumors of the pineal region (PTPR).
Neoplasms
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Neoplasms
Comparative effects of nodularin and microcystin-LR in zebrafish: 2. Uptake and molecular effects in eleuthero-embryos and adult liver with focus on endoplasmic reticulum stress.
Neoplasms
Comparative evaluation of serum acid phosphatase, urinary cholesterol, and androgens in diagnosis of prostatic cancer.
Neoplasms
Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia.
Neoplasms
Comparative proteomic analysis uncovers potential biomarkers involved in the anticancer effect of Scutellarein in human gastric cancer cells.
Neoplasms
Competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors, prenylated caged xanthones from Garcinia hanburyi and their inhibitory mechanism.
Neoplasms
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Neoplasms
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Neoplasms
Conformational Rigidity and Protein Dynamics at Distinct Timescales Regulate PTP1B Activity and Allostery.
Neoplasms
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells.
Neoplasms
Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
Neoplasms
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Neoplasms
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.
Neoplasms
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Neoplasms
Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
Neoplasms
Correlation between High Field MR Images and Histopathological Findings of Rat Transplanted Cancer Immediately after Partial Microwave Coagulation.
Neoplasms
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Neoplasms
Cross Talk between Wnt/?-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Neoplasms
Crystal structures of the apo form and a complex of human LMW-PTP with a phosphonic acid provide new evidence of a secondary site potentially related to the anchorage of natural substrates.
Neoplasms
Crystallization and preliminary X-ray diffraction analysis of rat protein tyrosine phosphatase eta.
Neoplasms
CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
Neoplasms
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Neoplasms
Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Neoplasms
Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Neoplasms
Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
Neoplasms
Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7.
Neoplasms
Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity.
Neoplasms
Cytogenetical assignment and physical mapping of the human R-PTP-kappa gene (PTPRK) to the putative tumor suppressor gene region 6q22.2-q22.3.
Neoplasms
Cytotoxicity of new alkylamino- and phenylamino-containing polyfluorinated derivatives of 1,4-naphthoquinone.
Neoplasms
Cytotoxicity of new polyfluorinated 1,4-naphtoquinones with diverse substituents in the quinone moiety.
Neoplasms
D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta.
Neoplasms
DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study.
Neoplasms
Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach.
Neoplasms
Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients.
Neoplasms
Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer.
Neoplasms
Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma.
Neoplasms
Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma.
Neoplasms
Decreased Glucocorticoid Signaling Potentiates Lipid-Induced Inflammation and Contributes to Insulin Resistance in the Skeletal Muscle of Fructose-Fed Male Rats Exposed to Stress.
Neoplasms
Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
Neoplasms
Deletion of inositol polyphosphate 4-phosphatase type-II B affects spermatogenesis in mice.
Neoplasms
Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23.
Neoplasms
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Neoplasms
Demonstrating the effect of SHP2 inhibitor on cervical squamous cell carcinoma from the perspective of ZAP70.
Neoplasms
DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients.
Neoplasms
Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance.
Neoplasms
Dephosphorylation of the adaptor LAT and phospholipase C-? by SHP-1 inhibits natural killer cell cytotoxicity.
Neoplasms
Dephosphorylation-directed tricyclic DNA amplification cascades for sensitive detection of protein tyrosine phosphatase.
Neoplasms
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.
Neoplasms
Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.
Neoplasms
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Neoplasms
Design and functional activity of phosphopeptides with potential immunomodulating capacity, based on the sequence of Grb2-associated binder 1.
Neoplasms
Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design.
Neoplasms
Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity.
Neoplasms
Design, synthesis, and functional evaluation of triazine-based bivalent agents that simultaneously target the active site and hot spot of phosphatase Cdc25B.
Neoplasms
Design, Synthesis, Biological Activity, and Structural Analysis of Lactam-Constrained PTPRJ Agonist Peptides.
Neoplasms
Detection of phosphotyrosine-containing proteins in polyomavirus middle tumor antigen-transformed cells after treatment with a phosphotyrosine phosphatase inhibitor.
Neoplasms
Development and application of a PCR-HRM molecular diagnostic method of SNPs linked with TNF inhibitor efficacy.
Neoplasms
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
Neoplasms
Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
Neoplasms
Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the ?-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study.
Neoplasms
Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells.
Neoplasms
Development of artificial chimerical gene regulatory elements specific for cancer gene therapy.
Neoplasms
Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis.
Neoplasms
Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis.
Neoplasms
Different p53 genotypes regulating different phosphorylation sites and subcellular location of CDC25C associated with the formation of polyploid giant cancer cells.
Neoplasms
Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells.
Neoplasms
Differential expression and translocation of protein tyrosine phosphatase 1B-related proteins in ME-180 tumor cells expressing apoptotic sensitivity and resistance to tumor necrosis factor: potential interaction with epidermal growth factor receptor.
Neoplasms
Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma.
Neoplasms
Differential expression of SHP2, a protein-tyrosine phosphatase with SRC homology-2 domains, in various types of renal tumour.
Neoplasms
Differential gene expression in pristane-induced arthritis susceptible DA versus resistant E3 rats.
Neoplasms
Differential induction of glioblastoma migration and growth by two forms of pleiotrophin.
Neoplasms
Differential regulation of JNK activation and MKP-1 expression by peroxovanadium complexes.
Neoplasms
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Neoplasms
Digoxin enhances radiation response in radioresistant A549 cells by reducing protein phosphatase 2A.
Neoplasms
Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich ascites carcinoma cells.
Neoplasms
Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice
Neoplasms
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
Neoplasms
Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein.
Neoplasms
Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.
Neoplasms
Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1.
Neoplasms
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias.
Neoplasms
Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing.
Neoplasms
Discovery of Cdc25A Lead Inhibitors with a Novel Chemotype by Virtual Screening: Application of Pharmacophore Modeling Based on a Training Set with a Limited Number of Unique Components.
Neoplasms
Discovery of novel inhibitor of human leukocyte common antigen-related phosphatase.
Neoplasms
Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.
Neoplasms
Discovery of PTPRJ Agonist Peptides That Effectively Inhibit in Vitro Cancer Cell Proliferation and Tube Formation.
Neoplasms
Disrupting the transmembrane domain-mediated oligomerization of protein tyrosine phosphatase receptor J inhibits EGFR-driven cancer cell phenotypes.
Neoplasms
Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
Neoplasms
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Neoplasms
Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.
Neoplasms
Dissecting molecular events in thyroid neoplasia provides evidence for distinct evolution of follicular thyroid adenoma and carcinoma.
Neoplasms
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
Neoplasms
Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.
Neoplasms
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Neoplasms
DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.
Neoplasms
DNA damage-induced down-regulation of human Cdc25C and Cdc2 is mediated by cooperation between p53 and maintenance DNA (cytosine-5) methyltransferase 1.
Neoplasms
DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter.
Neoplasms
Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity.
Neoplasms
Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme?
Neoplasms
Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
Neoplasms
Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein?
Neoplasms
Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.
Neoplasms
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Neoplasms
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Neoplasms
Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression.
Neoplasms
Down-regulated expression of the protein-tyrosine phosphatase 1B (PTP1B) is associated with aggressive clinicopathologic features and poor prognosis in hepatocellular carcinoma.
Neoplasms
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Neoplasms
Down-regulation of the human PRL-3 gene is associated with the metastasis of primary non-small cell lung cancer.
Neoplasms
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.
Neoplasms
Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Neoplasms
Downregulated genes by silencing MYC pathway identified with RNA-SEQ analysis as potential prognostic biomarkers in gastric adenocarcinoma.
Neoplasms
Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.
Neoplasms
Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Neoplasms
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Neoplasms
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.
Neoplasms
Downregulation of PTPRK Promotes Cell Proliferation and Metastasis of NSCLC by Enhancing STAT3 Activation.
Neoplasms
Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter.
Neoplasms
Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Neoplasms
Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
Neoplasms
Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Neoplasms
Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors.
Neoplasms
Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.
Neoplasms
Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
Neoplasms
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Neoplasms
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Neoplasms
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Neoplasms
Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.
Neoplasms
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
Neoplasms
Duplication of ALK F1245 missense mutation due to acquired uniparental disomy associated with aggressive progression in a patient with relapsed neuroblastoma.
Neoplasms
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.
Neoplasms
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.
Neoplasms
DUSP26 negatively affects the proliferation of epithelial cells, an effect not mediated by dephosphorylation of MAPKs.
Neoplasms
Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner.
Neoplasms
DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
Neoplasms
DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.
Neoplasms
DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.
Neoplasms
Dynamic recruitment of protein tyrosine phosphatase PTPD1 to EGF stimulation sites potentiates EGFR activation.
Neoplasms
Dysidavarones A-D, new sesquiterpene quinones from the marine sponge Dysidea avara.
Neoplasms
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
Neoplasms
Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
Neoplasms
Effect of leuprolide on growth of rat prostatic tumor (R 3327) and weight of male accessory sex organs.
Neoplasms
Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs).
Neoplasms
Effects of alkaloids from Sophora flavescens on osteoblasts infected with Staphylococcus aureus and osteoclasts.
Neoplasms
Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression.
Neoplasms
Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo.
Neoplasms
EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing.
Neoplasms
EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.
Neoplasms
ELECTRON-MICROSCOPIC STUDIES OF ACID PHOSPHATASE ACTIVITY IN THE LIVER OF PATIENTS WITH CANCER OF THE ALIMENTARY TRACT.
Neoplasms
Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors.
Neoplasms
Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
Neoplasms
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Neoplasms
Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain dependent manner.
Neoplasms
Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis.
Neoplasms
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
Neoplasms
Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A.
Neoplasms
Endurance training prevents inflammation and apoptosis in hypothalamic neurons of obese mice.
Neoplasms
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice.
Neoplasms
Enhanced cell growth inhibition following PTEN nonviral gene transfer using polyethylenimine and photochemical internalization in endometrial cancer cells.
Neoplasms
Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature.
Neoplasms
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome.
Neoplasms
Enhancement of doxorubicin-induced cytotoxicity by hyperthermia in Ehrlich ascites cells.
Neoplasms
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Neoplasms
Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Neoplasms
Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
Neoplasms
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Neoplasms
Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.
Neoplasms
Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Neoplasms
Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
Neoplasms
Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.
Neoplasms
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Neoplasms
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Neoplasms
Epithelial Protein-Tyrosine Phosphatase 1B (PTP1B) Contributes to the Induction of Mammary Tumors by HER2/Neu but is not Essential for Tumor Maintenance.
Neoplasms
Epithelial Src homology region 2 domain-containing phosphatase-1 restrains intestinal growth, secretory cell differentiation, and tumorigenesis.
Neoplasms
Epitope-specific engagement of the protein tyrosine phosphatase CD45 induces tumor necrosis factor-alpha gene expression via transcriptional mechanisms.
Neoplasms
ER stress-related ATF6 upregulates CIP2A and contributes to poor prognosis of colon cancer.
Neoplasms
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
Neoplasms
Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Neoplasms
Erratum to: Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Neoplasms
Escape from p21-mediated Oncogene-induced Senescence Leads to Cell Dedifferentiation and Dependence on Anti-apoptotic Bcl-xL and MCL1 Proteins.
Neoplasms
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Neoplasms
Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.
Neoplasms
Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity.
Neoplasms
Ethacrynic acid inhibits STAT3 activity through the modulation of SHP2 and PTP1B tyrosine phosphatases in DU145 prostate carcinoma cells.
Neoplasms
Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.
Neoplasms
ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells.
Neoplasms
Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer.
Neoplasms
Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1.
Neoplasms
Evaluation of PHA-P reactivity of lymphocytes in tumor development by acid phosphatase activity.
Neoplasms
Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Neoplasms
Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia.
Neoplasms
Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1.
Neoplasms
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
Neoplasms
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome.
Neoplasms
Exploring the effect of aplidin on low molecular weight protein tyrosine phosphatase by molecular docking and molecular dynamic simulation study.
Neoplasms
Expression analysis and essential role of the putative tyrosine phosphatase His-domain-containing protein tyrosine phosphatase (HD-PTP).
Neoplasms
Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP.
Neoplasms
Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins.
Neoplasms
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
Neoplasms
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
Neoplasms
Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma.
Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Neoplasms
Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors.
Neoplasms
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Neoplasms
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Neoplasms
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
Neoplasms
Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma.
Neoplasms
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Neoplasms
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line.
Neoplasms
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Neoplasms
Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer.
Neoplasms
Expression of Dual-Specificity Phosphatase 2 (DUSP2) in Patients with Serous Ovarian Carcinoma and in SKOV3 and OVCAR3 Cells In Vitro.
Neoplasms
Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Neoplasms
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Neoplasms
Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis.
Neoplasms
Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Neoplasms
Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma.
Neoplasms
Expression of phosphatase of regenerating liver-3 (PRL-3) in endometrioid cancer and lymph nodes metastases.
Neoplasms
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix.
Neoplasms
Expression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor.
Neoplasms
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Neoplasms
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Neoplasms
Expression of PRL-3 regulates proliferation and invasion of breast cancer cells in vitro.
Neoplasms
Expression of protein tyrosine phosphatase alpha (RPTPalpha) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo.
Neoplasms
Expression of protein tyrosine phosphatases and its significance in esophageal cancer.
Neoplasms
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Neoplasms
Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer.
Neoplasms
Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73.
Neoplasms
Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
Neoplasms
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Neoplasms
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
Neoplasms
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
Neoplasms
Expression of transmembrane protein tyrosine phosphatase gamma (PTPgamma) in normal and neoplastic human tissues.
Neoplasms
Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Neoplasms
Expression Profiling during Mammary Epithelial Cell Three-Dimensional Morphogenesis Identifies PTPRO as a Novel Regulator of Morphogenesis and ErbB2-Mediated Transformation.
Neoplasms
Expression, generation, and purification of unphosphorylated and phospho-Ser-380/Thr-382/Thr-383 form of recombinant PTEN phosphatase.
Neoplasms
Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease.
Neoplasms
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
Neoplasms
FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.
Neoplasms
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Neoplasms
Fetal cell microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair.
Neoplasms
Fish oil positively regulates anabolic signalling alongside an increase in whole-body gluconeogenesis in ageing skeletal muscle.
Neoplasms
Fish oil suppresses cell growth and metastatic potential by regulating PTEN and NF-?B signaling in colorectal cancer.
Neoplasms
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Neoplasms
Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK.
Neoplasms
Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Neoplasms
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.
Neoplasms
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Neoplasms
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Neoplasms
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Neoplasms
From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis.
Neoplasms
From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase.
Neoplasms
Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTPgamma) in human breast cancer cell line MCF-7.
Neoplasms
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Neoplasms
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma.
Neoplasms
Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells.
Neoplasms
Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment.
Neoplasms
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Neoplasms
Functional short tandem repeat polymorphism of PTPN11 and susceptibility to hepatocellular carcinoma in Chinese populations.
Neoplasms
Functional STR within PTPN11: a novel potential risk factor for colorectal cancer.
Neoplasms
Fusaresters A-E, new ?-pyrone-containing polyketides from fungus Fusarium sp. Hungcl and structure revision of fusariumin D.
Neoplasms
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.
Neoplasms
Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a.
Neoplasms
Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
Neoplasms
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Neoplasms
Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis.
Neoplasms
Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Neoplasms
Gene expression profiles in cells transformed by overexpression of the IGF-I receptor.
Neoplasms
Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Neoplasms
Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.
Neoplasms
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Neoplasms
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Neoplasms
Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Neoplasms
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Neoplasms
Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Neoplasms
Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.
Neoplasms
Genetic profile of PTEN gene in Indian oral squamous cell carcinoma primary tumors.
Neoplasms
Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1 depleted cancers.
Neoplasms
Genetic variants in PPP2CA are associated with gastric cancer risk in a Chinese population.
Neoplasms
Genome-scale screening of deubiquitinase subfamily identifies USP3 as a stabilizer of Cdc25A regulating cell cycle in cancer.
Neoplasms
Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis.
Neoplasms
Genome-wide disease association study in chewing tobacco associated oral cancers.
Neoplasms
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Neoplasms
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Neoplasms
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva.
Neoplasms
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization.
Neoplasms
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Neoplasms
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Neoplasms
Genomic gain of the PRL-3 gene may represent poor prognosis of primary colorectal cancer, and associate with liver metastasis.
Neoplasms
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Neoplasms
Genomic structure, chromosomal location, and mutation analysis of the human CDC14A gene.
Neoplasms
Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression.
Neoplasms
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.
Neoplasms
Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer.
Neoplasms
Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.
Neoplasms
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Neoplasms
Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C.
Neoplasms
Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
Neoplasms
Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell.
Neoplasms
Global phosphotyrosine proteomics identifies PKC? as a marker of responsiveness to Src inhibition in colorectal cancer.
Neoplasms
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Neoplasms
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.
Neoplasms
HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain.
Neoplasms
Heat shock inhibition of lipopolysaccharide-mediated tumor necrosis factor expression is associated with nuclear induction of MKP-1 and inhibition of mitogen-activated protein kinase activation.
Neoplasms
Helicobacter pylori CagA -- a bacterial intruder conspiring gastric carcinogenesis.
Neoplasms
Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice.
Neoplasms
Heparin Decreases in Tumor Necrosis Factor ? (TNF?)-induced Endothelial Stress Responses Require Transmembrane Protein 184A and Induction of Dual Specificity Phosphatase 1.
Neoplasms
Hepatic inflammation facilitates transcription-associated mutagenesis via AID activity and enhances liver tumorigenesis.
Neoplasms
Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.
Neoplasms
Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Neoplasms
Heptad repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/NF-kappaB essential modulator and are targeted by human T-lymphotropic virus type 1 tax.
Neoplasms
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Neoplasms
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.
Neoplasms
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Neoplasms
High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia.
Neoplasms
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
Neoplasms
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Neoplasms
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
Neoplasms
High Expression of PTPN3 Predicts Progression and Unfavorable Prognosis of Glioblastoma.
Neoplasms
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
Neoplasms
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
Neoplasms
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Neoplasms
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.
Neoplasms
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Neoplasms
High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes.
Neoplasms
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
Neoplasms
High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFR C677T polymorphism.
Neoplasms
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Neoplasms
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Neoplasms
High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma.
Neoplasms
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Neoplasms
Hinokitiol suppresses growth of B16 melanoma by activating ERK/MKP3/proteosome pathway to downregulate survivin expression.
Neoplasms
Histiocytic Sarcoma Associated with Coombs Negative Acute Hemolytic Anemia: A Rare Presentation.
Neoplasms
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Neoplasms
Histochemically demonstrable protein tyrosine phosphatase in human breast and colorectal cancer: large decrease in its activity in colorectal cancer suggests a tumor suppressor role in colorectal mucosal cells.
Neoplasms
Histone acetylation and activation of cAMP-response element-binding protein regulate transcriptional activation of MKP-M in lipopolysaccharide-stimulated macrophages.
Neoplasms
Histopathologic and ultrastructural features and claudin expression in papillary tumors of the pineal region: a multicenter analysis.
Neoplasms
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Neoplasms
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
Neoplasms
Homozygous losses detected by array comparative genomic hybridization in multiplex urothelial carcinomas of the bladder.
Neoplasms
Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target
Neoplasms
Human Cancer-Associated Mutations in the A{alpha} Subunit of Protein Phosphatase 2A Increase Lung Cancer Incidence in A{alpha} Knock-In and Knockout Mice.
Neoplasms
Human Cdc25A phosphatase has a non-redundant function in G2 phase by activating Cyclin A-dependent kinases.
Neoplasms
Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes.
Neoplasms
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Neoplasms
Human osteogenic sarcoma. Study of the ultrastructure, with special notes on the localization of alkaline and acid phosphatase.
Neoplasms
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Neoplasms
Human papillomavirus and prostate cancer: The role of viral expressed proteins in the inhibition of anoikis and induction of metastasis.
Neoplasms
Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.
Neoplasms
Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Neoplasms
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
Neoplasms
Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Neoplasms
Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.
Neoplasms
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells.
Neoplasms
ICDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy.
Neoplasms
Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14.
Neoplasms
Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.
Neoplasms
Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases.
Neoplasms
Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer.
Neoplasms
Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors.
Neoplasms
Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.
Neoplasms
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
Neoplasms
Identification of an Apis cerana cerana MAP kinase phosphatase 3 gene (AccMKP3) in response to environmental stress.
Neoplasms
Identification of binding sites on the regulatory A subunit of protein phosphatase 2A for the catalytic C subunit and for tumor antigens of simian virus 40 and polyomavirus.
Neoplasms
Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps.
Neoplasms
Identification of CDC25C as a Potential Biomarker in Hepatocellular Carcinoma Using Bioinformatics Analysis.
Neoplasms
Identification of common microRNA-mRNA regulatory biomodules in human epithelial cancers.
Neoplasms
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Neoplasms
Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2.
Neoplasms
Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC.
Neoplasms
Identification of Differentially Expressed Genes Involved in the Formation of Multicellular Tumor Spheroids by HT-29 Colon Carcinoma Cells.
Neoplasms
Identification of genes and signaling pathways associated with the pathogenesis of juvenile spondyloarthritis.
Neoplasms
Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning.
Neoplasms
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3.
Neoplasms
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Neoplasms
Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.
Neoplasms
Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.
Neoplasms
Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking.
Neoplasms
Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.
Neoplasms
Identification of novel inhibitors for a low molecular weight protein tyrosine phosphatase via virtual screening.
Neoplasms
Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening.
Neoplasms
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Neoplasms
Identification of proteins suppressing the functions of oncogenic phosphatase of regenerating liver 1 and 3.
Neoplasms
Identification of PTPN1 as a novel negative regulator of the JNK MAPK pathway using a synthetic screening for pathway-specific phosphatases.
Neoplasms
Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'.
Neoplasms
Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.
Neoplasms
Identification of structural elements involved in the interaction of simian virus 40 small tumor antigen with protein phosphatase 2A.
Neoplasms
Identification of target proteins of N-acetylglucosaminyl transferase V in human colon cancer and implications of protein tyrosine phosphatase kappa in enhanced cancer cell migration.
Neoplasms
Identification of the quinolinedione inhibitor binding site in Cdc25 phosphatase B through docking and molecular dynamics simulations.
Neoplasms
Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells.
Neoplasms
Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling.
Neoplasms
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.
Neoplasms
IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases.
Neoplasms
IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Neoplasms
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Neoplasms
Immunohistochemical assessment of PRL-3 (PTP4A3) expression in tumor buds, invasion front, central region of tumor and metastases of colorectal cancer.
Neoplasms
Immunohistochemical Detection of Hematopoietic Cell-specific Protein-Tyrosine Phosphatase (Tyrosine Phosphatase SHP-1) in a Series of Endometrioid and Serous Endometrial Carcinoma.
Neoplasms
Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Neoplasms
Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats.
Neoplasms
Immunohistochemical expression of dual-specificity protein phosphatase 4 in patients with colorectal adenocarcinoma.
Neoplasms
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Neoplasms
Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
Neoplasms
Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.
Neoplasms
Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.
Neoplasms
In Vitro and In Vivo Effects of Tumor Suppressor Gene PTEN on Endometriosis: An Experimental Study.
Neoplasms
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.
Neoplasms
In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.
Neoplasms
In-gel digestion coupled with mass spectrometry (GeLC-MS/MS)-based salivary proteomic profiling of canine oral tumors.
Neoplasms
Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase.
Neoplasms
Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Neoplasms
Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma.
Neoplasms
Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.
Neoplasms
Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Neoplasms
Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Neoplasms
Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Neoplasms
Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma.
Neoplasms
Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Neoplasms
Increased expression of tyrosine phosphatase SHP2 in experimental pneumococcal meningitis: correlation with tumor necrosis factor-alpha and cerebrospinal fluid pleocytosis.
Neoplasms
Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1.
Neoplasms
Increased miR-155-5p expression in dermal mesenchymal stem cells of psoriatic patients: comparing the microRNA expression profile by microarray.
Neoplasms
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Neoplasms
Increased SHP-1 expression results in radioresistance, inhibition of cellular senescence, and cell cycle redistribution in nasopharyngeal carcinoma cells.
Neoplasms
Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice.
Neoplasms
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.
Neoplasms
Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence.
Neoplasms
Induction of Cdc25B expression by epidermal growth factor and transforming growth factor-alpha.
Neoplasms
Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers.
Neoplasms
Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B.
Neoplasms
Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B.
Neoplasms
Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.
Neoplasms
Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-?B pathway dependent repression of PP2Ac.
Neoplasms
Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro.
Neoplasms
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Neoplasms
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Neoplasms
Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation.
Neoplasms
Inhibition of cell growth and spreading by stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) through dephosphorylation of p130cas.
Neoplasms
Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma.
Neoplasms
Inhibition of conjugated linoleic acid on mouse forestomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms.
Neoplasms
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Neoplasms
Inhibition of growth and stimulation of apoptosis by beta-sitosterol treatment of MDA-MB-231 human breast cancer cells in culture.
Neoplasms
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Neoplasms
Inhibition of KIF22 suppresses cancer cell proliferation by delaying mitotic exit through upregulating CDC25C expression.
Neoplasms
Inhibition of MAP kinase by sphingosine and its methylated derivative, N,N-dimethylsphingosine.
Neoplasms
Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells.
Neoplasms
Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D.
Neoplasms
Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
Neoplasms
Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Neoplasms
Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation.
Neoplasms
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
Neoplasms
Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Neoplasms
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Neoplasms
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Neoplasms
Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.
Neoplasms
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Neoplasms
Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Neoplasms
Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Neoplasms
Inhibition of tumor necrosis factor-[alpha]-induced SHP-2 phosphatase activity by shear stress: a mechanism to reduce endothelial inflammation.
Neoplasms
Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase.
Neoplasms
Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells.
Neoplasms
Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Neoplasms
Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Neoplasms
Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway.
Neoplasms
Integrated analyses of murine breast cancer models reveal critical parallels with human disease.
Neoplasms
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Neoplasms
Integrating omics data and protein interaction networks to prioritize driver genes in cancer.
Neoplasms
Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
Neoplasms
Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Neoplasms
Interaction of the protein tyrosine phosphatase PTPL1 with the PtdIns(3,4)P2-binding adaptor protein TAPP1.
Neoplasms
Interdependence between EGFR and Phosphatases Spatially Established by Vesicular Dynamics Generates a Growth Factor Sensing and Responding Network.
Neoplasms
Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo.
Neoplasms
Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
Neoplasms
Interpretations on the Interaction between Protein Tyrosine Phosphatase and E7 Oncoproteins of High and Low-Risk HPV: A Computational Perception.
Neoplasms
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Neoplasms
Intracellular ethanol-mediated oxidation and apoptosis in HepG2/CYP2E1 cells impaired by two active peptides from seahorse (Hippocampus kuda bleeler) protein hydrolysates via the Nrf2/HO-1 and akt pathways.
Neoplasms
Intratumor microvessel density in biopsy specimens predicts local response of hypopharyngeal cancer to radiotherapy.
Neoplasms
Investigation of circRNA-miRNA-mRNA network in colorectal cancer using an integrative bioinformatics approach.
Neoplasms
Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.
Neoplasms
Investigation of the component of Propionibacterium acnes (Corynebacterium parvum) responsible for macrophage activation.
Neoplasms
Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: A report from the children's oncology group.
Neoplasms
Involvement of a putative protein-tyrosine phosphatase and I kappa B-alpha serine phosphorylation in nuclear factor kappa B activation by tumor necrosis factor.
Neoplasms
Involvement of Akt in mitochondria-dependent apoptosis induced by a cdc25 phosphatase inhibitor naphthoquinone analog.
Neoplasms
Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents.
Neoplasms
Involvement of Cdc25A phosphatase in Hep3B hepatoma cell growth inhibition induced by novel K vitamin analogs.
Neoplasms
Involvement of reactive oxygen species/c-Jun NH(2)-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells.
Neoplasms
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Neoplasms
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Neoplasms
Isolation and Functional Characterization of Peptide Agonists of PTPRJ, a Tyrosine Phosphatase Receptor Endowed with Tumor Suppressor Activity.
Neoplasms
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Neoplasms
Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability.
Neoplasms
JAK/STAT signal transduction: Regulators and implication in hematological malignancies.
Neoplasms
JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells.
Neoplasms
Key insights into the protein tyrosine phosphatase PTPN11/SHP2 associated with noonan syndrome and cancer.
Neoplasms
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Neoplasms
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Neoplasms
Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B.
Neoplasms
Knockdown of PRL-3 increases mitochondrial superoxide anion production through transcriptional regulation of RAP1.
Neoplasms
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
Neoplasms
Knocking Down Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Reverts Chemoresistance through Inactivation of Src and Bcr-Abl Proteins.
Neoplasms
Koelreuteria Formosana Extract Induces Growth Inhibition and Cell Death in Human Colon Carcinoma Cells via G2/M Arrest and LC3-II Activation-Dependent Autophagy.
Neoplasms
LAR-PTPase cDNA transfection suppression of tumor growth of neu oncogene-transformed human breast carcinoma cells.
Neoplasms
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Neoplasms
LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation.
Neoplasms
Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress.
Neoplasms
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Neoplasms
Linking epithelial polarity and carcinogenesis by multitasking Helicobacter pylori virulence factor CagA.
Neoplasms
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Neoplasms
Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
Neoplasms
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
Neoplasms
Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
Neoplasms
LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.
Neoplasms
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
Neoplasms
lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway.
Neoplasms
Localization of gallium in tumor cells. Electron microscopy, electron probe microanalysis and analytical ion microscopy.
Neoplasms
LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.
Neoplasms
Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.
Neoplasms
Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206.
Neoplasms
Long Noncoding RNA PTPRG Antisense RNA 1 Reduces Radiosensitivity of Nonsmall Cell Lung Cancer Cells Via Regulating MiR-200c-3p/TCF4.
Neoplasms
Loss of DUSP3 activity radiosensitizes human tumor cell lines via attenuation of DNA repair pathways.
Neoplasms
Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Neoplasms
Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex.
Neoplasms
Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer.
Neoplasms
Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression.
Neoplasms
Loss of protein phosphatase 2A regulatory subunit B56? promotes spontaneous tumorigenesis in vivo.
Neoplasms
Loss of Protein Tyrosine Phosphatase Receptor J Expression Predicts an Aggressive Clinical Course in Patients with Esophageal Squamous Cell Carcinoma.
Neoplasms
Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Neoplasms
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.
Neoplasms
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
Neoplasms
Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells.
Neoplasms
Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence.
Neoplasms
Loss of SHP-1 phosphatase alters cytokine expression in the mouse hindbrain following cochlear ablation.
Neoplasms
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma.
Neoplasms
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
Neoplasms
Loss of TAK1 increases cell traction force in a ROS-dependent manner to drive epithelial-mesenchymal transition of cancer cells.
Neoplasms
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.
Neoplasms
Loss of the Protein-Tyrosine Phosphatase DEP-1/PTPRJ Drives Meningioma Cell Motility.
Neoplasms
Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Neoplasms
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Neoplasms
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Neoplasms
Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk.
Neoplasms
Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c.
Neoplasms
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Neoplasms
Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.
Neoplasms
Low molecular weight protein tyrosine phosphatase as signaling hub of cancer hallmarks.
Neoplasms
Low molecular weight protein tyrosine phosphatase genetic polymorphism and susceptibility to cancer development.
Neoplasms
Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.
Neoplasms
Low Molecular Weight Protein Tyrosine Phosphatase Slow Isoform Knockdown in MDA-MB-435 Cells Decreases RAW 264.7 Osteoclastic Differentiation.
Neoplasms
Low molecular weight protein tyrosine phosphatase: Multifaceted functions of an evolutionarily conserved enzyme.
Neoplasms
Low P66shc with High SerpinB3 Levels Favors Necroptosis and Better Survival in Hepatocellular Carcinoma.
Neoplasms
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature.
Neoplasms
Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Neoplasms
Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Neoplasms
Luteolin sensitizes the antiproliferative effect of interferon ?/? by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Neoplasms
Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Neoplasms
Maintenance of stemness by miR-589-5p in hepatocellular carcinoma cells promotes chemoresistance via STAT3 signaling.
Neoplasms
MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation.
Neoplasms
MAPKAPK2 plays a crucial role in the progression of head and neck squamous cell carcinoma by regulating transcript stability.
Neoplasms
Mapping of the gene encoding the B56 beta subunit of protein phosphatase 2A (PPP2R5B) to a 0.5-Mb region of chromosome 11q13 and its exclusion as a candidate gene for multiple endocrine neoplasia type 1 (MEN1).
Neoplasms
Mass spectrometry study of PRL-3 phosphatase inactivation by disulfide bond formation and cysteine into glycine conversion.
Neoplasms
Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
Neoplasms
MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
Neoplasms
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Neoplasms
Measuring p66Shc Signaling Pathway Activation and Mitochondrial Translocation in Cultured Cells.
Neoplasms
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
Neoplasms
Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation.
Neoplasms
Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Neoplasms
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Neoplasms
Meroterpenoids with Protein Tyrosine Phosphatase 1B Inhibitory Activity from a Hyrtios sp. Marine Sponge.
Neoplasms
Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase.
Neoplasms
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Neoplasms
Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk.
Neoplasms
Metalloproteinase- and gamma-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z.
Neoplasms
Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion.
Neoplasms
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
Neoplasms
Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Neoplasms
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Neoplasms
Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Neoplasms
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Neoplasms
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Neoplasms
Methylation of gene encoding the growth suppressor protein tyrosine phosphatase receptor-type O (PTPRO) in human hepatocellular carcinoma and identification of VCP as its bona fide substrate.
Neoplasms
Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen.
Neoplasms
MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Neoplasms
Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias.
Neoplasms
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Neoplasms
Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products.
Neoplasms
Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
Neoplasms
MicroRNA miR-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling.
Neoplasms
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.
Neoplasms
microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells.
Neoplasms
MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Neoplasms
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Neoplasms
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
Neoplasms
MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
Neoplasms
MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma.
Neoplasms
MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
Neoplasms
Microtubule disruption and tumor suppression by mitogen-activated protein kinase phosphatase 4.
Neoplasms
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
Neoplasms
miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25?CDC25A?.
Neoplasms
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
Neoplasms
miR-146b Regulates Cell Proliferation and Apoptosis in Gastric Cancer by Targeting PTP1B.
Neoplasms
miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression.
Neoplasms
miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
Neoplasms
MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
Neoplasms
miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
Neoplasms
MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1.
Neoplasms
miR-383 Down-Regulates the Oncogene CIP2A to Influence Glioma Proliferation and Invasion.
Neoplasms
MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A.
Neoplasms
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
Neoplasms
miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma.
Neoplasms
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
Neoplasms
miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB.
Neoplasms
MiR-6803-5p Promotes Cancer Cell Proliferation and Invasion via PTPRO/NF-?B Axis in Colorectal Cancer.
Neoplasms
miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression.
Neoplasms
miRNA-497 Negatively Regulates the Growth and Motility of Chondrosarcoma Cells by Targeting Cdc25A.
Neoplasms
miRNA-7a-2-3p Inhibits Neuronal Apoptosis in Oxygen-Glucose Deprivation (OGD) Model.
Neoplasms
Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers.
Neoplasms
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Neoplasms
Mitochondrial-associated nitric oxide synthase activity inhibits cytochrome c oxidase: Implications for breast Cancer.
Neoplasms
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer.
Neoplasms
Mitogen-activated protein kinase (MAPK) phosphatase-3 (MKP-3) displays a p-JNK-MAPK substrate preference in astrocytes in vitro.
Neoplasms
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.
Neoplasms
Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity.
Neoplasms
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Neoplasms
Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin.
Neoplasms
Mitogen-Activated Protein Kinase Phosphatase-1 Is Required for Cisplatin Resistance.
Neoplasms
Mitogen-activated protein kinase phosphatase-1 prevents lipopolysaccharide-induced apoptosis in immature rat intestinal epithelial cells.
Neoplasms
Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulation.
Neoplasms
Mitogen-Activated Protein Kinase Phosphatase-2 Deletion Impairs Synaptic Plasticity and Hippocampal-Dependent Memory.
Neoplasms
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Neoplasms
Modelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri.
Neoplasms
Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.
Neoplasms
Modification of the effects of hyperthermia and neutron radiation on the activity of acid phosphatase in CaNT tumors.
Neoplasms
Modulation of the cytotoxic activity of tumor necrosis factor by protein tyrosine kinase and protein tyrosine phosphatase inhibitors.
Neoplasms
Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor.
Neoplasms
Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism.
Neoplasms
Molecular analysis of Aedes aegypti classical protein tyrosine phosphatases uncovers an ortholog of mammalian PTP-1B implicated in the control of egg production in mosquitoes.
Neoplasms
Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.
Neoplasms
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Neoplasms
Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines.
Neoplasms
Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Neoplasms
Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Neoplasms
Molecular dynamics simulation of the interaction between protein tyrosine phosphatase 1B and aryl diketoacid derivatives.
Neoplasms
Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent.
Neoplasms
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.
Neoplasms
Molecular mechanism of T-cell protein tyrosine phosphatase (TCPTP) activation by mitoxantrone.
Neoplasms
Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.
Neoplasms
Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: protein phosphatase 2A targeting and MAPK cascade activation.
Neoplasms
Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens.
Neoplasms
Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis.
Neoplasms
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Neoplasms
Mononuclear phagocyte function in head and neck cancer. Chemotactic responsiveness of blood monocytes in correlation between histologic grade of the tumor and infiltration of these cells into the tumor area.
Neoplasms
Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma.
Neoplasms
Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1.
Neoplasms
Morin-dependent inhibition of low molecular weight protein tyrosine phosphatase (LMW-PTP) restores sensitivity to apoptosis during colon carcinogenesis: Studies in vitro and in vivo, in an Apc-driven model of colon cancer.
Neoplasms
Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways.
Neoplasms
mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1, Fas-associating protein with death domain/FADD, and receptor-interacting protein/RIP) in human leukaemia/lymphoma cell lines.
Neoplasms
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Neoplasms
Multiple granular cell tumors are an associated feature of LEOPARD syndrome caused by mutation in PTPN11.
Neoplasms
Multiple unexpected lesions of metachondromatosis detected by technetium-99m methylene diphosphonate SPECT/CT: A case report.
Neoplasms
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas.
Neoplasms
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Neoplasms
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
Neoplasms
Mutational analysis of mononucleotide repeats in dual specificity tyrosine phosphatase genes in gastric and colon carcinomas with microsatellite instability.
Neoplasms
Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Neoplasms
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Neoplasms
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary.
Neoplasms
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Neoplasms
Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity.
Neoplasms
Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-? production in tumor microenvironment.
Neoplasms
Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis.
Neoplasms
Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy.
Neoplasms
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
Neoplasms
Negative Feed-forward Control of Tumor Necrosis Factor (TNF) by Tristetraprolin (ZFP36) Is Limited by the Mitogen-activated Protein Kinase Phosphatase, Dual-specificity Phosphatase 1 (DUSP1): IMPLICATIONS FOR REGULATION BY GLUCOCORTICOIDS.
Neoplasms
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
Neoplasms
Network-Based Predictors of Progression in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells.
Neoplasms
Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling.
Neoplasms
Neutrophil acid phosphatase activity in patients with gastric or rectum carcinoma during surgical treatment.
Neoplasms
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Neoplasms
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Neoplasms
New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone.
Neoplasms
NF?B and TGF? contribute to the expression of PTPN3 in activated human lymphocytes.
Neoplasms
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Neoplasms
Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis.
Neoplasms
Non-canonical activation of ?-catenin by PRL-3 phosphatase in acute myeloid leukemia.
Neoplasms
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Neoplasms
Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases.
Neoplasms
Notable roles of EZH2 and DNMT1 in epigenetic dormancy of the SHP1 gene during the progression of chronic myeloid leukaemia.
Neoplasms
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Neoplasms
Novel acyclic enediynes inhibit Cyclin A and Cdc25C expression and induce apoptosis phenomenon to show potent antitumor proliferation.
Neoplasms
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Neoplasms
Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells.
Neoplasms
Novel function of MKP-5/DUSP10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas.
Neoplasms
Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties.
Neoplasms
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Neoplasms
Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents.
Neoplasms
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.
Neoplasms
Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas.
Neoplasms
Nox4 redox regulation of PTP1B contributes to the proliferation and migration of glioblastoma cells by modulating tyrosine phosphorylation of coronin-1C.
Neoplasms
NPAS2 promotes cell survival of hepatocellular carcinoma by transactivating CDC25A.
Neoplasms
NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
Neoplasms
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
Neoplasms
NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs.
Neoplasms
Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats.
Neoplasms
Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer.
Neoplasms
Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death.
Neoplasms
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Neoplasms
Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells.
Neoplasms
On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.
Neoplasms
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Neoplasms
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Neoplasms
Oncogenic role of ALX3 in cervical cancer cells through KDM2B-mediated histone demethylation of CDC25A.
Neoplasms
Oncoprotein CIP2A promotes the disassembly of primary cilia and inhibits glycolytic metabolism.
Neoplasms
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.
Neoplasms
Organic Synthesis Toward Small-Molecule Probes and Drugs Special Feature: Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors.
Neoplasms
Osteoglycin-induced VEGF Inhibition Enhances T Lymphocytes Infiltrating in Colorectal Cancer.
Neoplasms
Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma.
Neoplasms
Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Neoplasms
Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.
Neoplasms
Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc.
Neoplasms
Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.
Neoplasms
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
Neoplasms
Overexpression of CDC25B overrides radiation-induced G2-M arrest and results in increased apoptosis in esophageal cancer cells.
Neoplasms
Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
Neoplasms
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
Neoplasms
Overexpression of Cdc25C predicts response to radiotherapy and survival in esophageal squamous cell carcinoma patients treated with radiotherapy followed by surgery.
Neoplasms
Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Neoplasms
Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas.
Neoplasms
Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Neoplasms
Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer.
Neoplasms
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
Neoplasms
Overexpression of phosphoprotein phosphatase 2A predicts worse prognosis in patients with breast cancer: a 15-year follow-up.
Neoplasms
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Neoplasms
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Neoplasms
Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis.
Neoplasms
Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity.
Neoplasms
Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT.
Neoplasms
Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death.
Neoplasms
Overexpression of the Protein Tyrosine Phosphatase PRL-2 Correlates with Breast Tumor Formation and Progression.
Neoplasms
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression.
Neoplasms
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Neoplasms
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
Neoplasms
Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug Aplidin.
Neoplasms
Oxidative stress induces B lymphocyte DNA damage and apoptosis by upregulating p66shc.
Neoplasms
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
Neoplasms
p14(ARF) Triggers G(2) Arrest Through ERK-Mediated Cdc25C Phosphorylation, Ubiquitination and Proteasomal Degradation.
Neoplasms
p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling.
Neoplasms
p63 regulates cell proliferation and cell cycle progression?associated genes in stromal cells of giant cell tumor of the bone.
Neoplasms
p66Shc activation promotes increased oxidative phosphorylation and renders CNS cells more vulnerable to amyloid beta toxicity.
Neoplasms
P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers.
Neoplasms
p66Shc as a switch in bringing about contrasting responses in cell growth: implications on cell proliferation and apoptosis.
Neoplasms
p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.
Neoplasms
p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas.
Neoplasms
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Neoplasms
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Neoplasms
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Neoplasms
Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
Neoplasms
Papillary tumor of the pineal region in pediatric populations: An additional case and systematic review of a rare tumor entity.
Neoplasms
Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder.
Neoplasms
Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma.
Neoplasms
Pathophysiological significance of N-myc downstream-regulated gene 2 in cancer development through protein phosphatase 2A phosphorylation regulation.
Neoplasms
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Neoplasms
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Neoplasms
PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Neoplasms
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation.
Neoplasms
Peptide-templated gold nanoparticle nanosensor for simultaneous detection of multiple posttranslational modification enzymes.
Neoplasms
Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors.
Neoplasms
Perphenazine exerts antitumor effects on HUT78 cells through Akt dephosphorylation by protein phosphatase 2A.
Neoplasms
Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.
Neoplasms
PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway.
Neoplasms
Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
Neoplasms
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.
Neoplasms
Phelligridimer A, a highly oxygenated and unsaturated 26-membered macrocyclic metabolite with antioxidant activity from the fungus Phellinus igniarius.
Neoplasms
Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression.
Neoplasms
Phosphatase 2A associated with polyomavirus small-T or middle-T antigen is an okadaic acid-sensitive tyrosyl phosphatase.
Neoplasms
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Neoplasms
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Neoplasms
Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
Neoplasms
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Neoplasms
Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.
Neoplasms
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Neoplasms
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Neoplasms
Phosphatase of regenerating liver-3 directly interacts with integrin ?1 and regulates its phosphorylation at tyrosine 783.
Neoplasms
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Neoplasms
Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Neoplasms
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells.
Neoplasms
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
Neoplasms
Phosphatase of regenerating liver-3 regulates cancer cell metabolism in multiple myeloma.
Neoplasms
Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells.
Neoplasms
Phosphoamino acid phosphatases in normal and cancerous tissues of the human uterus, cervix and ovary.
Neoplasms
Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.
Neoplasms
Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.
Neoplasms
Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.
Neoplasms
Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration.
Neoplasms
Phosphorylation of a C-SRC-related protein in macrophages activated in vitro with lymphokine.
Neoplasms
Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: A potential novel prognostic marker for breast cancer.
Neoplasms
Phosphorylation-Specific Peptidyl-Prolyl Isomerization of Neuronal Cytoskeletal Proteins by Pin1: Implications for Therapeutics in Neurodegeneration.
Neoplasms
Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration.
Neoplasms
Phosphotyrosine phosphatase activity in the macrophage is enhanced by lipopolysaccharide, tumor necrosis factor alpha, and granulocyte/macrophage-colony stimulating factor: correlation with priming of the respiratory burst.
Neoplasms
Photoaffinity labeling of protein phosphatase 2A, the receptor for a tumor promoter okadaic acid, by [27-3H]methyl 7-O-(4-azidobenzoyl)okadaate.
Neoplasms
Piceamycin and its N-acetylcysteine adduct is produced by Streptomyces sp. GB 4-2.
Neoplasms
PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
Neoplasms
Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer.
Neoplasms
Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2).
Neoplasms
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo.
Neoplasms
PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells.
Neoplasms
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Neoplasms
Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.
Neoplasms
Posttranscriptional Inhibition of Protein Tyrosine Phosphatase Nonreceptor Type 23 by Staphylococcal Nuclease and Tudor Domain Containing 1: Implications for Hepatocellular Carcinoma.
Neoplasms
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration.
Neoplasms
Potential Protein Phosphatase 2A Agents from Traditional Chinese Medicine against Cancer.
Neoplasms
Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
Neoplasms
PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
Neoplasms
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Neoplasms
PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
Neoplasms
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Neoplasms
PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential.
Neoplasms
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Neoplasms
PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.
Neoplasms
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neoplasms
PP2AC Phospho-Tyr307 Antibodies Are Not Specific for this Modification but Are Sensitive to Other PP2AC Modifications Including Leu309 Methylation.
Neoplasms
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Neoplasms
PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers.
Neoplasms
PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
Neoplasms
PR55?-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.
Neoplasms
Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer.
Neoplasms
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Neoplasms
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Neoplasms
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Neoplasms
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
Neoplasms
PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Neoplasms
PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
Neoplasms
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Neoplasms
PRL-3 disrupts epithelial architecture by altering the post-mitotic midbody position.
Neoplasms
PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.
Neoplasms
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK.
Neoplasms
PRL-3 improves colorectal cancer cell proliferation and invasion through IL-8 mediated glycolysis metabolism.
Neoplasms
PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Neoplasms
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.
Neoplasms
PRL-3 overexpression in epithelial cells is induced by surrounding stromal fibroblasts.
Neoplasms
PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly.
Neoplasms
PRL-3 promotes gastric cancer migration and invasion through a NF-?B-HIF-1?-miR-210 axis.
Neoplasms
PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma.
Neoplasms
PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
Neoplasms
PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
Neoplasms
PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels.
Neoplasms
PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1.
Neoplasms
PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.
Neoplasms
PRL-3, an Emerging Marker of Carcinogenesis, is Strongly Associated with Poor Prognosis.
Neoplasms
Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
Neoplasms
Production of DUSP1 protein using the baculovirus insect cell expression system and its in vitro effects on cancer cells.
Neoplasms
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
Neoplasms
Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
Neoplasms
Prognostic implication of CDC25A and cyclin E expression on primary breast cancer patients.
Neoplasms
Prognostic significance of CDC25C in lung adenocarcinoma: An analysis of TCGA data.
Neoplasms
Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.
Neoplasms
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Neoplasms
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Neoplasms
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Neoplasms
Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.
Neoplasms
Proinflammatory genotype is associated with the frailty phenotype in the English Longitudinal Study of Ageing.
Neoplasms
Protective effect of zinc on N-methyl-N-nitrosourea and testosterone-induced prostatic intraepithelial neoplasia in the dorsolateral prostate of Sprague Dawley rats.
Neoplasms
Protein dynamics analysis reveals that missense mutations in cancer-related genes appear frequently on hinge-neighboring residues.
Neoplasms
Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells.
Neoplasms
Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Neoplasms
Protein phosphatase 1B dephosphorylates Rho guanine nucleotide dissociation inhibitor 1 and suppresses cancer cell migration and invasion.
Neoplasms
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Neoplasms
Protein Phosphatase 2A (PP2A) Regulation of Markers of Extracellular Matrix Remodelling in HCC Cells: Functional Consequences for Tumour Invasion.
Neoplasms
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Neoplasms
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Neoplasms
Protein phosphatase 2A and phosphatidylinositol 3-kinase regulate the activity of Sp1-responsive promoters.
Neoplasms
Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer's Disease.
Neoplasms
Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation.
Neoplasms
Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer.
Neoplasms
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
Neoplasms
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Neoplasms
Protein phosphatase 2A is essential to maintain active Wnt signaling and its A? tumor suppressor subunit is not expressed in colon cancer cells.
Neoplasms
Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia.
Neoplasms
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Neoplasms
Protein phosphatase 2A promotes endothelial survival via stabilization of translational inhibitor 4E-BP1 following exposure to tumor necrosis factor-?.
Neoplasms
Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen.
Neoplasms
Protein Phosphatase Methyl-Esterase PME-1 Protects Protein Phosphatase 2A from Ubiquitin/Proteasome Degradation.
Neoplasms
Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants.
Neoplasms
Protein tyrosine Phosphatase (PTP1B): A promising Drug Target against life threatening ailments.
Neoplasms
Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Neoplasms
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Neoplasms
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Neoplasms
Protein tyrosine phosphatase 1B expression contributes to the development of breast cancer.
Neoplasms
Protein tyrosine phosphatase 1B regulates fibroblasts proliferation, motility and extracellular matrix synthesis via the MAPK/ERK signalling pathway in keloid.
Neoplasms
Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.
Neoplasms
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Neoplasms
Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide.
Neoplasms
Protein tyrosine phosphatase epsilon activates Yes and Fyn in Neu-induced mammary tumor cells.
Neoplasms
Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
Neoplasms
Protein tyrosine phosphatase epsilon inhibits signaling by mitogen-activated protein kinases.
Neoplasms
Protein tyrosine phosphatase H1 is a target of the E6 oncoprotein of high-risk genital human papillomaviruses.
Neoplasms
Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.
Neoplasms
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting I?B?.
Neoplasms
Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.
Neoplasms
Protein tyrosine phosphatase N2 regulates TNF?-induced signalling and cytokine secretion in human intestinal epithelial cells.
Neoplasms
Protein tyrosine phosphatase non-receptor type 2 controls colorectal cancer development.
Neoplasms
Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Neoplasms
Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells.
Neoplasms
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Neoplasms
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Neoplasms
Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Neoplasms
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Neoplasms
Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Neoplasms
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.
Neoplasms
Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC.
Neoplasms
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene.
Neoplasms
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Neoplasms
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
Neoplasms
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Neoplasms
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Neoplasms
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating ?-catenin.
Neoplasms
Protein Tyrosine Phosphatase Receptor Type {gamma} Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia.
Neoplasms
Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
Neoplasms
Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer.
Neoplasms
Protein tyrosine phosphatase receptor-type ? acts as a negative regulator suppressing breast cancer.
Neoplasms
Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer.
Neoplasms
Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92.
Neoplasms
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Neoplasms
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Neoplasms
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Neoplasms
Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
Neoplasms
Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.
Neoplasms
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Neoplasms
Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R?2-Promoted Invasion and Metastasis in Cancer Cells.
Neoplasms
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Neoplasms
Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling.
Neoplasms
Protein tyrosine phosphatases receptor type D is a potential tumour suppressor gene inactivated by deoxyribonucleic acid methylation in paediatric acute myeloid leukaemia.
Neoplasms
Protein tyrosine phosphatome metabolic screen identifies TC-PTP as a positive regulator of cancer cell bioenergetics and mitochondrial dynamics.
Neoplasms
Protein-tyrosine Phosphatase 1B Antagonized Signaling by Insulin-like Growth Factor-1 Receptor and Kinase BRK/PTK6 in Ovarian Cancer Cells.
Neoplasms
Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-alpha-induced insulin resistance.
Neoplasms
Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.
Neoplasms
Protein-tyrosine Phosphatase DEP-1 Controls Receptor Tyrosine Kinase FLT3 Signaling.
Neoplasms
Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling.
Neoplasms
Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras OR neu.
Neoplasms
Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B.
Neoplasms
Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.
Neoplasms
Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells.
Neoplasms
Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches.
Neoplasms
Proteomic analysis reveals plasma haptoglobin, interferon-?, and interleukin-1? as potential biomarkers of pediatric refractory epilepsy.
Neoplasms
Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma.
Neoplasms
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway.
Neoplasms
PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
Neoplasms
PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1.
Neoplasms
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis.
Neoplasms
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity.
Neoplasms
PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.
Neoplasms
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.
Neoplasms
PTP1B Contributes to Calreticulin-Induced Metastatic Phenotypes in Esophageal Squamous Cell Carcinoma.
Neoplasms
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
Neoplasms
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
Neoplasms
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
Neoplasms
PTP1B expression is an independent positive prognostic factor in human breast cancer.
Neoplasms
PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer.
Neoplasms
PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p.
Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Neoplasms
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
Neoplasms
PTP1B targets the endosomal sorting machinery: dephosphorylation of regulatory sites on the endosomal sorting complex required for transport component STAM2.
Neoplasms
PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.
Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Neoplasms
PTPIP51 regulates mouse cardiac ischemia/reperfusion through mediating the mitochondria-SR junction.
Neoplasms
PTPIP51, a positive modulator of the MAPK/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3? and PTP1B in situ.
Neoplasms
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
Neoplasms
PTPL1 suppresses lung cancer cell migration via inhibiting TGF-?1-induced activation of p38 MAPK and Smad 2/3 pathways and EMT.
Neoplasms
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Neoplasms
PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival.
Neoplasms
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Neoplasms
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
Neoplasms
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
Neoplasms
PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
Neoplasms
PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Neoplasms
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.
Neoplasms
PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.
Neoplasms
PTPN12 inhibits oral squamous epithelial carcinoma cell proliferation and invasion and can be used as a prognostic marker.
Neoplasms
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Neoplasms
PTPN12/PTP-PEST Regulates Phosphorylation-Dependent Ubiquitination and Stability of Focal Adhesion Substrates in Invasive Glioblastoma Cells.
Neoplasms
PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Neoplasms
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
Neoplasms
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Neoplasms
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
Neoplasms
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
Neoplasms
PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signaling.
Neoplasms
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
Neoplasms
PTPN2 induced by inflammatory response and oxidative stress contributed to glioma progression.
Neoplasms
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Neoplasms
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.
Neoplasms
PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells.
Neoplasms
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity.
Neoplasms
PTPN21 Overexpression Promotes Osteogenic and Adipogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells but Inhibits the Immunosuppressive Function.
Neoplasms
PTPN3 acts as a tumor suppressor and boosts TGF-? signaling independent of its phosphatase activity.
Neoplasms
PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody-type immune checkpoint inhibitor.
Neoplasms
PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K/AKT signaling.
Neoplasms
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Neoplasms
PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Neoplasms
PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer.
Neoplasms
PTPN9 promotes cell proliferation and invasion in Eca109 cells and is negatively regulated by microRNA-126.
Neoplasms
PTPRA facilitates cancer growth and migration via the TNF-?-mediated PTPRA-NF-?B pathway in MCF-7 breast cancer cells.
Neoplasms
PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
Neoplasms
PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition.
Neoplasms
PTPRD copy number variants and Ewing's sarcoma: Strengthening the association and therapeutic implications.
Neoplasms
PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.
Neoplasms
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin.
Neoplasms
PTPRF as a novel tumor suppressor through deactivation of ERK1/2 signaling in gastric adenocarcinoma.
Neoplasms
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
Neoplasms
PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.
Neoplasms
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.
Neoplasms
PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Neoplasms
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
Neoplasms
PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
Neoplasms
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Neoplasms
PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.
Neoplasms
PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.
Neoplasms
PTPRO-Associated Hepatic Stellate Cell Activation Plays a Critical Role in Liver Fibrosis.
Neoplasms
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Neoplasms
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
Neoplasms
PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer.
Neoplasms
PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Neoplasms
PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating Hippo/YAP Signaling Pathway.
Neoplasms
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.
Neoplasms
pTyr(421) Cortactin Is Overexpressed in Colon Cancer and Is Dephosphorylated by Curcumin: Involvement of Non-Receptor Type 1 Protein Tyrosine Phosphatase (PTPN1).
Neoplasms
Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.
Neoplasms
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Neoplasms
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Neoplasms
Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias.
Neoplasms
Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies.
Neoplasms
R3327 prostate adenocarcinoma clonogenic cells: epithelial properties and hormone response.
Neoplasms
Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression.
Neoplasms
Ras-induced and ERK1/2 Phosphorylation-Dependent Isomerization of PTP-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST.
Neoplasms
Rational Design of Selective Organoruthenium Inhibitors of Protein Tyrosine Phosphatase 1B.
Neoplasms
Rational Design, Synthesis and Biological Evaluation of Modular Fluorogenic Substrates with High Affinity and Selectivity for PTP1B.
Neoplasms
Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Neoplasms
Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Neoplasms
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B.
Neoplasms
Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival.
Neoplasms
Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21.
Neoplasms
Receptor-type tyrosine-protein phosphatase ? directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Neoplasms
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Neoplasms
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Neoplasms
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Neoplasms
Reduced expression of protein tyrosine phosphatase gamma in lung and ovarian tumors.
Neoplasms
Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.
Neoplasms
Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives.
Neoplasms
Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTPepsilon C.
Neoplasms
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Neoplasms
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Neoplasms
Regulated expression of PTPRJ/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli.
Neoplasms
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Neoplasms
Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.
Neoplasms
Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity.
Neoplasms
Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways.
Neoplasms
Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Neoplasms
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Neoplasms
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Neoplasms
Regulation of RPTPbeta/phosphacan expression and glycosaminoglycan epitopes in injured brain and cytokine-treated glia.
Neoplasms
Regulation of tumor cell migration by protein tyrosine phosphatase (PTP)-proline-, glutamate-, serine-,and threonine-rich sequence (PEST).
Neoplasms
Regulative Loop between ?-catenin and Protein Tyrosine Receptor Type ? in Chronic Myeloid Leukemia.
Neoplasms
Relationship between CD45 antigen expression and putative stages of differentiation in B-cell malignancies.
Neoplasms
Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.
Neoplasms
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Neoplasms
Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1.
Neoplasms
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Neoplasms
Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells.
Neoplasms
Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
Neoplasms
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Neoplasms
Resistance to TNF-alpha cytotoxicity can be achieved through different signaling pathways in rat mesangial cells.
Neoplasms
Resistin induces breast cancer cells epithelial to mesenchymal transition (EMT) and stemness through both adenylyl cyclase-associated protein 1 (CAP1)-dependent and CAP1-independent mechanisms.
Neoplasms
Response of small intestinal epithelial cells to acute disruption of cell division through CDC25 deletion.
Neoplasms
Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Neoplasms
Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo.
Neoplasms
Reversible oxidation of phosphatase and tensin homolog (PTEN) alters its interactions with signaling and regulatory proteins.
Neoplasms
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.
Neoplasms
Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Neoplasms
Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti- Cancer Drug Target.
Neoplasms
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Neoplasms
Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).
Neoplasms
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Neoplasms
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
Neoplasms
Rosette forming glioneuronal tumor in the optico-chiasmatic region-a novel entity in a new location.
Neoplasms
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
Neoplasms
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Neoplasms
Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis.
Neoplasms
S-Nitrosylation of mitogen activated protein kinase phosphatase-1 suppresses radiation-induced apoptosis.
Neoplasms
Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors.
Neoplasms
Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
Neoplasms
SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
Neoplasms
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Neoplasms
Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis.
Neoplasms
Screening the active constituents of Chinese medicinal herbs as potent inhibitors of Cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2 kinase.
Neoplasms
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein tyrosine phosphatase 1B.
Neoplasms
Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment.
Neoplasms
Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene.
Neoplasms
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Neoplasms
Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in?vitro and in?vivo.
Neoplasms
Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase.
Neoplasms
Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7.
Neoplasms
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Neoplasms
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin's lymphoma: a predictor of aggressive disease and new treatment target.
Neoplasms
SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
Neoplasms
SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
Neoplasms
SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).
Neoplasms
SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells.
Neoplasms
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Neoplasms
SHP-2 Interacts with CD81 and Regulates the Malignant Evolution of Colorectal Cancer by Inhibiting Epithelial-Mesenchymal Transition.
Neoplasms
SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.
Neoplasms
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Neoplasms
SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively.
Neoplasms
SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro.
Neoplasms
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Neoplasms
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.
Neoplasms
SHP2 positively regulates TGF?1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Neoplasms
SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
Neoplasms
SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3? signaling pathway.
Neoplasms
Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.
Neoplasms
Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice.
Neoplasms
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
Neoplasms
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Neoplasms
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Neoplasms
Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown.
Neoplasms
Significant relationship of combined ACP1/PTPN22 genotype variants with the growth of uterine leiomyomas.
Neoplasms
Silencing CDC25A inhibits the proliferation of liver cancer cells by downregulating IL?6 in vitro and in vivo.
Neoplasms
Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Neoplasms
Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis.
Neoplasms
Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor.
Neoplasms
Simian virus 40 small tumor antigen inhibits dephosphorylation of protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation.
Neoplasms
Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs.
Neoplasms
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Neoplasms
SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration.
Neoplasms
Small amplicons high resolution melting analysis (SA-HRMA) allows successful genotyping of acid phosphatase 1 (ACP1) polymorphisms in the Italian population.
Neoplasms
Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2.
Neoplasms
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.
Neoplasms
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Neoplasms
Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
Neoplasms
Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.
Neoplasms
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
Neoplasms
SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways.
Neoplasms
Solution NMR studies reveal no global flexibility in the catalytic domain of CDC25B.
Neoplasms
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Neoplasms
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Neoplasms
Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.
Neoplasms
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
Neoplasms
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Neoplasms
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis.
Neoplasms
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Neoplasms
SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
Neoplasms
Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Neoplasms
Specificity of HCPTP variants toward EphA2 tyrosines by quantitative selected reaction monitoring.
Neoplasms
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
Neoplasms
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Neoplasms
Spirulina phycocyanin induces differential protein expression and apoptosis in SKOV-3 cells.
Neoplasms
Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.
Neoplasms
Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3.
Neoplasms
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis.
Neoplasms
Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.
Neoplasms
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Neoplasms
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Neoplasms
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.
Neoplasms
Statement of Retraction. Iria Nieto-Vázquez, Sonia Fernández-Veledo, Cristina de Alvaro, Cristina M. Rondinone, Angela M. Valverde, and Margarita Lorenzo. Protein-Tyrosine Phosphatase 1B-Deficient Myocytes Show Increased Insulin Sensitivity and Protection Against Tumor Necrosis Factor-?-Induced Insulin Resistance. Diabetes 2007;56:404-413. https://doi.org/10.2337/db06-0989.
Neoplasms
Statistical completion of a partially identified graph with applications for the estimation of gene regulatory networks.
Neoplasms
Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its ubiquitination.
Neoplasms
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Neoplasms
Structural analysis of the PTEN:P-Rex2 signaling complex reveals how cancer-associated mutations coordinate to hyperactivate Rac1.
Neoplasms
Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40.
Neoplasms
Structural and functional characterization of the PDZ domain of the human phosphatase PTPN3 and its interaction with the human papillomavirus E6 oncoprotein.
Neoplasms
Structural basis for recognition of the tumor suppressor protein PTPN14 by the oncoprotein E7 of human papillomavirus.
Neoplasms
Structural Basis for Selective Interaction between the ESCRT Regulator HD-PTP and UBAP1.
Neoplasms
Structural Basis for Specific Interaction of TGF? Signaling Regulators SARA/Endofin with HD-PTP.
Neoplasms
Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Neoplasms
Structural Insight into the Critical Role of the N-Terminal Region in the Catalytic Activity of Dual-Specificity Phosphatase 26.
Neoplasms
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
Neoplasms
Structural Stability of Human Protein Tyrosine Phosphatase ? Catalytic Domain: Effect of Point Mutations.
Neoplasms
Structure and backbone dynamics of vanadate-bound PRL-3: comparison of 15N nuclear magnetic resonance relaxation profiles of free and vanadate-bound PRL-3.
Neoplasms
Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion.
Neoplasms
Structure and functions of His domain protein tyrosine phosphatase in receptor trafficking and cancer.
Neoplasms
Structure of human dual-specificity phosphatase 7, a potential cancer drug target.
Neoplasms
Structure of the complex of an iminopyridinedione PTP4A3 phosphatase inhibitor with human serum albumin.
Neoplasms
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Neoplasms
Structure-functional implications of longevity protein p66Shc in health and disease.
Neoplasms
Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the Fungus Phellinus igniarius.
Neoplasms
Studies on alkaline phosphatase activity cultured cells from a patient with fibrodysplasia ossificans progressiva.
Neoplasms
Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines.
Neoplasms
Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility.
Neoplasms
Suppressed MKP-1 is an independent predictor of outcome in patients with hepatocellular carcinoma.
Neoplasms
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Neoplasms
Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains.
Neoplasms
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Neoplasms
Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.
Neoplasms
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile, and inhibits gastric cancer cell growth.
Neoplasms
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.
Neoplasms
Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.
Neoplasms
Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases.
Neoplasms
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
Neoplasms
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Neoplasms
Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways.
Neoplasms
Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.
Neoplasms
Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.
Neoplasms
Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
Neoplasms
Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
Neoplasms
Synthetic peptides containing ITIM-like domains block expression of inflammatory mediators and migration/invasion of cancer cells through activation of SHP-1 and PI3K.
Neoplasms
Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.
Neoplasms
T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice.
Neoplasms
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Neoplasms
TAFs contributes the function of PTPN2 in colorectal carcinogenesis through activating JAK/STAT signaling pathway.
Neoplasms
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo.
Neoplasms
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
Neoplasms
Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back.
Neoplasms
Targeting 14-3-3?-CDC25A interactions to trigger apoptotic cell death in skin cancer.
Neoplasms
Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Neoplasms
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Neoplasms
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
Neoplasms
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Neoplasms
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer.
Neoplasms
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
Neoplasms
Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.
Neoplasms
Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.
Neoplasms
Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Neoplasms
Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor.
Neoplasms
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
Neoplasms
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Neoplasms
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Neoplasms
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Neoplasms
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma.
Neoplasms
Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth.
Neoplasms
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Neoplasms
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Neoplasms
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
Neoplasms
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
Neoplasms
TGF-?1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.
Neoplasms
The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling.
Neoplasms
The Anti-Tumor Agent Sodium Selenate Decreases Methylated PP2A, Increases GSK3?Y216 Phosphorylation, Including Tau Disease Epitopes and Reduces Neuronal Excitability in SHSY-5Y Neurons.
Neoplasms
The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway.
Neoplasms
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
Neoplasms
The B56?3 regulatory subunit-containing protein phosphatase 2A outcompetes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1.
Neoplasms
The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1.
Neoplasms
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
Neoplasms
The binding affinity of PTPN13's tandem PDZ2/3 domain is allosterically modulated.
Neoplasms
The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions.
Neoplasms
The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1.
Neoplasms
The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer.
Neoplasms
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.
Neoplasms
The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Neoplasms
The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
Neoplasms
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Neoplasms
The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms.
Neoplasms
The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity.
Neoplasms
The Dual Specificity Phosphatase Cdc25C is a Direct Target for Transcriptional Repression by the Tumor Suppressor p53.
Neoplasms
The Dual-Specificity Phosphatase 10 (DUSP10): Its Role in Cancer, Inflammation, and Immunity.
Neoplasms
The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-?B activation by dephosphorylating the protein kinase TAK1.
Neoplasms
The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling.
Neoplasms
The effect of YAP expression in tumor cells and tumor stroma on the prognosis of patients with squamous cell carcinoma of the oral cavity floor and oral surface of the tongue.
Neoplasms
The effects of ACTH on acid phosphatase activity in endosomes, GERL and lysosomes of cultured adrenal tumor cells.
Neoplasms
The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
Neoplasms
The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
Neoplasms
The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Neoplasms
The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats.
Neoplasms
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Neoplasms
The Expression of the Phosphatase Regenerating Liver 3 Gene is Associated with Outcome in Patients with Colorectal Cancer.
Neoplasms
The Expression, Functions, Interactions and Prognostic Values of PTPRZ1: A Review and Bioinformatic Analysis.
Neoplasms
The EYA tyrosine phosphatase activity is pro-angiogenic and is inhibited by benzbromarone.
Neoplasms
The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells.
Neoplasms
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
Neoplasms
The function of mitogen-activated protein kinase phosphatase-1 in peptidoglycan-stimulated macrophages.
Neoplasms
The Functional Variant in the 3'UTR of PTPRT with the Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population.
Neoplasms
The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application.
Neoplasms
The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/?-catenin signaling pathway.
Neoplasms
The gene for leukocyte antigen-related tyrosine phosphatase (LAR) is localized to human chromosome 1p32, a region frequently deleted in tumors of neuroectodermal origin.
Neoplasms
The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.
Neoplasms
The High Expression of PTPRH Is Associated with Poor Prognosis of Human Lung Adenocarcinoma.
Neoplasms
The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
Neoplasms
The HNF1?-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
Neoplasms
The homophilic receptor PTPRK selectively dephosphorylates multiple junctional regulators to promote cell-cell adhesion.
Neoplasms
The impact of hepatocyte nuclear factor-1? on liver malignancies and cell stemness with metabolic consequences.
Neoplasms
The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation.
Neoplasms
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
Neoplasms
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
Neoplasms
The Involvement of the Mammalian Target of Rapamycin, Protein Tyrosine Phosphatase 1b and Dipeptidase 4 Signaling Pathways in Cancer and Diabetes: A Narrative Review.
Neoplasms
The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
Neoplasms
The mechanism of binding of the second PDZ domain from the Protein Tyrosine Phosphatase-BL to the Adenomatous Polyposis Coli tumor suppressor.
Neoplasms
The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation.
Neoplasms
The mitogen-activated protein kinase phosphatase-1 (MKP-1) gene is a potential methylation biomarker for malignancy of breast cancer.
Neoplasms
The murine orthologue of the Golgi-localized TPTE protein provides clues to the evolutionary history of the human TPTE gene family.
Neoplasms
The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
Neoplasms
The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints.
Neoplasms
The natural tumorcide Manumycin-A targets protein phosphatase 1? and reduces hydrogen peroxide to induce lymphoma apoptosis.
Neoplasms
The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis.
Neoplasms
The Nonreceptor-Type Tyrosine Phosphatase PTPN13 Is a Tumor Suppressor Gene in Non-Small Cell Lung Cancer.
Neoplasms
The open architecture of HD-PTP phosphatase provides new insights into the mechanism of regulation of ESCRT function.
Neoplasms
The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response.
Neoplasms
The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells.
Neoplasms
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
Neoplasms
The p53-p66shc-Manganese Superoxide Dismutase (MnSOD) network: a mitochondrial intrigue to generate reactive oxygen species.
Neoplasms
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth.
Neoplasms
The phosphatase of regenerating liver 3 (PRL-3) promotes cell migration via Arf-activity dependent stimulation of integrin alpha5 recycling.
Neoplasms
The phosphatase PRL-3 affects intestinal homeostasis by altering the crypt cell composition.
Neoplasms
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
Neoplasms
The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function.
Neoplasms
The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Neoplasms
The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Neoplasms
The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.
Neoplasms
The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer.
Neoplasms
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.
Neoplasms
The Protein Tyrosine Phosphatase Activity of Eyes Absent Contributes to Tumor Angiogenesis and Tumor Growth.
Neoplasms
The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis.
Neoplasms
The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function.
Neoplasms
The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis.
Neoplasms
The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells.
Neoplasms
The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion.
Neoplasms
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
Neoplasms
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.
Neoplasms
The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
Neoplasms
The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas.
Neoplasms
The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation.
Neoplasms
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue.
Neoplasms
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.
Neoplasms
The receptor protein-tyrosine phosphatase, Dep1, acts in arterial/venous cell fate decisions in zebrafish development.
Neoplasms
The receptor-like protein-tyrosine phosphatase DEP-1 is constitutively associated with a 64-kDa protein serine/threonine kinase.
Neoplasms
The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.
Neoplasms
The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.
Neoplasms
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review.
Neoplasms
The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.
Neoplasms
The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis.
Neoplasms
The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer.
Neoplasms
The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38.
Neoplasms
The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors.
Neoplasms
The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis.
Neoplasms
The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells.
Neoplasms
The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.
Neoplasms
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
Neoplasms
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.
Neoplasms
The subcellular location of cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance.
Neoplasms
The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA.
Neoplasms
The TNF-?-induced expression of miR-130b protects cervical cancer cells from the cytotoxicity of TNF-?.
Neoplasms
The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2.
Neoplasms
The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).
Neoplasms
The tumor suppressor PTPRK promotes ZNRF3 internalization and is required for Wnt inhibition in the Spemann organizer.
Neoplasms
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Neoplasms
The tumor-selective somatostatin analog, TT2-32 induces a biphasic activation of phosphotyrosine phosphatase activity in human colon tumor cell line, SW620.
Neoplasms
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Neoplasms
The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Neoplasms
The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation.
Neoplasms
The tyrosine phosphatase HD-PTP (PTPN23) is degraded by calpains in a calcium-dependent manner.
Neoplasms
The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis.
Neoplasms
The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.
Neoplasms
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Neoplasms
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Neoplasms
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
Neoplasms
The tyrosine343 residue of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
Neoplasms
The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration.
Neoplasms
The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation.
Neoplasms
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Neoplasms
Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.
Neoplasms
Thyroid hormone antagonizes tumor necrosis factor-alpha signaling in pituitary cells through the induction of dual specificity phosphatase 1.
Neoplasms
Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling.
Neoplasms
Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma.
Neoplasms
Toll-like receptor-mediated IRE1? activation as a therapeutic target for inflammatory arthritis.
Neoplasms
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Neoplasms
Toxoplasma GRA16 Inhibits NF-?B Activation through PP2A-B55 Upregulation in Non-Small-Cell Lung Carcinoma Cells.
Neoplasms
Transcriptome analysis of potential candidate genes and molecular pathways in colitis-associated colorectal cancer of Mkp-1-deficient mice.
Neoplasms
Transcriptome profiling analysis on whole bodies of microbial challenged Eriocheir sinensis larvae for immune gene identification and SNP development.
Neoplasms
Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
Neoplasms
Transduction motif analysis of gastric cancer based on a human signaling network.
Neoplasms
Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.
Neoplasms
Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Neoplasms
Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.
Neoplasms
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Neoplasms
Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
Neoplasms
Treatment with DHA Modifies the Response of MDA-MB-231 Breast Cancer Cells and Tumors from nu/nu Mice to Doxorubicin through Apoptosis and Cell Cycle Arrest.
Neoplasms
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Neoplasms
TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Neoplasms
Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.
Neoplasms
Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA.
Neoplasms
Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
Neoplasms
Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Neoplasms
Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation.
Neoplasms
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
Neoplasms
Tumor necrosis factor-?-mediated suppression of dual-specificity phosphatase 4: crosstalk between NF?B and MAPK regulates endothelial cell survival.
Neoplasms
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Neoplasms
Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells.
Neoplasms
Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases.
Neoplasms
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
Neoplasms
Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.
Neoplasms
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.
Neoplasms
Tumor vessel up-regulation of INSR revealed by single-cell expression analysis of the tyrosine kinome and phosphatome in human cancers.
Neoplasms
Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner.
Neoplasms
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion.
Neoplasms
Tumor-Suppression Mechanisms of Protein Tyrosine Phosphatase O and Clinical Applications.
Neoplasms
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Neoplasms
Tumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression.
Neoplasms
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth.
Neoplasms
Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer.
Neoplasms
Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.
Neoplasms
Tuning the Protein Phosphorylation by Receptor Type Protein Tyrosine Phosphatase Epsilon (PTPRE) in Normal and Cancer Cells.
Neoplasms
Two-photon imaging of multicellular tumor spheroids: A novel method for evaluating the efficacy of CDC25 phosphatase inhibitors.
Neoplasms
Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells.
Neoplasms
Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
Neoplasms
Tyrosine phosphatase PTP? contributes to HER2-evoked breast tumor initiation and maintenance.
Neoplasms
Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44.
Neoplasms
Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression.
Neoplasms
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Neoplasms
Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells.
Neoplasms
Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer.
Neoplasms
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Neoplasms
Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Neoplasms
Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.
Neoplasms
Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents.
Neoplasms
Ultrastructure of tumor cell interaction with alveolar macrophages stimulated by vitamin A.
Neoplasms
Understanding the effect of alternative splicing in the folding and function of the second PDZ from protein tyrosine phosphatase-BL.
Neoplasms
Unknown primary adenocarcinoma: incidence of overinvestigation and natural history.
Neoplasms
Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.
Neoplasms
Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage.
Neoplasms
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Neoplasms
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression.
Neoplasms
Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion.
Neoplasms
Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
Neoplasms
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Neoplasms
Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma.
Neoplasms
Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer.
Neoplasms
USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
Neoplasms
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
Neoplasms
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
Neoplasms
VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
Neoplasms
Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis.
Neoplasms
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
Neoplasms
VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C.
Neoplasms
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Neoplasms
Virtual Screening of Novel and Selective Inhibitors of Protein Tyrosine Phosphatase 1B over T-Cell Protein Tyrosine Phosphatase Using a Bidentate Inhibition Strategy.
Neoplasms
Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes.
Neoplasms
Vitamin C transiently arrests cancer cell cycle progression in S phase and G2/M boundary by modulating the kinetics of activation and the subcellular localization of Cdc25C phosphatase.
Neoplasms
Vitamin K3 induces cell cycle arrest and cell death by inhibiting Cdc25 phosphatase.
Neoplasms
Whole exome sequencing in Dandy-Walker variant with intellectual disability reveals an activating CIP2A mutation as novel genetic cause.
Neoplasms
Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.
Neoplasms
Woodylides A-C, New Cytotoxic Linear Polyketides from the South China Sea Sponge Plakortis simplex.
Neoplasms
YAP and TAZ, Hippo Signaling Targets, Act as a Rheostat for Nuclear SHP2 Function.
Neoplasms
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.
Neoplasms
Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Neoplasms
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Neoplasms
Zanthoxylum avicennae extracts induce cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and block tumor growth in xenografted nude mice.
Neoplasms
[Acid phosphatase activity and non-specific esterase D of alpha-naphthyl acetate in the lymphocytes of patients with digestive system neoplasms after surgical treatment]
Neoplasms
[Acid phosphatase activity and phagocytic capabilities of reticuloendothelial system cells of mice with experimental tumors]
Neoplasms
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells]
Neoplasms
[Association between diversity in the Src homology 2 domain-containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis 2004;189:820-827]
Neoplasms
[Change in brain alkaline and acid phosphatase activity under the action of adrenocorticotrophic hormone and hydrocortisone in experimental transplanted cancer of the rat mammary gland]
Neoplasms
[Changes of phenotypes associated with activated Src by overexpressed PTPalpha in NIH3T3 cells]
Neoplasms
[Construction and expression of PRL-3 plasmid with C104S point mutation and CAAX deletion.]
Neoplasms
[Cutaneous histiocytosarcoma: clinical, immunohistochemical and ultrastructural aspects; difficulties of study and problems of nosology (author's transl)]
Neoplasms
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
Neoplasms
[Enzyme cytochemical and immunocytological differentiation of infiltrative cells in the skin in mycosis fungoides]
Neoplasms
[Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy]
Neoplasms
[Expression and its relationship of PRL-3 and RhoC in non-small cell lung cancer]
Neoplasms
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Neoplasms
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
Neoplasms
[Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma]
Neoplasms
[Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]
Neoplasms
[Expression of SHP-1 mRNA in Patients with Myelogenous Leukemia and Its Clinical Significance].
Neoplasms
[Gene expression profiles in squamous esophageal cancer tissues and adjacent almost normal tissues]
Neoplasms
[Inhibition of pinocytosis and of acid phosphatase activity caused by lack of serum in the culture medium of Ehrlich ascites tumor cells (author's transl)]
Neoplasms
[Molecular mechanism and clinical impact of insulin resistance in type 2 diabetes mellitus]
Neoplasms
[Prostate and menadiol sodium diphosphate - menadiol sodium diphosphate as a new substrate for measuring acid phosphatase activity and a discussion on prostatic tumor model ]
Neoplasms
[Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer]
Neoplasms
[Screening and identification of tumor related genes in early stages of transformed NIH3T3 cells associated with overexpressed PTPalpha]
Neoplasms
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
Neoplasms
[The clinical significance of PRL-3,VEGF expression in sinonasalsquamous cell carcinoma].
Neoplasms
[The effects of PTEN gene on migration and FAK phosphorylation of SMMC-7721 human hepatocarcinoma cell line]
Neoplasms
[The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]
Neoplasms
[The significance of acid phosphatase activity in the cytologic diagnosis of thyroid malignancy (author's transl)]
Neoplasms
{Gamma}-tocotrienol but not {gamma}-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Neoplasms, Germ Cell and Embryonal
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Neoplasms, Germ Cell and Embryonal
Tumor-suppressive Function of Protein-tyrosine Phosphatase Non-receptor Type 23 in Testicular Germ Cell Tumors Is Lost upon Overexpression of miR142-3p microRNA.
Neoplasms, Glandular and Epithelial
Association of PTP4A3 expression and tumour size in functioning pituitary adenoma: a descriptive study.
Neoplasms, Neuroepithelial
CP6 Anopthalmia and dysembryoplastic neuroepithelial tumours in a family with Noonan syndrome and a novel PTPN11 mutation.
Neoplastic Cells, Circulating
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Neoplastic Cells, Circulating
Protein tyrosine phosphatase receptor type O expression in the tumor niche correlates with reduced tumor growth, angiogenesis, circulating tumor cells and metastasis of breast cancer.
Nephritis
A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles.
Nephritis
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Nephritis
Glomerular epithelial protein 1 and podocalyxin-like protein 1 in inflammatory glomerular disease (crescentic nephritis) in rabbit and man.
Nephritis
Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation.
Nephritis, Hereditary
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Nephritis, Interstitial
Oxidative stress-inducible protein tyrosine phosphatase in glomerulonephritis.
Nephrosis
Early changes in gene expression that influence the course of primary glomerular disease.
Nephrosis
GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. A marker of acute podocyte injury.
Nephrotic Syndrome
Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome.
Nephrotic Syndrome
Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome.
Nervous System Diseases
Aging is associated with dimerization and inactivation of the brain-enriched tyrosine phosphatase STEP.
Nervous System Diseases
Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.
Nervous System Diseases
Extreme enrichment of VNTR-associated polymorphicity in human subtelomeres: genes with most VNTRs are predominantly expressed in the brain.
Nervous System Diseases
Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation.
Nervous System Diseases
Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease.
Neural Tube Defects
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Neuralgia
BDNF contributes to the development of neuropathic pain by induction of spinal long-term potentiation via SHP2 associated GluN2B-containing NMDA receptors activation in rats with spinal nerve ligation.
Neuralgia
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1.
Neuralgia
Carnosic acid attenuates neuropathic pain in rat through the activation of spinal sirtuin1 and down-regulation of p66shc expression.
Neuralgia
Inhibition of protein tyrosine phosphatase 1B in spinal cord dorsal horn of rats attenuated diabetic neuropathic pain.
Neuralgia
MiR-101 promotes pain hypersensitivity in rats with chronic constriction injury via the MKP-1 mediated MAPK pathway.
Neuralgia
p66shc siRNA-Encapsulated PLGA Nanoparticles Ameliorate Neuropathic Pain Following Spinal Nerve Ligation.
Neuralgia
PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain.
Neuralgia
Spinal SIRP?1-SHP2 interaction regulates spinal nerve ligation-induced neuropathic pain via PSD-95-dependent NR2B activation in rats.
Neurilemmoma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Neuroblastoma
Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas.
Neuroblastoma
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Neuroblastoma
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Neuroblastoma
Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis.
Neuroblastoma
Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.
Neuroblastoma
Atomic structure of dual-specificity phosphatase 26, a novel p53 phosphatase.
Neuroblastoma
Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2.
Neuroblastoma
Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Neuroblastoma
Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma.
Neuroblastoma
Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma.
Neuroblastoma
Functional analysis of the putative tumor suppressor PTPRD in neuroblastoma cells.
Neuroblastoma
Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition.
Neuroblastoma
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Neuroblastoma
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Neuroblastoma
Initiation and maintenance of CNTF-Jak/STAT signaling in neurons is blocked by protein tyrosine phosphatase inhibitors.
Neuroblastoma
Interactions Between Glycogen Synthase Kinase 3beta, Protein Kinase B, and Protein Phosphatase 2A in Tau Phosphorylation in Mouse N2a Neuroblastoma Cells.
Neuroblastoma
Leucine Carboxyl Methyltransferase 1 (LCMT1)-dependent Methylation Regulates the Association of Protein Phosphatase 2A and Tau Protein with Plasma Membrane Microdomains in Neuroblastoma Cells.
Neuroblastoma
Liprin alfa 2 gene expression is increased by cannabis use and associated with neuropsychological function.
Neuroblastoma
MKP-1 contributes to oxidative stress-induced apoptosis via inactivation of ERK1/2 in SH-SY5Y cells.
Neuroblastoma
Molecular Basis of the Interaction of the Human Protein Tyrosine Phosphatase Non-receptor Type 4 (PTPN4) with the Mitogen-activated Protein Kinase p38?.
Neuroblastoma
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Neuroblastoma
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Neuroblastoma
Neuroblastoma PTPome analysis unveils association of DUSP5 and PTPN1 expression with poor prognosis.
Neuroblastoma
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Neuroblastoma
Over-expression of map kinase phosphatase-1 (MKP-1) suppresses neuronal death through regulating JNK signaling in hypoxia/re-oxygenation.
Neuroblastoma
Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation.
Neuroblastoma
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
Neuroblastoma
Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.
Neuroblastoma
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase a oncogene.
Neuroblastoma
Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP.
Neuroblastoma
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
Neuroblastoma
Proteomic investigation of Cbl and Cbl-b in neuroblastoma cell differentiation highlights roles for SHP-2 and CDK16.
Neuroblastoma
Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A.
Neuroblastoma
Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation.
Neuroblastoma
Receptor tyrosine phosphatase beta (RPTPbeta) activity and signaling are attenuated by glycosylation and subsequent cell surface galectin-1 binding.
Neuroblastoma
Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells.
Neuroblastoma
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
Neuroblastoma
Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration.
Neuroblastoma
Subcellular Localization and Differentiation-Induced Redistribution of the Protein Tyrosine Phosphatase PTP-BL in Neuroblastoma Cells.
Neuroblastoma
TC-PTP Dephosphorylates the Guanine Nucleotide Exchange Factor C3G (RapGEF1) and Negatively Regulates Differentiation of Human Neuroblastoma Cells.
Neuroblastoma
The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Neuroblastoma
The testosterone metabolite 3?-androstanediol inhibits oxidative stress-induced ERK phosphorylation and neurotoxicity in SH-SY5Y cells through an MKP3/DUSP6-dependent mechanism.
Neuroblastoma
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Neuroblastoma
Transcriptional response to muscarinic acetylcholine receptor stimulation: regulation of Egr-1 biosynthesis by ERK, Elk-1, MKP-1, and calcineurin in carbachol-stimulated human neuroblastoma cells.
Neuroblastoma
Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence.
Neuroblastoma
Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers.
Neuroblastoma
Vanadate protects human neuroblastoma SH-SY5Y cells against peroxynitrite-induced cell death.
Neurodegenerative Diseases
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
Neurodegenerative Diseases
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.
Neurodegenerative Diseases
Alterations of STEP46 and STEP61 Expression in the Rat Retina with Age and AMD-Like Retinopathy Development.
Neurodegenerative Diseases
Co-chaperone CHIP stabilizes aggregate-prone malin, a ubiquitin ligase mutated in Lafora disease.
Neurodegenerative Diseases
Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases.
Neurodegenerative Diseases
CSP? reduces aggregates and rescues striatal dopamine release in ?-synuclein transgenic mice.
Neurodegenerative Diseases
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Neurodegenerative Diseases
Genetic determinants at the interface of cancer and neurodegenerative disease.
Neurodegenerative Diseases
Heterozygous Meg2 Ablation Causes Intraocular Pressure Elevation and Progressive Glaucomatous Neurodegeneration.
Neurodegenerative Diseases
Immunohistochemical Localization of Fas-associated phosphatase-1 (FAP-1) in Alzheimer disease hippocampus.
Neurodegenerative Diseases
Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin.
Neurodegenerative Diseases
Laforin, a dual specificity protein phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Neurodegenerative Diseases
Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3?/PP2A pathway in Parkinson's disease.
Neurodegenerative Diseases
Molecular crosstalk between cancer and neurodegenerative diseases.
Neurodegenerative Diseases
Molecular underpinnings of neurodegenerative disorders: striatal-enriched protein tyrosine phosphatase signaling and synaptic plasticity.
Neurodegenerative Diseases
Neuroprotective Effects of Protein Tyrosine Phosphatase 1B Inhibition against ER Stress-Induced Toxicity.
Neurodegenerative Diseases
Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease.
Neurodegenerative Diseases
Phosphorylation-Specific Peptidyl-Prolyl Isomerization of Neuronal Cytoskeletal Proteins by Pin1: Implications for Therapeutics in Neurodegeneration.
Neurodegenerative Diseases
Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration.
Neurodegenerative Diseases
PP2AC? of Alveolar Macrophages Is a Novel Protective Factor for LPS-Induced Acute Respiratory Distress Syndrome.
Neurodegenerative Diseases
Protein Phosphatase 2a (Pp2a) Regulates Innate Immune and Proteolytic Responses to Cigarette Smoke Exposure in the Lung.
Neurodegenerative Diseases
Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2.
Neurodegenerative Diseases
Protein Phosphatase 2A: a Double-Faced Phosphatase of Cellular System and Its Role in Neurodegenerative Disorders.
Neurodegenerative Diseases
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Neurodegenerative Diseases
PTPIP51 regulates mouse cardiac ischemia/reperfusion through mediating the mitochondria-SR junction.
Neurodegenerative Diseases
PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells.
Neurodegenerative Diseases
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Neurodegenerative Diseases
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Neurodegenerative Diseases
Synthesis of benzopentathiepin analogs and their evaluation as inhibitors of the phosphatase STEP.
Neurodegenerative Diseases
The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits.
Neurodegenerative Diseases
The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2.
Neurodegenerative Diseases
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Neurodegenerative Diseases
The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival.
Neurodermatitis
[Neutrophil alkaline and acid phosphatase activity in the blood of children with neurodermatitis]
Neuroectodermal Tumors
LAR tyrosine phosphatase receptor: alternative splicing is preferential to the nervous system, coordinated with cell growth and generates novel isoforms containing extensive CAG repeats.
Neuroectodermal Tumors
Leukocyte common antigen-related receptor-linked tyrosine phosphatase. Regulation of mRNA expression.
Neuroendocrine Tumors
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Neuroendocrine Tumors
PTPRM, a candidate tumor suppressor gene in small intestinal neuroendocrine tumors.
Neurofibroma
Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
Neurofibromatoses
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Neurofibromatoses
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Neurofibromatoses
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Neurofibromatoses
Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
Neurofibromatoses
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
Neurofibromatoses
Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Neurofibromatoses
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Neurofibromatoses
Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.
Neurofibromatosis 1
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Neurofibromatosis 1
Clinical variability of neurofibromatosis 1: A modifying role of cooccurring PTPN11 variants and atypical brain MRI findings.
Neurofibromatosis 1
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Neurofibromatosis 1
Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Neurofibromatosis 1
Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
Neurofibromatosis 1
Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.
Neurofibrosarcoma
Protein Tyrosine Phosphatase Receptor S Acts as a Metastatic Suppressor in Malignant Peripheral Nerve Sheath Tumor via Profilin 1-Induced Epithelial-Mesenchymal Transition.
Neuroinflammatory Diseases
A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation.
Neuroinflammatory Diseases
AGK2 Alleviates Lipopolysaccharide Induced Neuroinflammation through Regulation of Mitogen-Activated Protein Kinase Phosphatase-1.
Neuroinflammatory Diseases
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1.
Neuroinflammatory Diseases
Comparative Analysis of Protein Tyrosine Phosphatases Regulating Microglial Activation.
Neuroinflammatory Diseases
Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia.
Neuroinflammatory Diseases
Distribution of different isoforms of receptor protein tyrosine phosphatase ? (Ptprg-RPTP ?) in adult mouse brain: upregulation during neuroinflammation.
Neuroinflammatory Diseases
Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Neuroinflammatory Diseases
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
Neuroinflammatory Diseases
PTP1B inhibitor alleviates deleterious microglial activation and neuronal injury after ischemic stroke by modulating the ER stress-autophagy axis via PERK signaling in microglia.
Neuroinflammatory Diseases
Role of protein tyrosine phosphatase 1B inhibitor in central insulin resistance and associated cognitive deficits.
Neuromyelitis Optica
HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica.
Neuronal Ceroid-Lipofuscinoses
A cluster of palmitoylated cysteines are essential for aggregation of cysteine-string protein mutants that cause neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Oligomerization of Cysteine String Protein alpha mutants causing adult neuronal ceroid lipofuscinosis.
Neuronal Ceroid-Lipofuscinoses
Recurrent mutations in DNAJC5 cause autosomal dominant Kufs Disease.
Neutropenia
SH2-containing protein tyrosine phosphatases SHP-1 and SHP-2 are dramatically increased at the protein level in neutrophils from patients with severe congenital neutropenia (Kostmann's syndrome).
Niemann-Pick Disease, Type C
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Niemann-Pick Diseases
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
Niemann-Pick Diseases
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
Non-alcoholic Fatty Liver Disease
Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells.
Non-alcoholic Fatty Liver Disease
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Dual-specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice through TAK1 Suppression.
Non-alcoholic Fatty Liver Disease
Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.
Non-alcoholic Fatty Liver Disease
Dual-Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression.
Non-alcoholic Fatty Liver Disease
Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21.
Non-alcoholic Fatty Liver Disease
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
Non-alcoholic Fatty Liver Disease
Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPAR?
Non-alcoholic Fatty Liver Disease
Interrogating Endogenous Protein Phosphatase Activity with Rationally Designed Chemosensors.
Non-alcoholic Fatty Liver Disease
Polymorphism of Receptor-Type Tyrosine-Protein Phosphatase Delta gene in the development of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Non-alcoholic Fatty Liver Disease
PTPROt aggravates inflammation by enhancing NF-?B activation in liver macrophages during nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
SHP-1 ameliorates nonalcoholic steatohepatitis by inhibiting proinflammatory cytokine production.
Non-alcoholic Fatty Liver Disease
Targeting DUSP16/TAK1 signaling alleviates hepatic dyslipidemia and inflammation in high fat diet (HFD)-challenged mice through suppressing JNK MAPK.
Non-alcoholic Fatty Liver Disease
Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade.
Non-alcoholic Fatty Liver Disease
The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Utility of a new model to diagnose an alcohol basis for steatohepatitis.
Non-alcoholic Fatty Liver Disease
Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.
Non-ST Elevated Myocardial Infarction
Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes.
Noonan Syndrome
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Noonan Syndrome
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
Noonan Syndrome
A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Noonan Syndrome
A de novo T73I Mutation in PTPN11 in a Neonate with Severe and Prolonged Congenital Thrombocytopenia and Noonan Syndrome.
Noonan Syndrome
A First Case Report of Subependymoma in PTPN11 Mutation-Associated Noonan Syndrome.
Noonan Syndrome
A mother and son with Noonan syndrome resulting from a PTPN11 mutation: first report of molecularly proven cases from Turkey.
Noonan Syndrome
A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.
Noonan Syndrome
A new PTPN11 mutation in juvenile myelomonocytic leukaemia associated with Noonan syndrome.
Noonan Syndrome
A novel approach using long-read sequencing and ddPCR to investigate gonadal mosaicism and estimate recurrence risk in two families with developmental disorders.
Noonan Syndrome
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
Noonan Syndrome
A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome.
Noonan Syndrome
A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.
Noonan Syndrome
A PTPN11 Gene Mutation (Y63C) Causing Noonan Syndrome is Not Associated with Short Stature in General Population.
Noonan Syndrome
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Noonan Syndrome
Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome.
Noonan Syndrome
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Noonan Syndrome
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Noonan Syndrome
Acute Lymphoblastic Leukemia Developing in a Patient With Noonan Syndrome Harboring a PTPN11 Germline Mutation.
Noonan Syndrome
Acute myeloid leukemia in an adult Noonan syndrome patient with PTPN11 mutation.
Noonan Syndrome
Analysis of giant cell tumour of bone cells for Noonan syndrome/Cherubism-related mutations.
Noonan Syndrome
Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Noonan Syndrome
Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation.
Noonan Syndrome
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Noonan Syndrome
Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions.
Noonan Syndrome
Clinical and hematologic findings in Noonan syndrome patients with PTPN11 gene mutations.
Noonan Syndrome
Clinical and Molecular Analysis of Patients with RASopathies in Turkish Patients.
Noonan Syndrome
Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Noonan Syndrome
Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.
Noonan Syndrome
Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome.
Noonan Syndrome
Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
Noonan Syndrome
Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?
Noonan Syndrome
Cochlear implantation and clinical features in patients with Noonan syndrome and Noonan syndrome with multiple lentigines caused by a mutation in PTPN11.
Noonan Syndrome
Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy.
Noonan Syndrome
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Noonan Syndrome
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
Noonan Syndrome
Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.
Noonan Syndrome
Congenital sensorineural hearing loss as the initial presentation of PTPN11-associated Noonan syndrome with multiple lentigines or Noonan syndrome: clinical features and underlying mechanisms.
Noonan Syndrome
Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Noonan Syndrome
Coronary artery dilatation in LEOPARD syndrome. A child case and literature review.
Noonan Syndrome
Counteracting Effects Operating on Src Homology 2 Domain-containing Protein-tyrosine Phosphatase 2 (SHP2) Function Drive Selection of the Recurrent Y62D and Y63C Substitutions in Noonan Syndrome.
Noonan Syndrome
CP6 Anopthalmia and dysembryoplastic neuroepithelial tumours in a family with Noonan syndrome and a novel PTPN11 mutation.
Noonan Syndrome
Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Noonan Syndrome
Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noonan Syndrome
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.
Noonan Syndrome
Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Noonan Syndrome
Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS).
Noonan Syndrome
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Noonan Syndrome
Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human Disease.
Noonan Syndrome
Does the rare A172G mutation of PTPN11 gene convey a mild Noonan syndrome phenotype?
Noonan Syndrome
Duplication of chromosome band 12q24.11q24.23 results in apparent Noonan syndrome.
Noonan Syndrome
Electrocardiography in Noonan syndrome PTPN11 gene mutation--phenotype characterization.
Noonan Syndrome
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Noonan Syndrome
Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.
Noonan Syndrome
Evolutionary constraint and disease associations of post-translational modification sites in human genomes.
Noonan Syndrome
Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance.
Noonan Syndrome
Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Noonan Syndrome
Expanding the clinical spectrum of ocular anomalies in Noonan syndrome: Axenfeld-anomaly in a child with PTPN11 mutation.
Noonan Syndrome
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
Noonan Syndrome
Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study.
Noonan Syndrome
First-year growth in children with Noonan syndrome: Associated with feeding problems?
Noonan Syndrome
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
Noonan Syndrome
Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Noonan Syndrome
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
Noonan Syndrome
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome.
Noonan Syndrome
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
Noonan Syndrome
Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene.
Noonan Syndrome
Genetic evaluation and management of fetal chylothorax: review and insights from a case of Noonan syndrome.
Noonan Syndrome
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Noonan Syndrome
Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Noonan Syndrome
Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Noonan Syndrome
High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome.
Noonan Syndrome
Hodgkin's lymphoma in a patient with Noonan syndrome with germ-line PTPN11 mutations.
Noonan Syndrome
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11).
Noonan Syndrome
Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2.
Noonan Syndrome
IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene.
Noonan Syndrome
Impact of Growth Hormone Therapy on Adult Height in Patients with PTPN11 Mutations Related to Noonan Syndrome.
Noonan Syndrome
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.
Noonan Syndrome
Insulin resistance and exaggerated insulin sensitivity triggered by single-gene mutations in the insulin signaling pathway.
Noonan Syndrome
Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.
Noonan Syndrome
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Noonan Syndrome
Key insights into the protein tyrosine phosphatase PTPN11/SHP2 associated with noonan syndrome and cancer.
Noonan Syndrome
Lack of Catch-Up Growth with Growth Hormone Treatment in a Child Born Small for Gestational Age Leading to a Diagnosis of Noonan Syndrome with a Pathogenic PTPN11 Variant.
Noonan Syndrome
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Noonan Syndrome
Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Noonan Syndrome
Mitochondrial DNA haplogroup 'R' is associated with Noonan syndrome of south India.
Noonan Syndrome
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
Noonan Syndrome
Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.
Noonan Syndrome
Molecular characterization of a balanced rearrangement of chromosome 12 in two siblings with Noonan syndrome.
Noonan Syndrome
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Noonan Syndrome
Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies.
Noonan Syndrome
Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.
Noonan Syndrome
Mutational analysis of PTPN11 gene in Taiwanese children with Noonan syndrome.
Noonan Syndrome
Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
Noonan Syndrome
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
Noonan Syndrome
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Noonan Syndrome
Myelodysplastic syndrome with multilineage dysplasia evolving to acute myeloid leukemia: Noonan syndrome with c.218C>T mutation in PTPN11 gene.
Noonan Syndrome
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Noonan Syndrome
Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Noonan Syndrome
New Mutations Associated with Rasopathies in a Central European Population and Genotype-Phenotype Correlations.
Noonan Syndrome
No mutation in the gene for Noonan syndrome, PTPN11, in 18 patients with Costello syndrome.
Noonan Syndrome
Nonspecific phenotype of Noonan syndrome diagnosed by whole exome sequencing.
Noonan Syndrome
Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Noonan Syndrome
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Noonan Syndrome
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
Noonan Syndrome
Noonan Syndrome Case Report: PTPN11 and Other Potential Genetic Factors Contributing to Lethal Hypertrophic Right Ventricular Cardiomyopathy.
Noonan Syndrome
Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.
Noonan Syndrome
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
Noonan Syndrome
Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Noonan Syndrome
Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.
Noonan Syndrome
Noonan Syndrome with Multiple Lentigines and PTPN11 Mutation: A Case with Intracerebral Hemorrhage.
Noonan Syndrome
Noonan syndrome with multiple lentigines with PTPN11 (T468M) gene mutation accompanied with solitary granular cell tumor.
Noonan Syndrome
Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Noonan Syndrome
Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.
Noonan Syndrome
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Noonan Syndrome
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
Noonan Syndrome
Noonan syndrome/leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and angiogenesis.
Noonan Syndrome
Noonan syndrome: Prenatal diagnosis in a woman carrying a PTPN11 gene mutation.
Noonan Syndrome
Noonan syndrome: relationships between genotype, growth, and growth factors.
Noonan Syndrome
Novel mutations in PTPN11 gene in two girls with Noonan syndrome phenotype.
Noonan Syndrome
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Noonan Syndrome
Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants.
Noonan Syndrome
Paternal germline origin and sex-ratio distortion in transmission of PTPN11 mutations in Noonan syndrome.
Noonan Syndrome
Pathogenic gene screening in 91 Chinese patients with short stature of unknown etiology with a targeted next-generation sequencing panel.
Noonan Syndrome
Pathogenic PTPN11 variants involving the poly-glutamine Gln255 -Gln256 -Gln257 stretch highlight the relevance of helix B in SHP2's functional regulation.
Noonan Syndrome
Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.
Noonan Syndrome
Phenotype-genotype analysis of 242 individuals with RASopathies: 18-year experience of a tertiary center in Brazil.
Noonan Syndrome
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
Noonan Syndrome
Prenatal detection of Noonan syndrome by mutation analysis of the PTPN11 and the KRAS genes.
Noonan Syndrome
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
Noonan Syndrome
Probable Noonan syndrome in a boy without PTPN11 mutation, manifesting unusual complications.
Noonan Syndrome
Prolonged thrombocytopenia in a neonate with Noonan syndrome: a case report.
Noonan Syndrome
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
Noonan Syndrome
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
Noonan Syndrome
Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Noonan Syndrome
Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome.
Noonan Syndrome
Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Noonan Syndrome
PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Noonan Syndrome
PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.
Noonan Syndrome
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Noonan Syndrome
PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings.
Noonan Syndrome
Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
Noonan Syndrome
PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype.
Noonan Syndrome
PTPN11 Mutation Associated with Aortic Dilation and Hypertrophic Cardiomyopathy in a Pediatric Patient with Noonan Syndrome.
Noonan Syndrome
PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning.
Noonan Syndrome
PTPN11 mutation in a young man with Noonan syndrome and retinitis pigmentosa.
Noonan Syndrome
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Noonan Syndrome
PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
Noonan Syndrome
PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Noonan Syndrome
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
Noonan Syndrome
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Noonan Syndrome
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Noonan Syndrome
Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia.
Noonan Syndrome
Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk.
Noonan Syndrome
Recurrent ganglioneuroma in PTPN11-associated Noonan syndrome: A case report and literature review.
Noonan Syndrome
Redox Regulation of a Gain-of-Function Mutation (N308D) in SHP2 Noonan Syndrome.
Noonan Syndrome
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Noonan Syndrome
Response to Growth Hormone Therapy in Children with Noonan Syndrome: Correlation with or without PTPN11 Gene Mutation.
Noonan Syndrome
Severe aortic valvar stenosis in familial Noonan syndrome with mutation of the PTPN11 gene.
Noonan Syndrome
Severe congenital thrombocytopaenia--first clinical manifestation of Noonan syndrome.
Noonan Syndrome
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Noonan Syndrome
Shp2 in myocytes is essential for cardiovascular and neointima development.
Noonan Syndrome
SHP2 mutations induce precocious gliogenesis of Noonan syndrome-derived iPSCs during neural development in vitro.
Noonan Syndrome
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Noonan Syndrome
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.
Noonan Syndrome
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.
Noonan Syndrome
SOS1 mutations in Noonan syndrome: Cardiomyopathies and not only congenital heart defects! Report of six patients including two novel variants and literature review.
Noonan Syndrome
Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome.
Noonan Syndrome
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
Noonan Syndrome
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
Noonan Syndrome
Structural, Functional, and Clinical Characterization of a Novel PTPN11 Mutation Cluster Underlying Noonan Syndrome.
Noonan Syndrome
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis.
Noonan Syndrome
Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders.
Noonan Syndrome
Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis.
Noonan Syndrome
Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
Noonan Syndrome
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies.
Noonan Syndrome
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
Noonan Syndrome
The Fetal Phenotype of Noonan Syndrome Caused by Severe, Cancer-Related PTPN11 Variants.
Noonan Syndrome
The first Noonan syndrome gene: PTPN11, which encodes the protein tyrosine phosphatase SHP-2.
Noonan Syndrome
The first PTPN1 1 mutations in hotspot exons reported in Moroccan children with Noonan syndrome and comparison of mutation rate to previous studies.
Noonan Syndrome
The molecular genetics of congenital heart disease: a review of recent developments.
Noonan Syndrome
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Noonan Syndrome
The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
Noonan Syndrome
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Noonan Syndrome
Therapy-related acute myeloid leukemia in a child with Noonan syndrome and clonal duplication of the germline PTPN11 mutation.
Noonan Syndrome
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
Noonan Syndrome
Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
Noonan Syndrome
Tumor spectrum in children with Noonan syndrome and SOS1 or RAF1 mutations.
Noonan Syndrome
Twin infant with lymphatic dysplasia diagnosed with Noonan syndrome by molecular genetic testing.
Noonan Syndrome
Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.
Noonan Syndrome
[Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway]
Noonan Syndrome
[Molecular genetic mutation analysis of the PTPN11 gene in the multiple lentigines (LEOPARD) syndrome]
Noonan Syndrome
[Multiple granular cell tumours in a patient with Noonan's syndrome and juvenile myelomonocytic leukaemia].
Noonan Syndrome
[Noonan syndrome and Leopard syndrome linked to mutation of the gene PTPN11]
Noonan Syndrome
[Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]
Noonan Syndrome
[Variability in clinical expression of Noonan syndrome--the report of two familial cases]
Obesity
1484insG polymorphism of the PTPN1 gene is associated with insulin resistance in an Iranian population.
Obesity
4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phosphatase 1B.
Obesity
A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors.
Obesity
A new bioactive steroidal ketone from the South China Sea sponge Xestospongia testudinaria.
Obesity
A novel screening model for the molecular drug for diabetes and obesity based on tyrosine phosphatase Shp2.
Obesity
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.
Obesity
A re-examination of the difluoromethylenesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition.
Obesity
A simple and visible colorimetric method through Zr(4+)-phosphate coordination for the assay of protein tyrosine phosphatase 1B and screening of its inhibitors.
Obesity
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.
Obesity
Absolute configuration and protein tyrosine phosphatase 1B inhibitory activity of xanthoepocin, a dimeric naphtopyrone from Penicillium sp. IQ-429.
Obesity
Absolute structures and bioactivities of euryspongins and eurydiene obtained from the marine sponge Euryspongia sp. collected at Iriomote Island.
Obesity
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese.
Obesity
Adipocyte-Specific Protein Tyrosine Phosphatase 1B Deletion Increases Lipogenesis, Adipocyte Cell Size and Is a Minor Regulator of Glucose Homeostasis.
Obesity
Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes.
Obesity
An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A).
Obesity
An investigation of obesity susceptibility genes in Northern Han Chinese by targeted resequencing.
Obesity
An Isoform-Selective PTP1B Inhibitor Derived from Nitrogen-Atom Augmentation of Radicicol.
Obesity
An RNA aptamer that selectively inhibits the enzymatic activity of protein tyrosine phosphatase 1B in vitro.
Obesity
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population.
Obesity
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Obesity
Antiobesity and Antidiabetes Effects of a Cudrania tricuspidata Hydrophilic Extract Presenting PTP1B Inhibitory Potential.
Obesity
Apparent lack of effect of obesity on the soluble phosphatidic acid phosphatase activity in human adipose tissue.
Obesity
Assessment of biochemical parameters and characterization of TNF? -308G/A and PTPN22 +1858C/T gene polymorphisms in the risk of obesity in adolescents.
Obesity
Association of PTPN1 polymorphisms with breast cancer risk: A case-control study in Chinese females.
Obesity
Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B.
Obesity
Azide-alkyne cycloaddition-mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools.
Obesity
Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli.
Obesity
Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study.
Obesity
Brominated polyunsaturated lipids with protein tyrosine phosphatase-1B inhibitory activity from Chinese marine sponge Xestospongia testudinaria.
Obesity
Caged xanthones displaying protein tyrosine phosphatase 1B (PTP1B) inhibition from Cratoxylum cochinchinense.
Obesity
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
Obesity
Cembrane diterpenoids from the soft coral Sarcophyton trocheliophorum Marenzeller as a new class of PTP1B inhibitors.
Obesity
Characterization of Protein Tyrosine Phosphatase 1B Inhibition by Chlorogenic Acid and Cichoric Acid.
Obesity
Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors.
Obesity
Combined Ligand- and Receptor-Based Virtual Screening Methodology to Identify Structurally Diverse Protein Tyrosine Phosphatase 1B Inhibitors.
Obesity
Combined Neural Inactivation of SOCS-3 and PTP-1B Reveal Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance.
Obesity
Competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors, prenylated caged xanthones from Garcinia hanburyi and their inhibitory mechanism.
Obesity
Computational Insight into Protein Tyrosine Phosphatase 1B Inhibition: A Case Study of the Combined Ligand- and Structure-Based Approach.
Obesity
Computational revelation of binding mechanisms of inhibitors to endocellular protein tyrosine phosphatase 1B using molecular dynamics simulations.
Obesity
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
Obesity
Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity.
Obesity
Correlation Between Nasal Epithelial Injury and In Vitro Cytotoxicity Using a Series of Small Molecule Protein Tyrosine Phosphatase 1B Inhibitors Investigated for Reversal of Leptin Resistance in Obesity.
Obesity
Dammaranes from Gynostemma pentaphyllum and synthesis of their derivatives as inhibitors of protein tyrosine phosphatase 1B.
Obesity
Dehydroepiandrosterone-enhanced dual specificity protein phosphatase (DDSP) prevents diet-induced and genetic obesity.
Obesity
Deletion of Protein Tyrosine Phosphatase 1b Improves Peripheral Insulin Resistance and Vascular Function in Obese, Leptin-Resistant Mice via Reduced Oxidant Tone.
Obesity
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension.
Obesity
Deletion of protein tyrosine phosphatase 1B rescues against myocardial anomalies in high fat diet-induced obesity: Role of AMPK-dependent autophagy.
Obesity
Dephosphorylation of CCAAT/enhancer-binding protein ? by protein phosphatase 2A containing B56? is required at the early time of adipogenesis.
Obesity
Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.
Obesity
Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase.
Obesity
Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy.
Obesity
Design, Synthesis, Biological Activity and Molecular Dynamics Studies of Specific Protein Tyrosine Phosphatase 1B Inhibitors over SHP-2.
Obesity
Development of Accessible Peptidic Tool Compounds To Study the Phosphatase PTP1B in Intact Cells.
Obesity
Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening.
Obesity
Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.
Obesity
Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Obesity
Discovery of Bisindole as a Novel Scaffold for Protein Tyrosine Phosphatase 1B Inhibitors.
Obesity
Discovery of core-structurally novel PTP1B inhibitors with specific selectivity containing oxindole-fused spirotetrahydrofurochroman by one-pot reaction.
Obesity
Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TC-PTP via modification interacting with C site.
Obesity
Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity.
Obesity
Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.
Obesity
Distribution of the number of false discoveries in large-scale family-based association testing with application to the association between PTPN1 and hypertension and obesity.
Obesity
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Obesity
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
Obesity
Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
Obesity
Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice.
Obesity
Effects of adenovirus-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo.
Obesity
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models.
Obesity
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
Obesity
Exercise training decreases mitogen-activated protein kinase phosphatase-3 expression and suppresses hepatic gluconeogenesis in obese mice.
Obesity
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Obesity
Flavonoids as potent allosteric inhibitors of protein tyrosine phosphatase 1B: molecular dynamics simulation and free energy calculation.
Obesity
Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency.
Obesity
Functional properties of Claramine: A novel PTP1B inhibitor and insulin-mimetic compound.
Obesity
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
Obesity
Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Obesity
Genomic characterization of the human and mouse protein tyrosine phosphatase-1B genes.
Obesity
Harnessing insulin- and leptin-induced oxidation of PTP1B for therapeutic development.
Obesity
Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis.
Obesity
Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2.
Obesity
Hepatocyte-specific Ptpn6 deletion promotes hepatic lipid accretion, but reduces NAFLD in diet-induced obesity: Potential role of PPAR?
Obesity
HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms.
Obesity
High-fat diet alters PP2A, TC10, and CIP4 expression in visceral adipose tissue of rats.
Obesity
High-throughput methods in identification of protein tyrosine phosphatase inhibitors and activators.
Obesity
Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation.
Obesity
Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFbeta/Smad2 signaling.
Obesity
Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps.
Obesity
Identification of novel PTPRQ phosphatase inhibitors based on the virtual screening with docking simulations.
Obesity
Improved metabolic phenotype of hypothalamic PTP1B-deficiency is dependent upon the leptin receptor.
Obesity
Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue.
Obesity
In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
Obesity
In silico modeling of protein tyrosine phosphatase 1B inhibitors with cellular activity.
Obesity
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Obesity
Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects.
Obesity
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene.
Obesity
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.
Obesity
Indole- and Pyrazole-Glycyrrhetinic Acid Derivatives as PTP1B Inhibitors: Synthesis, In Vitro and In Silico Studies.
Obesity
Inducible Knockdown of Endothelial Protein Tyrosine Phosphatase-1B Promotes Neointima Formation in Obese Mice by Enhancing Endothelial Senescence.
Obesity
Inhibition of protein tyrosine phosphatase (PTP1B) and ?-glucosidase by geranylated flavonoids from Paulownia tomentosa.
Obesity
Inhibition of protein tyrosine phosphatase 1B (PTP1B) and ?-glucosidase by xanthones from Cratoxylum cochinchinense, and their kinetic characterization.
Obesity
Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity.
Obesity
Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum.
Obesity
Inhibition of protein tyrosine phosphatase 1B by lupeol and lupenone isolated from Sorbus commixta.
Obesity
Inhibition of Protein Tyrosine Phosphatase 1B by Prenylated Isoflavonoids Isolated from the Stem Bark of Erythrina addisoniae1.
Obesity
Inhibition of Protein Tyrosine Phosphatase 1B by Ursane-Type Triterpenes Isolated from Symplocos paniculata.
Obesity
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
Obesity
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Obesity
Inhibition of PTP1B disrupts cell-cell adhesion and induces anoikis in breast epithelial cells.
Obesity
Inhibition of Src homology 2 domain containing protein tyrosine phosphatase as the possible mechanism of metformin-assisted amelioration of obesity induced insulin resistance in high fat diet fed C57BL/6J mice.
Obesity
Inhibition of Src homology 2 domain-containing phosphatase 1 increases insulin sensitivity in high-fat diet-induced insulin-resistant mice.
Obesity
Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus.
Obesity
Inter-Tissue Gene Co-Expression Networks between Metabolically Healthy and Unhealthy Obese Individuals.
Obesity
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Obesity
Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity.
Obesity
Investigating mammalian tyrosine phosphatase inhibitors as potential 'piggyback' leads to target Trypanosoma brucei transmission.
Obesity
Investigating the impact of Asp181 point mutations on interactions between PTP1B and phosphotyrosine substrate.
Obesity
Investigation of selective binding of inhibitors to PTP1B and TCPTP by accelerated molecular dynamics simulations.
Obesity
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Obesity
Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer.
Obesity
Knocking down amygdalar PTP1B in diet-induced obese rats improves insulin signaling/action, decreases adiposity and may alter anxiety behavior.
Obesity
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.
Obesity
Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver.
Obesity
Leptin Signaling in the Arcuate Nucleus Reduces Insulin's Capacity to Suppress Hepatic Glucose Production in Obese Mice.
Obesity
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
Obesity
Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A Special Emphasis on PTP1B Inhibitors.
Obesity
Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms.
Obesity
Magnolia officinalis Extract Contains Potent Inhibitors against PTP1B and Attenuates Hyperglycemia in db/db Mice.
Obesity
Mammalian life-span determinant p66shcA mediates obesity-induced insulin resistance.
Obesity
MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice.
Obesity
Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus.
Obesity
Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models.
Obesity
Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling.
Obesity
Methylenedisalicylic acid derivatives: new PTP1B inhibitors that confer resistance to diet-induced obesity.
Obesity
Mice lacking DUSP6/8 have enhanced ERK1/2 activity and resistance to diet-induced obesity.
Obesity
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Obesity
MKP-5 Relieves Lipotoxicity-Induced Islet ?-Cell Dysfunction and Apoptosis via Regulation of Autophagy.
Obesity
Modulation of Obesity and Insulin Resistance by the Redox Enzyme and Adaptor Protein p66Shc.
Obesity
Molecular analysis of Aedes aegypti classical protein tyrosine phosphatases uncovers an ortholog of mammalian PTP-1B implicated in the control of egg production in mosquitoes.
Obesity
Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B.
Obesity
Molecular docking and virtual screening for novel protein tyrosine phosphatase 1B (PTP1B) inhibitors.
Obesity
Molecular Dynamics Approach to Probe the Allosteric Inhibition of PTP1B by Chlorogenic and Cichoric Acid.
Obesity
Molecular dynamics simulation of the interaction between protein tyrosine phosphatase 1B and aryl diketoacid derivatives.
Obesity
Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling.
Obesity
Molecular Dynamics Simulations of A27S and K120A Mutated PTP1B Reveals Selective Binding of the Bidentate Inhibitor.
Obesity
MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress.
Obesity
Multiple machine learning based descriptive and predictive workflow for the identification of potential PTP1B inhibitors.
Obesity
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
Obesity
New prenylated flavanones from Erythrina abyssinica with Protein tyrosine phosphatase 1B (PTP1B) inhibitory activity.
Obesity
No Association of PTPN1 Polymorphisms With Macronutrient Intake and Measures of Adiposity.
Obesity
Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.
Obesity
Novel chromenedione derivatives displaying inhibition of protein tyrosine phosphatase 1B (PTP1B) from Flemingia philippinensis.
Obesity
Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Obesity
Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Obesity
Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methanesulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic.
Obesity
Obesity Increases Mitogen-Activated Protein Kinase Phosphatase-3 Levels in the Hypothalamus of Mice.
Obesity
Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica.
Obesity
Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
Obesity
Optimization of extraction parameters of PTP1? (protein tyrosine phosphatase 1?), inhibitory polyphenols, and anthocyanins from Zea mays L. using response surface methodology (RSM).
Obesity
Osteoarthritis Is a Low-Grade Inflammatory Disease: Obesity's Involvement and Herbal Treatment.
Obesity
Overexpression of Mitogen-activated protein kinase phosphatase-3 (MKP-3) reduces FoxO1 phosphorylation in mice hypothalamus.
Obesity
Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C.
Obesity
p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans.
Obesity
Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice.
Obesity
Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus.
Obesity
Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis.
Obesity
Possible modulation of FAS and PTP-1B signaling in ameliorative potential of Bombax ceiba against high fat diet induced obesity.
Obesity
Protein tyrosine phosphatase 1B (PTP1B) inhibitory constituents from the aerial parts of Tradescantia spathacea Sw.
Obesity
Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases.
Obesity
Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Obesity
Protein tyrosine phosphatase 1B gene polymorphisms and essential hypertension: a case-control study in Chinese population.
Obesity
Protein tyrosine phosphatase 1B inhibitors for the treatment of type 2 diabetes and obesity: recent advances.
Obesity
Protein tyrosine phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus.
Obesity
Protein tyrosine phosphatase 1B inhibitory activity of amentoflavone and its cellular effect on tyrosine phosphorylation of insulin receptors.
Obesity
Protein tyrosine phosphatase 1B inhibitory activity of Indonesian herbal medicines and constituents of Cinnamomum burmannii and Zingiber aromaticum.
Obesity
Protein tyrosine phosphatase 1B inhibitory by dammaranes from Vietnamese Giao-Co-Lam tea.
Obesity
Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.
Obesity
Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNF? action in obesity.
Obesity
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Obesity
Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.
Obesity
Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line.
Obesity
Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis.
Obesity
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation.
Obesity
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Obesity
Protein tyrosine phosphatase 1B, a major regulator of leptin-mediated control of cardiovascular function.
Obesity
Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities.
Obesity
Protein tyrosine phosphatase alpha inhibits hypothalamic leptin receptor signaling and regulates body weight in vivo.
Obesity
Protein Tyrosine Phosphatase, Receptor Type B (PTPRB) Inhibits Brown Adipocyte Differentiation through Regulation of VEGFR2 Phosphorylation.
Obesity
Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii.
Obesity
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
Obesity
Protein tyrosine phosphatases: the quest for negative regulators of insulin action.
Obesity
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
Obesity
Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Obesity
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
Obesity
PTP1B inhibitory activity of kaurane diterpenes isolated from Siegesbeckia glabrescens.
Obesity
PTP1B inhibitory effects of tridepside and related metabolites isolated from the Antarctic lichen Umbilicaria antarctica.
Obesity
PTP1B Inhibitory Secondary Metabolites from Marine-Derived Fungal Strains Penicillium spp. and Eurotium sp.
Obesity
PTPIP51 interaction with PTP1B and 14-3-3? in adipose tissue of insulin-resistant mice.
Obesity
PTPRJ Inhibits Leptin Signaling, and Induction of PTPRJ in the Hypothalamus Is a Cause of the Development of Leptin Resistance.
Obesity
PTPRS and PER3 methylation levels are associated with childhood obesity: results from a genome-wide methylation analysis.
Obesity
Pyrrolo[1,2-a]quinoxal-5-inium salts and 4,5-dihydropyrrolo[1,2-a]quinoxalines: Synthesis, activity and computational docking for protein tyrosine phosphatase 1B.
Obesity
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media.
Obesity
Rational Design, Synthesis and Biological Evaluation of Modular Fluorogenic Substrates with High Affinity and Selectivity for PTP1B.
Obesity
Recent Advances in Protein Tyrosine Phosphatase 1B Targeted Drug Discovery for Type II Diabetes and Obesity.
Obesity
Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer.
Obesity
Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B.
Obesity
Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats.
Obesity
Regulation of the insulin antagonistic protein tyrosine phosphatase 1B by dietary Se studied in growing rats.
Obesity
Regulation of the SNARE-interacting protein Munc18c tyrosine phosphorylation in adipocytes by protein-tyrosine phosphatase 1B.
Obesity
Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation.
Obesity
Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy.
Obesity
Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance.
Obesity
Role of Receptor Protein Tyrosine Phosphatases (RPTPs) in Insulin Signaling and Secretion.
Obesity
Rosiglitazone attenuates tumor necrosis factor-?-induced protein tyrosine phosphatase-1B production in HepG2 cells.
Obesity
Sarcophytrols G - L, Novel Minor Metabolic Components from South China Sea Soft Coral Sarcophyton trocheliophorum Marenzeller.
Obesity
Selective binding modes and allosteric inhibitory effects of lupane triterpenes on protein tyrosine phosphatase 1B.
Obesity
Selective inhibition of PTP1B by Vitalboside A from Syzygium cumini enhances insulin sensitivity and attenuates lipid accumulation via partial agonism to PPAR?: In Vitro and In Silico investigation.
Obesity
Sesquiterpenoids with PTP1B Inhibitory Activity and Cytotoxicity from the Edible Mushroom Pleurotus citrinopileatus.
Obesity
Short-term Cudrania tricuspidata fruit vinegar administration attenuates obesity in high-fat diet-fed mice by improving fat accumulation and metabolic parameters.
Obesity
SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations.
Obesity
Shp2 suppresses the adipogenic differentiation of preadipocyte 3T3-L1 cells at an early stage.
Obesity
Single nucleotide polymorphisms in protein tyrosine phosphatase 1beta (PTPN1) are associated with essential hypertension and obesity.
Obesity
Single nucleotide polymorphisms of protein tyrosine phosphatase 1B gene are associated with obesity in morbidly obese French subjects.
Obesity
Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance.
Obesity
Spirobiflavonoid stereoisomers from the endangered conifer Glyptostrobus pensilis and their protein tyrosine phosphatase 1B inhibitory activity.
Obesity
Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites.
Obesity
Structural and stereochemical studies of five new pregnane steroids from the stem bark of Toona ciliata var. pubescens.
Obesity
Structural Basis of Fullerene Derivatives as Novel Potent Inhibitors of Protein Tyrosine Phosphatase 1B: Insight into the Inhibitory Mechanism through Molecular Modeling Studies.
Obesity
Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B.
Obesity
Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta.
Obesity
Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.
Obesity
Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors.
Obesity
Structure-functional implications of longevity protein p66Shc in health and disease.
Obesity
Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein.
Obesity
Sustained High Protein-tyrosine Phosphatase 1B Activity in the Sperm of Obese Males Impairs the Sperm Acrosome Reaction.
Obesity
Synthesis and biological evaluation of 4,4-dimethyl lithocholic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B.
Obesity
Synthesis and Biological Evaluation of Oleanolic Acid Derivatives As Inhibitors of Protein Tyrosine Phosphatase 1B.
Obesity
Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors.
Obesity
Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.
Obesity
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
Obesity
The LIM domain only 4 protein is a metabolic responsive inhibitor of protein tyrosine phosphatase 1B that controls hypothalamic leptin signaling.
Obesity
The low molecular weight protein tyrosine phosphatase promotes adipogenesis and subcutaneous adipocyte hypertrophy.
Obesity
The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
Obesity
Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice.
Obesity
Toward a treatment of diabesity: Rational design, synthesis and biological evaluation of benzene-sulfonamide derivatives as a new class of PTP-1B inhibitors.
Obesity
Unraveling the allosteric inhibition mechanism of PTP1B by free energy calculation based on umbrella sampling.
Obesity
Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake.
Obesity
Varic acid analogues from fungus as PTP1B inhibitors: Biological evaluation and structure-activity relationships.
Obesity
Ventromedial hypothalamus-specific Ptpn1 deletion exacerbates diet-induced obesity in female mice.
Obesity
Virtual Screening of Novel and Selective Inhibitors of Protein Tyrosine Phosphatase 1B over T-Cell Protein Tyrosine Phosphatase Using a Bidentate Inhibition Strategy.
Obesity
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B.
Obesity
[Does inhibition of tyrosine phosphatase 1B protect from obesity and type 2 diabetes?]
Obesity
[Search for Protein Tyrosine Phosphatase 1B Inhibitors from Marine Organisms and Induced Production of New Fungal Metabolites by Modulating Culture Methods].
Obesity, Maternal
Dynamic changes in p66Shc mRNA expression in peripheral blood mononuclear cells following resistance training intervention in old frail women born to obese mothers: a pilot study.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Odontogenic Cysts
Odontogenic keratocysts: a clinical and histological study with special reference to enzyme histochemistry.
Oligodendroglioma
Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes.
Oligodendroglioma
Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma.
Onchocerciasis
Histochemical differentiation of filarial larvae found in Simulium damnosum s.l. in West Africa.
Oncogene Addiction
Critical relevance of genomic gains of PRL-3/EGFR/c-myc pathway genes in liver metastasis of colorectal cancer.
Opisthorchiasis
Protein tyrosine phosphatase, opisthorchiasis and dengue: A proteomics interrelationship.
Opisthorchiasis
Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection.
Optic Nerve Injuries
Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity.
Oral Submucous Fibrosis
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Osteitis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Osteoarthritis
Abnormal PTPN11 enhancer methylation promotes rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and joint inflammation.
Osteoarthritis
Deletion of Dual Specificity Phosphatase 1 Does Not Predispose Mice to Increased Spontaneous Osteoarthritis.
Osteoarthritis
Dual specificity phosphatase 1 has a protective role in osteoarthritis fibroblast?like synoviocytes via inhibition of the MAPK signaling pathway.
Osteoarthritis
Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis.
Osteoarthritis
Localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity in synovium from patients with inflammatory or degenerative arthritis.
Osteoarthritis
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Osteoarthritis
p66shc siRNA Nanoparticles Ameliorate Chondrocytic Mitochondrial Dysfunction in Osteoarthritis.
Osteoarthritis
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Osteoarthritis
PTPN14 phosphatase and YAP promote TGF? signalling in rheumatoid synoviocytes.
Osteoarthritis
Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase Promotes Inflammation and Accelerates Osteoarthritis by Activating ?-Catenin.
Osteoarthritis
Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal.
Osteoarthritis
The differentiation of prehypertrophic into hypertrophic chondrocytes drives an OA-remodeling program and IL-34 expression.
Osteochondroma
A rare association of pathological variant of Alport's syndrome caused by hemizygous 5' splice mutation in intron 10 of COL4A5 gene with metachondromatosis due to heterozygous missense variation in protein tyrosine phosphatase nonreceptor type 11 gene.
Osteochondroma
From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis.
Osteochondroma
Intraosseous atypical chondroid tumor or chondrosarcoma grade 1 in patients with multiple osteochondromas.
Osteogenesis Imperfecta
Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.
Osteolysis
Dual Specificity Phosphatase 1 null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis.
Osteolysis
Inhibition of protein phosphatase 2A attenuates titanium-particle induced suppression of bone formation.
Osteolysis
Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Osteomyelitis
The receptor-type protein tyrosine phosphatase CD45 promotes onset and severity of IL-1?-mediated autoinflammatory osteomyelitis.
Osteoporosis
Effects of garlic oil on postmenopausal osteoporosis using ovariectomized rats: comparison with the effects of lovastatin and 17beta-estradiol.
Osteoporosis
Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate.
Osteoporosis
Identification of N-(5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as novel protein tyrosine phosphatase epsilon inhibitors exhibiting anti-osteoclastic activity.
Osteoporosis
M1 macrophage-derived exosomes aggravate bone loss in postmenopausal osteoporosis via a microRNA-98/DUSP1/JNK axis.
Osteoporosis
Mitogen-activated protein kinase phosphatase-1: function and regulation in bone and related tissues.
Osteoporosis
Prevention of bone loss by oil extract of garlic (Allium sativum Linn.) in an ovariectomized rat model of osteoporosis.
Osteoporosis
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Osteosarcoma
Circular RNA circCCDC66 Contributes to Malignant Phenotype of Osteosarcoma by Sponging miR-338-3p to Upregulate the Expression of PTP1B.
Osteosarcoma
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Osteosarcoma
Effect of the traditional Chinese medicine Qi Teng Xiao Zhuo granules on chronic glomerulonephritis rats studied by using long noncoding RNAs expression profiling.
Osteosarcoma
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Osteosarcoma
High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.
Osteosarcoma
Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Osteosarcoma
Interrogating PP1 Activity in the MAPK Pathway with Optimized PP1-Disrupting Peptides.
Osteosarcoma
Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration and invasion by regulating microRNA-21.
Osteosarcoma
MicroRNA-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion by targeting DUSP1 in osteosarcoma.
Osteosarcoma
miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.
Osteosarcoma
MiRNA-98-5p inhibits the progression of osteosarcoma by regulating cell cycle via targeting CDC25A expression.
Osteosarcoma
Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.
Osteosarcoma
Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases.
Osteosarcoma
Protein phosphatase 2A C? regulates proliferation, migration, and metastasis of osteosarcoma cells.
Osteosarcoma
PTPN14, a target gene of miR-4295, restricts the growth and invasion of osteosarcoma cells through inactivation of YAP1 signaling.
Osteosarcoma
Retraction of: DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Osteosarcoma
Significance of "high" acid phosphatase activity in the serum of normal children.
Osteosarcoma
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Osteosarcoma
The phosphatase PTPRG controls FGFR1 activity and influences sensitivity to FGFR kinase inhibitors.
Osteosarcoma
The Protein Tyrosine Phosphatase Rptp? Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.
Osteosarcoma
Triptolide induces mitochondrial apoptosis through modulating dual specificity phosphatase 1/mitogen-activated protein kinases cascade in osteosarcoma cells.
Osteosarcoma
Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.
Otitis Media
Bone resorption in chronic otitis media. A light-microscopical and histochemical investigation of acid phosphatase activity.
Otitis Media
Curcumin Inhibits NTHi-Induced MUC5AC Mucin Overproduction in Otitis Media via Upregulation of MAPK Phosphatase MKP-1.
Otitis Media
Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.
Ovarian Neoplasms
Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells.
Ovarian Neoplasms
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Ovarian Neoplasms
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Ovarian Neoplasms
Antiproliferative Signaling of Luteinizing Hormone-Releasing Hormone in Human Endometrial and Ovarian Cancer Cells through G Protein? I-Mediated Activation of Phosphotyrosine Phosphatase.
Ovarian Neoplasms
Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.
Ovarian Neoplasms
ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer.
Ovarian Neoplasms
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
Ovarian Neoplasms
Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer.
Ovarian Neoplasms
CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.
Ovarian Neoplasms
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.
Ovarian Neoplasms
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
Ovarian Neoplasms
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis.
Ovarian Neoplasms
DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells.
Ovarian Neoplasms
Dysregulation of the TGF-beta postreceptor signaling pathway in cell lines derived from primary or metastatic ovarian cancer.
Ovarian Neoplasms
ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Ovarian Neoplasms
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.
Ovarian Neoplasms
Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.
Ovarian Neoplasms
Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells.
Ovarian Neoplasms
Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.
Ovarian Neoplasms
Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
Ovarian Neoplasms
Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Ovarian Neoplasms
Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells.
Ovarian Neoplasms
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
Ovarian Neoplasms
MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12.
Ovarian Neoplasms
Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Ovarian Neoplasms
Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.
Ovarian Neoplasms
Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas.
Ovarian Neoplasms
p21-Activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Ovarian Neoplasms
p66Shc longevity protein regulates the proliferation of human ovarian cancer cells.
Ovarian Neoplasms
PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells.
Ovarian Neoplasms
Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer.
Ovarian Neoplasms
Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
Ovarian Neoplasms
Protein tyrosine phosphatase inhibition induces anti-tumor activity: Evidence of Cdk2/p27(kip1) and Cdk2/SHP-1 complex formation in human ovarian cancer cells.
Ovarian Neoplasms
Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer.
Ovarian Neoplasms
Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating ?-catenin.
Ovarian Neoplasms
Protein-tyrosine Phosphatase 1B Antagonized Signaling by Insulin-like Growth Factor-1 Receptor and Kinase BRK/PTK6 in Ovarian Cancer Cells.
Ovarian Neoplasms
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Ovarian Neoplasms
PTN signaling: Components and mechanistic insights in human ovarian cancer.
Ovarian Neoplasms
PTP1B promotes the malignancy of ovarian cancer cells in a JNK-dependent mechanism.
Ovarian Neoplasms
PTPN12 controls PTEN and the AKT signalling to FAK and HER2 in migrating ovarian cancer cells.
Ovarian Neoplasms
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Ovarian Neoplasms
PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations.
Ovarian Neoplasms
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A.
Ovarian Neoplasms
Screening and prognostic value of potential biomarkers for ovarian cancer.
Ovarian Neoplasms
Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER.
Ovarian Neoplasms
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Ovarian Neoplasms
The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.
Ovarian Neoplasms
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Ovarian Neoplasms
Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression.
Ovarian Neoplasms
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Ovarian Neoplasms
Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK.
Ovarian Neoplasms
[Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3]
Overnutrition
Early overnutrition impairs insulin signaling in the heart of adult Swiss mice.
Overnutrition
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Pancreatic Neoplasms
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Pancreatic Neoplasms
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.
Pancreatic Neoplasms
An ITIM-like motif within the CCK2 receptor sequence required for interaction with SHP-2 and the activation of the AKT pathway.
Pancreatic Neoplasms
Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A.
Pancreatic Neoplasms
Blockade of dual-specificity phosphatase 28 decreases chemo-resistance and migration in human pancreatic cancer cells.
Pancreatic Neoplasms
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Pancreatic Neoplasms
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Pancreatic Neoplasms
DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
Pancreatic Neoplasms
Effects of cerulein on keratin 8 phosphorylation and perinuclear reorganization in pancreatic cancer cells: Involvement of downregulation of protein phosphatase 2A and alpha4.
Pancreatic Neoplasms
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
Pancreatic Neoplasms
Expression of TMEFF2 in Human Pancreatic Cancer Tissue and the Effects of TMEFF2 Knockdown on Cell, Proliferation, and Apoptosis in Human Pancreatic Cell Lines.
Pancreatic Neoplasms
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis.
Pancreatic Neoplasms
Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
Pancreatic Neoplasms
Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.
Pancreatic Neoplasms
Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture.
Pancreatic Neoplasms
Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
Pancreatic Neoplasms
Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells.
Pancreatic Neoplasms
Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair.
Pancreatic Neoplasms
Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1?-VEGF mediated angiogenesis.
Pancreatic Neoplasms
Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway.
Pancreatic Neoplasms
Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1.
Pancreatic Neoplasms
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
Pancreatic Neoplasms
miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-?B Signaling Pathways.
Pancreatic Neoplasms
Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers.
Pancreatic Neoplasms
Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.
Pancreatic Neoplasms
Phorbol ester reduces phosphorylation of epidermal growth factor receptor in pancreatic cancer cells by activation of a tyrosine phosphatase.
Pancreatic Neoplasms
PR55? subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling.
Pancreatic Neoplasms
PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.
Pancreatic Neoplasms
Receptor-type protein tyrosine phosphatase gamma (PTPgamma), a new identifier for myeloid dendritic cells and specialized macrophages.
Pancreatic Neoplasms
Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Pancreatic Neoplasms
Regulation of the src homology 2 domain-containing protein tyrosine phosphatase PTP1C by glucocorticoids in rat pancreatic AR42J cells.
Pancreatic Neoplasms
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Pancreatic Neoplasms
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
Pancreatic Neoplasms
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Pancreatic Neoplasms
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer.
Pancreatic Neoplasms
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Pancreatic Neoplasms
The use of protein phosphatase 2A activators in combination therapies for pancreas cancer.
Pancreatic Neoplasms
[Construction and primary application of oligonucleotide microarray specialized for pancreatic adenocarcinoma-associated genes]
Pancreatic Neoplasms
[Down regulation of mitogen activated protein kinase phosphatase-1 mediate acquired multidrug resistance in pancreatic adenocarcinoma cell line SW1990/Fu]
Pancreatic Neoplasms
[Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth].
Pancreatitis
Acid phosphatase activity in different organs as a marker of acute pancreatitis.
Pancreatitis
Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats.
Pancreatitis
Modulation in the expression of SHP-1, SHP-2 and PTP1B due to the inhibition of MAPKs, cAMP and neutrophils early on in the development of cerulein-induced acute pancreatitis in rats.
Pancreatitis
Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice.
Pancreatitis
Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis.
Pancreatitis
PAR2 exerts local protection against acute pancreatitis via modulation of MAP kinase and MAP kinase phosphatase signaling.
Pancreatitis
Rolipram and SP600125 Suppress the Early Increase in PTP1B Expression During Cerulein-Induced Pancreatitis in Rats.
Pancreatitis, Chronic
Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.
Papilloma
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Papilloma
G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv.
Papilloma
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Papilloma
The p53-p66Shc apoptotic pathway is dispensable for tumor suppression whereas the p66Shc-generated oxidative stress initiates tumorigenesis.
Papillomavirus Infections
EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Papillomavirus Infections
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Papillomavirus Infections
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
Paralysis
Impaired embryonic motility in dusp27 mutants reveals a developmental defect in myofibril structure.
Paralysis
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
Paralysis
Morphological and functional effects of altered cysteine string protein at the Drosophila larval neuromuscular junction.
Paralysis
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Paralysis
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Paralysis
The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells.
Paraneoplastic Cerebellar Degeneration
Gene expression profile following stable expression of the cellular prion protein.
Paraparesis, Spastic
Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.
Paraproteinemias
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Paraproteinemias
[Cytological study of acid phosphatase activity of plasma cells in monoclonal gammopathies]
Paraproteinemias
[Plasma cell acid phosphatase in the differential diagnosis of monoclonal gammopathies]
Parasitemia
Direct exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increases infectivity of human erythrocytes to a malarial parasite.
Parasitic Diseases
Expression on human eosinophils of CD148: a membrane tyrosine phosphatase. Implications in the effector function of eosinophils.
Paratuberculosis
Immunoreactivity of protein tyrosine phosphatase A (PtpA) in sera from sheep infected with Mycobacterium avium subspecies paratuberculosis.
Paratuberculosis
Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection.
Paratuberculosis
Relationship of acid phosphatase activity to ultrastructural features in mice inoculated with Mycobacterium paratuberculosis.
Parkinson Disease
Autophagy inhibition rescues structural and functional defects caused by the loss of mitochondrial chaperone Hsc70-5 in Drosophila.
Parkinson Disease
Blocking receptor protein tyrosine phosphatase beta/zeta: a potential therapeutic strategy for Parkinson's disease.
Parkinson Disease
Connecting Parkinson's Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches.
Parkinson Disease
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Parkinson Disease
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Parkinson Disease
Phosphorylation of ?-synuclein is crucial in compensating for proteasomal dysfunction.
Parkinson Disease
Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
Parkinson Disease
Protein tyrosine phosphatase inhibition reduces degeneration of dopaminergic substantia nigra neurons and projections in 6-OHDA treated adult rats.
Parkinson Disease
Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus.
Parkinson Disease
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Parkinson Disease
Role of Receptor Protein Tyrosine Phosphatase ?/? in Neuron-Microglia Communication in a Cellular Model of Parkinson's Disease.
Parkinson Disease
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Parkinson Disease
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Parkinson Disease
The Molecular Mechanism of Alpha-Synuclein Dependent Regulation of Protein Phosphatase 2A Activity.
Parkinson Disease
Therapeutic Role of Protein Tyrosine Phosphatase 1B in Parkinson's Disease via Antineuroinflammation and Neuroprotection In Vitro and In Vivo.
Parkinsonian Disorders
Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations.
Pediatric Obesity
Effect of PTP1B inhibitors and taurine on blood lipid profiles in adolescent obesity.
Pediatric Obesity
Genome-wide copy number variation analysis identifies novel candidate loci associated with pediatric obesity.
Pediatric Obesity
PTPRS and PER3 methylation levels are associated with childhood obesity: results from a genome-wide methylation analysis.
Pediatric Obesity
The association of genetically controlled CpG methylation (cg158269415) of protein tyrosine phosphatase, receptor type N2 (PTPRN2) with childhood obesity.
Pemphigus
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Pemphigus
Region 1p13.2 including the RSBN1, PTPN22, AP4B1 and long non-coding RNA genes does not bear risk factors for endemic pemphigus foliaceus (fogo selvagem).
Pericarditis
A polymorphism upstream MIR1279 gene is associated with pericarditis development in Systemic Lupus Erythematosus and contributes to definition of a genetic risk profile for this complication.
Periodontal Diseases
Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss.
Periodontal Diseases
Functionalized nanoparticles containing MKP-1 agonists reduce periodontal bone loss.
Periodontal Diseases
[Alkaline and acid phosphatase activity in human saliva in parodontosis]
Periodontitis
Comparison of Experimental Diabetic Periodontitis Induced by Porphyromonas gingivalis in Mice.
Periodontitis
Effect of environmental tobacco smoke on COX-2 and SHP-2 expression in a periodontitis rat model.
Periodontitis
Porphyromonas gingivalis Tyrosine Phosphatase Php1 Promotes Community Development and Pathogenicity.
Periodontitis
Tyrosine-protein phosphatase non-receptor type 2 inhibits alveolar bone resorption in diabetic periodontitis via dephosphorylating CSF1 receptor.
Periodontitis
Ultrastructural localization of acid phosphatase activity in plasma cells containing Russell's bodies in periodontitis.
Periodontitis
[Affect of protein tyrosine phosphatase non-receptor type 2 and nuclear factor-kappaB on periodontal destruction with diabetes].
Peripheral Arterial Disease
Dual specificity phosphatase 5 regulates perfusion recovery in experimental peripheral artery disease.
Peripheral Arterial Disease
Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease.
Peripheral Nerve Injuries
Mitogen activated protein kinase phosphatase-1 prevents the development of tactile sensitivity in a rodent model of neuropathic pain.
Peripheral Vascular Diseases
Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Peritonitis
Non-Lyn Src Family Kinases Activate SIRP?-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization.
Peritonitis
TBK1 and IKK? act like an OFF switch to limit NLRP3 inflammasome pathway activation.
Persistent Infection
B Cell-Intrinsic SHP1 Expression Promotes the Gammaherpesvirus-Driven Germinal Center Response and the Establishment of Chronic Infection.
Persistent Infection
CDC25B is associated with the risk of hepatocellular carcinoma, but not related to persistent infection of hepatitis B virus in a Chinese population.
Persistent Infection
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Peutz-Jeghers Syndrome
Gene for the human transmembrane-type protein tyrosine phosphatase H (PTPRH): genomic structure, fine-mapping and its exclusion as a candidate for Peutz-Jeghers syndrome.
Pheochromocytoma
Enhancement or induction of neurite formation by a protein tyrosine phosphatase inhibitor, 3,4-dephostatin, in growth factor-treated PC12h cells.
Pheochromocytoma
Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma.
Pheochromocytoma
Loss of heterozygosity on the short arm of chromosome 1 in pheochromocytoma and abdominal paraganglioma.
Pheochromocytoma
Overexpression of striatal enriched phosphatase (STEP) promotes the neurite outgrowth induced by a cAMP analogue in PC12 cells.
Pheochromocytoma
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Pheochromocytoma
Rapid deactivation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP-1.
Pheochromocytoma
The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase.
Pheochromocytoma
The tyrosine phosphatase Shp-2 mediates intracellular signaling initiated by Ret mutants.
Pheochromocytoma
Vanadate stimulates differentiation and neurite outgrowth in rat pheochromocytoma PC12 cells and neurite extension in human neuroblastoma SH-SY5Y cells.
Pinealoma
Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
Pinealoma
Papillary Tumor of the Pineal Region in Children: Presentation of a Case and Comprehensive Literature Review.
Pinealoma
Recurrent pineocytoma-like papillary tumor of the pineal region - a case report and literature review.
Pituitary Neoplasms
Computational analysis identifies invasion-associated genes in pituitary adenomas.
Pituitary Neoplasms
Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
Placental Insufficiency
Dual specificity phosphatase 9 (DUSP9) expression is down-regulated in the severe pre-eclamptic placenta.
Plague
Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate.
Plague
High-resolution structure of the Yersinia pestis protein tyrosine phosphatase YopH in complex with a phosphotyrosyl mimetic-containing hexapeptide.
Plague
Investigations of linker structure on the potency of a series of bidentate protein tyrosine phosphatase inhibitors.
Plague
Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH.
Plague
Yersinia pestis and Approaches to Targeting its Outer Protein H Protein-Tyrosine Phosphatase (YopH).
Pleural Effusion
Prenatal DNA diagnosis of Noonan syndrome in a fetus with massive hygroma colli, pleural effusion and ascites.
Pneumonia
Manganese-dependent protein O-phosphatases in prokaryotes and their biological functions.
Pneumonia
Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury.
Pneumonia
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
Pneumonia
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Pneumonia
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors.
Pneumonia
[Characteristics of the diagnosis and treatment of secondary pneumonia in acute leukemia]
Pneumonia
[Features of the diagnosis and treatment of paracancerous pneumonia in bronchogenic pulmonary carcinoma]
Pneumonia
[Immunological indices and the acid phosphatase activity of the blood serum in patients with suppurative and destructive complications of acute pneumonia during the treatment/process]
Pneumoperitoneum
Influence of CO2 pneumoperitoneum on intracellular pH and signal transduction in cancer cells.
Polycystic Kidney Diseases
Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease.
Polycystic Kidney Diseases
MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
Polycystic Kidney Diseases
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Polycystic Kidney, Autosomal Dominant
PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3.
Polycythemia
Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly.
Polycythemia
The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera.
Polycythemia Vera
Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells.
Polycythemia Vera
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells.
Polyendocrinopathies, Autoimmune
PTPN22 and CTLA-4 Polymorphisms are Associated with Polyglandular Autoimmunity.
Polyhydramnios
Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.
Polymyalgia Rheumatica
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Polymyositis
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.
Polyneuropathies
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Prader-Willi Syndrome
Malignant fibrous histiocytoma-pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study.
Pre-Eclampsia
Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia.
Pre-Eclampsia
Evaluation of MicroRNA-210 and Protein tyrosine phosphatase, non-receptor type 2 in Pre-eclampsia.
Pre-Eclampsia
MiRNA-548c-5p downregulates inflammatory response in preeclampsia via targeting PTPRO.
Pre-Eclampsia
Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia Developing in a Patient With Noonan Syndrome Harboring a PTPN11 Germline Mutation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical and molecular epidemiology of neonatal leukemia in brazil.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA methylation of membrane bound tyrosine phosphatase genes in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of mutations in FLT3, PTPN11, and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and p38 Activation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Morphologic and ultrastructural characteristics of T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin lymphoma and T-cell non-Hodgkin lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTPN21-CDSlong isoform inhibits the response of acute lymphoblastic leukemia cells to NK-mediated lysis via the KIR/HLA-I axis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The leukocyte common antigen (CD45) on human pre-B leukemia cells: variant glycoprotein form expression during the cell exposure to phorbol ester is blocked by a nonselective protein kinase inhibitor H7.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Acute lymphoblastic leukemia with a mature B-lymphocyte phenotype and preferential centrosomal acid phosphatase activity]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Differential diagnostic value of acid phosphatase and beta-glucuronidase in acute leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Efficient and repetitive production of hematopoietic and endothelial cells from feeder-free monolayer culture system of primate embryonic stem cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Suppression of protein tyrosine phosphatase PTPN22 gene induces apoptosis in T-cell leukemia cell line (Jurkat) through the AKT and ERK pathways.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
Prediabetic State
An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies.
Prediabetic State
HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes.
Prediabetic State
HLA-DR4-associated T and B cell responses to specific determinants on the IA-2 autoantigen in type 1 diabetes.
Prediabetic State
Human SHC-transforming protein 1 and its isoforms p66shc: A novel marker for prediabetes.
Prediabetic State
Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.
Prediabetic State
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Premature Birth
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Premature Birth
Functional variation of SHP-2 promoter is associated with preterm birth and delayed myelination and motor development in preterm infants.
Premature Birth
Genome-wide association study identifies a novel maternal gene?×?stress interaction associated with spontaneous preterm birth.
Primary Immunodeficiency Diseases
Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22).
Primary Myelofibrosis
Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.
Primary Myelofibrosis
CDC25c expression in patients with myelofibrosis is associated with stronger myeloproliferation and shorter overall survival.
Prion Diseases
Reduced expression of the presynaptic co-chaperone cysteine string protein alpha (CSP?) does not exacerbate experimentally-induced ME7 prion disease.
Proctitis
Association of PTPN22 gene (rs2488457) polymorphism with ulcerative colitis and high levels of PTPN22 mRNA in ulcerative colitis.
Progeria
P66SHC deletion improves fertility and progeric phenotype of late-generation TERC-deficient mice but not their short lifespan.
Prostatic Diseases
[Immunological colorimetric determination of serum prostatic acid phosphatase activity in patients with prostatic diseases comparing with RIA and Kind-King modified methods]
Prostatic Hyperplasia
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Prostatic Intraepithelial Neoplasia
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Prostatic Neoplasms
Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis.
Prostatic Neoplasms
Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.
Prostatic Neoplasms
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
Prostatic Neoplasms
Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.
Prostatic Neoplasms
Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation.
Prostatic Neoplasms
Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
Prostatic Neoplasms
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1.
Prostatic Neoplasms
Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Prostatic Neoplasms
Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.
Prostatic Neoplasms
Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.
Prostatic Neoplasms
Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture.
Prostatic Neoplasms
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.
Prostatic Neoplasms
Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells.
Prostatic Neoplasms
Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells.
Prostatic Neoplasms
Checkpoint kinase 1 regulates diallyl trisulfide-induced mitotic arrest in human prostate cancer cells.
Prostatic Neoplasms
Cross Talk between Wnt/?-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Prostatic Neoplasms
Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells.
Prostatic Neoplasms
Determination of serum acid phosphatase in Gaucher's disease using 4-methylumbelliferyl phosphate.
Prostatic Neoplasms
Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis.
Prostatic Neoplasms
Diallyl Trisulfide-Induced G2/M Phase Cell Cycle Arrest in DU145 Cells Is Associated with Delayed Nuclear Translocation of Cyclin-Dependent Kinase 1.
Prostatic Neoplasms
Diallyl trisulfide-induced prostate cancer cell death is associated with Akt/PKB dephosphorylation mediated by P-p66shc.
Prostatic Neoplasms
Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2.
Prostatic Neoplasms
Down-regulation of CK2 activity results in a decrease in the level of cdc25C phosphatase in different prostate cancer cell lines.
Prostatic Neoplasms
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells.
Prostatic Neoplasms
Downregulation of Snail by DUSP1 Impairs Cell Migration and Invasion through the Inactivation of JNK and ERK and Is Useful as a Predictive Factor in the Prognosis of Prostate Cancer.
Prostatic Neoplasms
Dual specificity phosphatase 1 expression inversely correlates with NF-?B activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Prostatic Neoplasms
Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells.
Prostatic Neoplasms
Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer.
Prostatic Neoplasms
ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
Prostatic Neoplasms
ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion.
Prostatic Neoplasms
Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.
Prostatic Neoplasms
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Prostatic Neoplasms
G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).
Prostatic Neoplasms
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.
Prostatic Neoplasms
High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Prostatic Neoplasms
Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis.
Prostatic Neoplasms
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
Prostatic Neoplasms
Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods
Prostatic Neoplasms
Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Prostatic Neoplasms
Immunoreactive prostatic acid phosphatase in prostatic cancer: diagnosis and followup of patients.
Prostatic Neoplasms
Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway.
Prostatic Neoplasms
Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer.
Prostatic Neoplasms
Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells via Mitogen-Activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D.
Prostatic Neoplasms
Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer.
Prostatic Neoplasms
Integrative analysis of N-linked human glycoproteomic data sets reveals PTPRF ectodomain as a novel plasma biomarker candidate for prostate cancer.
Prostatic Neoplasms
Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells.
Prostatic Neoplasms
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.
Prostatic Neoplasms
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Prostatic Neoplasms
Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery.
Prostatic Neoplasms
Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Prostatic Neoplasms
Loss of receptor protein tyrosine phosphatase ?/? (RPTP?/?) promotes prostate cancer metastasis.
Prostatic Neoplasms
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
Prostatic Neoplasms
Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer.
Prostatic Neoplasms
Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
Prostatic Neoplasms
Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Prostatic Neoplasms
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Prostatic Neoplasms
miRNA-627 inhibits cell proliferation and cell migration, promotes cell apoptosis in prostate cancer cells through upregulating MAP3K1, PTPRK and SRA1.
Prostatic Neoplasms
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.
Prostatic Neoplasms
Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.
Prostatic Neoplasms
Modulation of protein phosphatase 2A (PP2A) activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Prostatic Neoplasms
Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
Prostatic Neoplasms
Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.
Prostatic Neoplasms
Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta.
Prostatic Neoplasms
Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.
Prostatic Neoplasms
p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells.
Prostatic Neoplasms
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Prostatic Neoplasms
p66Shc regulates migration of castration-resistant prostate cancer cells.
Prostatic Neoplasms
p66Shc--a longevity redox protein in human prostate cancer progression and metastasis : p66Shc in cancer progression and metastasis.
Prostatic Neoplasms
Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Prostatic Neoplasms
Physapubescin B Exhibits Potent Activity against Human Prostate Cancer In Vitro and In Vivo.
Prostatic Neoplasms
Potential biomarkers screening to predict side effects of dexamethasone in different cancers.
Prostatic Neoplasms
Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naïve Prostate Cancer.
Prostatic Neoplasms
Procyanidin B2 3,3?-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.
Prostatic Neoplasms
Prostate cancer cell proliferation is suppressed by microRNA-3160-5p via targeting of F-box and WD repeat domain containing 8.
Prostatic Neoplasms
Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase.
Prostatic Neoplasms
Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.
Prostatic Neoplasms
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
Prostatic Neoplasms
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
Prostatic Neoplasms
PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer.
Prostatic Neoplasms
PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.
Prostatic Neoplasms
PTPL1 and PKC? contribute to proapoptotic signalling in prostate cancer cells.
Prostatic Neoplasms
PTPN14 acts as a candidate tumor suppressor in prostate cancer and inhibits cell proliferation and invasion through modulating LATS1/YAP signaling.
Prostatic Neoplasms
Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.
Prostatic Neoplasms
Reactive-oxygen-species-mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate, and molybdate in the PC-3 human prostate cancer cell line.
Prostatic Neoplasms
Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells.
Prostatic Neoplasms
Receptor-like protein tyrosine phosphatase ? negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.
Prostatic Neoplasms
Resveratrol promotes apoptosis through the induction of dual specificity phosphatase 1 and sensitizes prostate cancer cells to cisplatin.
Prostatic Neoplasms
Role of Reactive Oxygen Species in the Cytotoxicity of Arsenic Trioxide and Pamidronate for Human Prostate Cancer Cells.
Prostatic Neoplasms
Role of the protein tyrosine phosphatase SHP-1 in Interleukin-6 regulation of prostate cancer cells.
Prostatic Neoplasms
shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells.
Prostatic Neoplasms
Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
Prostatic Neoplasms
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression.
Prostatic Neoplasms
Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Prostatic Neoplasms
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Prostatic Neoplasms
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Prostatic Neoplasms
The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
Prostatic Neoplasms
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
Prostatic Neoplasms
Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site.
Prostatic Neoplasms
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Prostatic Neoplasms
Unpredictable fluctuations in serum acid phosphatase activity in prostatic cancer.
Prostatic Neoplasms
[Enzymological study of prostatic cancer. II. Serum lactic dehydrogenase, alkaline phosphatase, leucine aminopeptidase, total acid phosphatase, prostatic acid phosphatase activity and lactic dehydrogenase isoenzymes in prostatic cancer, with special reference to relation with stage and histological malignancy]
Prostatic Neoplasms
[ERK1/2 and p38 kinases are important regulators in P2Y receptor-mediated prostate cancer invasion]
Prostatitis
Protein profiling of isolated leukocytes, myofibroblasts, epithelial, Basal, and endothelial cells from normal, hyperplastic, cancerous, and inflammatory human prostate tissues.
protein-long-chain fatty-acyl-lysine deacylase (nad+) deficiency
Sirtuin 6 is a negative regulator of Fc?RI signaling and anaphylactic responses.
Protein-Losing Enteropathies
A PTPN11 mutation in a woman with Noonan syndrome and protein-losing enteropathy.
Protein-Losing Enteropathies
Somatic PTPN11 Mutation in a Child With Neuroblastoma and Protein Losing Enteropathy.
protein-serine/threonine phosphatase deficiency
pmp1+, a suppressor of calcineurin deficiency, encodes a novel MAP kinase phosphatase in fission yeast.
protein-tyrosine-phosphatase deficiency
A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
protein-tyrosine-phosphatase deficiency
A critical role for protein tyrosine phosphatase nonreceptor type 5 in determining individual susceptibility to develop stress-related cognitive and morphological changes.
protein-tyrosine-phosphatase deficiency
A key role for PTP1B in dendritic cell maturation, migration, and T cell activation.
protein-tyrosine-phosphatase deficiency
A new form of inherited thrombocytopenia caused by loss-of-function mutations in PTPRJ.
protein-tyrosine-phosphatase deficiency
Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice.
protein-tyrosine-phosphatase deficiency
Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli.
protein-tyrosine-phosphatase deficiency
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
protein-tyrosine-phosphatase deficiency
CD5-mediated inhibition of TCR signaling proceeds normally in the absence of SHP-1.
protein-tyrosine-phosphatase deficiency
CDC25B promotes influenza A virus replication by regulating the phosphorylation of nucleoprotein.
protein-tyrosine-phosphatase deficiency
CDRH3 length is the target of selection of disease-associated IgM autoantibodies.
protein-tyrosine-phosphatase deficiency
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
protein-tyrosine-phosphatase deficiency
circ-PRKCB acts as a ceRNA to regulate p66Shc-mediated oxidative stress in intestinal ischemia/reperfusion.
protein-tyrosine-phosphatase deficiency
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.
protein-tyrosine-phosphatase deficiency
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
protein-tyrosine-phosphatase deficiency
Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells.
protein-tyrosine-phosphatase deficiency
Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice.
protein-tyrosine-phosphatase deficiency
Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing.
protein-tyrosine-phosphatase deficiency
Deficiency of PTP1B in Leptin Receptor-Expressing Neurons Leads to Decreased Body Weight and Adiposity in Mice.
protein-tyrosine-phosphatase deficiency
Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.
protein-tyrosine-phosphatase deficiency
Developmental switch from prolonged insulin action to increased insulin sensitivity in protein tyrosine phosphatase 1B-deficient hepatocytes.
protein-tyrosine-phosphatase deficiency
Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase.
protein-tyrosine-phosphatase deficiency
Disruption of protein-tyrosine phosphatase 1B expression in the pancreas affects ?-cell function.
protein-tyrosine-phosphatase deficiency
Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.
protein-tyrosine-phosphatase deficiency
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.
protein-tyrosine-phosphatase deficiency
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
protein-tyrosine-phosphatase deficiency
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
protein-tyrosine-phosphatase deficiency
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.
protein-tyrosine-phosphatase deficiency
Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging.
protein-tyrosine-phosphatase deficiency
Essential role of protein-tyrosine phosphatase 1B in the modulation of insulin signaling by acetaminophen in hepatocytes.
protein-tyrosine-phosphatase deficiency
Expression and clinical relations of protein tyrosine phosphatase receptor type S in esophageal squamous cell carcinoma.
protein-tyrosine-phosphatase deficiency
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
protein-tyrosine-phosphatase deficiency
Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency.
protein-tyrosine-phosphatase deficiency
Hepatic protein-tyrosine phosphatase 1B disruption and pharmacological inhibition attenuate ethanol-induced oxidative stress and ameliorate alcoholic liver disease in mice.
protein-tyrosine-phosphatase deficiency
Hepatic PTP1B Deficiency: The Promise of a Treatment for Metabolic Syndrome?
protein-tyrosine-phosphatase deficiency
Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.
protein-tyrosine-phosphatase deficiency
In control at the ER: PTP1B and the down-regulation of RTKs by dephosphorylation and endocytosis.
protein-tyrosine-phosphatase deficiency
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
protein-tyrosine-phosphatase deficiency
Increased negative selection impairs neonatal B cell repertoire but does not directly lead to generation of disease-associated IgM auto-antibodies.
protein-tyrosine-phosphatase deficiency
Inducible liver-specific knockdown of protein tyrosine phosphatase 1B improves glucose and lipid homeostasis in adult mice.
protein-tyrosine-phosphatase deficiency
Inhibiting PTPN12-Regulated RTKs May Be Therapeutic in TNBC.
protein-tyrosine-phosphatase deficiency
IRS2-deficient mice show sensorineural hearing loss that is delayed by concomitant PTP1B loss of function.
protein-tyrosine-phosphatase deficiency
Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice.
protein-tyrosine-phosphatase deficiency
Knockout of MAPK Phosphatase-1 Exaggerates Type I IFN Response during Systemic Escherichia coli Infection.
protein-tyrosine-phosphatase deficiency
Levels of protein tyrosine phosphatase 1B determine susceptibility to apoptosis in serum-deprived hepatocytes.
protein-tyrosine-phosphatase deficiency
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice.
protein-tyrosine-phosphatase deficiency
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition.
protein-tyrosine-phosphatase deficiency
Loss of SHP-2 activity in CD4(+) T cells promotes melanoma progression and metastasis.
protein-tyrosine-phosphatase deficiency
Loss of the Protein Tyrosine Phosphatase PTPN22 Reduces Mannan-Induced Autoimmune Arthritis in SKG Mice.
protein-tyrosine-phosphatase deficiency
Macrophage fusion is controlled by the cytoplasmic protein tyrosine phosphatase PTP-PEST/PTPN12.
protein-tyrosine-phosphatase deficiency
Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.
protein-tyrosine-phosphatase deficiency
MAP kinase phosphatase 1 is necessary for T cell activation and function.
protein-tyrosine-phosphatase deficiency
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
protein-tyrosine-phosphatase deficiency
MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy.
protein-tyrosine-phosphatase deficiency
MAP kinase phosphatase-1, a gatekeeper of the acute innate immune response.
protein-tyrosine-phosphatase deficiency
MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.
protein-tyrosine-phosphatase deficiency
Mitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels.
protein-tyrosine-phosphatase deficiency
MKP-1 Modulates Mitochondrial Transcription Factors, Oxidative Phosphorylation, and Glycolysis.
protein-tyrosine-phosphatase deficiency
Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease.
protein-tyrosine-phosphatase deficiency
Monocytic MKP-1 is a Sensor of the Metabolic Environment and Regulates Function and Phenotypic Fate of Monocyte-Derived Macrophages in Atherosclerosis.
protein-tyrosine-phosphatase deficiency
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.
protein-tyrosine-phosphatase deficiency
Myeloid-cell protein tyrosine phosphatase-1B deficiency in mice protects against high-fat diet and lipopolysaccharide-induced inflammation, hyperinsulinemia, and endotoxemia through an IL-10 STAT3-dependent mechanism.
protein-tyrosine-phosphatase deficiency
Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells.
protein-tyrosine-phosphatase deficiency
Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues.
protein-tyrosine-phosphatase deficiency
Neuronal PTP1B regulates body weight, adiposity and leptin action.
protein-tyrosine-phosphatase deficiency
NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22.
protein-tyrosine-phosphatase deficiency
Norathyriol reverses obesity- and high-fat-diet-induced insulin resistance in mice through inhibition of PTP1B.
protein-tyrosine-phosphatase deficiency
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
protein-tyrosine-phosphatase deficiency
p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells.
protein-tyrosine-phosphatase deficiency
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from ?-arrestin at early endosomes.
protein-tyrosine-phosphatase deficiency
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
protein-tyrosine-phosphatase deficiency
p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.
protein-tyrosine-phosphatase deficiency
P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
protein-tyrosine-phosphatase deficiency
Pancreatic Protein Tyrosine Phosphatase 1B Deficiency Exacerbates Acute Pancreatitis in Mice.
protein-tyrosine-phosphatase deficiency
Pancreatic T cell protein-tyrosine phosphatase deficiency affects beta cell function in mice.
protein-tyrosine-phosphatase deficiency
Pancreatic T cell protein-tyrosine phosphatase deficiency ameliorates cerulein-induced acute pancreatitis.
protein-tyrosine-phosphatase deficiency
Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase 1B (PTP1B) Deficiency Accelerates Hepatic Regeneration in Mice.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B (PTP1B) is dispensable for IgE-mediated cutaneous reaction in vivo.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B deficiency potentiates PERK/eIF2? signaling in brown adipocytes.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase 1B Inhibitors from the Stems of Akebia quinata.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B is involved in efficient type I interferon secretion upon viral infection.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B modulates GSK3?/Nrf2 and IGFIR signaling pathways in acetaminophen-induced hepatotoxicity.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase N2 Is a Positive Regulator of Lipopolysaccharide Signaling in Raw264.7 Cell through Derepression of Src Tyrosine Kinase.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase receptor type R deficient mice exhibit increased exploration in a new environment and impaired novel object recognition memory.
protein-tyrosine-phosphatase deficiency
Protein tyrosine phosphatase SHP-1 positively regulates TLR-induced IL-12p40 production in macrophages through inhibition of phosphatidylinositol 3-kinase.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
protein-tyrosine-phosphatase deficiency
Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-? (TGF-?)-induced suppressor effects in hepatocytes.
protein-tyrosine-phosphatase deficiency
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling.
protein-tyrosine-phosphatase deficiency
Protein-tyrosine phosphatase 1B deficiency protects against Fas-induced hepatic failure.
protein-tyrosine-phosphatase deficiency
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance.
protein-tyrosine-phosphatase deficiency
Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
protein-tyrosine-phosphatase deficiency
PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia.
protein-tyrosine-phosphatase deficiency
PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers.
protein-tyrosine-phosphatase deficiency
PTP1B deficiency enhances liver growth during suckling by increasing the expression of insulin-like growth factor-I.
protein-tyrosine-phosphatase deficiency
PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo.
protein-tyrosine-phosphatase deficiency
PTP1B deficiency improves hypothalamic insulin sensitivity resulting in the attenuation of AgRP mRNA expression under high-fat diet conditions.
protein-tyrosine-phosphatase deficiency
PTP1B deficiency increases glucose uptake in neonatal hepatocytes: involvement of IRA/GLUT2 complexes.
protein-tyrosine-phosphatase deficiency
PTP1B negatively regulates nitric oxide-mediated Pseudomonas aeruginosa killing by neutrophils.
protein-tyrosine-phosphatase deficiency
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages.
protein-tyrosine-phosphatase deficiency
PTPBR7 Binding Proteins in Myelinating Neurons of the Mouse Brain.
protein-tyrosine-phosphatase deficiency
PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy.
protein-tyrosine-phosphatase deficiency
PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.
protein-tyrosine-phosphatase deficiency
PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
protein-tyrosine-phosphatase deficiency
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
protein-tyrosine-phosphatase deficiency
PTPN22 alters the development of regulatory T cells in the thymus.
protein-tyrosine-phosphatase deficiency
PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells.
protein-tyrosine-phosphatase deficiency
PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.
protein-tyrosine-phosphatase deficiency
PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
protein-tyrosine-phosphatase deficiency
PTPRR Protein Tyrosine Phosphatase Isoforms and Locomotion of Vesicles and Mice.
protein-tyrosine-phosphatase deficiency
Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment.
protein-tyrosine-phosphatase deficiency
Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B.
protein-tyrosine-phosphatase deficiency
Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways.
protein-tyrosine-phosphatase deficiency
Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B.
protein-tyrosine-phosphatase deficiency
Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC.
protein-tyrosine-phosphatase deficiency
Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL.
protein-tyrosine-phosphatase deficiency
Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development.
protein-tyrosine-phosphatase deficiency
Restricted CDR3 length of the heavy chain is characteristic of six randomly isolated disease-associated VH J558+ IgM autoantibodies in lupus prone motheaten mice.
protein-tyrosine-phosphatase deficiency
Role of protein tyrosine phosphatases in regulating the immune system: implications for chronic intestinal inflammation.
protein-tyrosine-phosphatase deficiency
Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance.
protein-tyrosine-phosphatase deficiency
Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling.
protein-tyrosine-phosphatase deficiency
Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure.
protein-tyrosine-phosphatase deficiency
Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency.
protein-tyrosine-phosphatase deficiency
SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.
protein-tyrosine-phosphatase deficiency
SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased lyn kinase activity.
protein-tyrosine-phosphatase deficiency
SHP-1 deficient mast cells are hyperresponsive to stimulation and critical in initiating allergic inflammation in the lung.
protein-tyrosine-phosphatase deficiency
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
protein-tyrosine-phosphatase deficiency
Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells.
protein-tyrosine-phosphatase deficiency
Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt.
protein-tyrosine-phosphatase deficiency
SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production.
protein-tyrosine-phosphatase deficiency
Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase.
protein-tyrosine-phosphatase deficiency
Survival and inflammation promotion effect of PTPRO in fulminant hepatitis is associated with NF-?B activation.
protein-tyrosine-phosphatase deficiency
T cell developmental defects in 'viable motheaten' mice deficient in SHP-1 protein-tyrosine phosphatase. Developmental defects are corrected in vitro in the presence of normal hematopoietic-origin stromal cells and in vivo by exogenous IL-7.
protein-tyrosine-phosphatase deficiency
T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.
protein-tyrosine-phosphatase deficiency
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
protein-tyrosine-phosphatase deficiency
T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
protein-tyrosine-phosphatase deficiency
TCPTP Regulates Insulin Signaling in AgRP Neurons to Coordinate Glucose Metabolism With Feeding.
protein-tyrosine-phosphatase deficiency
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
protein-tyrosine-phosphatase deficiency
The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism.
protein-tyrosine-phosphatase deficiency
The autoimmune susceptibility gene, PTPN2, restricts expansion of a novel mouse adherent-invasive E. coli.
protein-tyrosine-phosphatase deficiency
The effect of the autoimmunity-associated gene, PTPN22, on a BXSB-derived model of lupus.
protein-tyrosine-phosphatase deficiency
The expression of interleukin-12 is increased by MAP kinase phosphatase-1 through a mechanism related to interferon regulatory factor 1.
protein-tyrosine-phosphatase deficiency
The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency.
protein-tyrosine-phosphatase deficiency
The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases.
protein-tyrosine-phosphatase deficiency
The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II.
protein-tyrosine-phosphatase deficiency
The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity.
protein-tyrosine-phosphatase deficiency
The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity.
protein-tyrosine-phosphatase deficiency
The protein tyrosine phosphatase SHP-1 regulates integrin-mediated adhesion of macrophages.
protein-tyrosine-phosphatase deficiency
The role of the Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and signaling.
protein-tyrosine-phosphatase deficiency
The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system.
protein-tyrosine-phosphatase deficiency
Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis.
protein-tyrosine-phosphatase deficiency
Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Proteinuria
Antibodies to Protein Tyrosine Phosphatase Receptor Type O (PTPro) increase Glomerular Albumin Permeability (Palb).
Proteinuria
Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B.
Proteinuria
Curcumin protects against fructose-induced podocyte insulin signaling impairment through upregulation of miR-206.
Proteinuria
Early changes in gene expression that influence the course of primary glomerular disease.
Proteinuria
Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis.
Proteinuria
Protein tyrosine phosphatase 1B inhibition protects against podocyte injury and proteinuria.
Proteinuria
Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria.
Proteinuria
PTPN2 improved renal injury and fibrosis by suppressing STAT-induced inflammation in early diabetic nephropathy.
Proteinuria
Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy.
Pseudomonas Infections
Pharmacological modulation of mitochondrial calcium uniporter controls lung inflammation in cystic fibrosis.
Pseudomonas Infections
Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection.
Psoriasis
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene.
Psoriasis
Associations between PTPN2 gene polymorphisms and psoriasis in Northeastern China.
Psoriasis
Different epigenome regulation and transcriptome expression of CD4+ and CD8+ T cells from monozygotic twins discordant for psoriasis.
Psoriasis
Evaluation of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) Functional Polymorphisms in Psoriasis Susceptibility in Egypt.
Psoriasis
Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients.
Psoriasis
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22.
Psoriasis
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Psoriasis
Genome-wide Study Identifies Association between HLA-B?55:01 and Self-Reported Penicillin Allergy.
Psoriasis
Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes.
Psoriasis
Integration of expression quantitative trait loci and pleiotropy identifies a novel psoriasis susceptibility gene, PTPN1.
Psoriasis
Levels of miR-31 and its target genes in dermal mesenchymal cells of patients with psoriasis.
Psoriasis
LITAF, HHEX, and DUSP1 expression in mesenchymal stem cells from patients with psoriasis.
Psoriasis
MAPK Phosphatase-1 Deficiency Exacerbates the Severity of Imiquimod-Induced Psoriasiform Skin Disease.
Psoriasis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Psoriasis
Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis.
Psoriasis
Protein tyrosine kinase and protein phosphotyrosine phosphatase in normal and psoriatic skin.
Psoriasis
Protein tyrosine phosphatase gene PTPN22 polymorphism in psoriasis: lack of evidence for association.
Psoriasis
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
Psoriasis
SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis.
Psoriasis
The protein tyrosine phosphatase, non-receptor type 22 R620W polymorphism does not confer susceptibility to psoriasis in the genetic homogeneous population of Crete.
Psoriasis
The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.
Psoriasis
Unraveling the genetics of complex diseases: Susceptibility genes for rheumatoid arthritis and psoriasis.
Puberty, Delayed
Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
Pulmonary Arterial Hypertension
Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.
Pulmonary Arterial Hypertension
The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
?1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.
Pulmonary Disease, Chronic Obstructive
Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
Pulmonary Disease, Chronic Obstructive
Curcumin ameliorates alveolar epithelial injury in a rat model of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Identification of hub genes and functional modules in colon adenocarcinoma based on public databases by bioinformatics analysis.
Pulmonary Disease, Chronic Obstructive
p66Shc Mediates Mitochondrial Dysfunction Dependent on PKC Activation in Airway Epithelial Cells Induced by Cigarette Smoke.
Pulmonary Disease, Chronic Obstructive
Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.
Pulmonary Disease, Chronic Obstructive
Protein tyrosine phosphatase 1B negatively regulates S100A9-mediated lung damage during respiratory syncytial virus exacerbations.
Pulmonary Disease, Chronic Obstructive
RBC membrane damage and decreased band 3 phospho-tyrosine phosphatase activity are markers of COPD progression.
Pulmonary Disease, Chronic Obstructive
Role of mitogen-activated protein kinase phosphatase-1 in corticosteroid insensitivity of chronic oxidant lung injury.
Pulmonary Disease, Chronic Obstructive
Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation.
Pulmonary Disease, Chronic Obstructive
The GPx1-PTP1B-PP2A Axis: A Key Determinant of Airway Inflammation and Alveolar Destruction.
Pulmonary Disease, Chronic Obstructive
TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis.
Pulmonary Disease, Chronic Obstructive
Urban PM2.5 induces ROS generation and RBC damage in COPD patients.
Pulmonary Edema
Protection Against LPS-Induced Pulmonary Edema Through the Attenuation of PTP1B Oxidation.
Pulmonary Fibrosis
Blocking protein phosphatase 2A with a peptide protects mice against bleomycin-induced pulmonary fibrosis.
Pulmonary Fibrosis
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Pulmonary Fibrosis
How Do We Know What We Are Missing? Loss of Signaling through CD148 Drives Fibroblast Activation in Pulmonary Fibrosis.
Pulmonary Fibrosis
Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis.
Pulmonary Fibrosis
Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis.
Pulmonary Fibrosis
Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
Pulmonary Fibrosis
Syndecan-2 Attenuates Radiation-induced Pulmonary Fibrosis and Inhibits Fibroblast Activation by Regulating PI3K/Akt/ROCK Pathway via CD148.
Pulmonary Valve Stenosis
Bleeding diathesis in Noonan syndrome: Is acquired von Willebrand syndrome the clue?
Pulmonary Valve Stenosis
Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
Pulmonary Valve Stenosis
Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.
Pulmonary Valve Stenosis
Clinical and molecular characterization of 40 patients with Noonan syndrome.
Pulmonary Valve Stenosis
Elevated calcium transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan Syndrome with Multiple Lentigines.
Pulmonary Valve Stenosis
Genotype-phenotype correlation analysis in Japanese patients with Noonan syndrome.
Pulmonary Valve Stenosis
LEOPARD Syndrome with PTPN11 Gene Mutation Showing Six Cardinal Symptoms of LEOPARD.
Pulmonary Valve Stenosis
LEOPARD Syndrome Without Hearing Loss or Pulmonary Stenosis: A Report of 2 Cases.
Pulmonary Valve Stenosis
Leopard syndrome: the potential cardiac defect underlying skin phenotypes.
Pulmonary Valve Stenosis
Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.
Pulmonary Valve Stenosis
PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Pulmonary Valve Stenosis
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
Pulmonary Valve Stenosis
PTPN11 mutations play a minor role in isolated congenital heart disease.
Pulmonary Valve Stenosis
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Pulmonary Valve Stenosis
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Pulmonary Valve Stenosis
The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome.
Pulmonary Valve Stenosis
[Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation]
Purpura
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Purpura
Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schönlein purpura (IgA vasculitis).
Purpura, Thrombocytopenic, Idiopathic
Increased representation of the PTPN22 mutation in patients with immune thrombocytopenia.
Purpura, Thrombocytopenic, Idiopathic
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Purpura, Thrombocytopenic, Idiopathic
No impact of PTPN22, PTPRJ and ACP1 genes polymorphisms on the risk of immune thrombocytopenia in French adult patients.
Purpura, Thrombocytopenic, Idiopathic
PTPN22 -1123G?>?C polymorphism is associated with susceptibility to primary immune thrombocytopenia in Chinese population.
Purpura, Thrombocytopenic, Idiopathic
PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children.
Purpura, Thrombocytopenic, Idiopathic
The role of PTPN22 gene polymorphism in childhood immune thrombocytopenic purpura.
Pyloric Stenosis
Mosaic partial deletion of PTPN12 in a child with interrupted aortic arch type A.
Pyoderma Gangrenosum
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
Pyoderma Gangrenosum
The systemic autoinflammatory diseases: inborn errors of the innate immune system.
receptor protein-tyrosine kinase deficiency
PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
Rectal Neoplasms
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy.
Rectal Neoplasms
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer.
Rectal Neoplasms
Protein expression following gamma-irradiation relevant to growth arrest and apoptosis in colon cancer cells.
Rectal Neoplasms
Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Reperfusion Injury
Amyloid beta-peptide worsens cognitive impairment following cerebral ischemia-reperfusion injury.
Reperfusion Injury
Anti-apoptotic cardioprotective effects of SHP-1 gene silencing against ischemia-reperfusion injury: Use of deoxycholic acid-modified low molecular weight polyethyleneimine as a cardiac siRNA-carrier.
Reperfusion Injury
Lack of Contribution of p66shc and Its Mitochondrial Translocation to Ischemia-Reperfusion Injury and Cardioprotection by Ischemic Preconditioning.
Reperfusion Injury
Lentivirus-Mediated Silencing of Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 2 Inhibits Release of Inflammatory Cytokines and Apoptosis in Renal Tubular Epithelial Cells Via Inhibition of the TLR4/NF-kB Pathway in Renal Ischemia-Reperfusion Injury.
Reperfusion Injury
microRNA-135a protects against myocardial ischemia-reperfusion injury in rats by targeting protein tyrosine phosphatase 1B.
Reperfusion Injury
Modulating the p66shc signaling pathway with protocatechuic acid protects the intestine from ischemia-reperfusion injury and alleviates secondary liver damage.
Reperfusion Injury
New aspects of p66Shc in ischemia reperfusion injury and cardiovascular diseases.
Reperfusion Injury
PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-?B.
Reperfusion Injury
SHP-1 inhibits renal ischemia reperfusion injury via dephosphorylating ASK1 and suppressing apoptosis.
Reperfusion Injury
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.
Reperfusion Injury
The Potential Role of Protein Tyrosine Phosphatase, Receptor Type C (CD45) in the Intestinal Ischemia-Reperfusion Injury.
Restless Legs Syndrome
Case-Control and Family-Based Association Study of Specific PTPRD Variants in Restless Legs Syndrome.
Restless Legs Syndrome
Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome.
Restless Legs Syndrome
Mouse model for PTPRD associations with WED/RLS and addiction: reduced expression alters locomotion, sleep behaviors and cocaine-conditioned place preference.
Restless Legs Syndrome
PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome.
Restless Legs Syndrome
PTPRD as a candidate druggable target for therapies for restless legs syndrome?
Restless Legs Syndrome
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes.
Retinal Degeneration
Deficiency of SHP-1 Protein-Tyrosine Phosphatase in "Viable Motheaten" Mice Results in Retinal Degeneration.
Retinal Degeneration
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Retinal Detachment
Protein tyrosine phosphatase 1B regulates the activity of retinal pigment epithelial cells.
Retinal Dystrophies
Expression of the protein tyrosine phosphatase, phosphatase of regenerating liver 1, in the outer segments of primate cone photoreceptors.
Retinal Perforations
Phagocytic and digestive activities of retinal pigment epithelium at experimentally produced retinal tears.
Retinitis Pigmentosa
Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients.
Retinitis Pigmentosa
PTPN11 mutation in a young man with Noonan syndrome and retinitis pigmentosa.
Retinitis Pigmentosa
Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina.
Retinoblastoma
A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo.
Retinoblastoma
A Conserved Amino Acid in the C Terminus of Human Papillomavirus E7 Mediates Binding to PTPN14 and Repression of Epithelial Differentiation.
Retinoblastoma
Bovine papillomavirus E2 protein activates a complex growth-inhibitory program in p53-negative HT-3 cervical carcinoma cells that includes repression of cyclin A and cdc25A phosphatase genes and accumulation of hypophosphorylated retinoblastoma protein.
Retinoblastoma
Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.
Retinoblastoma
Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7.
Retinoblastoma
Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.
Retinoblastoma
Development of a Novel Nonradioisotopic Assay and Cdc25B Overexpression Cell Lines for Use in Screening for Cdc25B Inhibitors.
Retinoblastoma
Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
Retinoblastoma
Expression of CDC25A and CDC25B phosphatase proteins in human retinoblastoma and its correlation with clinicopathological parameters.
Retinoblastoma
Further characterization of BC3H1 myogenic cells reveals lack of p53 activity and underexpression of several p53 regulated and extracellular matrix-associated gene products.
Retinoblastoma
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Retinoblastoma
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Retinoblastoma
Identification of candidate growth-regulating genes that are overexpressed in late gestation fetal liver in the rat.
Retinoblastoma
Induction of G?/M Arrest by Berberine via Activation of PI3K/Akt and p38 in Human Chondrosarcoma Cell Line.
Retinoblastoma
Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery.
Retinoblastoma
mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25.
Retinoblastoma
MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.
Retinoblastoma
Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation.
Retinoblastoma
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Retinoblastoma
PTPN14 degradation by high-risk human papillomavirus E7 limits keratinocyte differentiation and contributes to HPV-mediated oncogenesis.
Retinoblastoma
Serum-induced expression of the cdc25A gene by relief of E2F-mediated repression.
Retinoblastoma
The B55? regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.
Retinoblastoma
The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis.
Retinoblastoma
The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.
Retinoblastoma
Trichodermin Induces G0/G1 Cell Cycle Arrest by Inhibiting c-Myc in Ovarian Cancer Cells and Tumor Xenograft-Bearing Mice.
Rhabdomyosarcoma
Acid phosphatase response in murine rhabdomyosarcoma for various tumour volumes and after different doses of neutron irradiation, alone or combined with exogenous ATP.
Rhabdomyosarcoma
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.
Rhabdomyosarcoma
Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.
Rhabdomyosarcoma
Cloning and expression of PTP-PEST. A novel, human, nontransmembrane protein tyrosine phosphatase.
Rhabdomyosarcoma
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Rheumatic Diseases
Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK.
Rheumatic Diseases
Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes.
Rheumatic Diseases
The PTPN22 R620W polymorphism is not associated with systemic rheumatic diseases in South Africans.
Rheumatic Diseases
[Acid phosphatase activity and the autoimmune processes in rheumatism and rheumatoid arthritis]
Rheumatic Fever
[Beta-glucuronidase and acid phosphatase activity in children with rheumatic fever]
Rheumatic Heart Disease
Influence of protein tyrosine phosphatase gene (PTPN22) polymorphisms on rheumatic heart disease susceptibility in North Indian population.
Rheumatic Heart Disease
No association of PTPN22 R620 W gene polymorphism with rheumatic heart disease and systemic lupus erythematosus.
Rhinitis, Allergic
Associations of single nucleotide polymorphisms of PTPN22 and Ctla4 genes with the risk of allergic rhinitis in a Chinese Han population.
Rhinitis, Allergic
Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis.
Rhinitis, Allergic
Regulation of nasal airway homeostasis and inflammation in mice by SHP-1 and Th2/Th1 signaling pathways.
Riboflavin Deficiency
Effect of riboflavin or pyridoxine deficiency on inflammatory response.
RNA Virus Infections
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Rubella
Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients.
Rubella
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
Salmonella Infections
Role of tyrosine kinases and the tyrosine phosphatase SptP in the interaction of Salmonella with host cells.
Sarcoidosis
Dysregulation of p38 and MKP-1 in Response to NOD1/TLR4 Stimulation in Sarcoid Bronchoalveolar Cells.
Sarcoidosis
Search for sarcoidosis candidate genes by integration of data from genomic, transcriptomic and proteomic studies.
Sarcoidosis
[Cytochemical study of macrophages in sarcoidosis patients in skin window exudates]
Sarcoma
A homozygous deletion within the carbonic anhydrase-like domain of the Ptprg gene in murine L-cells.
Sarcoma
Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity.
Sarcoma
Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease.
Sarcoma
High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues.
Sarcoma
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/?-catenin target gene, CDC25A.
Sarcoma
Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues.
Sarcoma
Impact of Wnt/?-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas.
Sarcoma
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.
Sarcoma
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Sarcoma
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Sarcoma
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Sarcoma
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
Sarcoma
SHP2 protects endothelial cell barrier through suppressing VE-cadherin internalization regulated by MET-ARF1.
Sarcoma
Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.
Sarcoma
[Phosphotyrosine]protein phosphatase in rat brain. A major [phosphotyrosine]protein phosphatase is a 23 kDa protein distinct from acid phosphatase.
Sarcoma, Alveolar Soft Part
Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma.
Sarcoma, Avian
FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells.
Sarcoma, Avian
Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes.
Sarcoma, Avian
TPCK and quercetin act synergistically with vanadate to increase protein-tyrosine phosphorylation in avian cells.
Sarcoma, Avian
[Effect of Rous sarcoma virus on the acid phosphatase activity in cells sensitive and naturally resistant to the virus]
Sarcoma, Ewing
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Sarcoma, Ewing
PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.
Sarcoma, Ewing
PTPRD copy number variants and Ewing's sarcoma: Strengthening the association and therapeutic implications.
Sarcoma, Ewing
Valosin containing protein (VCP/p97) is a novel substrate for the protein tyrosine phosphatase PTPL1.
Sarcoma, Synovial
SS18-SSX fusion protein-induced Wnt/?-catenin signaling is a therapeutic target in synovial sarcoma.
Sarcopenia
Activated protein phosphatase 2A disrupts nutrient sensing balance between mTORC1 and AMPK causing sarcopenia in alcoholic liver disease.
Sarcopenia
MAP kinase phosphatase-1--a new player at the nexus between sarcopenia and metabolic disease.
Scleritis
Identification of susceptibility SNPs in CTLA-4 and PTPN22 for scleritis in Han Chinese.
Scleroderma, Systemic
Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis.
Scleroderma, Systemic
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Scleroderma, Systemic
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.
Scleroderma, Systemic
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis.
Scleroderma, Systemic
Enhanced frequency of a PTPRC (CD45) exon A mutation (77C-->G) in systemic sclerosis.
Scleroderma, Systemic
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Scleroderma, Systemic
Lack of association of the PTPN22 gene polymorphism R620W with systemic sclerosis.
Scleroderma, Systemic
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Scleroderma, Systemic
No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene.
Scleroderma, Systemic
Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE).
Scleroderma, Systemic
The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis.
Scleroderma, Systemic
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis.
Scleroderma, Systemic
The PTPN22 C1858T variant as a risk factor for rheumatoid arthritis and systemic lupus erythematosus but not for systemic sclerosis in the Colombian population.
Scleroderma, Systemic
Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22.
Scoliosis
Pathogenesis of adolescent idiopathic scoliosis in girls - a double neuro-osseous theory involving disharmony between two nervous systems, somatic and autonomic expressed in the spine and trunk: possible dependency on sympathetic nervous system and hormones with implications for medical therapy.
Scoliosis
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Scurvy
[Consequences of scurvy on testicular and muscular acid phosphatase activity in guinea pigs]
Seizures
Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity.
Seizures
Kainic acid-induced convulsions cause prolonged changes in the chondroitin sulfate proteoglycans neurocan and phosphacan in the limbic structures.
Seizures
MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase.
Seizures
Plasmin-mediated processing of protein tyrosine phosphatase receptor type Z in the mouse brain.
Seizures
Seizure-Induced Regulations of Amyloid-?, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity.
Seizures
Temporal and spatial regulation of the expression of BAD2, a MAP kinase phosphatase, during seizure, kindling, and long-term potentiation.
Seizures
Transient expression of the mitogen-activated protein kinase phosphatase MKP-1 (3CH134/ERP1) in the rat brain after limbic epilepsy.
Seminoma
Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis.
Sepsis
Dynamic regulation of neutrophil survival through tyrosine phosphorylation or dephosphorylation of caspase-8.
Sepsis
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Sepsis
Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality.
Sepsis
GLUTAMINE PREVENTS ACTIVATION OF NF-kappaB AND STRESS KINASE PATHWAYS, ATTENUATES INFLAMMATORY CYTOKINE RELEASE, AND PREVENTS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) FOLLOWING SEPSIS.
Sepsis
Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis.
Sepsis
Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice.
Sepsis
Mitogen Activated Protein Kinase Phosphatase 2, MKP-2, regulates the Inflammatory Response in Sepsis.
Sepsis
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Sepsis
Sepsis-induced brain mitochondrial dysfunction is associated with altered mitochondrial Src and PTP1B levels.
Sepsis
Sepsis-Induced Cardiac Mitochondrial Dysfunction Involves Altered Mitochondrial-Localization of Tyrosine Kinase Src and Tyrosine Phosphatase SHP2.
Sepsis
The inhibitory effect of ghrelin on sepsis-induced inflammation is mediated by the MAPK phosphatase-1.
Sepsis
Wedelolactone improves the renal injury induced by lipopolysaccharide in HK-2 cells by upregulation of protein tyrosine phosphatase non-receptor type 2.
Sepsis-Associated Encephalopathy
Disruption of Striatal-Enriched Protein Tyrosine Phosphatase Signaling Might Contribute to Memory Impairment in a Mouse Model of Sepsis-Associated Encephalopathy.
Sertoli Cell-Only Syndrome
Association of spermatogenic failure with decreased CDC25A expression in infertile men.
Severe Combined Immunodeficiency
Mitogen-activated protein kinase phosphatase-1 expression in macrophages is controlled by lymphocytes during macrophage activation.
Severe Combined Immunodeficiency
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease.
Sex Chromosome Aberrations
De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy.
Sezary Syndrome
SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
Shock, Septic
Association Between PTPN22 Polymorphisms and IgE Responses to Staphylococcal Superantigens in Chronic Urticaria.
Shock, Septic
Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin.
Shock, Septic
Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock.
Shock, Septic
Dual-Specificity Phosphatase 3 Deletion Protects Female, but Not Male, Mice from Endotoxemia-Induced and Polymicrobial-Induced Septic Shock.
Shock, Septic
Gene Expression of Protein Tyrosine Phosphatase 1B and Endoplasmic Reticulum Stress During Septic Shock.
Shock, Septic
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock.
Shock, Septic
MAP kinase phosphatase-1, a critical negative regulator of the innate immune response.
Shock, Septic
Protein tyrosine phosphatase 1B regulates endothelial endoplasmic reticulum stress; role in endothelial dysfunction.
Shock, Septic
Reduced Insulin Resistance Contributes to the Beneficial Effect of Protein Tyrosine Phosphatase-1B Deletion in a Mouse Model of Sepsis.
Shwachman-Diamond Syndrome
Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
Silicosis
Evaluation of differential serum expression of three factors and pulmonary function in patients with silicosis.
Silicosis
Protein Expression Profile in Rat Silicosis Model Reveals Upregulation of PTPN2 and Its Inhibitory Effect on Epithelial-Mesenchymal Transition by Dephosphorylation of STAT3.
Sjogren's Syndrome
[Polymorphic markers of certain genes in the development of dry keratoconjunctivitis in patients with rheumatoid arthritis and Sjogren's syndrome].
Skin Diseases
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
Skin Diseases
ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis.
Skin Diseases
Binding of the trichodysplasia spinulosa-associated polyomavirus small T antigen to protein phosphatase 2A: elucidation of a potential pathogenic mechanism in a rare skin disease.
Skin Diseases
Cutting Edge: Dysregulated CARD9 Signaling in Neutrophils Drives Inflammation in a Mouse Model of Neutrophilic Dermatoses.
Skin Diseases
Distinct Roles for Neutrophils and Dendritic Cells in Inflammation and Autoimmunity in motheaten Mice.
Skin Diseases
Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.
Skin Diseases
Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.
Skin Diseases
RIP1-driven autoinflammation targets IL-1? independently of inflammasomes and RIP3.
Skin Diseases
SHP-1 (PTPN6) keeps the inflammation at bay: limiting IL-1?-mediated neutrophilic dermatoses by preventing Syk kinase activation.
Skin Diseases
Spontaneous insertion of a b2 element in the ptpn6 gene drives a systemic autoinflammatory disease in mice resembling neutrophilic dermatosis in humans.
Skin Diseases
Tyrosine Kinase SYK Licenses MyD88 Adaptor Protein to Instigate IL-1?-Mediated Inflammatory Disease.
Skin Neoplasms
Accelerated elimination of ultraviolet-induced DNA damage through apoptosis in CDC25A-deficient skin.
Skin Neoplasms
Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
Skin Neoplasms
CDC25B and CDC25C overexpression in nonmelanoma skin cancer suppresses cell death.
Skin Neoplasms
Epidermal-specific deletion of TC-PTP promotes UVB-induced epidermal cell survival through the regulation of Flk-1/JNK signaling.
Skin Neoplasms
Targeting 14-3-3? activates apoptotic signaling to prevent cutaneous squamous cell carcinoma.
Skin Neoplasms
The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.
Skin Neoplasms
Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion.
Sleep Apnea, Obstructive
Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1.
Small Cell Lung Carcinoma
Coexisting amplifications of the chromosome 1p32 genes (PTPRF and MYCL1) encoding protein tyrosine phosphatase LAR and L-myc in a small cell lung cancer line.
Small Cell Lung Carcinoma
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
Small Cell Lung Carcinoma
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
Small Cell Lung Carcinoma
PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.
Small Cell Lung Carcinoma
Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
Small Cell Lung Carcinoma
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Small Cell Lung Carcinoma
[Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer]
Small Cell Lung Carcinoma
[Expression of CDC25A in non-small cell lung cancer and its relationship with let-7 gene].
Smallpox
OH1 from Orf Virus: A New Tyrosine Phosphatase that Displays Distinct Structural Features and Triple Substrate Specificity.
Smallpox
Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus.
Smoldering Multiple Myeloma
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
Spastic Paraplegia, Hereditary
Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia.
Spinal Cord Injuries
A new role for RPTPsigma in spinal cord injury: signaling chondroitin sulfate proteoglycan inhibition.
Spinal Cord Injuries
Axonal regeneration through regions of chondroitin sulfate proteoglycan deposition after spinal cord injury: a balance of permissiveness and inhibition.
Spinal Cord Injuries
Corticospinal tract regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma deficient mice.
Spinal Cord Injuries
Decorin promotes robust axon growth on inhibitory CSPGs and myelin via a direct effect on neurons.
Spinal Cord Injuries
Decorin suppresses neurocan, brevican, phosphacan and NG2 expression and promotes axon growth across adult rat spinal cord injuries.
Spinal Cord Injuries
Identification of the potential dual inhibitor of protein tyrosine phosphatase sigma and leukocyte common antigen-related phosphatase by virtual screen, molecular dynamic simulations and post-analysis.
Spinal Cord Injuries
L1 Cell Adhesion Molecule Overexpression Down Regulates Phosphacan and Up Regulates Structural Plasticity-Related Genes Rostral and Caudal to the Complete Spinal Cord Transection.
Spinal Cord Injuries
NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury.
Spinal Cord Injuries
Protein Tyrosine Phosphatase ? Inhibitory Peptide Promotes Recovery of Diaphragm Function and Sprouting of Bulbospinal Respiratory Axons after Cervical Spinal Cord Injury.
Spinal Cord Injuries
PTP{sigma} Is a Receptor for Chondroitin Sulfate Proteoglycan, an Inhibitor of Neural Regeneration.
Spinal Cord Injuries
Recombinant Human Erythropoietin Protects Against Experimental Spinal Cord Trauma Injury by Regulating Expression of the Proteins MKP-1 and p-ERK.
Spinal Cord Injuries
RXR? Blocks Nerve Regeneration after Spinal Cord Injury by Targeting p66shc.
Spinal Cord Injuries
Small-molecule protein tyrosine phosphatase inhibition as a neuroprotective treatment after spinal cord injury in adult rats.
Spinal Cord Injuries
Spatiotemporal distribution of chondroitin sulfate proteoglycans after optic nerve injury in rodents.
Spinal Cord Injuries
The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury.
Spinal Cord Injuries
[Study on expression of mkp-1 and P-ERK in acutecontusive spinal cord injury rat's model]
Spinal Curvatures
Regulation of bone and skeletal development by the SHP-2 protein tyrosine phosphatase.
Spinocerebellar Ataxias
A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration.
Spinocerebellar Ataxias
Gene expression profile following stable expression of the cellular prion protein.
Spinocerebellar Ataxias
Generation of a human induced pluripotent stem cell line JHUi003-A with homozygous mutation for spinocerebellar ataxia type 12 using genome editing.
Spinocerebellar Ataxias
The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission.
Spondylarthropathies
Treatment with TNF? blockers induces phenotypical and functional aberrations in peripheral B cells.
Spondylitis, Ankylosing
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
Spondylitis, Ankylosing
A variant within intron 1 of the PTPN22 gene decreases the genetic susceptibility of ankylosing spondylitis in a central south Chinese Han population.
Spondylitis, Ankylosing
Association Between Protein Tyrosine Phosphatase Non-Receptor Type 22 (PTPN22) Polymorphisms and Risk of Ankylosing Spondylitis: A Meta-analysis.
Spondylitis, Ankylosing
Association of PTPN22 polymorphsims and ankylosing spondylitis susceptibility.
Spondylitis, Ankylosing
Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.
Spondylitis, Ankylosing
Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility marker for autoimmunity.
Spondylitis, Ankylosing
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Spondylitis, Ankylosing
Potential role of PTPN22 in ankylosing spondylitis, comment on: associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis.
Spondylitis, Ankylosing
Protein tyrosine phosphatase nonreceptor type 2: an important regulator of lnterleukin-6 production in rheumatoid arthritis synovial fibroblasts.
Squamous Cell Carcinoma of Head and Neck
AlloDriver: a method for the identification and analysis of cancer driver targets.
Squamous Cell Carcinoma of Head and Neck
Cancerous Inhibitor of Protein Phosphatase 2A as a Molecular Marker for Aggressiveness and Survival in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells.
Squamous Cell Carcinoma of Head and Neck
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Squamous Cell Carcinoma of Head and Neck
Differential molecular signature alterations of RBSP3, LIMD1 and CDC25A in normal oral epithelium during oral tumorigenesis.
Squamous Cell Carcinoma of Head and Neck
Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.
Squamous Cell Carcinoma of Head and Neck
Down-regulation of lncRNA HCG11 promotes cell proliferation of oral squamous cell carcinoma through sponging miR-455-5p.
Squamous Cell Carcinoma of Head and Neck
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
FAP-1 and NF-?B expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis.
Squamous Cell Carcinoma of Head and Neck
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization.
Squamous Cell Carcinoma of Head and Neck
High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Increased Expression of the PRL-3 Gene in Human Oral Squamous Cell Carcinoma and Dysplasia Tissues.
Squamous Cell Carcinoma of Head and Neck
Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.
Squamous Cell Carcinoma of Head and Neck
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients.
Squamous Cell Carcinoma of Head and Neck
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Squamous Cell Carcinoma of Head and Neck
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).
Squamous Cell Carcinoma of Head and Neck
MKP-1 is required to limit myeloid-cell mediated oral squamous cell carcinoma progression and regional extension.
Squamous Cell Carcinoma of Head and Neck
Noninvasive Molecular Detection of Head and Neck Squamous Cell Carcinoma: An Exploratory Analysis.
Squamous Cell Carcinoma of Head and Neck
Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.
Squamous Cell Carcinoma of Head and Neck
Parathyroid Hormone-Like Hormone is a Poor Prognosis Marker of Head and Neck Cancer and Promotes Cell Growth via RUNX2 Regulation.
Squamous Cell Carcinoma of Head and Neck
Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.
Squamous Cell Carcinoma of Head and Neck
Protein tyrosine phosphatase receptor R and Z1 expression are independent prognostic indicators in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Receptor-type Protein tyrosine phosphatase ? regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Relationship between the Levels of mRNA Expression for Protein Phosphatase 1B and Proteins Involved in Cytoskeleton Remodeling in Squamous Cell Carcinoma of the Larynx and Hypopharynx.
Squamous Cell Carcinoma of Head and Neck
SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Squamous Cell Carcinoma of Head and Neck
STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Systematic Analysis of Sex-Linked Molecular Alterations and Therapies in Cancer.
Squamous Cell Carcinoma of Head and Neck
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Squamous Cell Carcinoma of Head and Neck
[Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance].
Staphylococcal Infections
[Fibroblast phosphatase activity in the staphylococcal infection process]
Starvation
Changes in expression of soluble inorganic pyrophosphatases of Phaseolus vulgaris under phosphate starvation
Starvation
Changes in expression of soluble inorganic pyrophosphatases of Phaseolus vulgaris under phosphate starvation.
Starvation
Cytochemical determination of acid phosphatase activity in isolated rat hepatocytes during starvation-induced proteolysis.
Starvation
Differential increase in activity of acid phosphatase induced by phosphate starvation in Tetrahymena.
Starvation
Focal adhesion and stress fiber formation is regulated by tyrosine phosphatase activity.
Starvation
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Starvation
Functional significance and morphological characterization of starvation-induced autophagy in the adult heart.
Starvation
Identification of nutrient-dependent changes in extracellular pH and acid phosphatase secretion in Aspergillus nidulans.
Starvation
Identification, structure analysis, and transcript profiling of purple acid phosphatases under Pi deficiency in tomato (Solanum lycopersicum L.) and its wild relatives.
Starvation
Induction of p53 dependent apoptosis upon overexpression of a nuclear protein tyrosine phosphatase.
Starvation
Influence of glucose starvation on the pathway of death in insect cell line Sl: apoptosis follows autophagy.
Starvation
microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells.
Starvation
OsUEV1B, an Ubc enzyme variant protein, is required for phosphate homeostasis in rice.
Starvation
Quiescence versus apoptosis: Myc abundance determines pathway of exit from the cell cycle.
Starvation
Regulation of dimorphism in Saccharomyces cerevisiae: involvement of the novel protein kinase homolog Elm1p and protein phosphatase 2A.
Starvation
State transitions in the TORC1 signaling pathway and information processing in Saccharomyces cerevisiae.
Starvation
Studies on the activities of an acid phosphomonoesterase and an alkaline pyrophosphatase during the growth of Physarum polycephalum.
Starvation
The effect of starvation, restricted feed intake and refeeding on acid phosphatase activity of the hypothalamus and frontal cerebral cortex of the rat.
Starvation
The purple acid phosphatase GmPAP21 enhances internal phosphorus utilization and possibly plays a role in symbiosis with rhizobia in soybean.
Starvation
The THO/TREX Complex Active in miRNA Biogenesis Negatively Regulates Root-Associated Acid Phosphatase Activity Induced by Phosphate Starvation.
Starvation
Use of the p-nitrophenyl phosphate method for the demonstration of acid phosphatase during starvation and cell autolysis in the planarian Polycelis tenuis Iijima.
Starvation
ZmAPRG, an uncharacterized gene, enhances acid phosphatase activity and Pi concentration in maize leaf during phosphate starvation.
Status Epilepticus
Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau.
Status Epilepticus
Upregulated SHP-2 expression in the epileptogenic zone of temporal lobe epilepsy and various effects of SHP099 treatment on a pilocarpine model.
stearoyl-coa 9-desaturase deficiency
Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle.
Steatorrhea
Demonstration of acid phosphatase activity in the Golgi apparatus of the jejunal epithelium cell in patients with idiopathic steatorrhea.
Stiff-Person Syndrome
Humoral and cellular immune parameters before and during immunosuppressive therapy of a patient with stiff-man syndrome and insulin dependent diabetes mellitus.
Stomach Diseases
Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese.
Stomach Diseases
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Stomach Neoplasms
Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency.
Stomach Neoplasms
Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells.
Stomach Neoplasms
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
Stomach Neoplasms
Association between serum pepsinogens and polymorphismof PTPN11 encoding SHP-2 among Helicobacter pylori seropositive Japanese.
Stomach Neoplasms
Association of polymorphism of PTPN 11 encoding SHP-2 with gastric atrophy but not gastric cancer in Helicobacter pylori seropositive Chinese population.
Stomach Neoplasms
Association of Tyrosine PRL-3 Phosphatase Protein Expression with Peritoneal Metastasis of Gastric Carcinoma and Prognosis.
Stomach Neoplasms
Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese.
Stomach Neoplasms
Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Stomach Neoplasms
Biological function of protein tyrosine phosphatase H-type receptor and its progress in tumor.
Stomach Neoplasms
CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR.
Stomach Neoplasms
Chemotherapy Effectiveness and Prognosis of Gastric Cancer Influenced by PTPN11 Polymorphisms.
Stomach Neoplasms
Comprehensive analysis of vascular endothelial growth factor-C related factors in stomach cancer.
Stomach Neoplasms
Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo.
Stomach Neoplasms
Correction: Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.
Stomach Neoplasms
Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding.
Stomach Neoplasms
Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line.
Stomach Neoplasms
Dysregulation of Stem Cell Signaling Network Due to Germline Mutation, SNP, Helicobacter pylori Infection, Epigenetic Change and Genetic Alteration in Gastric Cancer.
Stomach Neoplasms
Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients.
Stomach Neoplasms
Epigenetic regulation and anti-tumorigenic effects of SH2-containing protein tyrosine phosphatase 1 (SHP1) in human gastric cancer cells.
Stomach Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.
Stomach Neoplasms
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Stomach Neoplasms
Expression of Concern: microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
Stomach Neoplasms
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.
Stomach Neoplasms
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
Stomach Neoplasms
Frequent amplification of PTP1B is associated with poor survival of gastric cancer patients.
Stomach Neoplasms
Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.
Stomach Neoplasms
Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients.
Stomach Neoplasms
Genetic Susceptibility on CagA-Interacting Molecules and Gene-Environment Interaction with Phytoestrogens: A Putative Risk Factor for Gastric Cancer.
Stomach Neoplasms
Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.
Stomach Neoplasms
Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
Stomach Neoplasms
Helicobacter pylori-induced protein tyrosine phosphatase receptor type C as a prognostic biomarker for gastric cancer.
Stomach Neoplasms
High expression of PRL-3 can promote growth of gastric cancer and exhibits a poor prognostic impact on patients.
Stomach Neoplasms
High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis.
Stomach Neoplasms
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
Stomach Neoplasms
Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer.
Stomach Neoplasms
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
Stomach Neoplasms
Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer.
Stomach Neoplasms
Inhibitory Effect of Artesunate on Growth and Apoptosis of Gastric Cancer Cells.
Stomach Neoplasms
Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Stomach Neoplasms
Knockdown of protein tyrosine phosphatase receptor U inhibits growth and motility of gastric cancer cells.
Stomach Neoplasms
Long Noncoding RNA UCA1 Regulates PRL-3 Expression by Sponging MicroRNA-495 to Promote the Progression of Gastric Cancer.
Stomach Neoplasms
Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Stomach Neoplasms
Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1.
Stomach Neoplasms
Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1.
Stomach Neoplasms
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Stomach Neoplasms
Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
Stomach Neoplasms
MicroRNA-217 suppressed epithelial-to-mesenchymal transition in gastric cancer metastasis through targeting PTPN14.
Stomach Neoplasms
microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer.
Stomach Neoplasms
MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3).
Stomach Neoplasms
MicroRNA?181a promotes cell proliferation and inhibits apoptosis in gastric cancer by targeting RASSF1A.
Stomach Neoplasms
miR-146b Regulates Cell Proliferation and Apoptosis in Gastric Cancer by Targeting PTP1B.
Stomach Neoplasms
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B.
Stomach Neoplasms
miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3.
Stomach Neoplasms
New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.
Stomach Neoplasms
Nonreceptor tyrosine phosphatase 14 promotes proliferation and migration through regulating phosphorylation of YAP of Hippo signaling pathway in gastric cancer cells.
Stomach Neoplasms
Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric Carcinomas.
Stomach Neoplasms
Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma.
Stomach Neoplasms
Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
Stomach Neoplasms
Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
Stomach Neoplasms
PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.
Stomach Neoplasms
PRL-3 promotes gastric cancer migration and invasion through a NF-?B-HIF-1?-miR-210 axis.
Stomach Neoplasms
PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo.
Stomach Neoplasms
PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN.
Stomach Neoplasms
Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer.
Stomach Neoplasms
Prognostic Significance of High Phosphatase of Regenerating Liver-3 Expression in Patients with Gastric Cancer Who Underwent Curative Gastrectomy.
Stomach Neoplasms
Protein tyrosine-phosphatase expression profiling in gastric cancer tissues.
Stomach Neoplasms
PTP4A3 (PRL-3) expression correlate with lymphatic metastases in gastric cancer.
Stomach Neoplasms
PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma.
Stomach Neoplasms
PTPRU, As A Tumor Suppressor, Inhibits Cancer Stemness By Attenuating Hippo/YAP Signaling Pathway.
Stomach Neoplasms
Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer.
Stomach Neoplasms
Reduced PTEN expression in gastric cancer and in the gastric mucosa of gastric cancer relatives.
Stomach Neoplasms
RING finger protein 38 induces gastric cancer cell growth by decreasing the stability of the protein tyrosine phosphatase SHP-1.
Stomach Neoplasms
Role of silencing phosphatase of regenerationg liver-3 expression by microRNA interference in the growth of gastric cancer.
Stomach Neoplasms
SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis.
Stomach Neoplasms
Stability of Helicobacter pylori CagA oncoprotein in human gastric epithelial cells.
Stomach Neoplasms
Suppression of PTP1B in gastric cancer cells in vitro induces a change in the genome-wide expression profile, and inhibits gastric cancer cell growth.
Stomach Neoplasms
The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa.
Stomach Neoplasms
The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Stomach Neoplasms
The Expression of p66Shc Protein in Benign, Premalignant, and Malignant Gastrointestinal Lesions.
Stomach Neoplasms
The expression patterns and the diagnostic/prognostic roles of PTPN family members in digestive tract cancers.
Stomach Neoplasms
The prognostic value of Cyclin-Dependent Kinase 5 and Protein Phosphatase 2A in Gastric Cancer.
Stomach Neoplasms
Therapeutic Potential of PRL-3 Targeting and Clinical Significance of PRL-3 Genomic Amplification in Gastric Cancer.
Stomach Neoplasms
Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry.
Stomach Neoplasms
Unsaturated fatty acids bind Myc-Max transcription factor and inhibit Myc-Max-DNA complex formation.
Stomach Neoplasms
YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Stomach Neoplasms
[CagA tyrosine phosphorylation motif structure and SHP-2 binding ability of Helicobacter pylori studied in stomach cancer and duodenal ulcer cell lines]
Stomach Neoplasms
[Difference in methylation of genomic DNA between gastric primary cancer and lymph nodes with metastatic gastric cancer]
Stomach Neoplasms
[Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation]
Stomach Neoplasms
[Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer]
Stomach Neoplasms
[Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma]
Stomach Neoplasms
[The overexpression and significance of MKP-1 in oxygen-deprived gastric cancer cell line SGC7901]
Stomach Ulcer
Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori.
Stomatitis
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Stomatitis
The protein tyrosine phosphatase PTP1B is required for efficient delivery of N-cadherin to the cell surface.
Stroke
Age and blood pressure related changes in cholesterol esterase activity and cholesterol content in aortas of stroke prone spontaneously hypertensive rats, spontaneously hypertensive rats and normotensive Wistar Kyoto rats.
Stroke
Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling.
Stroke
Brevican and phosphacan expression and localization following transient middle cerebral artery occlusion in the rat.
Stroke
DJ-1 exerts anti-inflammatory effects and regulates NLRX1-TRAF6 via SHP-1 in stroke.
Stroke
Egr-1 regulates expression of the glial scar component phosphacan in astrocytes after experimental stroke.
Stroke
Inhibition of mitogen-activated protein kinase phosphatase-1 (MKP-1) increases experimental stroke injury.
Stroke
Neuronal protein-tyrosine phosphatase 1B hinders sensory-motor functional recovery and causes affective disorders in two different focal ischemic stroke models.
Stroke
Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke.
Stroke
Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3.
Stroke
PTPN22 Gene Polymorphisms Are Associated with Susceptibility to Large Artery Atherosclerotic Stroke and Microembolic Signals.
Subarachnoid Hemorrhage
Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.
Supranuclear Palsy, Progressive
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Supranuclear Palsy, Progressive
PTPRC Expression in Blood is Downregulated in Parkinson's and Progressive Supranuclear Palsy Disorders.
Sweet Syndrome
Alteration in the Gene Encoding Protein Tyrosine Phosphatase Nonreceptor Type 6 (PTPN6/SHP1) May Contribute to Neutrophilic Dermatoses.
Synovitis
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved?
Synovitis
T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice.
Systemic Vasculitis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to Henoch-Schönlein purpura.
Tachycardia, Supraventricular
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Tachycardia, Ventricular
Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.
Tachycardia, Ventricular
Implantable cardioverter defibrillator for progressive hypertrophic cardiomyopathy in a patient with LEOPARD syndrome and a novel PTPN11 mutation Gln510His.
Takayasu Arteritis
An association study in PTPN22 suggests that is a risk factor to Takayasu's arteritis.
Tauopathies
Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy.
Tauopathies
Methionine-Mediated Protein Phosphatase 2A Catalytic Subunit (PP2Ac) Methylation Ameliorates the Tauopathy Induced by Manganese in Cell and Animal Models.
Tauopathies
Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.
Tauopathies
Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies.
Tauopathies
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
Tay-Sachs Disease
FINE STRUCTURAL LOCALIZATION OF ACID PHOSPHATASE ACTIVITY IN NEURONS OF TAY-SACHS DISEASE.
Telangiectasia, Hereditary Hemorrhagic
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Telangiectasis
Erbb2 Suppresses DNA Damage-Induced Checkpoint Activation and UV-Induced Mouse Skin Tumorigenesis.
Telangiectasis
Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.
Telangiectasis
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia.
Telangiectasis
Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
Teratocarcinoma
Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C.
Testicular Neoplasms
OCT4 Represses Inflammation and Cell Injury During Orchitis by Regulating CIP2A Expression.
Tetanus
GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Tetanus
Spontaneous peripheral T-cell responses to the IA-2beta (phogrin) autoantigen in young nonobese diabetic mice.
Tetralogy of Fallot
A common variant in the PTPN11 gene contributes to the risk of tetralogy of Fallot.
Tetralogy of Fallot
Polymorphism C242T of the gene of the p22phox subunit for nicotinamide adenine dinucleotide phosphate oxidase, and erythrocytic antioxidant enzymes, in patients with tetralogy of Fallot.
thioredoxin-dependent peroxiredoxin deficiency
Peroxiredoxin II is an antioxidant enzyme that negatively regulates collagen-stimulated platelet function.
Thrombocythemia, Essential
A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
Thrombocytopenia
A de novo T73I Mutation in PTPN11 in a Neonate with Severe and Prolonged Congenital Thrombocytopenia and Noonan Syndrome.
Thrombocytopenia
A new form of inherited thrombocytopenia caused by loss-of-function mutations in PTPRJ.
Thrombocytopenia
Interplay between the tyrosine kinases Chk, Csk and phosphatase PTPRJ is critical for regulating platelets in mice.
Thrombocytopenia
Polymorphisms of protein tyrosine phosphatase CD148 influence Fc?RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
Thrombocytopenia
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Thrombocytopenia
Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia.
Thrombosis
Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.
Thrombosis
Identification of key genes in hepatocellular carcinoma and validation of the candidate gene, cdc25a, using gene set enrichment analysis, meta?analysis and cross?species comparison.
Thrombosis
Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.
Thrombosis
Oncogenic function and prognostic significance of protein tyrosine phosphatase PRL-1 in hepatocellular carcinoma.
Thrombosis
PECAM-1 regulates collagen-stimulated platelet function by modulating the association of PI3 Kinase with Gab1 and LAT.
Thrombosis
The endothelial tyrosine phosphatase SHP-1 plays an important role for vascular haemostasis in TNF? -induced inflammation in vivo.
Thrombosis
The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis.
Thrombosis
Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia.
Thymoma
Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase ?/? Regulation in the Ventral Tegmental Area.
Thymoma
Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity.
Thymoma
Autophagy controls neonatal myogenesis by regulating the GH-IGF1 system through a NFE2L2- and DDIT3-mediated mechanism.
Thymoma
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms.
Thymoma
Double-Stranded RNA-Activated Protein Kinase Is a Key Modulator of Insulin Sensitivity in Physiological Conditions and in Obesity in Mice.
Thymoma
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Thymoma
Effects of low-level laser irradiation on mesenchymal stem cell proliferation: a microarray analysis.
Thymoma
Expression and clinical significance of protein tyrosine phosphatase nonreceptor 22 in resected thymoma.
Thymoma
Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.
Thymoma
PTPN22 and CTLA-4 gene polymorphisms in resected thymomas and thymus for myasthenia gravis.
Thymoma
Regulation of Pleiotrophin, Midkine, Receptor Protein Tyrosine Phosphatase ?/?, and Their Intracellular Signaling Cascades in the Nucleus Accumbens During Opiate Administration.
Thymoma
The PTPN22(gain-of-function)+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis.
Thyroid Cancer, Papillary
Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
Thyroid Cancer, Papillary
DUSP4 inhibits autophagic cell death in PTC by inhibiting JNK-BCL2-Beclin1 signaling.
Thyroid Cancer, Papillary
DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer.
Thyroid Cancer, Papillary
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Thyroid Carcinoma, Anaplastic
Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
Thyroid Carcinoma, Anaplastic
Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor.
Thyroid Carcinoma, Anaplastic
Tyr Phosphatase-Mediated P-ERK Inhibition Suppresses Senescence in EIA + v-raf Transformed Cells, Which, Paradoxically, Are Apoptosis-Protected in a MEK-Dependent Manner.
Thyroid Diseases
A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene.
Thyroid Diseases
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Thyroid Diseases
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
Thyroid Diseases
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.
Thyroid Diseases
Association of Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) C1858T gene polymorphism with susceptibility to autoimmune thyroid diseases: a meta-analysis.
Thyroid Diseases
Association of the protein tyrosine phosphatase nonreceptor 22 haplotypes with autoimmune thyroid disease in the Japanese population.
Thyroid Diseases
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Thyroid Diseases
Associations Between Autoimmune Thyroid Disease Prognosis and Functional Polymorphisms of Susceptibility Genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, Previously Revealed in Genome-wide Association Studies.
Thyroid Diseases
Associations of GWAS-Supported Non-MHC Genes with Autoimmune Thyroiditis in Patients with Type 1 Diabetes.
Thyroid Diseases
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Thyroid Diseases
Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus.
Thyroid Diseases
Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West.
Thyroid Diseases
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer.
Thyroid Diseases
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
Thyroid Diseases
In children with autoimmune thyroiditis CTLA4 and FCRL3 genes - but not PTPN22 - are overexpressed when compared to adults.
Thyroid Diseases
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
Thyroid Diseases
R620W polymorphism of protein tyrosine phosphatase PTPN22 in Egyptian children and adolescents with systemic lupus erythematosus: relation to thyroid autoimmunity.
Thyroid Diseases
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.
Thyroid Diseases
Susceptibility influence of a PTPN22 haplotype with thyroid autoimmunity in Koreans.
Thyroid Diseases
The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes.
Thyroid Diseases
The R620W polymorphism of the protein tyrosine phosphatase 22 gene in autoimmune thyroid diseases and rheumatoid arthritis in the Tunisian population.
Thyroid Diseases
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
Thyroid Diseases
Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.
Thyroid Diseases
[Association of polymorphism of proteintyrosine phosphatase nonreceptor-22 gene with AITD.]
Thyroid Neoplasms
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo.
Thyroid Neoplasms
DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Thyroid Neoplasms
Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain dependent manner.
Thyroid Neoplasms
Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma.
Thyroid Neoplasms
Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.
Thyroid Neoplasms
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
Thyroid Neoplasms
Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
Thyroid Neoplasms
p66Shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling.
Thyroid Neoplasms
Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice.
Thyroid Neoplasms
Single nucleotide polymorphism analysis in the human phosphatase PTPrj gene using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry.
Thyroid Neoplasms
The interplay between p66Shc, reactive oxygen species and cancer cell metabolism.
Thyroid Neoplasms
The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.
Thyroid Neoplasms
Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer.
Thyroiditis
A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population.
Thyroiditis
Analysis of chosen polymorphisms rs2476601 a/G - PTPN22, rs1990760 C/T - IFIH1, rs179247 a/G - TSHR in pathogenesis of autoimmune thyroid diseases in children.
Thyroiditis
Association Studies of the GPR103 and BCL2L15 Genes in Autoimmune Thyroid Disease in the Japanese Population.
Thyroiditis
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant.
Thyroiditis
Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.
Thyroiditis
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Thyroiditis
Low bone mineral density and renal malformation in Mexican patients with Turner syndrome are associated with single nucleotide variants in vitamin D-metabolism genes.
Thyroiditis
No association between transmembrane protein-tyrosine-phosphatase receptor type C (CD45) exon A 77C>G transversion and Hashimoto's thyroiditis in a German population.
Thyroiditis
Novel missense mutation in PTPN22 in a Chinese pedigree with Hashimoto's thyroiditis.
Thyroiditis
Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.
Thyroiditis
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population.
Thyroiditis
The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis.
Thyroiditis
Tumor necrosis factor receptor II and PTPN22 genes polymorphisms and the risk of systemic lupus erythematosus in Egyptian children.
Thyroiditis
Upregulation Of Protein Tyrosine Phosphatase Receptor Type C Associates To The Combination Of Hashimoto's Thyroiditis And Papillary Thyroid Carcinoma And Is Predictive Of A Poor Prognosis.
Thyroiditis, Autoimmune
DNA hypermethylation of PTPN22 gene promoter in children and adolescents with Hashimoto thyroiditis.
Thyroiditis, Autoimmune
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis.
Thyroiditis, Autoimmune
In children with autoimmune thyroiditis CTLA4 and FCRL3 genes - but not PTPN22 - are overexpressed when compared to adults.
Thyroiditis, Autoimmune
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Tick Infestations
Allelic Variation in Protein Tyrosine Phosphatase Receptor Type-C in Cattle Influences Erythrocyte, Leukocyte and Humoral Responses to Infestation With the Cattle Tick Rhipicephalus australis.
Tourette Syndrome
Association between the low molecular weight cytosolic acid phosphatase gene ACP1*A and comorbid features of Tourette syndrome.
Toxemia
[Acid phosphatase activity in the neutrophils and peripheral lymphocytes in normal pregnancy and pregnancies complicated by RH-HR blood group incompatibility and toxemia]
transaldolase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Trauma, Nervous System
A new role for RPTPsigma in spinal cord injury: signaling chondroitin sulfate proteoglycan inhibition.
Trauma, Nervous System
Detection of Ca(2+)-dependent acid phosphatase activity identifies neuronal integrity in damaged rat central nervous system after application of bacterial melanin.
Trauma, Nervous System
Protein Tyrosine Phosphatase ? Inhibitory Peptide Promotes Recovery of Diaphragm Function and Sprouting of Bulbospinal Respiratory Axons after Cervical Spinal Cord Injury.
Trauma, Nervous System
The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival.
Triple Negative Breast Neoplasms
Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Triple Negative Breast Neoplasms
CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
Triple Negative Breast Neoplasms
Clinicopathological significance of PTPN12 expression in human breast cancer.
Triple Negative Breast Neoplasms
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
Triple Negative Breast Neoplasms
Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.
Triple Negative Breast Neoplasms
Epigenetic regulation of protein tyrosine phosphatase PTPN12 in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Triple Negative Breast Neoplasms
Expression of receptor protein tyrosine phosphatase ? is a risk factor for triple negative breast cancer relapse.
Triple Negative Breast Neoplasms
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.
Triple Negative Breast Neoplasms
HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/?-catenin signaling.
Triple Negative Breast Neoplasms
Loss of the oncogenic phosphatase PRL-3 promotes a TNF-R1 feedback loop that mediates triple-negative breast cancer growth.
Triple Negative Breast Neoplasms
Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
Triple Negative Breast Neoplasms
PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Triple Negative Breast Neoplasms
Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.
Triple Negative Breast Neoplasms
PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling.
Triple Negative Breast Neoplasms
Receptor-type protein tyrosine phosphatase alpha (PTP?) mediates MMP14 localization and facilitates triple-negative breast cancer cell invasion.
Triple Negative Breast Neoplasms
Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Triple Negative Breast Neoplasms
TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.
Triple Negative Breast Neoplasms
The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Trisomy 18 Syndrome
Alkaline phosphatase and phosphotyrosine phosphatase activities of cultured amniotic cells with trisomy 18.
Trisomy 18 Syndrome
Evaluation of two markers of cell maturation and proliferation in cultured amniotic cells of trisomic 18 fetuses at the 15th week of gestation.
Trypanosomiasis
Inhibition of Trypanosoma evansi Protein-Tyrosine Phosphatase by Myristic Acid Analogues Isolated from Khaya senegalensis and Tamarindus indica.
Trypanosomiasis, African
Investigating mammalian tyrosine phosphatase inhibitors as potential 'piggyback' leads to target Trypanosoma brucei transmission.
Tuberculosis
A facile hydroxyindole carboxylic acid based focused library approach for potent and selective inhibitors of Mycobacterium protein tyrosine phosphatase B.
Tuberculosis
A new family of phosphoinositide phosphatases in microorganisms: identification and biochemical analysis.
Tuberculosis
A variant of PTPN22 gene conferring risk to autoimmune diseases may protect against tuberculosis.
Tuberculosis
Alterporriol-type dimers from the mangrove endophytic fungus, Alternaria sp. (SK11), and their MptpB inhibitions.
Tuberculosis
Analysis of stress- and host cell-induced expression of the Mycobacterium tuberculosis inorganic pyrophosphatase.
Tuberculosis
Analyzing the catalytic mechanism of MPtpA: a low molecular weight protein tyrosine phosphatase from Mycobacterium tuberculosis through site-directed mutagenesis.
Tuberculosis
Asperlones A and B, dinaphthalenone derivatives from a mangrove endophytic fungus Aspergillus sp. 16-5C.
Tuberculosis
Asperterpenoid A, a new sesterterpenoid as an inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B from the culture of Aspergillus sp. 16-5c.
Tuberculosis
Association between the PTPN22 1858C/T gene polymorphism and tuberculosis resistance.
Tuberculosis
Association of PTPN22-C1858T Polymorphism With Susceptibility to Mycobacterium tuberculosis and Mycobacterium leprae Infection: A Meta-Analysis.
Tuberculosis
ATP synthase, an essential enzyme in growth and multiplication is modulated by protein tyrosine phosphatase in Mycobacterium tuberculosis H37Ra.
Tuberculosis
Backbone NMR assignment of the low-molecular-weight protein tyrosine phosphatase (MPtpA) from Mycobacterium tuberculosis.
Tuberculosis
Backbone resonance assignment and dynamics of 110 kDa hexameric inorganic pyrophosphatase from Mycobacterium tuberculosis.
Tuberculosis
Bioactive Metabolites from the Deep-Sea-Derived Fungus Diaporthe longicolla FS429.
Tuberculosis
Brunsvicamides A-C: sponge-related cyanobacterial peptides with Mycobacterium tuberculosis protein tyrosine phosphatase inhibitory activity.
Tuberculosis
Cefsulodin Inspired Potent and Selective Inhibitors of mPTPB, a Virulent Phosphatase from Mycobacterium tuberculosis.
Tuberculosis
Cis-2 and trans-2-eisocenoic fatty acids are novel inhibitors for Mycobacterium tuberculosis Protein tyrosine phosphatase A.
Tuberculosis
Combination of Gomori and Ziehl-Neelsen stains for showing acid phosphatase activity and Mycobacterium tuberculosis in macrophages.
Tuberculosis
Compound Molecular Logic in Accessing the Active Site of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Tuberculosis
Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition.
Tuberculosis
Crystal structure of low-molecular-weight protein tyrosine phosphatase from Mycobacterium tuberculosis at 1.9-A resolution.
Tuberculosis
Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.
Tuberculosis
Design, synthesis and inhibition activity of novel cyclic peptides against protein tyrosine phosphatase A from Mycobacterium tuberculosis.
Tuberculosis
Diaporisoindoles A-C: Three Isoprenylisoindole Alkaloid Derivatives from the Mangrove Endophytic Fungus Diaporthe sp. SYSU-HQ3.
Tuberculosis
Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold.
Tuberculosis
Discovery of a new class of inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B by biology-oriented synthesis.
Tuberculosis
Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach.
Tuberculosis
Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase B (PtpB) inhibitors from natural products.
Tuberculosis
Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs.
Tuberculosis
Diversity-Oriented Synthesis for Novel, Selective and Drug-like Inhibitors for a Phosphatase from Mycobacterium Tuberculosis.
Tuberculosis
Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
Tuberculosis
Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.
Tuberculosis
Dynamic active-site protection by the M. tuberculosis protein tyrosine phosphatase PtpB lid domain.
Tuberculosis
Dynamic substrate enhancement for the identification of specific, second-site-binding fragments targeting a set of protein tyrosine phosphatases.
Tuberculosis
Expression and localization of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Tuberculosis
Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Tuberculosis
High-Throughput Discovery of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B (MptpB) Inhibitors Using Click Chemistry.
Tuberculosis
Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
Tuberculosis
Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.
Tuberculosis
Identification of Bostrycin Derivatives as Potential Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase (MptpB).
Tuberculosis
Identification of fusarielin M as a novel inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB).
Tuberculosis
Identification of inhibitors for mycobacterial protein tyrosine phosphatase B (MptpB) by biology-oriented synthesis (BIOS).
Tuberculosis
Identification of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase B.
Tuberculosis
Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages.
Tuberculosis
Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: kinetics, molecular modeling, toxicity and effect on growth.
Tuberculosis
Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1.
Tuberculosis
Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.
Tuberculosis
MptpB, a virulence factor from Mycobacterium tuberculosis, exhibits triple-specificity phosphatase activity.
Tuberculosis
Mycobacterium tuberculosis promotes anti-apoptotic activity of the macrophage by PtpA protein-dependent dephosphorylation of host GSK3?.
Tuberculosis
Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification.
Tuberculosis
Mycobacterium tuberculosis protein tyrosine phosphatase PtpB structure reveals a diverged fold and a buried active site.
Tuberculosis
Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system.
Tuberculosis
Mycobacterium tuberculosis tyrosine phosphatase A (PtpA) activity is modulated by S-nitrosylation.
Tuberculosis
Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
Tuberculosis
New potential eukaryotic substrates of the mycobacterial protein tyrosine phosphatase PtpA: hints of a bacterial modulation of macrophage bioenergetics state.
Tuberculosis
New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB.
Tuberculosis
Ophiobolin-Type Sesterterpenoids from the Mangrove Endophytic Fungus Aspergillus sp. ZJ-68.
Tuberculosis
Organocatalytic multicomponent reaction for the acquisition of a selective inhibitor of mPTPB, a virulence factor of tuberculosis.
Tuberculosis
Peniisocoumarins A-J: Isocoumarins from Penicillium commune QQF-3, an Endophytic Fungus of the Mangrove Plant Kandelia candel.
Tuberculosis
Peniphenones A-D from the Mangrove Fungus Penicillium dipodomyicola HN4-3A as Inhibitors of Mycobacterium tuberculosis Phosphatase MptpB.
Tuberculosis
Peptides and polyketides isolated from the marine sponge-derived fungus Aspergillus terreus SCSIO 41008.
Tuberculosis
Phosphorylation control of protein tyrosine phosphatase A activity in Mycobacterium tuberculosis.
Tuberculosis
Polypropionate Derivatives with Mycobacterium tuberculosis Protein Tyrosine Phosphatase B Inhibitory Activities from the Deep-Sea-Derived Fungus Aspergillus fischeri FS452.
Tuberculosis
PP2Ac Modulates AMPK-Mediated Induction of Autophagy in Mycobacterium bovis-Infected Macrophages.
Tuberculosis
Protein tyrosine phosphatase PtpA is not required for Mycobacterium tuberculosis growth in mice.
Tuberculosis
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
Tuberculosis
S-nitrosylation of Mycobacterium tuberculosis tyrosine phosphatase A (PtpA) induces its structural instability.
Tuberculosis
Structural basis for selective inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase PtpB.
Tuberculosis
Structural insights into mode of actions of novel natural Mycobacterium protein tyrosine phosphatase B inhibitors.
Tuberculosis
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Tuberculosis
Substrate Activation of the Low-Molecular Weight Protein Tyrosine Phosphatase from Mycobacterium tuberculosis.
Tuberculosis
Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.
Tuberculosis
Synthesis, biological evaluation and molecular docking study of 1,2,3-1H-triazoles having 4H-pyrano[2,3-d]pyrimidine as potential Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.
Tuberculosis
Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA.
Tuberculosis
Synthetic thiosemicarbazones as a new class of Mycobacterium tuberculosis protein tyrosine phosphatase A inhibitors.
Tuberculosis
Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents.
Tuberculosis
The apo-structure of the low-molecular-weight protein tyrosine phosphatase A (MptpA) from Mycobacterium tuberculosis allows for better target-specific drug development.
Tuberculosis
The domain architecture of PtkA, the first tyrosine kinase from Mycobacterium tuberculosis, differs from the conventional kinase architecture.
Tuberculosis
The Influence of Mycobacterium tuberculosis sigma factors on the promotion efficiency of ptpAt promoter in Mycobacterium smegmatis.
Tuberculosis
The metabolic behaviour of the lymphocytes from serous effusions in various benign internal diseases.
Tuberculosis
Theoretical studies on the interaction of biphenyl inhibitors with Mycobacterium tuberculosis protein tyrosine phosphatase MptpB.
Tuberculosis
Three-dimensional structure and ligand interactions of the low molecular weight protein tyrosine phosphatase from Campylobacter jejuni.
Tuberculosis
Tyrosine phosphatase MptpA of Mycobacterium tuberculosis inhibits phagocytosis and increases actin polymerization in macrophages.
Tuberculosis
Xylanthraquinone, a new anthraquinone from the fungus Xylaria sp. 2508 from the South China Sea.
Tuberculosis
[Advances in the study of Mycobacterium tuberculosis protein phosphatase and its inhibitors].
Tuberculosis
[CHANGE OF ACID PHOSPHATASE ACTIVITY OF THE LIVER AND THE SPLEEN IN EXPERIMENTAL MOUSE TUBERCULOSIS.]
Tuberculosis
[Cytochemical study of macrophages in sarcoidosis patients in skin window exudates]
Tuberculosis
[Methylation Chip Screening and Verification of Differential Genes Related to Tuberculosis Infection].
Tuberculosis
[Microspectrophotometric study of acid phosphatase activity in human neutrophils under normal conditions and in tuberculosis]
Tuberculosis
[Role of molecular adjuvants TBhsp and MT in the preparation of monoclonal antibody against phosphatase of regenerating liver-3].
Tuberculosis, Multidrug-Resistant
Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo.
Tuberculosis, Pulmonary
Association of PTPN22 gene functional variants with development of pulmonary tuberculosis in Moroccan population.
Tuberculosis, Pulmonary
Influence of the polymorphism of the DUSP14 gene on the expression of immune-related genes and development of pulmonary tuberculosis.
Tuberculosis, Pulmonary
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene polymorphism in pulmonary tuberculosis in the Indian population.
Tuberculosis, Pulmonary
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) gene single nucleotide polymorphisms and its interaction with T2DM on pulmonary tuberculosis in Chinese Uygur population.
Tuberculosis, Pulmonary
PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.
Tuberculosis, Pulmonary
R620W functional polymorphism of protein tyrosine phosphatase non-receptor type 22 is not associated with pulmonary tuberculosis in Zahedan, southeast Iran.
Tuberculosis, Pulmonary
[Lymphocyte enzymes, activity of lipid peroxidation processes and the antioxidant protection of patients with tuberculosis of the lungs]
Tuberous Sclerosis
Developmental regulation of the activation of signaling components leading to translation initiation in skeletal muscle of neonatal pigs.
Turner Syndrome
Analysis of PTPN22, ZFAT and MYO9B polymorphisms in Turner Syndrome and risk of autoimmune disease.
Turner Syndrome
PTPN22 polymorphism is related to autoimmune disease risk in patients with Turner syndrome.
Ureteral Obstruction
Integrin-mediated type II TGF-? receptor tyrosine dephosphorylation controls SMAD-dependent profibrotic signaling.
Ureterocele
Maturation of ureter-bladder connection in mice is controlled by LAR family receptor protein tyrosine phosphatases.
Urinary Bladder Neoplasms
A novel synthetic 2-(3-methoxyphenyl)-6,7-methylenedioxoquinolin-4-one arrests the G2/M phase arrest via Cdc25c and induces apoptosis through caspase- and mitochondria-dependent pathways in TSGH8301 human bladder cancer cells.
Urinary Bladder Neoplasms
Acquisition of the Metastatic Phenotype Is Accompanied by H2O2-Dependent Activation of the p130Cas Signaling Complex.
Urinary Bladder Neoplasms
Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Urinary Bladder Neoplasms
Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.
Urinary Bladder Neoplasms
Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1.
Urinary Bladder Neoplasms
HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.
Urinary Bladder Neoplasms
High expression of Cdc25B and low expression of 14-3-3? is associated with the development and poor prognosis in urothelial carcinoma of bladder.
Urinary Bladder Neoplasms
Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Urinary Bladder Neoplasms
Identification of hub genes and pathways associated with bladder cancer based on co-expression network analysis.
Urinary Bladder Neoplasms
miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.
Urinary Bladder Neoplasms
MKP-1 overexpression is associated with chemoresistance in bladder cancer via the MAPK pathway.
Urinary Bladder Neoplasms
Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
Urinary Bladder Neoplasms
PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells.
Urinary Bladder Neoplasms
The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
Urticaria
Association of PTPN22 single nucleotide polymorphisms with chronic spontaneous urticaria.
Urticaria
PTPN22 Polymorphism Presumably Plays a Role in the Genetic Background of Chronic Spontaneous Autoreactive Urticaria.
Uterine Cervical Neoplasms
Blockage of PTPRJ promotes cell growth and resistance to 5-FU through activation of JAK1/STAT3 in the cervical carcinoma cell line C33A.
Uterine Cervical Neoplasms
Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis.
Uterine Cervical Neoplasms
Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Uterine Cervical Neoplasms
Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein.
Uterine Cervical Neoplasms
Divergent viral presentation among human tumors and adjacent normal tissues.
Uterine Cervical Neoplasms
Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer.
Uterine Cervical Neoplasms
Expression and significance of SHP-2 in human papillomavirus infected cervical cancer.
Uterine Cervical Neoplasms
Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis.
Uterine Cervical Neoplasms
HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response.
Uterine Cervical Neoplasms
High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer.
Uterine Cervical Neoplasms
High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation.
Uterine Cervical Neoplasms
Identification of Prognostic miRNA Signature and Lymph Node Metastasis-Related Key Genes in Cervical Cancer.
Uterine Cervical Neoplasms
Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
Uterine Cervical Neoplasms
Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells.
Uterine Cervical Neoplasms
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Uterine Cervical Neoplasms
LINC00662 contributes to the progression and the radioresistance of cervical cancer by regulating miR-497-5p and CDC25A.
Uterine Cervical Neoplasms
Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.
Uterine Cervical Neoplasms
Loss-of-Function Variants in the Tumor-Suppressor Gene PTPN14 Confer Increased Cancer Risk.
Uterine Cervical Neoplasms
MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1.
Uterine Cervical Neoplasms
miR-122-5p modulates the radiosensitivity of cervical cancer cells by regulating cell division cycle 25?CDC25A?.
Uterine Cervical Neoplasms
MiR-613 promotes cell proliferation and invasion in cervical cancer via targeting PTPN9.
Uterine Cervical Neoplasms
Molecular Analysis of the Interaction between Human PTPN21 and the Oncoprotein E7 from Human Papillomavirus Genotype 18.
Uterine Cervical Neoplasms
Oncogenic role of ALX3 in cervical cancer cells through KDM2B-mediated histone demethylation of CDC25A.
Uterine Cervical Neoplasms
PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.
Uterine Cervical Neoplasms
Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition.
Uterine Cervical Neoplasms
SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-? production.
Uterine Cervical Neoplasms
SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer.
Uterine Cervical Neoplasms
Shp2 expression is upregulated in cervical cancer, and Shp2 contributes to cell growth and migration and reduces sensitivity to cisplatin in cervical cancer cells.
Uterine Cervical Neoplasms
Significance of SHP-1 and SHP-2 Expression in Human Papillomavirus Infected Condyloma acuminatum and Cervical Cancer.
Uterine Neoplasms
PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
Uterine Neoplasms
Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Uveitis
Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.
Uveitis
Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis.
Uveitis, Anterior
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
Uveitis, Anterior
Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort.
Uveitis, Anterior
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Uveomeningoencephalitic Syndrome
A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.
Uveomeningoencephalitic Syndrome
Evaluation of PTPN22 polymorphisms and Vogt-Koyanagi-Harada disease in Japanese patients.
Uveomeningoencephalitic Syndrome
Glucocorticoid receptor ? and MKP-1 as candidate biomarkers for treatment response and disease activity in Vogt-Koyanagi-Harada disease.
Vaccinia
A protein phosphatase related to the vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus.
Vaccinia
A selective Seoul-Fluor-based bioprobe, SfBP, for vaccinia H1-related phosphatase--a dual-specific protein tyrosine phosphatase.
Vaccinia
Allosteric Impact of the Variable Insert Loop in Vaccinia H1-Related (VHR) Phosphatase.
Vaccinia
Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona sp.
Vaccinia
Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration.
Vaccinia
Dimeric quaternary structure of the prototypical dual specificity phosphatase VH1.
Vaccinia
Dimerization of vaccinia virus VH1 is essential for dephosphorylation of STAT1 at tyrosine 701.
Vaccinia
Dual-specificity protein phosphatase Yvh1p, which is required for vegetative growth and sporulation, interacts with yeast pescadillo homolog in Saccharomyces cerevisiae.
Vaccinia
Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2+ ion.
Vaccinia
Furanoterpenes, new types of protein tyrosine phosphatase 1B inhibitors, from two Indonesian marine sponges, Ircinia and Spongia spp.
Vaccinia
hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase.
Vaccinia
Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone.
Vaccinia
Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence.
Vaccinia
Molecular cloning and characterization of a novel dual-specificity protein phosphatase possibly involved in spermatogenesis.
Vaccinia
Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase: participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123.
Vaccinia
Negative signaling pathways of the killer cell inhibitory receptor and Fc gamma RIIb1 require distinct phosphatases.
Vaccinia
OH1 from Orf Virus: A New Tyrosine Phosphatase that Displays Distinct Structural Features and Triple Substrate Specificity.
Vaccinia
Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase.
Vaccinia
Protein tyrosine phosphatase 1B inhibitory activity of lavandulyl flavonoids from roots of Sophora flavescens.
Vaccinia
Protein tyrosine phosphatase 1B inhibitory properties of seco-cucurbitane triterpenes obtained from fruiting bodies of Russula lepida.
Vaccinia
Proteomic, cellular, and network analyses reveal new DUSP3 interactions with nucleolar proteins in HeLa cells.
Vaccinia
Small molecule tools for functional interrogation of protein tyrosine phosphatases.
Vaccinia
Specificity Profiling of Dual Specificity Phosphatase Vaccinia VH1-related (VHR) Reveals Two Distinct Substrate Binding Modes.
Vaccinia
Specificity profiling of protein phosphatases toward phosphoseryl and phosphothreonyl peptides.
Vaccinia
Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis.
Vaccinia
Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth.
Vaccinia
The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro.
Vaccinia
The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ.
Vaccinia
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
Vaccinia
Transcription mapping and functional analysis of the protein tyrosine/serine phosphatase (PTPase) gene of the Autographa californica nuclear polyhedrosis virus.
Vaccinia
Tyrosine phosphorylation of A17 during vaccinia virus infection: involvement of the H1 phosphatase and the F10 kinase.
Vaccinia
Unnatural amino acid mutagenesis reveals dimerization as a negative regulatory mechanism of VHR's phosphatase activity.
Vaccinia
Vaccinia H1-related Phosphatase Is a Phosphatase of ErbB Receptors and Is Down-regulated in Non-small Cell Lung Cancer.
Vaccinia
Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis.
Vascular Calcification
New Variants in Enpp1 and Ptpn6 Genes Cause Low Bone Density, Crystal-Related Arthropathy and Vascular Calcification.
Vascular Diseases
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Vascular Diseases
Protein-tyrosine phosphatases in the vessel wall: differential expression after acute arterial injury.
Vascular Diseases
Repression of P66Shc Expression by SIRT1 Contributes to the Prevention of Hyperglycemia-Induced Endothelial Dysfunction.
Vascular Diseases
The Phosphatase SHP-2 Activates HIF-1? in Wounds In Vivo by Inhibition of 26S Proteasome Activity.
Vascular Malformations
Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2.
Vascular Malformations
Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development.
Vascular System Injuries
Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation.
Vascular System Injuries
Endothelial cell-restricted disruption of FoxM1 impairs endothelial repair following LPS-induced vascular injury.
Vascular System Injuries
Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors.
Vascular System Injuries
Intravenous Immunoglobulins Modulate Neutrophil Activation and Vascular Injury Through Fc?RIII and SHP-1.
Vascular System Injuries
Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation.
Vasculitis
High Basal Activity of the PTPN22 Gain-of-Function Variant Blunts Leukocyte Responsiveness Negatively Affecting IL-10 Production in ANCA Vasculitis.
Vasculitis
Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis.
Vasculitis
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Vasculitis
The protein tyrosine phosphatase nonreceptor 22 C1858T polymorphism and vasculitis: a meta-analysis.
Vasculitis
The PTPN22 R620W polymorphism in anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexican Mestizos.
Vasospasm, Intracranial
Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage.
Ventricular Dysfunction, Left
Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc.
Vesicular Stomatitis
A conserved miRNA-183 cluster regulates the innate antiviral response.
Vesicular Stomatitis
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Vesicular Stomatitis
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Vestibular Diseases
Deafness and vestibular dysfunction in a Doberman Pinscher puppy associated with a mutation in the PTPRQ gene.
Virus Diseases
A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system.
Virus Diseases
A role for protein phosphatase 2A in regulating p38 mitogen activated protein kinase activation and tumor necrosis factor-alpha expression during influenza virus infection.
Virus Diseases
Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.
Virus Diseases
Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.
Virus Diseases
E4orf4 induces PP2A- and Src-dependent cell death in Drosophila melanogaster and at the same time inhibits classic apoptosis pathways.
Virus Diseases
Extrinsic Protein Tyrosine Phosphatase Non-Receptor 22 Signals Contribute to CD8 T Cell Exhaustion and Promote Persistence of Chronic Lymphocytic Choriomeningitis Virus Infection.
Virus Diseases
Frequent occurrence of RASSF1A promoter hypermethylation and merkel cell polyomavirus in merkel cell carcinoma.
Virus Diseases
Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia.
Virus Diseases
MAPK Phosphatase 5 Expression Induced by Influenza and Other RNA Virus Infection Negatively Regulates IRF3 Activation and Type I Interferon Response.
Virus Diseases
Phosphatase Cdc25A Negatively Regulates the Antiviral Immune Response by Inhibiting TBK1 Activity.
Virus Diseases
Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia.
Virus Diseases
Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.
Virus Diseases
Protein tyrosine phosphatase 1B is involved in efficient type I interferon secretion upon viral infection.
Virus Diseases
PTPN1/2-mediated dephosphorylation of MITA/STING promotes its 20S proteasomal degradation and attenuates innate antiviral response.
Virus Diseases
PTPN22 contributes to exhaustion of T lymphocytes during chronic viral infection.
Virus Diseases
PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Virus Diseases
SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells.
Virus Diseases
[Molecular genetics of type 1 diabetes mellitus: achievements and future trends]
Vitamin D Deficiency
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
Vitamin D Deficiency
Identification of rat osteoclasts in bone smears with quantification of acid phosphatase activity in vitamin D deficiency.
Vitamin E Deficiency
Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.
Vitiligo
A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo.
Vitiligo
Association of Functional Polymorphism in Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Gene with Vitiligo.
Vitiligo
Association of protein tyrosine phosphatase, non-receptor type 22 +1858C?T polymorphism and susceptibility to vitiligo: Systematic review and meta-analysis.
Vitiligo
Association of PTPN22 1858C/T polymorphism with vitiligo susceptibility in Gujarat population.
Vitiligo
Association of PTPN22 gene polymorphism with non-segmental vitiligo in South Indian Tamils.
Vitiligo
Clinical characteristics and PTPN22 1858C/T variant analysis in Jordanian Arab vitiligo patients.
Vitiligo
Lack of Association between PTPN22 Gene +1858 C>T Polymorphism and Susceptibility to Generalized Vitiligo in a Turkish Population.
Vitiligo
Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620W allele and systemic sclerosis in the French Caucasian population.
Vitiligo
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue.
Vitiligo
Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene R620W variant and sporadic idiopathic hypoparathyroidism in Asian Indians.
Vitiligo
Protein tyrosine phosphatase PTPN22 +1858C/T polymorphism is associated with active vitiligo.
Vitiligo
PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not.
Vitiligo
The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis.
Vitiligo
The PTPN22-1858C>T (R620W) functional polymorphism is associated with generalized vitiligo in the Romanian population.
Werner Syndrome
Physical map of the human chromosome 8p12-p21 encompassing tumor suppressor and Werner's syndrome gene loci.
Whooping Cough
Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness.
Whooping Cough
Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion.
Whooping Cough
Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase.
Whooping Cough
Antibody binding to cell surface amyloid precursor protein induces neuronal injury by deregulating the phosphorylation of focal adhesion signaling related proteins.
Whooping Cough
Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin.
Whooping Cough
Bordetella pertussis Adenylate Cyclase Toxin Blocks Induction of Bactericidal Nitric Oxide in Macrophages through cAMP-Dependent Activation of the SHP-1 Phosphatase.
Whooping Cough
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Whooping Cough
Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
Whooping Cough
Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.
Whooping Cough
G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification.
Whooping Cough
Galpha(i2) enhances insulin signaling via suppression of protein-tyrosine phosphatase 1B.
Whooping Cough
Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1.
Whooping Cough
Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits.
Whooping Cough
Inhibition of protein phosphatase 2A (PP2A) mimics suckling-induced sensitization of mammotropes: involvement of a pertussis toxin (PTX) sensitive G-protein and the adenylate cyclase (AC).
Whooping Cough
LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells.
Whooping Cough
Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition.
Whooping Cough
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.
Whooping Cough
Pertussis toxin modification of PC12 cells lowers cytoskeletal F-actin and enhances norepinephrine secretion: involvement of protein kinase C and protein phosphatases.
Whooping Cough
Potentiation by insulin and insulin-like growth factor-1 of glibenclamide-sensitive K+ currents in follicle-enclosed Xenopus oocytes.
Whooping Cough
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Whooping Cough
Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-initiated pathway.
Whooping Cough
Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells.
Whooping Cough
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
Whooping Cough
The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling.
Whooping Cough
Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein.
Wilms Tumor
Early changes in gene expression that influence the course of primary glomerular disease.
Wilms Tumor
Expression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor.
Wilms Tumor
Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.
Xanthogranuloma, Juvenile
Juvenile myelomonocytic leukaemia presentation after preceding juvenile xanthogranuloma harbouring an identical somatic PTPN11 mutation.
[phosphatase 2a protein]-leucine-carboxy methyltransferase deficiency
Circumventing embryonic lethality with Lcmt1 deficiency: generation of hypomorphic Lcmt1 mice with reduced protein phosphatase 2A methyltransferase expression and defects in insulin signaling.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0027
DADEpYLIPQQG
wild type PTPH1, in the presence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.0031
DADEpYLIPQQG
wild type PTPH1, in the absence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.0035
DADEpYLIPQQG
CCPGCC-insertion mutant PTPH1-816, in the absence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.0077
DADEpYLIPQQG
CCPGCC-insertion mutant PTPH1-816, in the presence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.077
DADEpYLIPQQG
wild type PTPalpha, in the presence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.082
DADEpYLIPQQG
wild type PTPalpha, in the absence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.084
DADEpYLIPQQG
CCPGCC-insertion mutant PTPalpha-406, in the absence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
0.1
DADEpYLIPQQG
CCPGCC-insertion mutant PTPalpha-406, in the presence of fluorescein arsenical hairpin binder, in 50 mM 3,3-dimethylglutarate at pH 7.0, 1 mM EDTA, and 50 mM NaCl, at 22°C
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
Michaelis-Menten kinetics
-
additional information
additional information
kinetic isotope effects. The active form of the substrate is the dianion
-
additional information
additional information
kinetic isotope effects. The active form of the substrate is the dianion
-
additional information
additional information
kinetic isotope effects. The active form of the substrate is the dianion
-
additional information
additional information
Michaelis-Menten kinetic modeling
-
additional information
additional information
steady-state kinetic study, Lineweaver-Burk plots
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.023 - 0.1
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.0003 - 0.113
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.019 - 0.109
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.00091 - 0.115
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.00061 - 0.147
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.00019 - 0.0038
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.00017 - 0.088
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
0.0042
2-[6-chloro-5-(1-naphthalyloxy)-1H-benzimidazol-2-yl]thio-N-(thiazol-2-yl)acetamide
pH 7.0, 37°C
0.0052
5-chloro-N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-1-methyl-2-(methylthio)-1H-benz-imidazole-6-carboxamide
pH 7.0, 37°C
0.0382
bis(3-hydroxy-2-methyl-4(1H)pyridinonato)oxidovanadium(IV)
pH 5.0, 22°C, recombinant enzyme, versus 4-nitrophenyl phosphate
0.0413
N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-2,2,2-trifluoroacetamide
pH 7.0, 37°C
additional information
additional information
inhibition kinetic analysis of (VO2+) chelates with PTP1B, Lineweaver-Burk plots, overview
-
0.023
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.027
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.03
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.1
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.1
(5R)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/D48N, pH 7.0, 25°C
0.0003
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.00033
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.00055
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.057
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.113
(5S)-2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.019
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.02
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.048
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.1
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.109
2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.00091
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.00094
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.00128
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.08
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.115
2-((carboxycarbonyl)amino)-5-((1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.00061
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.00067
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.00073
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.084
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.147
2-((carboxycarbonyl)amino)-5-((4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.00019
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, pH 7.0, 25°C
0.00031
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.00061
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.00061
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.0038
2-((carboxycarbonyl)amino)-5-((4-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.00017
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant D48N, H 7.0, 25°C
0.00019
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, mutant R47N/D48N, pH 7.0, 25°C
0.00049
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, pH 7.0, 25°C
0.064
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTP1B, pH 7.0, 25°C
0.088
2-((carboxycarbonyl)amino)-5-((5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid
isoform PTPbeta, mutant N47R/N48D, pH 7.0, 25°C
0.00014
bis(2-ethyl-maltolato)oxidovanadium(IV)
pH 5.0, 22°C, recombinant enzyme, versus DADE(pY)LIPQQG
0.0148
bis(2-ethyl-maltolato)oxidovanadium(IV)
pH 5.0, 22°C, recombinant enzyme, versus 4-nitrophenyl phosphate
0.00016
bis(acetylacetonato)oxidovanadium(IV)
pH 5.0, 22°C, recombinant enzyme, versus DADE(pY)LIPQQG
0.0065
bis(acetylacetonato)oxidovanadium(IV)
pH 5.0, 22°C, recombinant enzyme, versus 4-nitrophenyl phosphate
0.000017
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant TCPTP-187
-
0.000038
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant PTPH1-816
-
0.000039
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant PTPHalpha-406
-
0.000046
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant PTP1B-186
-
0.000053
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant PTP-PEST-204
-
0.000089
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant HePTPH-211
-
0.00037
fluorescein arsenical hairpin binder
CCPGCC-insertion mutant FAP-1-2364
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0083
(3alpha,5beta,8alpha,9beta,10alpha,13alpha)-3-[[(2E)-4-phenylbut-2-enoyl]oxy]kaur-16-en-18-oic acid
Homo sapiens
pH 6.0, 37°C
0.028
(5beta,8alpha,9beta,10alpha,13alpha)-kaur-16-en-18-oic acid
Homo sapiens
pH 6.0, 37°C
0.0066
(5Z)-3-benzyl-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-3-benzyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0072
(5Z)-3-benzyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0206
(5Z)-3-butyl-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0096
(5Z)-3-butyl-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0298
(5Z)-5-(4-hydroxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0142
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0082
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0121
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0223
(5Z)-5-(5-bromo-2,4-dimethoxybenzylidene)-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0049
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0123
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-(5-bromo-4-butoxy-2-methoxybenzylidene)-3-butyl-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0113
(5Z)-5-(5-bromo-4-hydroxy-2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0122
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0227
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-[2-methoxy-5-(prop-2-en-1-yl)-4-(tetrahydro-2H-pyran-2-yloxy)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0076
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0103
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0081
(5Z)-5-[4-(benzyloxy)-5-bromo-2-methoxybenzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0293
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.012
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(3-methylbut-2-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(prop-2-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0064
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-(propan-2-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.03
(5Z)-5-[4-hydroxy-2-methoxy-5-(prop-2-en-1-yl)benzylidene]-3-methyl-1,3-thiazolidine-2,4-dione
Homo sapiens
IC50 above 0.03 mM, in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0081
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.017
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0079
(5Z)-5-[5-bromo-2-methoxy-4-(prop-2-en-1-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0046
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0097
(5Z)-5-[5-bromo-2-methoxy-4-(propan-2-yloxy)benzylidene]-3-butyl-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0053
(5Z)-5-[5-bromo-2-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]benzylidene]-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.01
(5Z)-5-[5-bromo-2-methoxy-4-[(4-methylpent-3-en-1-yl)oxy]benzylidene]-3-(4-methylpent-3-en-1-yl)-1,3-thiazolidine-2,4-dione
Homo sapiens
in 50 mM citrate (pH 6.0), 0.1 M NaCl, 1 mM EDTA and 1 mM dithiothreitol, at 37°C
0.0084
2-[6-chloro-5-(1-naphthalyloxy)-1H-benzimidazol-2-yl]thio-N-(thiazol-2-yl)acetamide
Homo sapiens
pH 7.0, 37°C
0.008
3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-[4-(1,3-thiazol-2-ylsulfamoyl)phenyl]-1-benzofuran-6-sulfonamide
Homo sapiens
pH and temperature not specified in the publication
0.01
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0042
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0051
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenoxyphenyl)methylidene]thiazolidin-3-yl) methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0019
4-(((5Z)-2-(4-fluorophenylimino)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]thiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0071
4-(((5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0057
4-(((5Z)-4-oxo-5-[(3-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0106
4-(((5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.005
4-(((5Z)-4-oxo-5-[(4-phenylmethoxyphenyl)methylidene]-2-thioxothiazolidin-3-yl)methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0109
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0025
4-([(2E,5Z)-2-[(4-methoxyphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0104
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0022
4-([(2E,5Z)-2-[(4-tert-butylphenyl)imino]-4-oxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0051
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0056
4-([(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.003
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-methoxyphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0014
4-([(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2-[(4-tert-butylphenyl)imino]-4-oxo-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.018
4-([(5Z)-2,4-dioxo-5-[(3-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0028
4-([(5Z)-2,4-dioxo-5-[(4-phenoxyphenyl)methylidene]-1,3-thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0145
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([3-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0015
4-([(5Z)-2-(4-fluorophenylimino)-4-oxo-5-([4-(2-phenylethoxy)phenyl]methylidene)thiazolidin-3-yl]methyl)benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0019
4-([(5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0035
4-([(5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene)-2-thioxothiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0019
4-[[(2E,5Z)-4-oxo-5-[(3-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0011
4-[[(2E,5Z)-4-oxo-5-[(4-phenoxyphenyl)methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0046
4-[[(2E,5Z)-4-oxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0015
4-[[(2E,5Z)-4-oxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0038
4-[[(2E,5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0011
4-[[(2E,5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-4-oxo-2-(phenylimino)-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0095
4-[[(5Z)-2,4-dioxo-5-[[3-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0026
4-[[(5Z)-2,4-dioxo-5-[[4-(2-phenylethoxy)phenyl]methylidene]-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0011
4-[[(5Z)-5-[[3-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0016
4-[[(5Z)-5-[[4-(benzyloxy)phenyl]methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]methyl]benzoic acid
Homo sapiens
pH 7.0, 37°C
0.0075
5-chloro-N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-1-methyl-2-(methylthio)-1H-benz-imidazole-6-carboxamide
Homo sapiens
pH 7.0, 37°C
0.003
7-(2-((1H-imidazol-2-yl)thio)ethoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0016
7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.004
7-(2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.005
7-(2-(4-nitro-1H-imidazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0079
7-(2-(5-methyl-1H-tetrazol-1-yl)ethoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.007
7-(3-(4-nitro-1H-imidazol-1-yl)propoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0039
7-(4-((1H-imidazol-2-yl)thio)butoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0036
7-(4-(1H-1,2,4-triazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0069
7-(4-(2-methyl-5-nitro-1H-imidazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0151
7-(4-(5-methyl-1H-tetrazol-1-yl)butoxy)-2-phenyl-4H-chromen-4-one
Homo sapiens
pH 7.2, 37°C
0.0313
N-[6-chloro-5-(2,3-dichlorophenoxy)-1H-benzimidazol-2-yl]-2,2,2-trifluoroacetamide
Homo sapiens
pH 7.0, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
664046, 664302, 691235, 692320, 707634, 708122, 709102, 729379, 730324, 730789, 749934, 749953, 750022, 750029, 750047, 750305, 750465, 751130, 751625, 752277
SwissProt
brenda
isoform PTP1B, amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail
SwissProt
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
physiological function
additional information
evolution
protein tyrosine phosphatase 1B (PTP1B) belongs to class I of the cysteine-based protein tyrosine phosphatases
evolution
the enzyme is a member of the PTP superfamily. The Trp residue, W179 in PTP1B, is highly conserved in the PTP family and is one of the residues in the flexible loop that bears the general acid
physiological function
isoform PTP1B (PTPN1) regulates the insulin and leptin signalling pathway and is implicated in cancer and obesity/diabetes
physiological function
protein tyrosine phosphatase 1B is a negative regulator of insulin signaling
physiological function
the phosphatase PTP1B is a key regulator of insulin and leptin signaling
additional information
a consensus sequence H/V-C-X5-R-S/T characterizes the active sites of PTPases
additional information
a conserved aspartic acid, which functions as a general acid for nucleophilic attack on the substrate in the first step of catalysis, must appear in the WPD loop among active PTPs
additional information
a conserved aspartic acid, which functions as a general acid for nucleophilic attack on the substrate in the first step of catalysis, must appear in the WPD loop among active PTPs
additional information
a conserved aspartic acid, which functions as a general acid for nucleophilic attack on the substrate in the first step of catalysis, must appear in the WPD loop among active PTPs
additional information
a conserved aspartic acid, which functions as a general acid for nucleophilic attack on the substrate in the first step of catalysis, must appear in the WPD loop among active PTPs
additional information
a conserved aspartic acid, which functions as a general acid for nucleophilic attack on the substrate in the first step of catalysis, must appear in the WPD loop among active PTPs
additional information
phosphatases do not alter the transition state for phosphoryl transfer. Active site structure and WPD loop analysis. Slowlier loop dynamics in PTP1B may reflect its key physiological roles in which turnover rates must meet the requirements of other activities in the cell
additional information
phosphatases do not alter the transition state for phosphoryl transfer. Active site structure and WPD loop analysis. Slowlier loop dynamics in PTP1B may reflect its key physiological roles in which turnover rates must meet the requirements of other activities in the cell
additional information
phosphatases do not alter the transition state for phosphoryl transfer. Active site structure and WPD loop analysis. Slowlier loop dynamics in PTP1B may reflect its key physiological roles in which turnover rates must meet the requirements of other activities in the cell
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). PTN1_HUMAN
435
1
49967
Swiss-Prot
other Location (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
PTPB1 possesses a P-loop, a WPD-loop, a Q-loop, a Lys-loop, and a pTyr-recognition loop, that show conformational changes during formation of the transition state
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
active site mutant C215S in complex with substrates bis-(para-phosphophenyl) methane and 4-nitrophenyl phosphate
in complex with inhibitors 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N,N-dimethyl-1-benzofuran-6-sulfonamide, 3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-(1,3-thiazol-2-ylsulfamoyl)phenyl)-1-benzofuran-6-sulfonamide and 3-((3,5-dibromo-4-hydroxyphenyl)carbonyl)-2-ethyl-N-(4-sulfamoylphenyl)-1-benzofuran-6-sulfonamide
molecular dynamics simulations of the crystal structure of the enzyme catalytic domain and of mutant R47V/D48N/M258C/G259Q, both in complex with substrate 4-nitrophenyl phosphate and as cysteine-phosphor complex
two transition-state analogues, by sitting drop vapor diffusion method, 4°C, mixing of 0.002 ml of protein solution, containing native PTPB1, peptide DADEYL, and Na3VO4 in 10 mM Tris, pH 7.5, 25 mM NaCl, 0.2 mM EDTA, and 3 mM DTT, with 0.0005 ml of sucrose 30% v/v solution, and 0.003 ml of precipitant solution, containing 0.1 M HEPES, pH 7.5, 0.2 M magnesium acetate and 15-17% PEG 8000, 3 days, X-ray diffraction structure determination and analysis at 2.25-2.3 A resolution
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
A122F
site-directed mutagenesis, affects inhibition by abietic acid and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
A189S
site-directed mutagenesis, affects inhibition by 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
C215D
active-site mutant, similar Km-values as wild type, but reduced kcat-values and activation by 1,2-epoxy-3-(p-nitrophenoxy)propane, use as substrate-trapping mutant
C215S
crystallization data, in complex with substrates bis-(para-phosphophenyl) methane and 4-nitrophenyl phosphate
C92A
site-directed mutagenesis, affects inhibition by abietic acid and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
F135Y
site-directed mutagenesis, affects inhibition by abietic acid, 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide, and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
F182H
isoform PTP1B, exchange of residue 182 with that of isoform PTPH1, modulation of functionality of catalytic center
F182Y
site-directed mutagenesis, affects inhibition by abietic acid and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
F196Y
site-directed mutagenesis, affects inhibition by abietic acid and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
F280Y
site-directed mutagenesis, does not affect abietane-type diterpenoids as inhibitors
G259S
site-directed mutagenesis, affects inhibition by 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
H175A
site-directed mutagenesis, affects inhibition by abietic acid and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
H182F
isoform PTP1B, exchange of residue 182 with that of isoform PTPB1, modulation of functionality of catalytic center
P87C/A122C
mutant asPTP1B, design of non-natural allosteric-inhibition sites in PTPs, in which a tricysteine moiety is engineered within the PTP catalytic domain at a conserved location outside of the active site. Introduction of the tricysteine motif, which does not exist in any wild-type PTP, serves to sensitize target PTPs to inhibition by a biarsenical compound, providing a generalizable strategy for the generation of allosterically sensitized (as) PTPs. The potency, selectivity, and kinetics of asPTP inhibition can be significantly improved by exploring the inhibitory action of a range of biarsenical compounds that differ in interarsenical distance, steric bulk, and electronic structure
R112A
site-directed mutagenesis, affects inhibition by abietic acid, 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide, and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
R47V/D48N/M258C/G259Q
molecular dynamics simulations of the crystal structure, in comparison to wild-type, movement of Q262 is restricted
S295F
affects minimally catalytic activity, significantly reduces the potency of inhibitors derived from 7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile
V113T
site-directed mutagenesis, does not affect abietane-type diterpenoids as inhibitors
W179F
site-directed mutagenesis, the mutation in PTP1B causes only a minor reduction in kcat of about 2fold at pH 5.5, and the pH-rate profile remains fully bell-shaped. The kinetic isotopic effects are similar to those of the wild-type PTP1B showing that general acid catalysis remains effective. The affinity of the competitive inhibitors tungstate and molybdate for the active site is not affected by the W179F mutation. Crystal structures of the W179F mutant of PTP1B show the availability of both the normal loop open and closed positions, consistent with the kinetic results
Y152A/Y153A
site-directed mutagenesis, the mutation attenuates allosteric communication between the C-terminus and the WPD loop, affects inhibition by abietic acid, 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-[4-(thiazol-2-ylsulfamyl)phenyl]-amide, and 2-[(carboxycarbonyl)amino]-4,5,6,7-tetrahydro-thieno[2,3-c]-pyridine-3-carboxylic acid
Y46A
site-directed mutagenesis, substitution of Y46 with alalnine in PTP1B results in a 380fold increase in Km using pNPP as a substrate
additional information
the mutants TCPTP-187 , PTP1B-186, HePTP-211, FAP-1-2364 , PTP-PEST-204 have a CCPGCC-insertion that leads to sensitisation toward fluorescein arsenical hairpin binder protein, the CCPGCC-insertion mutants PTPH1-816 and PTPalpha-406 are particularly attractive as inhibitor-sensitized enzymes in that they demonstrate kinetic parameters that are essentially indistinguishable (or marginally improved, in the case of PTPalpha-406) from the corresponding wild type enzymes in the absence of an allele-specific inhibitor
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant His-tagged wild-type and mutant enzymes from Escherichia coli strain BL21(DE3) by nickel affinity chromatography
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Mus musculus
gene PTP1B, recombinant expression of C-terminally His-tagged wild-type and mutant enzymes (PTP1B residues 1-321) in Escherichia coli strain BL21(DE3)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Pedersen, A.K.; Guo, X.L.; Moller, K.B.; Peters, G.H.; Andersen, H.S.; Kastrup, J.S.; Mortensen, S.B.; Iversen, L.F.; Zhang, Z.Y.; Moller, N.P.H.
Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis
Biochem. J.
378
421-433
2004
Homo sapiens (P18031)
brenda
Romsicki, Y.; Scapin, G.; Beaulieu-Audy, V.; Patel, S.; Becker, J.W.; Kennedy, B.P.; Asante-Appiah, E.
Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B
J. Biol. Chem.
278
29009-29015
2003
Homo sapiens (P18031)
brenda
Peters, G.H.; Iversen, L.F.; Andersen, H.S.; Moller, N.P.; Olsen, O.H.
Residue 259 in protein-tyrosine phosphatase PTP1B and PTPalpha determines the flexibility of glutamine 262
Biochemistry
43
8418-8428
2004
Homo sapiens (P18031)
brenda
Shim, Y.S.; Kim, K.C.; Lee, K.A.; Shrestha, S.; Lee, K.H.; Kim, C.K.; Cho, H.
Formylchromone derivatives as irreversible and selective inhibitors of human protein tyrosine phosphatase 1B. Kinetic and modeling studies
Bioorg. Med. Chem.
13
1325-1332
2005
Homo sapiens (P18031), Homo sapiens
brenda
Puius, Y.A.; Zhao, Y.; Sullivan, M.; Lawrence, D.S.; Almo, S.C.; Zhang, Z.Y.
Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design
Proc. Natl. Acad. Sci. USA
94
13420-13425
1997
Homo sapiens (P18031), Homo sapiens
brenda
Lund, I.K.; Andersen, H.S.; Iversen, L.F.; Olsen, O.H.; Moller, K.B.; Pedersen, A.K.; Ge, Y.; Holsworth, D.D.; Newman, M.J.; Axe, F.U.; Moller, N.P.
Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta
J. Biol. Chem.
279
24226-24235
2004
Homo sapiens (P18031), Homo sapiens
brenda
Montalibet, J.; Skorey, K.; McKay, D.; Scapin, G.; Asante-Appiah, E.; Kennedy, B.P.
Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding
J. Biol. Chem.
281
5258-5266
2006
Homo sapiens (P18031)
brenda
Wiesmann, C.; Barr, K.J.; Kung, J.; Zhu, J.; Erlanson, D.A.; Shen, W.; Fahr, B.J.; Zhong, M.; Taylor, L.; Randal, M.; McDowell, R.S.; Hansen, S.K.
Allosteric inhibition of protein tyrosine phosphatase 1B
Nat. Struct. Mol. Biol.
11
730-737
2004
Homo sapiens (P18031), Homo sapiens
brenda
Zhang, X.Y.; Chen, V.L.; Rosen, M.S.; Blair, E.R.; Lone, A.M.; Bishop, A.C.
Allele-specific inhibition of divergent protein tyrosine phosphatases with a single small molecule
Bioorg. Med. Chem.
16
8090-8097
2008
Homo sapiens (P18031)
brenda
Hendriks, W.J.; Elson, A.; Harroch, S.; Stoker, A.W.
Protein tyrosine phosphatases: functional inferences from mouse models and human diseases
FEBS J.
275
816-830
2008
Homo sapiens, Homo sapiens (O14522), Homo sapiens (P10586), Homo sapiens (P17706), Homo sapiens (P18031), Homo sapiens (P18433), Homo sapiens (P23467), Homo sapiens (P23468), Homo sapiens (P23469), Homo sapiens (P23470), Homo sapiens (P23471), Homo sapiens (P26045), Homo sapiens (P28827), Homo sapiens (P29074), Homo sapiens (P29350), Homo sapiens (P35236), Homo sapiens (P43378), Homo sapiens (P54829), Homo sapiens (Q05209), Homo sapiens (Q06124), Homo sapiens (Q0VAE8), Homo sapiens (Q12913), Homo sapiens (Q12923), Homo sapiens (Q13332), Homo sapiens (Q15256), Homo sapiens (Q15262), Homo sapiens (Q15678), Homo sapiens (Q16825), Homo sapiens (Q16827), Homo sapiens (Q16849), Homo sapiens (Q4JDK3), Homo sapiens (Q92729), Homo sapiens (Q92932), Homo sapiens (Q99952), Homo sapiens (Q9H3S7), Homo sapiens (Q9HD43), Homo sapiens (Q9UMZ3), Homo sapiens (Q9Y2R2)
brenda
Bustanji, Y.; Taha, M.O.; Al-Masri, I.M.; Mohammad, M.K.
Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B
Biol. Pharm. Bull.
32
640-645
2009
Homo sapiens (P18031), Homo sapiens
brenda
Maccari, R.; Ottana, R.; Ciurleo, R.; Paoli, P.; Manao, G.; Camici, G.; Laggner, C.; Langer, T.
Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase
ChemMedChem
4
957-962
2009
Homo sapiens (P18031)
brenda
Brandao, T.A.; Hengge, A.C.; Johnson, S.J.
Insights into the reaction of protein tyrosine phosphatase 1B. Crystal structures for transition-state analogs of both catalytic steps
J. Biol. Chem.
285
15874-15883
2010
Homo sapiens (P18031)
brenda
Wang, Z.; Liu, Z.; Lee, W.; Kim, S.N.; Yoon, G.; Cheon, S.H.
Design, synthesis and docking study of 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives as inhibitors of protein tyrosine phosphatase 1B
Bioorg. Med. Chem. Lett.
24
3337-3340
2014
Homo sapiens (P18031)
brenda
Bellomo, E.; Massarotti, A.; Hogstrand, C.; Maret, W.
Zinc ions modulate protein tyrosine phosphatase 1B activity
Metallomics
6
1229-1239
2014
Homo sapiens (P18031), Homo sapiens
brenda
Li, S.; Zhang, J.; Lu, S.; Huang, W.; Geng, L.; Shen, Q.; Zhang, J.
The mechanism of allosteric inhibition of protein tyrosine phosphatase 1B
PLoS ONE
9
e97668
2014
Homo sapiens (P18031)
brenda
Hjortness, M.; Riccardi, L.; Hongdusit, A.; Ruppe, A.; Zhao, M.; Kim, E.; Zwart, P.; Sankaran, B.; Arthanari, H.; Sousa, M.; De Vivo, M.; Fox, J.
Abietane-type diterpenoids inhibit protein tyrosine phosphatases by stabilizing an inactive enzyme conformation
Biochemistry
57
5886-5896
2018
Homo sapiens (P18031)
-
brenda
Hengge, A.C.
Kinetic isotope effects in the characterization of catalysis by protein tyrosine phosphatases
Biochim. Biophys. Acta
1854
1768-1775
2015
Yersinia sp., Homo sapiens (P18031), Homo sapiens (P51452), Homo sapiens (Q9BVJ7), Mus musculus (P35821), Schizosaccharomyces pombe (P41893), Schizosaccharomyces pombe ATCC 24843 (P41893)
brenda
Zhang, L.; Ge, Y.; Song, H.M.; Wang, Q.M.; Zhou, C.H.
Design, synthesis of novel azolyl flavonoids and their protein tyrosine Phosphatase-1B inhibitory activities
Bioorg. Chem.
80
195-203
2018
Homo sapiens (P18031)
brenda
Peti, W.; Page, R.
Strategies to make protein serine/threonine (PP1, calcineurin) and tyrosine phosphatases (PTP1B) druggable Achieving specificity by targeting substrate and regulatory protein interaction sites
Bioorg. Med. Chem.
23
2781-2785
2015
Homo sapiens (P18031)
brenda
Korntner, S.; Pomorski, A.; Krezel, A.; Bishop, A.C.
Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules
Bioorg. Med. Chem.
26
2610-2620
2018
Homo sapiens (P18031)
brenda
Abdjul, D.B.; Yamazaki, H.; Kanno, S.I.; Kirikoshi, R.; Tomizawa, A.; Takahashi, O.; Maarisit, W.; Losung, F.; Rotinsulu, H.; Wewengkang, D.S.; Sumilat, D.A.; Kapojos, M.M.; Namikoshi, M.
Absolute structures of wedelolide derivatives and structure-activity relationships of protein tyrosine phosphatase 1B inhibitory ent-kaurene diterpenes from aerial parts of Wedelia spp. collected in Indonesia and Japan
Chem. Pharm. Bull.
66
682-687
2018
Homo sapiens (P18031), Homo sapiens
brenda
Ottana, R.; Paoli, P.; Nass, A.; Lori, G.; Cardile, V.; Adornato, I.; Rotondo, A.; Graziano, A.C.E.; Wolber, G.; Maccari, R.
Discovery of 4-[(5-arylidene-4-oxothiazolidin-3-yl)methyl]benzoic acid derivatives active as novel potent allosteric inhibitors of protein tyrosine phosphatase 1B in silico studies and in vitro evaluation as insulinomimetic and anti-inflammatory agents
Eur. J. Med. Chem.
127
840-858
2017
Homo sapiens (P18031)
brenda
Hon, J.; Hwang, M.S.; Charnetzki, M.A.; Rashed, I.J.; Brady, P.B.; Quillin, S.; Makinen, M.W.
Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by vanadyl (VO2+) chelates
J. Biol. Inorg. Chem.
22
1267-1279
2017
Homo sapiens (P18031)
brenda
Sarabia-Sanchez, M.J.; Trejo-Soto, P.J.; Velazquez-Lopez, J.M.; Carvente-Garcia, C.; Castillo, R.; Hernandez-Campos, A.; Avitia-Dominguez, C.; Enriquez-Mendiola, D.; Sierra-Campos, E.; Valdez-Solana, M.; Salas-Pacheco, J.M.; Tellez-Valencia, A.
Novel mixed-type inhibitors of protein tyrosine phosphatase 1B. Kinetic and computational studies
Molecules
22
2262-2278
2017
Homo sapiens (P18031)
brenda
Chen, K.E.; Li, M.Y.; Chou, C.C.; Ho, M.R.; Chen, G.C.; Meng, T.C.; Wang, A.H.
Substrate specificity and plasticity of FERM-containing protein tyrosine phosphatases
Structure
23
653-664
2015
Homo sapiens (P18031), Homo sapiens (P26045), Homo sapiens (Q12923), Homo sapiens (Q15678), Homo sapiens (Q16825)
brenda
EXTERNAL LINKS (specific for EC-Number 3.1.3.48)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
